False	However, delayed-onset @DISEASE@ is a common adverse reaction, limiting the application of the drug.
False	We established a @DISEASE@ rat model.
False	The proliferation and apoptosis of intestinal cells were measured using immunohistochemical assays and a caspase-3 activity assay, respectively.
False	Preventive Effects of a Chinese Herbal Formula, @FORMULA@, on Irinotecan-Induced Delayed-Onset @DISEASE@ in Rats.
False	The study presented was designed to evaluate the preventive effects of @FORMULA@ (@FORMULA@) on irinotecan-induced @DISEASE@ and to explore the possible mechanisms of this action.
True	In conclusion, @FORMULA@ exhibited preventive effects on irinotecan-induced @DISEASE@, and this action was associated with an inhibitory effect on intestinal apoptosis and beta-glucuronidase and a promotive effect on intestinal cell proliferation due to increased maintenance of ISCs.
False	@FORMULA@ (@FORMULA@), a classical traditional Chinese medicine formula, is effective for the treatment of @DISEASE@ (@DISEASE@).
False	This study was designed to investigate the therapeutic effects of @FORMULA@ on @DISEASE@ and possible mechanisms.
True	Our results indicate that @FORMULA@ has a protective effect on DSS-induced @DISEASE@, which is attributable to its anti-inflammatory activity and intestinal barrier function-enhancing effects.
False	The administration of @FORMULA@ significantly ameliorated the clinical signs, suppressed the levels of proinflammatory cytokines, and reduced immune cell infiltrates into colonic tissues of DSS-induced @DISEASE@ model mice.
False	These results provide valuable insights into the pharmacological actions of @FORMULA@ for the treatment of @DISEASE@.
False	Dextran sulfate sodium (DSS, 3.5%) was used to induce @DISEASE@ in C57BL/6 mice.
False	TJ-14 (7.5 g/day) was administered orally.
False	We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced @DISEASE@.
False	CONCLUSION: TJ-14 was effective in preventing and controlling CPT-11-induced @DISEASE@.
False	Compared with the control group, the TJ-14 group showed a significant improvement in @DISEASE@ grades ( P=0.044) as well as a reduced frequency of @DISEASE@ grades 3 and 4 (one patient versus ten patients; P=0.018).
True	Preventive effect of Kampo medicine (@FORMULA@) against irinotecan-induced @DISEASE@ in @DISEASE@.
False	METHODS: Of 44 previously untreated patients with @DISEASE@ randomized, 41 (18 TJ-14 group, 23 control group) were available for evaluation.
False	To systematically evaluate the efficacy and safety of @FORMULA@ combined with conventional anti-hypertensive drugs in the treatment of @DISEASE@.
False	[Systematic evaluation and trial sequential analysis of @FORMULA@ combined with anti-hypertensive drugs in treatment of @DISEASE@].
False	There was no statistically significant difference between the test group and the control group in the incidence of adverse reactions.
False	No @DISEASE@ and @DISEASE@ occurred.
False	The clinical randomized controlled trials(RCTs) on the treatment of @DISEASE@ with @FORMULA@ combined with conventional anti-hypertensive drugs were searched in PubMed, EMbase, Cochrane Library, VIP, CNKI, Wanfang, SinoMed since the establishment of the databases to April 2020 based on inclusion and exclusion criteria, and Meta-analysis was conducted by using RevMan 5.3 software.
True	The clinical application of @FORMULA@ combined with conventional Western medicine in the treatment of @DISEASE@ and accompanying symptoms has clear efficacy and certain safety, so it is recommended for clinical application.
False	@FORMULA@ (@FORMULA@) is a traditional Chinese medicine prescription for the prevention and treatment of @DISEASE@.
True	Our results suggested that KLF4 may be the potential therapeutic target of @FORMULA@ for the treatment of @DISEASE@.
False	Our study is aimed to identify the potential therapeutic target of @FORMULA@.
False	Low KLF4 expression was significantly correlated with reductions of overall survival and recurrence rate.
False	The mRNA targets of @FORMULA@ were predicted by BATMAN-TCM database and were further identified by integrated analysis of expression data from TCGA.
False	BATMAN-TCM prediction showed that KLF4 was an mRNA target of @FORMULA@ and it was downregulated in @DISEASE@ by integrated analysis of expression data from TCGA.
False	Blood pressure and creatinine clearance were normal at the end of the trial in all but one group 2 patient, who developed @DISEASE@.
False	Forty-six of the 50 patients in group 1 and 48 of the 51 patients in group 2 completed their trial.
True	The present study demonstrates that 2-year @FORMULA@ treatment early in the course of disease is effective in children with @DISEASE@ showing focal/minimal mesangial proliferation.
False	Japanese Pediatric @DISEASE@ Treatment Study Group].
False	One hundred and one patients were randomly assigned to receive @FORMULA@ for 2 years (group 1) or no drug for 2 years (group 2).
False	Twenty-one group 1 patients (46%) had normal urine, but only 5 group 2 patients (10%) had normal urine at the end of the trial (p < 0.001).
False	METHODS: Anti-obesity, anti-hyperlipidemic, and anti-hypertensive effects of orally-administered @FORMULA@ extract were evaluated in high-fat diet- (HFD)-induced @DISEASE@ mice.
False	In vitro tests revealed that @FORMULA@ effectively inhibited porcine pancreatic lipase and ACE activities, with IC50 values of 7.58 mg/ml and 0.56 mg/ml, respectively.
False	BACKGROUND: @FORMULA@ (@FORMULA@) is a traditional plant-based medicine prescribed to promote blood circulation and to treat @DISEASE@ and @DISEASE@.
False	The effects of @FORMULA@ on angiotensin-1 converting enzyme (ACE) and pancreatic lipase activities were determined using in vitro inhibition assays.
False	@FORMULA@ also decreased serum total cholesterol, LDL-cholesterol, triglyceride, glucose, and leptin concentrations, and increased HDL-cholesterol and adiponectin levels in HFD mice.
True	CONCLUSIONS: These results validate traditional knowledge and suggest that @FORMULA@ may be potentially useful for managing @DISEASE@, @DISEASE@, @DISEASE@, and @DISEASE@.
False	Subsequent studies found that @FORMULA@ could inhibit M1 polarization and promote M2 polarization in colonic macrophages in DSS-induced @DISEASE@ mice.
False	An increasing body of evidence shows that macrophages play an important role in the pathogenesis of @DISEASE@ (@DISEASE@).
True	In summary, @FORMULA@ interferes with the p38MAPK, NF-kappaB and STAT6 signaling pathways to regulate M1/M2 polarization in macrophages, thereby protecting mice against DSS-induced @DISEASE@.
False	Macrophage polarization and changes in related signaling pathways are reported to have a protective effect on @DISEASE@.
False	Network pharmacology was used to predict potential targets and pathways, and further studies confirmed the related targets The results showed that @FORMULA@ gradually inhibits the activation of the P38MAPK and NF-kappaB signaling pathways and further activates the STAT6 signaling pathway.
False	Increasing evidence shows that @FORMULA@ can inhibit @DISEASE@ and repair @DISEASE@, but its effector mechanisms are unknown.
False	Serum samples were analyzed using UPLC-Q/TOF-MS techniques in order to determine differential metabolites to elucidate the functional mechanism of @FORMULA@ on YHS through metabolite profiling combined with multivariate analysis.
False	Unsupervised principal component analysis (PCA) patterns were constructed to dissect the variances of metabolic profiling.
False	Simultaneously, the exact diversification of YHS mice was elucidated using blood biochemistry indexes and histopathological examination, and the results indicated that YHS is markedly improved by @FORMULA@.
False	This demonstrates that metabolomic techniques are powerful means to explore the pathogenesis of CMS and the therapeutic effects of traditional Chinese formulae.
False	The present work demonstrates that the effectiveness of @FORMULA@ against YHS prompts distinct discrepancies in metabolic profiles by adjusting biomarkers and regulating @DISEASE@.
True	@FORMULA@ (@FORMULA@), a classic Chinese herbal formula, is characterized by its strong therapeutic effects of liver regulation and relief of @DISEASE@, especially Yanghuang syndrome (YHS).
False	A high dose (12 g/kg) of @FORMULA@ remarkably increased the expression of UGT1A1, bile salt export pump, MRP2, OATP1A4 in @DISEASE@ rats presented it exhibited the greatest ameliorative effect on @DISEASE@, also particularly in histopathological examination and reducing levels of alanine transaminase, aspartate transaminase, total bilirubin, direct bilirubin, and total bile acid.
False	By using ultra-high-performance liquid chromatography (UHPLC)-quadrupole time-of-flight mass spectrometry, 11 original active components and eight phase II metabolites were detected in rats after oral administration of @FORMULA@, including three new phase II metabolites.
False	And it indicated that phase II metabolism was one of the major metabolic pathway for most active components in @FORMULA@, which was similar to the metabolism process of bilirubin.
False	@FORMULA@ (@FORMULA@), a famous traditional Chinese formula, has been used for treating @DISEASE@ for 1000s of years.
False	The results indicated the pharmacokinetic behaviors of most components of @FORMULA@ were inhibited, which was hypothesized to be related to different levels of metabolic enzymes and transporters in rat liver.
True	Considering the metabolic process of bilirubin in vivo, the choleretic effect of @FORMULA@ is proven to be related to its regulatory action on expression of metabolic enzymes and transporters in @DISEASE@.
False	When prednisolone was orally administered at 3 mg kg(-1) day(-1) from day 1 to 6 after OVA inhalation, the @DISEASE@, the number of eosinophils in BAL fluids and @DISEASE@ were reduced in the OVA-sensitized mice.
True	These results suggest that at least a part of action mechanism of @FORMULA@ against OVA-sensitized @DISEASE@ in a mouse model is different from that of prednisolone.
False	However, prednisolone did not reduce the OVA-specific IgE antibody titer in BAL fluids and did not recover the expression of spectrin alpha2 in lung tissue.
False	When @FORMULA@ was orally administered at 0.5 g kg(-1) day(-1) from day 1 to 6 after OVA inhalation, @FORMULA@ reduced the @DISEASE@, the number of eosinophils and the OVA-specific immunoglobulin E (IgE) antibody titer in bronchoalveolar lavage (BAL) fluids at 7 days after the OVA inhalation.
False	"Proteomic Analysis of Anti-inflammatory Effects of a Kampo (Japanese Herbal) Medicine ""@FORMULA@ (@FORMULA@)"" on @DISEASE@ in a Mouse Model."
False	Western blot and immunohistochemical analyses of lung tissue also confirmed this result.
False	@FORMULA@ Treatment of DSS-Induced @DISEASE@ via Regulating Interaction With Inflammatory Dendritic Cells and Gut Microbiota.
False	It is known that inflammatory dendritic cells (DCs) and imbalance of gut microbiota play significant roles in the pathogenesis of @DISEASE@.
False	In the present study, the levels of inflammatory DCs and gut microbiota were analyzed by flow cytometry and 16S rDNA analysis.
False	@FORMULA@ (@FORMULA@) is a typical prescription in the pharmacopeia of traditional Chinese medicine (TCM), and is usually used to treat @DISEASE@ (@DISEASE@).
False	However, it is not clear whether @FORMULA@ can treat @DISEASE@ by regulating interaction of DCs and gut microbiota.
True	The results indicated that @FORMULA@ regulated the interaction between inflammatory DCs and gut microbiota to treat DSS-induced @DISEASE@.
False	It is the main cause of various @DISEASE@ including @DISEASE@, @DISEASE@, @DISEASE@, @DISEASE@ and certain forms of @DISEASE@.
False	@FORMULA@ treatment resulted in significantly increased relative abundance of bacteria including Bacteroidetes, Bacteroidetes/Firmicutes ratio, Akkermansia Bifidobacterium., Lactobacillus, and decreased the level of Firmicutes.
False	Our results showed that @FORMULA@ ameliorated body weight gain, decreased total body fat, regulated expression of leptin and adiponectin genes of adipose tissue and exerted an anti-diabetic effect by attenuating fasting glucose level and serum insulin level in HFD-fed animals.
True	CONCLUSION/MAJOR FINDINGS: The results of this study demonstrated that @FORMULA@ is an effective herbal formulation in attenuation of @DISEASE@ in HFD-fed mice through alteration of gene expressions and modulation of intestinal microbiota.
False	Using RT2 profiler PCR array, 39 (46%) genes were found to be differentially expressed in HFD-fed mice compared to normal control.
False	In addition, @FORMULA@-treatment significantly reduced total cholesterol (TC), triglycerides (TG) and increased high density lipoprotein-cholesterol (HDL), glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) levels in serum and reduced deposition of fat droplets in liver.
False	@FORMULA@ Prolongs the Survival of and Reduces TNF-alpha Expression in Mice with @DISEASE@.
False	Mice were randomly divided into five groups.
False	Cardiac expression in tumor necrosis factor-alpha (TNF-alpha) was significantly reduced in group C in comparison with group A, B or D on day 6 by immunohistochemical study.
False	Group A was administered oral saline from day 0 to day 4.
False	Group N included uninfected controls (n = 18), while group A, B and C underwent intraperitoneal injection of @DISEASE@ virus.
True	These findings suggest that timing of @FORMULA@ is crucial for preventing @DISEASE@ in mice with @DISEASE@.
False	Alleviation of hepatic oxidative stress by Chinese herbal medicine @FORMULA@ in @DISEASE@ mice with @DISEASE@.
True	The therapeutic mechanism of @FORMULA@ likely enhanced adiponectin and endothelial progenitor cells, and up-regulation of peroxisome proliferator-activated receptor gamma might be responsible for @DISEASE@ diseases.
False	In addition, @FORMULA@ anti-oxidative stress effect might be associated with inhibition of hepatic free fatty acid concentrations and elevation of the glutathione levels in hepatic tissues.
False	Furthermore, @FORMULA@ action mechanisms might promote senescence marker protein-30 metabolism that increase resistance to hepatic oxidative stress.
False	@DISEASE@ is associated with a complex systemic @DISEASE@ state that has been implicated in the development of @DISEASE@.
False	Mice were fed with high-fat diet for fifteen weeks.
False	He is the youngest to suffer @DISEASE@ due to @FORMULA@ in Japan, showing the possibility that @DISEASE@ occurs even in childhood.
False	The case is a 7-year-old boy.
False	On administration of @FORMULA@, the white blood cell count decreased.
False	With improvement in the symptoms thereafter, however, the IgG subclass normalized.
False	So, making careful observations is needed in administering @FORMULA@ to children with @DISEASE@ who use various immunosuppressants.
True	[@DISEASE@ complicated by @DISEASE@ during treatment and further by @DISEASE@ due to @FORMULA@ in 7-year-old].
False	RESULTS: @FORMULA@ treatment of @DISEASE@ involved 60 targets, enrichment analysis showed that @FORMULA@ treatment of @DISEASE@ involved Chemokine signaling pathway, NF-kappa B signaling pathway, and Fluid shear stress and @DISEASE@, etc.
False	OBJECTIVE: To explore the potential mechanism of @FORMULA@ (@FORMULA@) treatment and prevention of @DISEASE@ (@DISEASE@) occurrence and metastasis based on network pharmacological methods and immune infiltration analysis.
False	METHODS: The GEO database was used to obtain @DISEASE@ disease targets, the TCMSP database and the HERB database were used to obtain @FORMULA@ action targets, core genes were screened by protein interaction network, and the potential mechanism of @FORMULA@ in the treatment of @DISEASE@ was explored by enrichment analysis, prognostic analysis and immune infiltration analysis.
False	Immune infiltration analysis showed that @FORMULA@ could inhibit the immune cell infiltration of @DISEASE@ patients by acting on related targets.
False	Prognostic analysis revealed that @FORMULA@ had a certain ability to improve the prognosis of @DISEASE@ patients.
True	CONCLUSIONS: Our study identified the potential mechanism of @FORMULA@ in the treatment of @DISEASE@ through network pharmacology, and revealed the mechanism of @FORMULA@ in the prevention of @DISEASE@ metastasis through immune infiltration analysis and prognostic analysis.
False	To make a mouse model of paclitaxel-induced @DISEASE@, different single, intraperitoneally injected doses of this drug were tested in various groups of mice, and the optimal dose was determined.
False	To estimate the effects of @FORMULA@, the constituent herbal medicines Shakuyaku and Kanzo, and loxoprofen sodium as a non-steroidal anti-inflammatory drug on paclitaxel-induced @DISEASE@, @DISEASE@ and @DISEASE@ of the hind paw were assessed.
False	@FORMULA@ significantly relieved the @DISEASE@ and @DISEASE@ induced by paclitaxel (10mg/kg).
False	RESULTS: Paclitaxel administered at a dose of 10mg/kg or more produced @DISEASE@ and @DISEASE@; the time courses were similar to those of @DISEASE@ after paclitaxel administration in @DISEASE@ patients.
False	CONCLUSIONS: A single administration of paclitaxel (10mg/kg) produced @DISEASE@ and @DISEASE@ in mice, suggesting that it could be used as an animal model resembling the @DISEASE@ observed in humans medicated with this drug.
True	Using this model, @FORMULA@ was shown to relieve paclitaxel-induced @DISEASE@.
False	AIM OF THE STUDY: To investigate the molecular mechanisms underlying @FORMULA@-elicited improvement of the @DISEASE@.
False	Mechanistically, @FORMULA@ inhibited olanzapine-triggered hepatic over-phosphorylation of both IkappaB kinase (IKK)alpha/beta and nuclear factor (NF)kappaB p65 proteins, and mRNA overexpression of tumor necrosis factor alpha, interleukin 6, interleukin 1beta and CD68.
False	Blood parameters were determined enzymatically or by ELISA.
False	MATERIALS AND METHODS: Male rats were co-treated with olanzapine (5 mg/kg) and @FORMULA@ extract (50 and 500 mg/kg) for eight weeks.
False	Gene/protein expression was analyzed by Real-Time PCR, Western blot and/or immunohistochemistry.
True	CONCLUSIONS: The present results demonstrate that @FORMULA@ attenuates @DISEASE@ and @DISEASE@ by regulating the ACE2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.
False	Monoacylglycerol, ceramide, lysophosphatide, hydroxybutyric acid, palmitinic acid, 3-hydroxystearic acid, diethylarginine, neuraminic acid, phosphatidylserine were found in metabolites of their spleens.
False	[Metabonomic study on @FORMULA@ in radiation-induced blood deficient mice].
False	The model was established by general irradiation with 3.5 Gy60 Coy ray.
True	CONCLUSION: Analysis on physiological functions of these biological markers show that radiation could induce the @DISEASE@ and @DISEASE@ and affect the synthesis of some amino acids, and @FORMULA@ can reverse these effects.
False	RESULT: Compared with the control group, lysophosphatide, glucosiduronic acid, monoacylglycerol, erythronic acid, ceramide, aspartate phosphate ester, glyceryl phosphatide were obviously changed in the sera of the model group.
False	METHOD: Thirty six C57 mice were randomly divided into three groups: the control group and the model model groups and the @FORMULA@ group.
False	@FORMULA@ and its derived formulae not only had common targets and pathways, but also had their own emphasis.
False	This reflected the formulae effect mode of multi-ingredients, multi-targets and multi-pathways.
False	The targets information access was used to construct and visualize components-targets-pathways network model using the kyoto encyclopedia of genes and genomes (KEGG) pathway database and Cytoscape software.
False	Besides the same ones, @FORMULA@ had more effect on lipid metabolism, Xiangfu Siwu decoction on amino acid metabolism pathways, @FORMULA@ on carbohydrate metabolism, while, Qinlian Siwu decoction on ErbB, VEGF signal transduction pathway.
False	It may provide clues to deeper study of molecular mechanism of @FORMULA@ analogous formulae action.
True	[Network pharmacology study on major active compounds of @FORMULA@ analogous formulae for treating @DISEASE@ of gynecology blood stasis syndrome].
False	MATERIALS AND METHODS: @FORMULA@ was extracted using 50% ethanol.
False	A murine B16 @DISEASE@-bearing mouse model was employed to investigate the anti-melanoma effects of @FORMULA@. microRNA (miRNA) and mRNA levels were examined by RT-qPCR, and protein levels were measured by Western blotting.
False	RESULTS: @FORMULA@ significantly inhibited B16 @DISEASE@ growth in mice.
False	A traditional Chinese medicine formula inhibits @DISEASE@ growth in mice and regulates the miR-34b/c-Met/beta-catenin pathway.
False	@FORMULA@-based therapies have achieved good clinical outcomes in @DISEASE@ management.
True	CONCLUSIONS: In this study we found, for the first time, that @FORMULA@ exerts anti-melanoma effects and regulates the miR-34b/c-Met/beta-catenin pathway in a @DISEASE@ mouse model.
False	The chinese herbal decoction @FORMULA@ inhibits @DISEASE@ in a rat model of @DISEASE@.
False	@DISEASE@ was induced with CCl(4) and high-fat food for 6 weeks, and the rats were treated with oral doses of @FORMULA@ (6 g raw herbs/kg/d) and N-Acetyl-L-cysteine (NAC; 0.1 g/kg/d).
False	The results showed that both @FORMULA@ and NAC attenuated @DISEASE@ and @DISEASE@.
False	In this study, we investigated the anti-angiogenic effect of the Chinese herbal decoction @FORMULA@ (@FORMULA@; Radix Astragali and Radix Angelicae sinensis in 5 : 1 ratio) in a rat model of @DISEASE@, in order to elucidate its mechanisms of action against @DISEASE@.
False	@FORMULA@ decreased the expression of VEGF, Ang1 and TGF-beta1 and their signaling mediators, whereas NAC had no effect on VEGF and VEGFR2 expression.
True	These data clearly demonstrate that the anti-fibrotic properties of @FORMULA@ are related to its ability to inhibit @DISEASE@ and its anti-angiogenic mechanisms are associated with improving oxidative stress, regulating the expression and signaling of angiogenic factors, and especially modulating HIF-1alpha in @DISEASE@.
False	The ELISA results showed that the levels of IL-1beta, IL-6 and TNF-alpha were increased significantly in the model group(P&lt;0.01) compared with the blank group, and significantly down regulated in the @FORMULA@ treatment group(P&lt;0.05) compared with the model group.
False	The content of IL-1beta, IL-6 and TNF-alpha in colon were determined by ELISA.
False	Then the therapeutic targets were imported into the STRING for GO and KEGG enrichment analysis.
False	At the end of the experiment, HE staining was used to observe the @DISEASE@.
False	The effective components in plasma were determined by UPLC-Q-TOF-MS.
True	In conclusion, @FORMULA@ could alleviate the @DISEASE@ infiltration and mucosal damage in @DISEASE@ mice.
False	Thus, the present study demonstrates that AGEs play a role in the pathogenesis of @DISEASE@ and that AGE inhibition could reduce the @DISEASE@ reactions and oxidative lesions in @DISEASE@.
False	The aim of the present study was to explore whether the anti-inflammatory and anti-oxidative effects of @FORMULA@ were mediated by the AGEs/RAGE/NF-kappaB signaling pathway in rats with cationic bovine serum albumin (C-BSA)-induced @DISEASE@ (@DISEASE@).
False	@FORMULA@ (@FORMULA@), a traditional Chinese compound formula recorded in the Treatise on Febrile Diseases, has significant inhibitory effects on @DISEASE@ and oxidative lesions in rats, but its mechanism of action remains unclear.
False	The accumulation of AGEs, oxidative lesions and @DISEASE@ were reduced by an AGE inhibitor.
False	We found that @FORMULA@ significantly reduced the production of malondialdehyde (MDA), but enhanced the superoxide dismutase (SOD) activity.
True	In general, @FORMULA@ attenuated @DISEASE@, in part, by inhibiting the AGEs/RAGE/NF-kappaB pathway.
True	CONCLUSION: @FORMULA@ has definite therapeutic effect on @DISEASE@ caused @DISEASE@.
False	RESULTS: Comparison of the remarkable effective rate between the two groups showed significant difference.
False	OBJECTIVE: To observe the effect of @FORMULA@ (@FORMULA@) on the @DISEASE@ caused @DISEASE@ (CHBLF) and the portal hemodynamics.
False	Serum @DISEASE@ criteria and portal dynamical criteria were observed before and after treatment.
False	METHODS: Sixty patients with CHBLF were randomly divided into two groups, the 28 patients in the treated group were treated with oral intake of @FORMULA@ and conventional liver protective treatment, the 32 patients in the control group were treated with conventional liver protective treatment alone, the therapeutic course for both groups was 3 months.
False	[Clinical observation on effect of @FORMULA@ in treating patients with @DISEASE@ caused by @DISEASE@].
False	However, whether these conclusions are reliable or not requires meta-analysis.
False	Efficacy of @FORMULA@ on the Treatment of @DISEASE@: A Systematic Review and Meta-Analysis.
False	Risk of bias was assessed using criteria from the Cochrane Collaboration and meta-analysis was conducted on the screened literature data using Review Manage (RevMan 5.3).
False	According to GRADE criteria, the quality of evidence was low for all outcomes except for the cure rate (moderate-quality evidence) and the total effective rate (moderate-quality evidence).
False	In recent years, randomized controlled trials (RCTs) of @FORMULA@ for the treatment of @DISEASE@ have gradually increased.
True	CONCLUSION: The clinical efficacy of @FORMULA@ in the treatment of @DISEASE@ was more effective compared with the one of conventional WM alone.
False	The expression of positive ICCs and SCF were observed by immunohistochemical method and quantified image analyzer.
False	OBJECTIVE: To observe the effect of @FORMULA@ (@FORMULA@) on expression of the interstitial cells of Cajal (ICCs) and stem cell factor (SCF) in the antrum of rats with @DISEASE@ (@DISEASE@).
False	It could improve the gastric motility in @DISEASE@ rats by partially inverting abnormal changes of gastric antral ICCs and SCF.
False	The body weight and blood glucose of all rats were detected, and the gastric residual rates were detected with semisolid nutrient paste by gastrogavage.
False	An equal volume of distilled water was given by gastrogavage to those in the WM group and the control group for 8 successive weeks.
True	[Effect of @FORMULA@ on gastric antral interstitial cells of Cajal and stem cell factor in @DISEASE@ rats].
False	Treatment with @FORMULA@ inhibited the Abeta(25-35)-evoked increase in the calpain level and decrease in the calpastatin level.
False	Abeta(25-35)-induced @DISEASE@ in cortical culture was also markedly inhibited by @FORMULA@.
False	@FORMULA@ is composed of twelve crude drugs, some of which have already been shown to possess neurite extension properties in our previous studies.
False	RESULTS: Administration of @FORMULA@ for consecutive 3 days resulted in marked improvements of Abeta(25-35)-induced @DISEASE@ in mice.
False	@FORMULA@ also attenuated the calpain increase in the cerebral cortex and hippocampus.
True	CONCLUSION: In conclusion @FORMULA@ clearly improved the @DISEASE@ and losses of neurites and synapses.
False	@DISEASE@ was artificially induced by @DISEASE@ for 2 nights.
False	The primary outcome was a change in serum cortisol level; levels of biomarkers for stress hormones as well as oxidative stress and immunologic factors were also assessed, and questionnaires on @DISEASE@ and sleep quality were conducted.
False	Introduction:@FORMULA@ (@FORMULA@) is an herbal drug commonly used in Korea and China to combat @DISEASE@, but there are only few clinical studies on its effectiveness and experimental studies on its mechanism of action, and no randomized controlled trial of @FORMULA@ on the efficacy and mechanism of action has been reported.
False	An increase in serum cortisol appeared to be attenuated by @FORMULA@ administration (p = 0.25), but the effect was not statistically significant; a similar pattern was observed in salivary cortisol levels (p = 0.14).
False	Here, we performed an exploratory study to evaluate both questions regarding @FORMULA@ use in humans.
True	Overall, @FORMULA@ showed a tendency to reduce @DISEASE@ according to the Brief Fatigue Inventory (BFI, p = 0.07) and the Fatigue Severity Scale (FSS, p = 0.13) questionnaires.
True	Pharmacokinetics of monoester-diterpenoid alkaloids in @DISEASE@ and normal rats after oral administration of @FORMULA@ by microdialysis combined with liquid chromatography-tandem mass spectrometry.
False	The statistical results of pharmacokinetic parameters demonstrated that benzoylmesaconitine, benzoylaconitine and benzoylhypacoitine showed lower peak concentration, longer half-life, smaller area under the concentration-time curve, slower clearance, time to peak concentration and mean residence time in @DISEASE@ rats than in normal rats (p < 0.05), which indicated that monoester-diterpenoid alkaloids exhibited lower systemic exposure and slower elimination in the @DISEASE@ rats.
False	The results provided the experimental basis for understanding the metabolic fate and therapeutic effects of @FORMULA@.
False	In this work, an ultra-high-performance liquid chromatography-mass spectrometry combined with microdialysis method was successfully established and applied for investigating for the first time comparative plasma pharmacokinetics of three monoester-diterpenoid alkaloids (benzoylmesaconitine, benzoylaconitine and benzoylhypacoitine) in normal and @DISEASE@ rats after oral administration of @FORMULA@.
False	Monoester-diterpenoid alkaloids are the main bioactive components of @FORMULA@, which is a well-known traditional Chinese medicine formula for the treatment of @DISEASE@ (@DISEASE@) and @DISEASE@ in China.
False	Administration @FORMULA@ reduced @DISEASE@ significantly, also down-regulated TGF-beta1/Smad2 signaling in vivo and in vitro.
False	However, the molecular mechanism remains unclear.
False	MATERIALS AND METHODS: The @DISEASE@ rat model was established by exposure to cigarette smoke and intratracheal instillation of lipopolysaccharide, @FORMULA@ was administered to the animals.
False	Anti-inflammatory effect of @FORMULA@ via TGF-beta1 signaling suppression in rat model of @DISEASE@.
False	RESULTS: Administration of @FORMULA@ effectively alleviated @DISEASE@, suppressed releasing of pro-inflammatory cytokines and collagen deposition in @DISEASE@ animals (P<0.05), whereas exogenous TGF-beta1 promoted releasing of IL-1beta, IL-6, TNFalpha (P<0.05).
True	CONCLUSION: @FORMULA@ accomplished anti-inflammatory effects mainly by suppressing phosphorylation of Smad2, TGF-beta1/Smad2 signaling pathway was required for @FORMULA@ anti-inflammation in @DISEASE@ rats or CSE-treated Beas-2B cells.
False	The results revealed that the cell viability was significantly inhibited by AEXHP in a dose- and time-dependent manner.
True	Multiple effects of @FORMULA@ aqueous extract on the Hs578T @DISEASE@ cell line.
False	The aim of the present study was to investigate whether the aqueous extract of @FORMULA@ (AEXHP) has anti-proliferative activity against the Hs578T @DISEASE@ cell line, and to elucidate its molecular mechanisms of action.
False	@FORMULA@ (@FORMULA@) is a well-known Traditional Chinese Medicine with anticancer activity.
False	First, an MTT assay was used to evaluate the anti-proliferative activity of AEXHP on the Hs578T cell line; furthermore, the cell cycle distribution, mitochondrial membrane potential and apoptotic rate were determined by flow cytometry, and western blot analysis was used to assess the expression of apoptosis and cell cycle regulatory proteins to investigate the mechanisms of action.
False	Apoptosis and mitochondrial membrane potential loss were detected, and after treatment with 4, 8 and 12 mg/ml AEXHP for 24 h, cleaved caspase-3 was 1.70-, 1.81- and 1.84-fold of that of the control, while procaspase-3, procaspase-8, cleaved caspase-8, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and the Bcl-2/Bax ratio were not significantly affected.
True	[The effects of @FORMULA@ on @DISEASE@ in rats--possible effects on intraglomerular cell mediated immunity].
False	@FORMULA@ suppressed infiltrations of intraglomerular Ia positive cells (P less than 0.01) and T cells (P less than 0.01) on the 7th day and 14th day as well.
False	It has also found that @FORMULA@ has improved @DISEASE@ in @DISEASE@ as well as @DISEASE@ in man.
False	@FORMULA@, one of the herb drugs, has been demonstrated to have several effects.
False	The first group was the controlled group, had no treatment whatsoever.
False	The second group was administered with MPSL (solu-medrol 20 mg/kg, alternate day).
False	Network pharmacology analysis showed that components in @FORMULA@, such as kaempferol, ferulic acid and astragaloside IV, could be responsible for the pharmacological activity of @DISEASE@ by regulating the AGE-RAGE, PI3K/Akt, MAPK and NF-kappaB signaling pathways in @DISEASE@.
True	CONCLUSIONS: These results showed that @FORMULA@ may improve @DISEASE@ by affecting @DISEASE@, @DISEASE@ and lipid accumulation.
False	@FORMULA@ improved aberrant expression of several pathways related to lipidomics, including glycerophospholipid metabolism and sphingolipid metabolism.
False	AIM OF THE STUDY: The aim of this study was to evaluate the impact of @FORMULA@ on @DISEASE@ in @DISEASE@ mice and further explore its protective mechanism.
False	Qualitative and quantitative analysis of 6 compounds in @FORMULA@ was carried out by HPLC, including calycosin-7-glucoside, ferulic acid, ononin, calycosin, formononetin, and levostilide A.
False	RESULTS: Thirty-one significantly altered lipid metabolites were identified in the model group comparing with the control group.
False	Cognitive function was evaluated by Japanese versions of the Mini-Mental State Examination (MMSE-J) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS-J) test.
False	However, these studies are not comparative and are retrospective studies; thus, more evidence is needed.
False	There are a few reports that show @FORMULA@ and @FORMULA@ have a beneficial effect on the cognitive function of @DISEASE@ patients in clinical studies.
False	METHODS: The inclusion criteria for eligible patients were as follows: (1) imaging diagnosis (magnetic resonance imaging and single-photon emission computed tomography) of @DISEASE@, (2) a treatment regimen including acetylcholinesterase inhibitors (ChEIs), and (3) a Mini-Mental State Examination (MMSE) score >/=15.
False	ChEI dosage did not change during the study period.
True	CONCLUSION: @FORMULA@ improves cognitive function in @DISEASE@ patients.
False	Current treatment fails to produce an ideal outcome.
False	Here, we had established an animal model with @DISEASE@ and @FORMULA@ therapy was put into use to assess its therapeutic effect in vivo.
False	However, the treatment of @FORMULA@ impeded the generation of ROS and attenuated @DISEASE@-related proteins in @DISEASE@ through interference in the TGF-beta/Smad3 pathway.
True	@FORMULA@ Attenuates @DISEASE@ by Inhibiting @DISEASE@ via TGF-beta/Smad2/3 Pathway.
False	@FORMULA@ (@FORMULA@), a popular ancient Chinese medicine (TCM) prescription, has been applied to treat @DISEASE@-like syndromes according to TCM theory.
False	Our results indicated that @FORMULA@ attenuated oxidative stress, accompanied by preventing the production of @DISEASE@ through inhibiting the TGF-beta/Smad2/3 pathway.
False	Three of the five groups were treated with different concentrations of @FORMULA@ (4.25, 8.50, 17.00 g/kg), one with 0.1mg/kg of Colchicine (positive control), and one with physiologic saline (negative control).
False	METHODS: Sixty adult mice were equally divided into six study groups.
False	Inhibition of VEGF expression and downstream signaling were associated with these findings.
False	AIM: To document the effects of @FORMULA@ on @DISEASE@ disease activity, @DISEASE@ and VEGF signaling in a murine model of @DISEASE@.
False	The effects of @FORMULA@ on @DISEASE@ activity and @DISEASE@ in a murine model of @DISEASE@.
True	CONCLUSIONS: In this animal model of @DISEASE@, @FORMULA@ decreased @DISEASE@ disease and @DISEASE@.
True	These results suggest that @FORMULA@ is effective in the treatment of @DISEASE@.
False	In an earlier placebo-controlled study, we demonstrated that a kampo (Japanese herbal) medicine called @FORMULA@ (@FORMULA@ in Chinese) was effective in treating @DISEASE@.
False	Such items as spontaneity of conversation, lack of facial expression, decline in simple mathematical ability, global intellectual ability, @DISEASE@, @DISEASE@, @DISEASE@ or @DISEASE@, and putting on and taking off clothes were significantly improved at one or more evaluation points in those taking @FORMULA@ compared to those taking the placebo.
False	@FORMULA@ was statistically superior to the placebo in global improvement rating, utility rating, global improvement rating of subjective symptoms, global improvement rating of @DISEASE@ and global improvement rating of disturbance in daily living activities.
False	The study enrolled and analyzed 139 patients, 50 males and 89 females, with a mean age of 76.6 years.
False	To evaluate its efficacy using more objective criteria, we carried out a multi-center, double-blind study of @FORMULA@ extract (7.5 g/day) and a placebo, each given three times a day for 12 weeks to patients suffering from this condition.
False	The control group was treated with hormone replacement therapy, and the observation group was treated with @FORMULA@ and Tiaobu Chongren acupuncture and moxibustion therapy on the basis of the control group.
False	METHODS: From February 2018 to October 2019, 119 POI patients with deficiency-cold syndrome who met the selection criteria were randomly divided into the control group (n = 59) and the observation group (n = 60).
False	The bilateral AFC, mean ovarian volume, and endometrial thickness of the two groups increased compared with before treatment, and the observation group was higher than the control group (P < 0.05).
False	Both groups were treated continuously for 3 months.
False	After treatment, the index scores of traditional Chinese medicine syndromes in two groups were lower than before (P < 0.05), and the observation group was lower than the control group (P < 0.05).
True	CONCLUSION: On the basis of hormone replacement therapy, the combination of @FORMULA@ and Tiaobu Chongren acupuncture and moxibustion therapy is effective in treating @DISEASE@ patients with deficiency-cold syndrome, which can effectively regulate their serum sex hormone levels and promote the recovery of ovarian function.
False	Our data showed that @FORMULA@ effectively ameliorated @DISEASE@, @DISEASE@ and @DISEASE@.
False	Thus, the aim of this study was to determine whether @FORMULA@ mitigated PI-@DISEASE@ by modifying the gut microbiota.
False	Our previous studies have demonstrated that a Chinese formula, @FORMULA@, has the ability to mitigate @DISEASE@ and @DISEASE@ in PI-@DISEASE@ rats.
False	Moreover, @FORMULA@ promoted goblet cell proliferation in the colonic mucosa by increasing the release of mucin, up-regulating the distribution of tight junction proteins Occludin and ZO-1 and down-regulating the expression of MLCK in colonic epithelial cells.
False	However, little is known about the underlying mechanism and whether the gut microbiota mediate the effect of @FORMULA@ on PI-@DISEASE@.
True	These findings suggest that @FORMULA@ may remit @DISEASE@ by modulating the gut microbiota and stabilizing the gut mucosal barrier, indicating that the use of a classical formula of Traditional Chinese Medicine (TCM) that exhibits a prebiotic effect may be a promising strategy for PI-IBS treatment.
False	The hepatoprotective effect of @FORMULA@ (@FORMULA@), a Chinese medicinal prescription, was investigated in three kinds of experimental models.
False	The animals were treated with @FORMULA@ (300 mg/kg, p.o.) thrice at 2, 4 and 10 hours after administration with carbon tetrachloride (32 microliters/kg, i.p.), acetaminophen (600 mg/kg, i.p.) and beta-D-galactosamine (188 mg/kg, i.p.).
False	Serum enzyme activities in the carbon tetrachloride and acetaminophen experiments were significantly lower in the treated groups while the herbal prescription has no effect on the beta-D-galactosamine experiment.
False	Protective and therapeutic effects of @FORMULA@ on hepatotoxin-induced @DISEASE@.
True	These results demonstrated that @FORMULA@ has a hepatoprotective effect against experimental @DISEASE@ induced by specific hepatotoxins, and therefore may be useful in treating some, but not all, @DISEASE@.
False	These hepatoprotective effects were evidenced by comparing the serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) levels in @FORMULA@ treated and untreated groups.
False	RESULTS: Eighty-six potential @DISEASE@-related targets are identified by @FORMULA@; among them, nine core genes are screened.
False	Furthermore, GO enrichment analysis shows that the cancer-related signaling pathway, the PI3K-Akt signaling pathway, the HIF1 signaling pathway, and the TNF signaling pathway may play key roles in the treatment of @DISEASE@ by @FORMULA@.
False	The results of immunofluorescence and WB indicate that compared with the control group, protein expressions level of ZO-1, claudin-1, and Nrf2 in T84 cells is decreased and protein expressions level of HO-1, MDA, and COX-2 is increased after urinary toxin treatment.
False	Here, we explore the protective effect of @FORMULA@ on @DISEASE@ in @DISEASE@ through bioinformatic analysis and experimental verification.
False	Screening @DISEASE@ targets and identifying the corresponding @FORMULA@ components by network pharmacological methods is a practical strategy to explain the mechanism of @FORMULA@ in improving @DISEASE@ in @DISEASE@.
True	CONCLUSION: @FORMULA@ had a protective effect on urinary toxin-induced @DISEASE@ in @DISEASE@, and its mechanism may be related to the upregulation of Nrf2/HO-1 signal transduction and the inhibition of tissue oxidative stress and @DISEASE@.
False	Rotarod, locomotor activity, inclined plane and traction tests were used for behavioral assessment.
False	Immunohistochemistry was used for tyrosine hydrolase determination.
False	@FORMULA@ treatment significantly relieved behavioral and pathological symptoms of MPTP-induced @DISEASE@ mouse models with a potential mechanism of alleviating ALOX15-induced lipid peroxidation.
False	The mechanism of this action may be related to the direct inhibition of ALOX15 and the relief of lipid peroxidation.
False	Moreover, the results of molecular docking analysis show that compounds in @FORMULA@ might have interactions with ALOX15.
True	CONCLUSIONS: @FORMULA@ effectively improved the behavioral and dopaminergic neuron damage in diverse @DISEASE@ models.
False	@FORMULA@ inhibited the proliferation of @DISEASE@ cell lines and the survival of @DISEASE@ cells, especially MPC-1- immature @DISEASE@ cells, and induced apoptosis in @DISEASE@ cell lines via a mitochondria-mediated pathway by reducing mitochondrial membrane potential and activating caspase-9 and caspase-3.
False	Baicalein as well as baicalin suppressed the survival in vitro of MPC-1- immature @DISEASE@ cells rather than MPC-1+ @DISEASE@ cells from @DISEASE@ patients.
False	In the search for a more effective adjuvant therapy to treat @DISEASE@ (@DISEASE@), we investigated the effects of the traditional Chinese herbal medicines @FORMULA@ (@FORMULA@), @FORMULA@ (@FORMULA@), and @FORMULA@ (@FORMULA@) on the proliferation and apoptosis of @DISEASE@ cells.
True	Therefore, @FORMULA@ and Scutellaria radix have an antiproliferative effect on @DISEASE@ cells, especially MPC-1- immature @DISEASE@ cells, and baicalein may be responsible for the suppressive effect of Scutellaria radix by blocking IkB-alpha degradation.
False	Baicalein inhibited the phosphorylation of IkB-alpha, which was followed by decreased expression of the IL-6 and XIAP genes and activation of caspase-9 and caspase-3.
False	Further experiments confirmed that Scutellaria radix was responsible for the suppressive effect of @FORMULA@ on @DISEASE@ cell proliferation, and the baicalein in Scutellaria radix showed strong growth inhibition and induction of apoptosis in comparison with baicalin or wogonin.
False	[Effects of @FORMULA@ on normal animals and animal models of @DISEASE@].
False	CONCLUSIONS: The results suggest that @FORMULA@ possesses similar hypoglycemic action to meftormin and gliclazied.
False	METHODS: Normal mice, rats model of ailoxan (ALX)-induced @DISEASE@ (@DISEASE@), mice model of ALX-@DISEASE@ and rats model of dexamethasone (DX)-induced @DISEASE@ (@DISEASE@) were used.
False	OBJECT: To study the effects of @FORMULA@ on the blood glucose level in a variety of animal models and its mechanism.
True	RESULTS: @FORMULA@ was able to inhibit the @DISEASE@ by ALX-induced mice(P < 0.01), significantly reduce level of FBG in normal mice, @DISEASE@ mice and rats (P < 0.05-0.01), improve IGT and lower 2hBG (P < 0.01) after OGTT in DX-induced @DISEASE@ rats.
False	OBJECTIVE: To examine the efficacy and safety of bathing therapy with @FORMULA@ (, @FORMULA@) in the treatment of @DISEASE@ (@DISEASE@).
False	Primary and secondary outcome measures after 2 weeks of treatment showed no improvement (versus baseline) in both groups, with no differences between groups.
False	Clinical Efficacy and Safety of Bathing with Chinese Medicine @FORMULA@ () for Treatment of @DISEASE@: A Randomized Placebo-Controlled Trial.
False	Patients were randomized into a @FORMULA@ group (71 cases bathing with @FORMULA@ plus oral prednisone) or control group (71 cases bathing with placebo plus oral prednisone).
False	Bathing (40 degrees C, 30 min) of the upper and lower limbs was carried out once daily for 12 consecutive weeks.
True	CONCLUSIONS: Bathing with @FORMULA@ plus oral prednisone achieves better outcomes than oral prednisone alone in patients with @DISEASE@ and is not associated with serious adverse events.
False	These identified compounds effectively inhibited the development of inflammatory T cells using concentrations detected in @FORMULA@-treated rats.
False	Despite the well-investigated therapeutic efficacy of @FORMULA@, its immune regulatory properties are largely unknown.
False	Matrine, sinomenine and sophocarpine were identified as major bioactive compounds in @FORMULA@.
False	@FORMULA@-containing serum suppressed the phosphorylation of JNK and p65 in @DISEASE@ lymphocyte-stimulated normal monocytes and consequently inhibited iNOS and IL-1beta expression as well as IL-6 and IL-1beta production.
False	The compounds with high abundance in @FORMULA@ decoction and easily absorbed were taken as key anti-rheumatic components and used to treat blood-derived immune cells using in vitro experiments.
True	CONCLUSION: By targeting inflammatory T cells and monocytes as well as disrupting their interplay, @FORMULA@ improved immune environment in @DISEASE@ models especially during the active stages of disease.
False	The combined use of @FORMULA@ made it possible to decrease the necessary maintenance dose of PSL.
False	Relatively satisfactory hearing was maintained in these cases by long-term oral administration of prednisolone (PSL).
False	We identified these as cases of steroid-responsive @DISEASE@ (@DISEASE@).
True	Steroid-responsive @DISEASE@: combination therapy with prednisolone and @FORMULA@.
False	We observed cases of @DISEASE@ in which @DISEASE@ when steroid therapy was discontinued and improved upon re-administration.
False	The 10 cases of steroid-responsive @DISEASE@ were divided into two groups: 3 cases associated with @DISEASE@ (systemic type) and 7 cases with no known systemic disease (localized type).
False	METHODS: Here we investigated the anti-cancer effects and mechanisms of @FORMULA@, CC, ER, berberine, and evodiamine in cells and in intrahepatic xenograft mice.
False	However, the efficacies and mechanisms of @FORMULA@ and its alkaloid components on @DISEASE@ are still unclear.
False	Network analysis further showed that c-myc was the likely key molecule involved in the regulation of @FORMULA@-affected gene expression.
False	RESULTS: Treatment of HepG2 cells with @FORMULA@, CC, ER, berberine, and evodiamine significantly displayed cytotoxic effects in a dose- and time-dependent manner.
False	BACKGROUND: @FORMULA@ (@FORMULA@), a two-herb formula consisting of Coptis chinensis (CC) and Evodia rutaecarpa (ER), is commonly used in traditional Chinese medicine for the treatment of @DISEASE@.
True	CONCLUSIONS: In conclusion, our findings suggested for the first time that @FORMULA@ significantly suppressed human @DISEASE@ cell growth in orthotopic HepG2 xenograft-bearing immunocompetent mice.
False	"@DISEASE@ of @DISEASE@ is considered as ""chest stuffiness and heartache syndrome"" in traditional Chinese medicine, with the major syndrome type named Qi stagnation and blood stasis."
False	"After performing a stratified analysis, the @DISEASE@-specific health status and traditional Chinese medicine ""chest stuffiness and heartache syndrome"" were evaluated by self-reports using the associated questionnaire scales, respectively."
False	Qi-Regulating and Blood Circulation-Promoting Therapy Improves Health Status of @DISEASE@ Patients with @DISEASE@.
False	Interestingly, @FORMULA@ has been found to be more susceptible to improving ATP levels in patients with @DISEASE@, indicating that the improvement in serum ATP levels might account for the better efficacy of @FORMULA@ in patients with @DISEASE@.
False	@FORMULA@ also significantly improved the chest stuffiness and heartache syndrome in patients with @DISEASE@ (efficacy index is 61.24%, P < 0.05 versus baseline).
True	Our data provide prospective evidence that @FORMULA@ improves @DISEASE@-specific health status through regulating Qi and promoting blood circulation.
False	However, the mechanism by which @FORMULA@ contributes to the amelioration of @DISEASE@ remains unclear.
True	CONCLUSIONS: The cardioprotective effects of @FORMULA@ during @DISEASE@ were mediated by inhibiting autophagy via regulating AMPK-mTOR signaling pathways.
False	RESULTS: In this study, we investigated the effects of @FORMULA@ on @DISEASE@ induced @DISEASE@.
False	METHODS: H9C2 cells were cultured under the @DISEASE@ condition for 10 h and reoxygenated for 2 h.
False	Cell apoptosis was measured by western blotting.
False	Importantly, inhibition of autophagy by @FORMULA@ resulted in enhanced cell viability and decreased apoptosis.
False	However, the active components and mechanisms of @FORMULA@ are still arcane.
False	Then, topological parameters were calculated to identify the key targets in the network and, in turn, to import them into the David database to perform path enrichment analysis.
False	These targets were related to signal transduction, MAPK cascade, @DISEASE@, immune response, and the apoptotic process of @DISEASE@.
False	This study aimed to use a network pharmacology approach to find the bioactive compounds and potential action mechanisms of @FORMULA@ in the treatment of @DISEASE@.
False	Moreover, the PI3K-Akt signaling pathway, MAPK signaling pathway, toll-like receptor signaling pathway, and Prolactin signaling pathway were predicted to participate in @FORMULA@ treating @DISEASE@.
True	CONCLUSION: @FORMULA@ could alleviate @DISEASE@ through the predicted components and mechanisms.
False	Re-balanced levels of hemoglobin and alanine transaminase in serum indicated reduced MTX-induced @DISEASE@ and @DISEASE@ under the co-treatment of @FORMULA@.
True	All these clues suggested that inhibition on nucleic acid synthesis was essential to the immunosuppressive activity of @FORMULA@ in vivo, and could contribute great importance to its therapeutic effects on @DISEASE@.
False	@FORMULA@ (@FORMULA@) is a traditional Chinese medicine (TCM) formula used to treat Hot Syndrome-related @DISEASE@ (@DISEASE@).
False	Therapeutic effects of @FORMULA@ and its possible interactions with MTX in vivo were evaluated by clinical parameters, digital radiography assessment, histological/immunohistochemical examination, and serological biomarkers.
False	Metabolomics analysis showed that @FORMULA@ restored amino acids, fatty acids, and energy metabolisms in @DISEASE@ rats, which solidly supported its therapeutic effects on @DISEASE@.
False	@DISEASE@ (@DISEASE@) was developed in male SD rats.
False	The pathological scores in the pancreas for the MG were significantly higher than those for the SOG (P < 0.05).
False	Alanine transaminase (ALT) and aspartate transaminase (AST) in serum, inflammatory mediators in the liver and pathological scores were evaluated.
False	The high dose of @FORMULA@ showed a maximal effect in ameliorating the pathological damages, decreasing the pro-inflammatory mediators tumor necrosis factor-alpha and interleukin (IL)-6 and increasing anti-inflammatory mediators IL-4 and IL-10 in the liver.
False	AIM: To explore the pharmacokinetics and pharmacodynamics of @FORMULA@ (@FORMULA@) in the liver of rats with @DISEASE@ (@DISEASE@) based on an herbal recipe tissue pharmacology hypothesis.
False	The tissue concentrations of aloe-emodin, rhein, emodin, chrysophanol, honokiol, rheo chrysophanol, magnolol, hesperidin, naringenin and naringin in the liver of the treated rats were detected by high-performance liquid chromatography tandem mass spectrometry.
True	CONCLUSION: @FORMULA@ could alleviate @DISEASE@ by altering the @DISEASE@ in rats with @DISEASE@ based on the liver distribution of its components.
False	Additionally, the high throughput 16S ribosomal DNA (rDNA) sequence of intestinal bacteria in fecal samples of rat was also carried out.
False	A rat model of @DISEASE@ was established using @DISEASE@ (@DISEASE@) and behavioral scores were performed.
False	Protective Effect of @FORMULA@ on @DISEASE@ Caused by @DISEASE@ in @DISEASE@ Rats.
False	@FORMULA@ improved the imbalance of T cells, and inhibited the @DISEASE@.
False	@FORMULA@ (@FORMULA@) is a classic traditional Chinese medicine prescription for treating @DISEASE@.
True	Our presented results suggest that @FORMULA@ may improve the @DISEASE@ and its induced @DISEASE@ after @DISEASE@, which could be a new target and mechanism for the treatment of @DISEASE@.
True	CONCLUSION: @FORMULA@ treatment protected liver against the ConA-induced @DISEASE@ and improved liver function, which were associated with the modulation of gene expression related to immune/@DISEASE@.
False	Immunomodulation and liver protection of @FORMULA@ against concanavalin A-induced @DISEASE@ in mice.
False	Except of the normal control, mice received tail vein injection of ConA (10 mg/kg) on days 7, 14, 21, and 28, at 1 h after treatment with @FORMULA@ or dexamethasone or saline to induce @DISEASE@.
False	RESULTS: Repeated ConA injection induced @DISEASE@, which was evidenced by inflammatory cell infiltration and @DISEASE@, increased serum alanine aminotranferease activities, decreased albumin levels, and an imbalanced expression of immunoregulatory genes in the liver tissues including significantly enhanced interferon-gamma, interleukin-4, monocyte chemotactic protein-1, and cluster of differentiation 163 mRNA levels, and reduced tumor necrosis factor-alpha and interleukin-6 mRNA levels.
False	METHODS: Female BalB/c mice were randomly divided into 4 groups: normal control, ConA model, ConA model treated with @FORMULA@ (400 mg/kg, orally), and ConA model treated with dexamethasone (0.5 mg/kg, orally).
False	All treatments were given once a day for 28 d.
True	Our primary research showed that treatment with @FORMULA@ effectively improved the quality of life of @DISEASE@ patients by facilitating a change in the body microenvironment that controlled @DISEASE@ growth and prevented drug resistance.
False	CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, identifier ChiCTR-IIR-2000041413.
False	A total of 90 patients with @DISEASE@ who met the inclusion/exclusion criteria were randomly allocated to a treatment or control group.
False	Date of registration: 2017-06-07 (retrospective registration).
False	After treatment for 6 months, all indices related to the body microenvironment, as well as the tumor biomarkers and carcinoembryonic antigen, carbohydrate antigen 153, and angiogenic factor VEGF levels improved significantly to normal levels in the treatment group.
False	The treatment period was 6 months.
False	METHODS: @DISEASE@ was induced either by an application of prostaglandin E2 (PGE2), 10 microg/mL, to the cornea, or an intravenous injection of lipopolysaccharides (LPS), 0.5 microg/kg, in an ear vein.
False	For pretreatment, about 150 g/day of food containing @FORMULA@ (1% w/w) or @FORMULA@ (0.6% or 2% w/w) was given to two groups of animals for 5 days before experimental @DISEASE@ was induced.
False	Both 0.6% and 2% @FORMULA@ (AUC, 2,478, and 978) and beta-methasone (AUC, 443) did suppress the aqueous flare elevation induced by LPS significantly (P < .05).
False	A fourth group of rabbits with no herbal medicine or betamethasone pretreatment served as controls.
False	The AUC of PGE2 (10 microg/mL) and LPS (0.5 microg/mL) induced aqueous flare elevations were 1,119 and 4,950 arbitrary units, respectively.
True	CONCLUSION: @FORMULA@ could have an inhibitory effect on experimental @DISEASE@ induced by LPS.
False	@FORMULA@ enhance the effect of Western medicine in treating @DISEASE@: A meta-analysis of randomized controlled trials.
True	CONCLUSION: Adding @FORMULA@ to Western medicine might improve treatment outcomes of @DISEASE@, including FBG, 2hPG, response rates and control rates.
False	OBJECTIVE: To perform meta-analyses evaluating the efficacy of adding @FORMULA@ (, @FORMULA@) to Western medicine in improving treatment outcomes for @DISEASE@.
False	We found that adding @FORMULA@ can lower patients' FBG (MD=0.54 mmol/L, 95% CI [0.15, 0.93], P=0.007), 2hPG (MD=1.05 mmol/L, 95% CI [0.29, 1.81], P<0.01) and HbA1c (MD=0.23, 95% CI [0.02, 0.45], P=0.008).
False	RESULTS: Studies included in the analysis were less adequate than expected in terms of methodological quality.
False	A total of 1,609 patients from 18 studies were included.
False	Moreover, @FORMULA@ treatment up-regulated the expressions of BMP-2, RUNX2 and OSX with its downstream factors, ALP, OPN and BSP-1, in the femoral tissues.
False	The bone medullary cavity and deposition of collagen were investigated by histological analysis.
False	@DISEASE@ is a common @DISEASE@ in post-menopausal women.
False	Taken together, @FORMULA@ restored the bone minerals and improvement of bone integrity by bone-forming BMP-2 signaling pathway.
False	The level of bone mineral density (BMD) was analyzed in bone tissues by dual X-ray absorptiometry.
True	These results demonstrate that @FORMULA@ could be an ameliorative agent for @DISEASE@.
False	A metabolomics study revealed that the endogenous metabolites significantly affected by @FORMULA@ were related to bile acid (BA) biosynthesis and glutathione metabolism pathways.
False	@DISEASE@ is a serious symptom of @DISEASE@ with limited therapies.
False	Importantly, @FORMULA@ increased the nuclear expression of nuclear factor-E2-related factor-2 (Nrf2).
False	@FORMULA@ treatment ameliorated @DISEASE@.
False	@FORMULA@ treatment decreased the intrahepatic accumulation of cytotoxic BAs, normalized serum BA levels, and increased biliary and urinary BA excretion.
True	In conclusion, @FORMULA@ protects against @DISEASE@ by reversing the @DISEASE@.
False	Effects of @FORMULA@ in Rat @DISEASE@.
True	@FORMULA@ exhibited protective effects against @DISEASE@ through suppressing @DISEASE@ reaction and elevating antioxidation power.
False	Serum cytokine levels such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were measured by enzyme-linked immunoabsorbent assay (ELISA).
False	The @DISEASE@ severity of gingival tissue by HE staining was severe in model group but relieved in @FORMULA@ group obviously.
False	Moreover, @FORMULA@ inhibited expressions of AMPK and ERK1/2.
False	After 3 days rats were sacrificed and tissue samples were evaluated.
False	The herbal medicine, @FORMULA@, prevents endotoxin-induced @DISEASE@ in the guinea pig.
False	A total of 120 guinea pigs were used.
False	The incidence of @DISEASE@ in the low-dosage and the high-dosage groups was somewhat reduced compared with the saline-control group.
False	The saline-control group, the low-dosage group and the high-dosage group were then treated with intratympanic injection of 0.1 ml of lipopolysaccharide solution (100 micrograms/ml) derived from Klebsiella pneumoniae.
False	All 10 animals from the 4 groups were sacrificed 1, 3, and 7 days after the intratympanic injection, to examine ciliary activity, mucociliary clearance time, and mucosal pathology of the tubotympanum.
True	In conclusion, clinical application of @FORMULA@ could be an effective measure to prevent the occurrence of @DISEASE@ and also the recurrence of the disease, especially @DISEASE@-prone individuals.
False	@DISEASE@-like behavior and @DISEASE@ were observed in CORT-treated mice without @FORMULA@ treatment.
False	Recently, it has also been shown that @FORMULA@ improves @DISEASE@ in patients with @DISEASE@.
False	In this study, to investigate the mechanisms underlying the effects of @FORMULA@ on stress-induced @DISEASE@ such as a @DISEASE@ state and @DISEASE@, we examined whether @FORMULA@ prevents @DISEASE@ and @DISEASE@ in mice treated chronically with corticosterone (CORT).
True	@FORMULA@ may ameliorate stress-induced @DISEASE@ via prevention of adverse effects of CORT on cell survival, new-born immature neurons, spine density and neurotrophic factors.
False	@FORMULA@ prevented CORT-induced @DISEASE@-like behavior, @DISEASE@, and decreases in hippocampal cell survival, the number of hippocampal new-born immature neurons, accumbal dendritic spine density and GDNF mRNA.
False	Hippocampal cell survival, the number of hippocampal new-born immature neurons, hippocampal and accumbal dendritic spine density and mRNA levels for neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF) were decreased in CORT-treated mice without @FORMULA@ treatment.
False	@FORMULA@ recovered sleep both in wild-type and @DISEASE@ model flies.
False	Effects of @FORMULA@ and @FORMULA@ on Sleep Behavior of Wild Type and @DISEASE@ Model in Drosophila.
False	The @FORMULA@ and @FORMULA@ recovered 60-min sleep bouts number in the A30P @DISEASE@ model flies to the level of young (5 days after eclosion) flies.
False	@FORMULA@ ameliorates not only sleep but also motor function in @DISEASE@ model flies.
False	In Drosophila melanogaster disease model, human alpha-synuclein A30P overexpressing flies (A30P @DISEASE@ model) have been shown for levy body aggregation and @DISEASE@.
True	The data suggest that @FORMULA@ and @FORMULA@ might be useful for the @DISEASE@ in human @DISEASE@ patients as well as healthy human.
False	The RNA-seq assay showed that the high-dose @FORMULA@ resulted in a significant decrease in the levels of TLR9, TRAF6, TAB2, etc. in the lung tissue.
False	OBJECTIVE: The study identifies the possible mechanisms of @FORMULA@ on ovalbumin (OVA)-induced @DISEASE@ in mice.
False	Immunohistochemical assay confirmed the down-regulated of TLR9.
False	However, the anti-inflammation mechanism of @FORMULA@ remains unclear.
False	The expression levels of TLR9 in lung and trachea tissues were determined by immunohistochemical staining.
True	DISCUSSION AND CONCLUSIONS: @FORMULA@ could mitigate the pathological changes of @DISEASE@-like syndrome through inhibition of the TLR9 pathway.
False	The control group received conventional medical treatment, and the @FORMULA@ group was treated with integrated traditional Chinese medicine (TCM) and Western medicine.
False	Clinical Observation of Treatment Efficacy in @DISEASE@ Disease with Integrated Traditional Chinese and Western Medicine: A Randomized Controlled Trial.
False	The recovery of GI function and clinical efficacy rate in the @FORMULA@ group were significantly better than in the control group (P < .05, respectively).
False	OBJECTIVE: The study aimed to evaluate the treatment efficacy of the combination of @FORMULA@ (@FORMULA@) injected into the jejunum and as an enema in patients with critical diseases with @DISEASE@.
False	METHODS: In our double-blind randomized controlled study, 114 @DISEASE@ patients with @DISEASE@ were divided into 2 groups.
True	CONCLUSION: @FORMULA@ may be an effective method for treating patients with critical diseases with @DISEASE@ and is worthy of clinical application.
False	GO and KEGG analyses got top 10 significantly enriched terms and 10 enriched pathways.
False	The compounds and the potential protein targets of @FORMULA@ were obtained from TCMSP, and active compounds were selected according to their oral bioavailability and drug similarity.
False	There was a good binding activity between the components and the targets.
False	The association between @FORMULA@ treatment and @DISEASE@ was estimated by risk ratio (RR) and corresponding 95% confidence intervals (95% CIs).
False	The potential pathways related to genes were determined by GO and KEGG pathway enrichment analyses.
True	@FORMULA@ has the curative effect on @DISEASE@, and its mechanism is related to 10 compounds, 10 core targets, and 5 pathways.
False	MATERIAL AND METHODS: Ten rats received sham operation as the Sham group, and 30 @DISEASE@ model rats were randomly divided into three groups: the Model, @FORMULA@-Low (@FORMULA@-L), and @FORMULA@-High (@FORMULA@-H) groups.
False	ETHNOPHARMACOLOGICAL RELEVANCE: In the practice of traditional Chinese medicine, @DISEASE@ is believed to be caused by blood stasis and is characterised by @DISEASE@, which is difficult to control.
False	Finally, the distribution density of nerve fibres in endometrial tissue, the @DISEASE@ infiltration of the dorsal root ganglion (DRG), the expression of TRPV1 in the DRG, and the expression of IL-1beta, TNF-alpha, and IL-6 in ectopic tissue were measured.
False	Effect of @FORMULA@ on inflammatory factors and @DISEASE@ in rats with @DISEASE@.
False	The prescriptions composed of @FORMULA@ include Typhae Pollen and Faeces Trogopterori, both of which have anti-inflammatory activity.
True	CONCLUSIONS: @FORMULA@ could possibly inhibit the development of @DISEASE@ and relieve @DISEASE@ in patients with @DISEASE@ by reducing @DISEASE@ in ectopic tissue and the DRG.
False	RESULTS: @FORMULA@ significantly decreased the immobility time after acute treatment in the mouse TST (1300 mg/kg) but not in the FST compared with the control group.
False	Screening of the antidepressant-like effect of the traditional Chinese medicinal formula @FORMULA@ and their possible mechanism of action in mice.
False	Moreover, we investigated the neurochemical, neuroendocrine, and neurotrophin systems involved in the antidepressant-like effect of this formula.
True	CONCLUSION: The acute antidepressant-like action of @FORMULA@ is mediated by the monoaminergic and neuroendocrine systems although underlying mechanism still remains to be further elucidated, and this formula should be further investigated as an alternative therapeutic approach for the treatment of @DISEASE@.
False	However, the neuropharmacological and neuroendocrine mechanisms of the formula on antidepressant-like action have not been reported.
False	Moreover, acute @FORMULA@ (1300 mg/kg) decreased serum corticosterone levels, elevated serotonin (5-HT), norepinephrine (NE), and dopamine (DA) levels without affecting brain-derived neurotrophic factor (BDNF) levels in the whole brain exposed to TST.
False	Typhimurium @DISEASE@ through the regulation of the immune response.
False	Salmonella, a common @DISEASE@ pathogen, causes @DISEASE@ in both humans and animals.
False	Typhimurium invasion and TNF-alpha expression in RAW264.7 cells.
False	Minimum bactericidal concentration (MBC) of Coptidis rhizome (CR) against the reference strain tallied 12.5 mg/ml and against clinical isolate ST21 was 25 mg/ml.
False	Traditional Chinese Medicine (TCM) has been used to improve @DISEASE@ and to modify the immune response to @DISEASE@ for centuries.
True	CR and @FORMULA@ alleviated @DISEASE@-induced interferon-gamma levels in the serum and tissues, and tumor necrosis factor-alpha (TNF-alpha) levels in intestinal tissues.
False	It shows very strong antipyretic and anticoagulant effects and has been clinically applied to treat various type of @DISEASE@, @DISEASE@, @DISEASE@, and @DISEASE@.
False	PURPOSE: @FORMULA@ (@FORMULA@) is a classical formula of traditional Chinese medicine constituted of Cornu Bubali, Rehmannia glutinosa (Gaertn.)
False	DC., Paeonia lactiflora Pall., and Paeonia suffruticosa Andrews.
False	"It was first mentioned in the medical classic ""Beiji Qianjin Yaofang"" written by Simiao Sun in Tang Dynasty."
False	@DISEASE@ (@DISEASE@) is considered as a kind of acute febrile illness in children with @DISEASE@ as the main lesions.
True	CONCLUSION: Our findings demonstrated that @FORMULA@ mitigated @DISEASE@ of @DISEASE@ through suppressing endothelial cell damage via PI3K/Akt-NFkappaB signaling.
False	@FORMULA@ inhibits @DISEASE@-induced podocyte apoptosis by down-regulated Nox4/p53/Bax signaling in vitro and in vivo.
False	@FORMULA@ (@FORMULA@), a traditional Chinese medical formula, has been used to improve @DISEASE@ in China.
False	The present study was to investigate the protective effect of @FORMULA@ on podocyte apoptosis and the underlying molecular mechanism.
False	Contrarily, overexpression of Nox4 or p53 significantly abolished those efficacies of @FORMULA@.
False	Meanwhile, Nox4/p53/Bax signaling was down-regulated.
True	Accordingly, in vivo study showed that the @DISEASE@, @DISEASE@ and @DISEASE@ were significantly alleviated with @FORMULA@ treatment in @DISEASE@ mice, which paralleled by the marked inhibition of Nox4/p53/Bax signaling.
True	@FORMULA@ could treat @DISEASE@ by inhibiting oxidative stress, reducing @DISEASE@, and improving the @DISEASE@ of gut microbiota and the modulation of the taurine and hypotaurine metabolism, cysteine and methionine metabolism, and vitamin B6 metabolism pathways in serum.
False	The results showed that @FORMULA@ decreased the serum transaminases and lipid levels and improved the pathological changes in @DISEASE@ rats.
False	@FORMULA@ (@FORMULA@) can be used in the treatment of @DISEASE@.
False	In this study, we constructed a rat model with @DISEASE@ fed with high-fat chow and administered @FORMULA@ treatment.
False	In addition, we measured the effects of @FORMULA@ on @DISEASE@ and oxidative stress.
False	Correlation analysis showed that the effects of @FORMULA@ on taurine and hypotaurine metabolism, cysteine and methionine metabolism, and vitamin B6 metabolism pathways were associated with affecting in the abundance of Lactobacillus, Dubosiella, Lachnospiraceae, Desulfovibri, Romboutsia, Akkermansia, Intestinimonas, and Candidatus_saccharimonas in the gut.
False	RESULTS: As compared with the normal group, the pathological figures of the @DISEASE@ and @DISEASE@ and @DISEASE@ obviously appeared in the model rats, with the liver content of Hyp and alpha-SMA mRNA expression increased, and Afamin mRNA expression decreased significantly.
False	Medication for the three medicated groups began from the 9th week after modeling, with oral administering of @FORMULA@ (@FORMULA@, a recipe has been verified to be effective for @DISEASE@ and @DISEASE@), @FORMULA@ (@FORMULA@, a recipe with effects similar to @FORMULA@) and @FORMULA@ (@FORMULA@, a recipe functioned differently) respectively for four weeks.
False	[Syndrome identification of CCl4 induced @DISEASE@ model rats based on syndrome detecting from recipe used].
False	METHODS: Wistar rats were randomly divided into the normal group, the model group, and the three medicated groups.
False	All rats, except those in the normal group, were made into @DISEASE@ model by subcutaneously injecting CCI4 for 12 weeks.
True	CONCLUSION: The pharmacological effects of @FORMULA@ and @FORMULA@ were similar to some degree, which gives support to the cognition that the feature of @DISEASE@ model rat induced by CCI4 is attributable to @DISEASE@.
False	The protein-protein interaction (PPI) network was constructed using interaction gene library retrieval tools and Cytoscape software.
False	Mechanism underlying the effect of @FORMULA@ on @DISEASE@ in patients after first-line chemotherapy.
False	PPI network analysis screened out the top 10 central protein-coding genes with the highest nodal degree: IL2, PIWIL4, DICER1, PIWIL2, SAA1, XCL1, IL22RA1, ARHGAP11A, DCP1A, and GDNF.
True	IL2, PIWIL4, DICER1, PIWIL2, and DCP1A may have important roles in the mechanism of @FORMULA@ treatment against @DISEASE@.
False	In addition, the central protein-coding genes with high node degrees and high molecular complex detection (MCODE) scores were PIWIL4, DICER1, PIWIL2, and DCP1A, all of which are related to @DISEASE@ development.
False	The functional distribution of Gene Oncology (GO) genes showed that DEGs were mostly concentrated in extracellular regions, calcium ion binding, and transcriptase activity.
False	The therapeutic effects of @FORMULA@ on @DISEASE@ models.
False	@FORMULA@, a mixture of 11 herbal extracts, is known in traditional Korean medicine as a widely used treatment for @DISEASE@ diseases.
False	In this study, we aimed to investigate the anti-inflammatory effect of @FORMULA@ (@FORMULA@) extracts and confirm effects on @DISEASE@ models as the therapeutic agent using the @FORMULA@ extracted by various solvents.
False	Furthermore, pretreatment with @FORMULA@ protected @DISEASE@ and reduces @DISEASE@ by suppressing apoptosis mediator and inflammatory cytokines expression in concanavalin A (Con A)-induced @DISEASE@ mice model.
True	The findings here improve our understanding of @FORMULA@ extracted by 80% ethanol, suggesting that @FORMULA@ can be used as a therapeutic treatment for @DISEASE@.
False	In @DISEASE@-condition hepatic cell model, @FORMULA@ reduced IL-6 expression and lipid accumulation caused by treatment of IL-17 combination in hepatocyte cells.
False	MATERIALS AND METHODS: The usage, frequency of service, and the Chinese herbal products prescribed for @DISEASE@ were evaluated using a representative sample of one million subjects selected at random from the 22 million beneficiaries of the National Health Insurance scheme of Taiwan.
False	The traditional Chinese medicine prescription patterns for @DISEASE@ patients in Taiwan: a population-based study.
False	ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese medicine (TCM), when given for symptom relief, has gained widespread popularity among @DISEASE@ patients.
False	Overall, 81.2% of TCM visits involved the prescription of a Chinese herbal remedy or remedies and @FORMULA@, @FORMULA@, @FORMULA@, @FORMULA@, @FORMULA@, Qing-Shang-Juan-Tong-Tang, @FORMULA@, @FORMULA@, @FORMULA@, and @FORMULA@ were the ten most frequently prescribed formula for treating @DISEASE@ based on syndrome differentiation.
False	RESULTS: Overall, 89.3% (N=12,827) @DISEASE@ patients utilized TCM and 24.2% of them sought TCM with the intention of treating their @DISEASE@-related symptoms.
True	CONCLUSIONS: @FORMULA@, which contains sedative and anti-inflammatory agents, is the most commonly prescribed Chinese herbal formula for the treatment of @DISEASE@-related phenomena.
False	AMPKalpha knockdown abolished the inhibitory effects of ESMW on IL-6 and HSL pSer-660, revealing that the antilipolytic and anti-inflammatory activities of ESMW are AMPK dependent.
False	Different fractions of @FORMULA@ were prepared by membrane separation combined with macroporous resin and their antilipolytic activities were screened in fasted mice.
False	Conditional medium collected from ESMW-treated 3T3-L1 cells ameliorated insulin action on hepatic gluconeogenesis in liver cells, demonstrating the antilipolytic activity contributed to ESMW beneficial effects on hepatic glucose production.
False	Furthermore, ESMW ameliorated @DISEASE@ and suppressed lipolysis in HFD-fed mice.
True	In conclusion, ESMW, as the antilipolytic fraction of @FORMULA@, inhibited PKA-HSL related lipolysis by activating AMPK, thus inhibiting diacylglycerol (DAG) accumulation in the liver and thereby improving @DISEASE@ and hepatic gluconeogenesis.
False	@FORMULA@ (@FORMULA@) is a traditional Chinese formula, including Atractylodis Rhizoma, Achyranthis Bidentatae Radix, Phellodendri Chinensis Cortex and Coicis Semen at the ratio of 1:1:2:2.
False	The difference between the 2 groups was still significant for all outcome measures except the erythema score at the 12-week follow-up, 4 weeks after the 8-week treatment had ended.
False	The decrease in the total lesion score in the treatment group at 8 weeks was significantly greater than that of the placebo group (79.7 +/- 5.8% vs. 13.5 +/- 7.64%; p < 0.001).
False	There was also a statistically significant difference between the treatment and placebo groups with regard to erythema, surface damage, pruritus and sleep scores.
False	RESULTS: Fifty-six patients completed both the treatment and follow-up periods.
False	Patients reported no side effects from treatment, although some commented on the unpalatability of the medication.
True	CONCLUSION: Our study results suggest that the traditional Chinese herbal medicine @FORMULA@ may be an alternative choice of therapy for @DISEASE@.
False	The primary endpoint was incident of late-onset @DISEASE@.
False	RESULTS AND DISCUSSION: There was no statistical difference in age, concomitantly used drugs or UGT1A1 genotypes between the groups.
False	Grade 4 @DISEASE@ was not observed in either group.
False	METHODS: Patients with @DISEASE@ were randomized 1:1 to a TJ-14 (7.5 g/day) group or an oral alkalization (sodium bicarbonate, 1.8 g/day; ursodeoxycholic acid, 300 mg/day) group.
True	A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced @DISEASE@ between @FORMULA@ and oral alkalization in Japanese patients with @DISEASE@.
False	A total of 30 patients were randomized to either the TJ-14 group or the alkalization group.
True	Based on the clinical course and the exclusion of other etiologies, @FORMULA@ @DISEASE@ with @DISEASE@ was considered.
False	A 78-year-old man presented with @DISEASE@ and @DISEASE@.
False	The patient's bronchoalveolar lavage fluid was bloody and transbronchial lung biopsy specimens showed @DISEASE@, organizing @DISEASE@, and type 2 alveolar epithelial cell proliferation.
False	He had been taking @FORMULA@ for @DISEASE@.
False	@DISEASE@ with @DISEASE@ Induced by @FORMULA@.
False	The patient's @DISEASE@ resolved after the discontinuation of the drug and the administration of systemic corticosteroid therapy.
False	The data were sourced from the registry for beneficiaries, inpatient and ambulatory care claims, and Registry for @DISEASE@ from the National Health Insurance Research Database (NHIRD) in Taiwan between 1997 and 2011.
True	@FORMULA@, Shu-Jin-Huo-Xie-Tang, and @FORMULA@ might be associated with a lower risk of @DISEASE@.
False	Patients, who were newly diagnosed with @DISEASE@ between 1997 and 2010, were classified as the CHP group or non-CHP group depending on the presence of absence the adjunctive use of CHP following a diagnosis of @DISEASE@.
False	A further randomized control trial is required to clarify the casual relationship between these results.
False	Patients in the CHP group had a significantly lower risk of @DISEASE@ compared to patients in the non-CHP group (adjusted hazard ratio [aHR], 0.67; 95% confidence interval [CI], 0.52-0.86).
False	Finally, the use of CHP in combination with WM was associated with a decreased risk of @DISEASE@ in patients with @DISEASE@, especially among those who had used CHP for more than 30 days.
False	Mice in the @DISEASE@ group were fed with high cholesterol wild diet (WD).
False	Four weeks later, subtypes of monocytes in the peripheral blood were detected by FACS.
False	@FORMULA@ containing serum promoted in vitro differentiation of M2 macrophages and foam cells.
False	OBJECTIVE: To observe the effect of @FORMULA@ (@FORMULA@) in in vivo regulating differentiation of monocytes in an apolipoprotein E knockout (ApoE(-/-)) mouse model, and to observe the effect of @FORMULA@-containing serum in in vitro regulating differentiation of macrophages and foam cells.
False	Results of real-time quantitative PCR showed that the expression level of Arg1 mRNA could be up-regulated by @FORMULA@ containing serum (P < 0.05), and that of Nos2 mRNA down-regulated (P = 0.017). ox-LDL induced the differentiation of M2 subtype foam cells from BMDM, and @FORMULA@ containing serum could further elevate the ratio of CD206 + M2 foam cells and increase the Arg1 mRNA expression level (both P < 0.01).
True	@FORMULA@ attenuated and inhibited the occurrence and development of @DISEASE@ induced by @DISEASE@ possibly through regulating the functional differentiation of monocytes, macrophages, and foam cells.
False	Preliminary and final exhaustion times, anaerobic thresholds, and kinetic energies were determined.
False	During the eight weeks of the experiment, test subjects continued exercise as usual.
False	AIM: To study the effect of @FORMULA@ in reducing @DISEASE@ improvement in athletes.
True	CONCLUSION: @FORMULA@ reduced @DISEASE@ by increasing the oxygen uptake and the systemic utility of oxygen.
False	RESULTS: @FORMULA@ might increase exhaustion time, positively influence anaerobic threshold, and also enhance recovery from @DISEASE@.
False	METHODS: Twelve athletes were randomly separated into a control group, whose members were administered with placebos, and the experimental group, whose members were administered with @FORMULA@.
False	Although @FORMULA@ (@FORMULA@) has long been considered as a classical formula for @DISEASE@ like @DISEASE@, @DISEASE@ and @DISEASE@, its chemical ingredients that really exert the main efficacy are still obscure.
True	The MDCK cellular research results showed that, among nine predominant ingredients of @FORMULA@, L-methylephedrin (LMEP), L-ephedrine (LEP) and D-pseudo- ephedrine (DPEP) significantly inhibited the proliferation of @DISEASE@ A virus in vitro, and the inhibitory effect at 24 h after the treatment was more obvious than that at 48 h.
False	The overall findings demonstrate that, as effective and inexpensive natural substances, Ephedra alkaloids and @FORMULA@ may have potential utility in clinical management.
False	In this study we aimed to screen its antiviral components and investigate the potential mechanisms.
False	Screening of Antiviral Components of @FORMULA@ and Investigation on the Ephedra Alkaloids Efficacy on @DISEASE@ Virus Type A.
False	LEP and DPEP have certain protective effects on the @DISEASE@ mice, which may be associated with their abilities of effectively alleviating @DISEASE@, improving the immunologic function of @DISEASE@ mice and adjusting the host's TLRs and RIG-1 pathways.
False	The chemical components of @FORMULA@ were analyzed by LC-DAD-MS.
True	The results indicated that @FORMULA@ had good therapeutic effects for @DISEASE@.
False	The rabbits were divided into treatment and control groups.
False	The present study was carried out to investigate chemical components and therapeutic effects on @DISEASE@ of @FORMULA@ (@FORMULA@) in rabbits.
False	We evaluated the therapeutic effects of @FORMULA@ on @DISEASE@ in rabbits using B-ultrasound images, histopathologic examination, and hyaluronic acid content in serum.
False	@FORMULA@ was orally administered at a dose of 50 g/kg rabbit's weight in treatment group.
False	[Case of @FORMULA@-induced CD4 dominant @DISEASE@ diagnosed on day eight of the challenge test].
False	We report a case of drug-induced @DISEASE@ associated with the herbal medine @FORMULA@.
True	To the best of our knowledge, there has been no previous case of drug-induced @DISEASE@ due to @FORMULA@ reported in the world.
False	Cessation of the drug improved the patient's clinical and X-ray findings and then he was able to be discharged.
False	Drug-induced lymphocyte stimulation tests were negative, but bronchoalveolar lavage showed an increase in lymphocytes with an increased CD4/CD8 ratio.
False	He was admitted again for a challenge test.
False	@FORMULA@ (@FORMULA@) is a wellknown traditional Chinese medicine decoction used for @DISEASE@.
False	Among the targets, nuclear receptor corepressor 1 (NCoR1) is one of the most important proteins involved in myogenesis and metabolism.
False	The results demonstrated that the calcium signaling pathway, citrate cycle, biosynthetic and lipid metabolic process are affected by @FORMULA@.
False	Current pharmacological strategies exhibit poor efficacy.
False	To elucidate the underlying mechanisms, drugCIPHERCS methods were introduced to predict its potential targets, significantly enriched pathways and biological processes.
True	The results indicated that @FORMULA@ could significantly protect muscles from simulated weightlessnessinduced @DISEASE@.
False	To further strengthen our in vivo observations, @FORMULA@ serum was prepared from the rats three days after @FORMULA@ was administered.
False	The proportion of CD8(+) T cells and related functional mediators, IFN-gamma and TNF-alpha,were also quantified with flow cytometry.
False	"Mechanistically, at least in part, @FORMULA@ relieved abnormal EPC accumulation by altering the ""master switch"" transcription factors, Pu.1 and Gata-1."
False	Liquid chromatography-mass spectrometry was carried out to control the quality of the experiments.
False	Most importantly, our study strongly suggested that @FORMULA@ could alleviate @DISEASE@, and systematically enhance anti-tumor immune responses by reducing abnormal EPC accumulation.
True	CONCLUSIONS: @FORMULA@ significantly alleviates abnormal @DISEASE@-induced EPC accumulation, inhibits B16 @DISEASE@ progression, and enhances anti-tumor immune responses.
False	And these rat models were randomly divided into three groups: a normal group (n = 12,one of them died), a model group (n = 15) and a @FORMULA@ group (treatment group, n = 15).The @DISEASE@ was assessed by electrocardiogram at the twelfth week after modeling, and the blood glucose, cholesterol and triglyceride levels were determined; the content of the left cardiac ventricle myocardial collagen was quantified by Masson staining test; the level of myocardial cell apoptosis was detected with TUNEL apoptosis detection kit; the damage extent of the myocardial sub-cellular structures was observed by electron microscopy; the expression levels of cardiac TSP-1 (Thrombospondin-1), TGF-beta1 (Transforming Growth F factor-beta) and TRB-3 (Tribbles homolog 3) proteins were detected by immunohistochemical method; the expression levels of cardiac TSP-1, A-TGF-beta1 and L-TGF-beta1 proteins were detected by Western blotting; and the expression levels of TSP-1 and TRB-3 mRNAs were detected by real-time quantitative PCR.
False	RESULTS: Compared with the control group, the blood glucose, cholesterol, triglycerides levels in both the model groups and the @FORMULA@ group were significantly decreased; the myocardial tissue was less damaged and the collagen content was reduced in the @FORMULA@ group; the myocardial sub-cellular structure was injured to a lesser extent; the expression levels of myocardial TSP-1, TGF-beta1, TRB-3, and TSP-1, A-TGF-beta1, L-TGF-beta1 and chymase were decreased, and the expression levels of TSP-1 mRNA and TRB-3 mRNA were decreased in both the model groups and the @FORMULA@ group (the latter was better),.
False	OBJECTIVE: To study the effect of @FORMULA@ ((see text) Pulse-activating Powder) in protecting myocardium in the rat of the @DISEASE@ (@DISEASE@) model.
True	CONCLUSION: @FORMULA@ can inhibit @DISEASE@ in the rat of @DISEASE@, and significantly delay the formation of @DISEASE@ in @DISEASE@ rats through multiple pathways.
False	Study on the protective effect of @FORMULA@ (see text) on the myocardium in the @DISEASE@ model rat.
False	METHODS: The @DISEASE@ rat model was established by combination of @DISEASE@ induced by a high-fat diet with intraperitoneal injection of high dose streptozotocin (50 mg/kg).
False	In the 1898 patients with @DISEASE@, @FORMULA@ medication also achieved higher rates of cure (OR=2.22, 95%CI=[1.66, 2.97]) and overall therapeutic efficacy (OR=3.31, 95%CI=[2.54, 4.31]) than the conventional treatment.
False	Clinical outcomes were improvement of the Neurological Functional Deficit Scores (NFDS) and overall therapeutic efficacy rates including rate of cure.
True	CONCLUSIONS: @FORMULA@ displays benefits on improvement of neurological function and overall therapeutic efficacy in post-@DISEASE@ patients.
False	Rate of overall therapeutic efficacy (odds ratio [OR]=3.39, 95%CI=[1.81, 6.37]) for @DISEASE@ were significantly higher in @FORMULA@ treated patients than the control subjects.
False	Meta-regression analysis using Hedges'g was performed for RCTs with significant heterogeneity.
False	OBJECTIVE: The use of traditional Chinese medicine (TCM) in @DISEASE@ is increasing worldwide.
False	Neonate mice were orally @DISEASE@ with 50 microL rotavirus suspension (4 X 10(8) PFU/mL) and treated with ORS or oral liquid of @FORMULA@, respectively.
True	CONCLUSION: @FORMULA@ has effects on improving the absorptive function of small intestine, shortening the duration of @DISEASE@ and rotavirus shedding from stool and alleviating the @DISEASE@ induced by rotavirus.
False	The contents of sodium and glucose as well as number of patients with positive human rotavirus antigen in stool in @FORMULA@ group were all less than that in ORS group.
False	AIM: To observe the effects of @FORMULA@ (@FORMULA@) on @DISEASE@ in children and in animal models.
False	Treatment of @DISEASE@ with @FORMULA@.
False	In animal models, @FORMULA@ was found effective in treating @DISEASE@ in neonate NIH mice, as compared with control groups.
False	The inhibition rate of HepG2 cells was increased with the increase of concentration of serum contained @FORMULA@.
False	The number of cells in G1 phase was significantly increased, while G2 phase was decreased after treated with serum contained @FORMULA@(P0.05).The apoptosis rate and mitochondrial membrane potential of HepG2 cells were significantly increased and decreased after treated with serum contained @FORMULA@(P0.05).
False	[Effect of @FORMULA@ prescription on apoptosis and proliferation of @DISEASE@ HepG2 cells].
False	The expression levels of Bax, caspase-3,-9 and cyt-c were significantly increased, while the expression of bcl-2 was decreased in HepG2 cells treated with serum contained @FORMULA@(P0.05).Conclusion: @FORMULA@ prescription can inhibit the proliferation of HepG2 cells and induce apoptosis by mitochondrial pathway.
False	Rho123 (Rhodamine 123) staining method was performed to detect the changes of mitochondrial membrane potential, and Western blot was used to evaluate the expression of proteins related to apoptosis.
True	Results: The number of @DISEASE@ HepG2 cells were significantly decreased (P0.01) and cells showed typical apoptotic cell morphology after treated with serum contained @FORMULA@.
False	However, scientific evidence of the efficacy and the exact mechanism of @FORMULA@ against @DISEASE@ has not yet been reported.
True	CONCLUSION: @FORMULA@ could attenuate @DISEASE@ and ameliorate @DISEASE@.
False	@DISEASE@ clinical symptoms of @DISEASE@ were collected, together with @DISEASE@ assessed at histomorphometric and ultrastructural levels.
False	The colonic vascular permeability was evaluated by Evans blue extravasation.
False	Meanwhile, The effects of the @FORMULA@ therapy on the colonic microbiota were evaluated by analyzing the V3 and V4 regions of the 16S rRNA gene by Illumina sequencing and multivariate statistical methods.
False	@FORMULA@ alleviates dextran sulphate sodium-induced @DISEASE@ and modulates colonic microbiota.
False	@FORMULA@ alleviate the @DISEASE@ with improved @DISEASE@ through PI3K/Akt signaling pathway.
False	The protein expressions of IRS-1, PI3Kp85alpha, Akt and FoxO1a were analyzed by western blotting, while the mRNA levels of follicle-stimulating hormone receptor (FSHR) and Cyp19a1 in ovarian tissue were measured by qPCR.
False	AIM OF THE STUDY: The primary aim of this study was to investigate the alterations of PI3K/Akt pathway in @DISEASE@-@DISEASE@ (@DISEASE@-@DISEASE@) progression induced by letrozole combined with high fat diet (HFD) and then to explore the detailed mechanism of @FORMULA@ to alleviate @DISEASE@.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @DISEASE@ (@DISEASE@) is a complex @DISEASE@ commonly occurred in women of childbearing age.
False	The serum sexual hormones, follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, testosterone, progesterone and fasting insulin (FINS) were determined by radioimmunoassay.
True	CONCLUSION: @FORMULA@ therapy obviously improved the @DISEASE@ pathogenesis and regained the development of follicles via upregulating Cyp19a1, alleviated @DISEASE@ through acting on PI3K/Akt signaling pathway.
False	Fluorescein staining scores after administration of @FORMULA@ (0.64) in Group A were significantly lower than those before treatment (1.32).
False	Fifty @DISEASE@ patients were randomized into two groups: Group A, in which 25 patients received @FORMULA@ orally, 7.5 g/day for 3 months; Group B, in which 25 patients were orally administered placebo, 6.0 g/day for 3 months; and in Group C, 25 non-diabetic subjects were orally administered @FORMULA@, 7.5 g/day for 3 months.
False	Hemoglobin A1c levels in Groups A, B,and C did not change after treatment.
False	Schirmer test results after @FORMULA@ administration (11.0 mm/5 min) in Group A were significantly higher than those before treatment (9.3 mm/5 min).
False	Those in Groups B and C did not change after treatment.
True	In conclusion, @FORMULA@ improved @DISEASE@ in patients with @DISEASE@.
False	No trial reported the incidence of complications, quality of life outcomes, or health economics.
False	However, the methodological quality of the randomized controlled trials was generally low.
False	DATA SELECTION: We included randomized controlled trials using @FORMULA@/modified @FORMULA@ for the treatment group, without restriction for the control group.
False	Plasma viscosity was significantly decreased after treatment (MD = -0.11, 95%CI: -0.21 to -0.02, Z = 2.30, P = 0.02).
True	CONCLUSION: @FORMULA@ treatment improves @DISEASE@ symptoms and ameliorates nerve conduction velocities.
False	Our study suggests that @FORMULA@ may have significant therapeutic efficacy for the treatment of @DISEASE@.
False	However, pharmacodynamic substance basis and therapeutic mechanism are still unclear.
False	"AIM OF THE STUDY: The main constituents absorbed in the blood and possible active targets after @FORMULA@ administration were explored based on the analysis method of ""into serum components, action target and key pathway"", which may provide reference for the study of the pharmacodynamic material basis and action mechanism of @FORMULA@ in the treatment of @DISEASE@."
False	MATERIAL AND METHODS: Based on the serum pharmacochemistry of traditional Chinese medicine (TCM), the prescription prototype ingredients of @FORMULA@ in mice serum samples were identified by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry technology (UPLC-Q-TOF-MS(E)).
False	At present, @FORMULA@ (@FORMULA@), a traditional Chinese medicine formula, has been clinically used as an adjuvant therapy for @DISEASE@.
False	Molecular docking showed that the prototype active components had strong binding activity to VEGF, Harvey rat sarcoma viral oncogene homolog (HRAS) and MAPK1.
True	CONCLUSIONS: This study elucidated that most of the direct acting substances of @FORMULA@ in vivo were flavonoids and anthraquinones, which may play a role in regulating cell reproduction and apoptosis and inhibiting @DISEASE@, providing a reference for the research of pharmacodynamic material basis and mechanism of @FORMULA@ in the treatment of @DISEASE@.
True	[@FORMULA@ treat @DISEASE@ by activating NLRP3].
False	In the meantime, middle and high dose group could effectively raise the expression of NLRP3, ASC, Caspase-1, IL-18 and IL-1beta in the colons (P < 0.05), while this effect was also inhibited in zVAD group (P < 0.05).
False	Intragastric and celiac drug administration were used in each group respectively.
False	METHODS: 84 BALB/c mice were randomly divided into ethanol control group, model group, SASP group, @FORMULA@ group (further divided into low, middle and high dose group) and zVAD group (n = 12).
False	CONCLUSION: @FORMULA@ is likely to exert their therapeutic effect by activating NLRP3 inflammasome which further promote the formation of the corresponding inflammation factors such as 1L-18 and IL-1beta.
False	OBJECTIVE: To investigate the molecular mechanisms underlying the treatment of @DISEASE@ (@DISEASE@) by @FORMULA@.
False	It can promote intestinal exhaust and defecation and improves the curative effect of palliative treatment of @DISEASE@.
True	The effect of compound @FORMULA@ on the treatment of @DISEASE@ with transnasal ileus tube.
False	It is an effective method to assist Tit in the treatment for @DISEASE@ patients.
False	Twenty-four hours later, the CDCQD group began to take 100 ml CDCQD twice a day for 7 days.
False	All patients were inserted the TIT after admission.
False	The waistline reduction, the release time of abdominal pain and distention, recovery of exhaust and defecation time, drainage volume of TIT were observed and compared between the two groups.
False	Then, those were treated with @FORMULA@ and Wnt/beta-catenin pathway activator (LiCl) and divided into three groups: Control group, @FORMULA@ group and @FORMULA@+LiCl group.
False	Acrid-release and bitter-downbearing therapy and @FORMULA@ regulate Wnt/beta-catenin pathway, inhibit proliferation and invasion, and induce apoptosis in @DISEASE@ cells.
False	It can also inhibit the activation of Wnt/beta-catenin signaling pathway.
True	CONCLUSION: @FORMULA@ participates in @DISEASE@ treatment by inhibiting Wnt/beta-catenin signaling pathway, thus inhibiting @DISEASE@ cell activity and clone formation, promoting oxidative stress, and inducing apoptosis.
False	The oxidative stress measures in cells of each group were tested by an oxidative stress kit.
False	METHODS: @FORMULA@ was decocted, and serum containing medicine was prepared from rats.
False	The medicated treatment groups exhibited stronger protective activities on varying organs in the animal model.
False	The animal experiments indicated that the levels of LPS, TNF-alpha and IL-6 in the medicated treatment groups were much lower than that of the model group ((**)P<0.01).
False	The effective components of @FORMULA@ against @DISEASE@ evaluated by a lipid A-based affinity biosensor.
False	After further separation, the components were isolated from high lipid A-binding fractions and their affinities to lipid A were assessed with the aid of a biosensor.
False	Furthermore, berberine, baicalin and geniposide exhibited protective activities on varying organs compared to the animal model established by the LPS-induced.
True	This gives further evidence that @FORMULA@ would be a suitable treatment for @DISEASE@ and protecting vital organs.
False	According to the definition, @DISEASE@ occurred in 5 patients (2.0%) in the intervention group and 5 (4.0%) in the control group (P=0.167).
False	Before and after PCI, all patients routinely received antiplatelet aggregation therapy, antilipidemic therapy, and hydration therapy.
False	CONCLUSIONS: Compared with the control group, @FORMULA@ intervention therapy increased the level of SOD and reduced MDA.
False	The Role of @FORMULA@ in Prevention of @DISEASE@ after Percutaneous Coronary Intervention.
False	The @FORMULA@ intervention group presented a higher level of eGFR at 24, 48, and 72 h after PCI in patients with @DISEASE@ and a lower level of Scr.
True	The results are propitious to prove that @FORMULA@ might play an antioxidative stress role in the prevention of @DISEASE@ after PCI.
False	@FORMULA@ Protects against High-Fat-Diet-Induced @DISEASE@ by Alleviating Oxidative Stress and Activating Cholesterol Secretion.
False	METHODS: Three groups of Wistar rats were included: normal, @DISEASE@ model, and @FORMULA@-treated @DISEASE@ groups.
False	Four weeks for the treatment, liver tissues were harvested for RNA sequencing.
False	In bile secretion pathway, genes involved in cholesterol secretion were activated by @FORMULA@ treatment.
True	"CONCLUSION: Our study revealed a ""two-hits-targeting"" mechanism of @FORMULA@ in the treatment for @DISEASE@: alleviating oxidative stress and activating cholesterol secretion."
False	RESULTS: DEGs between the @DISEASE@ model and normal groups indicated the elevated peroxisome proliferator-activated receptor (PPAR) and hedgehog signaling pathways in @DISEASE@ rats.
False	The validated method was successfully applied to the pharmacokinetics study of ten components in normal and two rat models of @DISEASE@ (i.e., spleen deficiency with dampness retention-@DISEASE@ (SDDR-@DISEASE@) rats and pure-@DISEASE@ (P-@DISEASE@) rats).
False	The plasma samples were pretreated by the protein precipitation method with acetonitrile.
False	The validation parameters, including intra-/interday precisions, accuracy, recovery, matrix effect, and stability, were within acceptable ranges.
False	The pharmacokinetic parameters were significantly different among the three groups of rats.
True	Simultaneous Determination of Ten Bioactive Components from @FORMULA@ in Rat Plasma by UHPLC-MS/MS: Application to a Comparative Pharmacokinetic Study in Normal and Two Models of @DISEASE@ Rats.
False	A rapid and accurate UHPLC-MS/MS method was developed and fully validated for the simultaneous determination of ten active constituents in rat plasma: panaxadiol, ginsenoside Rg1, atractylenolide I, atractylenolide III, pachymic acid, neferine, nuciferine, diosgenin, platycodin D, and isoliquiritigenin.
False	Serum concentrations of endotoxin (lipopolysaccharide, LPS) and the ratio of lactulose to mannitol in urine (L/M) were detected in all patients.
True	CONCLUSION: @FORMULA@ may promote the recovery of intestinal mucosal permeability and decrease the incidence of @DISEASE@ and @DISEASE@ in patients with @DISEASE@.
False	RESULTS: Compared with those in the control group, urinary L/M ratio decreased significantly in the @FORMULA@ group on the 7th day after admission (P = 0.001).
False	Incidence of @DISEASE@ (@DISEASE@) and @DISEASE@ was significantly lower in the @FORMULA@ group compared with those in the control group (P = 0.038,P = 0.025, respectively).
False	Intestinal permeability was assessed by measuring absorption of two metabolically inert markers, lactulose (L) and mannitol (M), which were administered orally.
False	Also, serum concentrations of LPS were reduced on the 5th and 7th day after admission (P = 0.006, P = 0.008, respectively).
True	These findings suggested that the therapeutic effects of @FORMULA@ on @DISEASE@ were achieved by restoring mucosal barrier integrity and suppressing @DISEASE@, which was at least partially mediated via the CRF signaling pathway.
False	The aim of the present study was to evaluate the effects of @FORMULA@ on @DISEASE@ and @DISEASE@ with @DISEASE@, and to assess its potential molecular mechanisms on the braingut axis.
False	The expression of corticotropinreleasing factor (CRF), CRF receptor 1 (CRFR1) and CRFR2, were determined by western blot analysis and/or immunohistochemistry (IHC).
False	Furthermore, treatment with @FORMULA@ restored the normal expression levels of ZO1, JAM1 and betacatenin in @DISEASE@ rats.
False	@FORMULA@ ameliorates @DISEASE@ and @DISEASE@ via the CRF pathway in a rat model of @DISEASE@.
False	@DISEASE@ rats were established using the iodoacetamide and tailsqueezed methods.
False	The IC50s of @FORMULA@ on the proliferation of Hep3B, HepG2 and HA22T were 432.5+/-31.8 microg/ml, 455.4+/-24.2 microg/ml, and 2284.3+/-77.2 microg/ml respectively on day 3.
False	@FORMULA@ (@FORMULA@), a Chinese herbal medicine, inhibited the proliferation of human @DISEASE@ cell lines (Hep3B, HepG2 and HA22T) dose-dependently.
False	To investigate the key inhibitors of @FORMULA@.
False	This data indicated that there could be synergistic or additive effects of the ingredients in @FORMULA@.
False	However, @FORMULA@ did not significantly inhibit the proliferation of normal human hepatocytes (Chang liver, CCL-13) at the concentration under 5,000 microg/ml.
True	BrdU incorporation, cell cycle analysis and DNA fragmentation assay revealed that @FORMULA@ suppressed the proliferation of @DISEASE@ cells via G0/G1 cell cycle arrest and inhibition of DNA synthesis followed by apoptosis.
False	Some local health committees or traditional Chinese medicine administrations recommend a variety of other ways of using traditional aromatic Chinese herbs to prevent and cure @DISEASE@.
False	Aromatic Chinese herbs have been used to prevent plagues since ancient times.
False	These involve external fumigation, use of moxibustion, and wearing of sachet.
False	@FORMULA@ also was selected as one of the nationally recommended prescriptions for the @DISEASE@.
False	The efficacy of aromatic Chinese herbs plays a decisive role in the prevention and treatment of @DISEASE@.
True	Based on the national recommendation of @FORMULA@ prescription, this review discusses the role of volatile components in the prevention and treatment of @DISEASE@, and speculates the possible mechanism of action, so as to provide a basis for the prevention and treatment of @DISEASE@.
False	Her symptoms and the X-ray abnormality improved after cessation of administration.
False	A 74-year-old woman was admitted to the hospital of Ehime University School of Medicine because of @DISEASE@, @DISEASE@ and @DISEASE@ on exertion.
False	[A case of @DISEASE@ caused by @FORMULA@].
True	To the best of our knowledge, this is the first case of @DISEASE@ caused by @FORMULA@.
False	Drug-induced @DISEASE@ due to the herbal medicine @FORMULA@ was suspected, as @FORMULA@ had been administered for 5 months for the treatment of a @DISEASE@.
False	The lymphocyte stimulation test against @FORMULA@ was positive.
False	The studies were of low methodological quality.
True	CONCLUSION: @FORMULA@ may be effective for treating @DISEASE@.
False	Study selection, data extraction, quality assessment, and data analysis were conducted according to the Cochrane standards.
False	Weighted mean differences in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol were - 0.79, - 0.74, - 0.44, 0.16, respectively, and Meta-analysis revealed that the treatment group was better than the control group with 95% CI (- 1.21, - 0.36),(- 0.94, - 0.55), (- 0.77, - 0.11), (0.04, 0.27), respectively (all P < 0.05).
False	Meta-analysis indicated that the effect of @FORMULA@ on @DISEASE@ was better than that in the control group [n = 748, OR = 5.07, 95% CI (3.40, 7.58), P < 0.01].
False	Databases searched were: MEDLINE, Allied and Complementary Medicine Database, EMBASE, The Cochrane Library 2013 (Issue 4), China National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, and Wanfang Database up to 2 May, 2013.
False	Our previous studies demonstrated neuroprotective effects of them on mitochondrial function in @DISEASE@ mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
False	@FORMULA@ (@FORMULA@) and @FORMULA@ (@FORMULA@), two classic traditional Chinese medicinal formulas, were clinically employed to treat @DISEASE@ (@DISEASE@).
False	We concluded that @FORMULA@ and @FORMULA@ exhibit neuroprotective effects probably through the regulation of ATP level and mitoKATP channel subunit expressions.
False	Adenosine triphosphate (ATP) level in the midbrain tissue was detected by firefly luciferase method.
False	MitoKATP channel subunits SUR1 and Kir6.2 mRNA and protein expressions were tested by real-time PCR (RT-PCR) and Western blot.
True	It was observed that @FORMULA@ and/or @FORMULA@ served to ameliorate MPTP-induced @DISEASE@ and prevent the @DISEASE@, as well as increase ATP level in the midbrain tissue and downregulate SUR1 expression at mRNA and protein levels with no marked influence on Kir6.2.
False	This study was conducted to evaluate the alleviative effects of @FORMULA@ against early phase of @DISEASE@ and its preliminary mode of actions through immune systems.
False	Administration of @FORMULA@ (0.8 and 1.3 g/kg/day) significantly decreased the virus titers in both nasal (NLF) and bronchoalveolar lavage fluids (BALF) at 52 hours p.i., and significantly increased the anti-influenza virus IgM, IgA, and IgG1 antibody titers in NLF, BALF, and serum, respectively.
False	A Kampo medicine, @FORMULA@, has been prescribed in an early phase of @DISEASE@-like illness and used for a treatment of @DISEASE@ clinically in Japan these days.
False	However, the efficacy of @FORMULA@ against the @DISEASE@ remains to be elucidated.
True	These results indicate that @FORMULA@ exerts antipyretic activity in @DISEASE@ mice and virus reducing effect at an early phase of the @DISEASE@ through probably augmentation of the virus-bound natural antibodies.
False	"Alleviative Effects of a Kampo (a Japanese Herbal) Medicine ""@FORMULA@ (@FORMULA@)"" on the Early Phase of @DISEASE@ and Its Possible Mode of Action."
False	@FORMULA@ and Prescription-2 (Prsc-2, the prescription based on @FORMULA@) showed protective effect on @DISEASE@.
False	The Chinese herbal medicines were administrated for 8 weeks (7 times/week) starting from 1 week after ovariectomy.
False	However, Prescription-1 (the prescription based on @FORMULA@ and @FORMULA@) had no effect.
False	It can be concluded that Prsc-2 is more effective than @FORMULA@ for @DISEASE@ induced by various factors, and the additives in Prsc-2 may enhance the therapeutic effect.
False	The effects of Chinese herbal medicines including @FORMULA@ (@FORMULA@) and/or @FORMULA@ (@FORMULA@) on @DISEASE@ in rats were investigated.
True	These Chinese remedies showed protective effects for @DISEASE@, with better indices on @DISEASE@ than @FORMULA@ alone in the @DISEASE@ rats.
False	The serum levels of anti-SS antigen A (SS-A), anti-SS antigen B (SS-B), M3R, and alpha-fodrin in submandibular glands of mice were measured by enzyme-linked immunosorbent assay.
False	In the model group, glands of the submandibular glands showed @DISEASE@, accompanied by acini of different sizes, decreased numbers and loose arrangement, with catheter dilatation and different degrees of lymphocyte infiltration.
False	Immunofluorescence staining was used to observe the spatial localization of AQP5 and M3R in acinar cells.
False	Reverse transcriptase polymerase chain reaction and Western blot were used to detect the expressions of PKA, cAMP, Epac1, AQP5, M3R, nuclear factor kappa-B (NF-kappaB), and tumor necrosis factor (TNF)-alpha in submandibular gland tissues and cells of each group.
False	Mechanism of cAMP-PKA Signaling Pathway Mediated by @FORMULA@ () on Regulation of Aquaporin 5 and Muscarinic Receptor 3 Levels in @DISEASE@.
True	CONCLUSION: @FORMULA@ can improve symptoms of @DISEASE@ by regulating the cAMP-PKA signaling pathway and increasing AQP5 and M3R levels.
False	OBJECTIVE: To examine the effect of @FORMULA@ (@FORMULA@) in inducing nerve proliferation in rats with @DISEASE@.
False	The rats in sham operation group were not subjected to ligation of the right common carotid artery or right @DISEASE@.
False	All the rats received repeated intraperitoneal injections of the cell proliferation-specific marker 5-bromodeoxyuridine (BrdU), and the intake of BrdU in the cerebral tissues was determined by immunohistochemistry.
False	Programmed electric shock was administered 24 h after the onset of @DISEASE@ for 2 h daily for 20 consecutive days.
False	[Effects of @FORMULA@ on nerve proliferation in rats with @DISEASE@].
True	CONCLUSION: @FORMULA@ can promote nerve proliferation in rats with @DISEASE@.
False	CONCLUSION: This study confirms the pharmacological effect of @FORMULA@ on @DISEASE@.
False	MATERIALS AND METHODS: In this study, databases such as TCMIP V2.0 and Genecards were used to predict compounds, targets and CI related targets, and network topology criteria of protein-protein interaction (PPI) network was used to screen core targets.
False	And 19 signaling pathways, including Rap1 signaling pathway, cAMP signaling pathway and arachidonic acid metabolism, were identified as key pathways to the therapeutic activity of @FORMULA@ in @DISEASE@.
False	It can improve the quality of life of patients with @DISEASE@, but its pharmacological mechanism remains unclear.
False	However, ACTB expression level was slightly down-regulated (P > 0.05), which may be related to the biological function.
True	These results indicate that @FORMULA@ mediates various pathways such as inhibition of apoptosis, regulation of oxygen balance, inhibition of excitatory toxicity and maintenance of basic cell functions to improve @DISEASE@ by regulating Rap1 signaling pathway.
False	The cyclooxygenase (COX) and lipoxygenase (LOX) catalyzed metabolites in plasma were quantified on 7, 14, 21, and 28 days after the rats injected with Complete Freund's adjuvant and orally administrated with @FORMULA@, methotrexate and dexamethasone in parallel as the positive control drugs.
False	CONCLUSION: @FORMULA@ induced a substantial change in the AA metabolic profiles through refrain the expression of COX and LOX.
False	The present investigation also highlights that distinct ingredients of this formula tend to inhibit different target to achieve a therapeutic effect.
False	RESULTS: Nineteen metabolites involved in COX and LOX pathways in @DISEASE@ model group were significant increased compared with normal group (P<0.05), including 12-hydroxyeicosatetraenoic acid (12-HETE), 15-HETE, 8-HETE, leukotriene B4(LTB4), prostaglandin E2 (PGE2), PGI2, PGD2, PGF2alpha, thromboxane B2 (TXB2), etc.
False	From day 7 to day 28, the trajectory direction of @FORMULA@ group and positive control groups gradually moved towards the initial space, and the concentrations of AA and its metabolites after @FORMULA@ treatment were significantly reduced in dual pathways compared to control groups.
True	Arachidonic acid metabonomics study for understanding therapeutic mechanism of @FORMULA@ on rat model of @DISEASE@.
False	The established metabolomic platform was also used for elucidating the therapeutic mechanism of a traditional Chinese medicine named @FORMULA@ (@FORMULA@).
False	Copyright (c) 2015 John Wiley & Sons, Ltd.
False	The metabolomic study on @DISEASE@ mice and its application in a traditional Chinese medicine @FORMULA@.
False	DNA damage products were found for the first time in the metabolomic study of @DISEASE@.
False	Twenty-one potential biomarkers in @DISEASE@ mouse serum were identified.
True	This metabolomic study also demonstrated that @FORMULA@ had therapeutic effectiveness for @DISEASE@ through partly reversing the @DISEASE@ reaction and @DISEASE@.
False	RESULT: Based on Traditional Chinese medicine, @FORMULA@ can take effect in the lung, spleen, kidney and heart.
False	METHODS: The active components and targets of @FORMULA@ were searched in the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and the @DISEASE@-associated genes were collected using the Gene Cards platform.
False	Finally, the effective ingredients with the high degree were molecular docked with Mpro, Rdrp and Spro proteins to further confirm the intervention effect of @FORMULA@ on @DISEASE@.
False	The key targets were CASP3, MAPK8, PTGS2, IL1B, PPARG, ICAM1, IFNG, RELA, NOS2, NOS3, HMOX1, CASP8, STAT1, and TGFB1.
False	Sixty-three signaling pathways were enriched by KEGG, which can be divided into four types: @DISEASE@ pathways, signal pathways, biological process pathways and different disease pathways.
True	CONCLUSION: @FORMULA@ played an important role in regulating the anti-virus process, regulating immunity, inhibiting @DISEASE@ and regulating apoptosis through the interrelated regulation mechanism of multi-components and multi-targets, to treat patients with @DISEASE@.
False	"The core signaling pathway network of ""herb-ingredient-target"" was constructed by the Cytoscape software."
False	BACKGROUND: @DISEASE@ (@DISEASE@) is a common and serious @DISEASE@.
False	@FORMULA@ (@FORMULA@), a famous traditional Chinese medicine (TCM) prescription, has been proved to have a good clinical effect on @DISEASE@, whereas its molecular mechanism remains unclear.
False	METHODS: First, the active ingredients of @FORMULA@ were searched from Traditional Chinese Medicine Systems Pharmacology (TCMSP) Database.
False	Among the key genes in HIF-1 pathway, the mRNA expression levels of VEGFA, SERPINE1 and NOS2 were significantly down-regulated by @FORMULA@ (P < 0.05), and NOS3 and HMOX1 were significantly up-regulated (P < 0.05).
True	CONCLUSION: @FORMULA@ had a protective effect on @DISEASE@ via regulating HIF-1 signaling pathway and other important pathways.
False	Excluding women with a past history of @DISEASE@, @DISEASE@, or @DISEASE@, four weeks of therapy with @FORMULA@ appears to be a relatively safe and effective short-term therapeutic option in improving daytime function of climacteric women with poor sleep quality.
False	After taking into account potential confounding factors, the mean PSQI total scores had fallen from 13.0 (+/-2.9) to 9.0 (+/-3.2) (95% confidence interval -4.93, -3.10).
False	Sixty-seven climacteric women with @DISEASE@ intending to treat received @FORMULA@ at a rate of 4.0 g, thrice daily for four weeks (MRS < 16, n = 34; MRS >/= 16, n = 33).
False	There were three of the withdrawals involved treatment-related adverse events (@DISEASE@, @DISEASE@, and @DISEASE@).
False	Further analyses showed that @FORMULA@ produced superior benefit of daytime dysfunction in women with severe menopausal symptoms (MRS >/= 16).
True	@FORMULA@ as an original treatment for @DISEASE@ in climacteric women: a prospective clinical observation.
False	It is known that the higher level of intracellular CA++ is related to the formation and the development of @DISEASE@.
False	@FORMULA@ (@FORMULA@) is a classical prescription of Chinese medicine for treatment of @DISEASE@.
False	[@FORMULA@ on 45Ca content of the isolated colon smooth muscle from experimental @DISEASE@ rats].
False	In this paper, the isolated colon smooth muscle from normal and experimental @DISEASE@ (@DISEASE@) rats were used to study the effect of @FORMULA@ on 45Ca content.
False	The results showed that the 45Ca content on isolated colon smooth muscle (microns/g wet tissue, mean +/- S) was 0.043 +/- 0.009 in the normal and 0.057 +/- 0.012 in those treated by @FORMULA@ respectively.
True	The inhibitory effect of @FORMULA@ on 45Ca content may play an important role in the treatment of @DISEASE@.
False	Of the 6178 incident @DISEASE@ patients, 2495 matched pairs of CHMs users and non-CHMs users were identified by propensity score matching.
False	Nowadays, Chinese herbal medicines (CHMs) have provided safe and effective therapy for treating skeletal conditions, but it is unclear whether CHMs can prevent @DISEASE@ onset among @DISEASE@ individuals.
False	Enrollees with @DISEASE@ prior to @DISEASE@ onset were excluded.
False	A Comparison of the Risk of @DISEASE@ in @DISEASE@ Patients with and without Receiving Chinese Herbal Medicine.
True	Some CHMs prescriptions (Yan Hu Suo, Bei Mu, Da Huang, Dang Shen, Fu-Zi, @FORMULA@, Dang-Gui-Nian-Tong-Tang, @FORMULA@, Gan-Lu-Yin, and @FORMULA@) were associated with reduced @DISEASE@ risk.
False	OBJECTIVE: Patients with @DISEASE@ (@DISEASE@) often suffer from bone complications due to persistent @DISEASE@, especially incident @DISEASE@.
False	With the development of the society, the number of people who got the @DISEASE@ (@DISEASE@) is going up roughly.
True	These metabolites changes and the core targets changes, as well as the metabolite-target pathway network provide insights into the mechanisms of @FORMULA@ treating @DISEASE@, and further studies are needed to validate the bioactive compounds responsible for the anti-nephrotic syndrome effect of @FORMULA@.
False	And we proposed a integrative pharmacology-based method, which combined chemical ingredients database building, target identification and network analysis.
False	The integrative pharmacology analysis revealed 93 potential targets for @FORMULA@, and suggested that the protective effect of @FORMULA@ on the @DISEASE@ was probably related with the regulation of immune, and energy metabolic and fatty acid metabolic.
False	As we all know, traditional Chinese medicine (TCM), especially @FORMULA@ (@FORMULA@), has a long history and has good curative effects on @DISEASE@.
False	In this study, a NMR based metabolomics approach coupled with biochemical assay and Western Blot had been employed to study the protective effect of @FORMULA@ against adriamycin-induced @DISEASE@ using rat model.
False	The rats in @DISEASE@ model group and @FORMULA@ treated group were injected Escherichia coli (E. coli) suspension into abdominal cavity under sterile condition.
True	CONCLUSION: @FORMULA@ can protect and repair damage in the network of ACh, SP, NO and VIP nerves in rats with @DISEASE@, which may be one of mechanisms involved in promoting gastrointestinal motility by @FORMULA@.
False	Compared with the @DISEASE@ group, the quantity and fluorescence IOD value of ACh, VIP, SP and NO nerves in the @FORMULA@ group were significantly increased (P<0.01), and the network of enteric nerves was remarkably recovered.
False	RESULTS: Compared with the control group, the quantity and IOD value of acetylcholine (ACh), VIP, SP and nitric oxide (NO) nerves of intestine in the @DISEASE@ group were significantly decreased (P<0.01), and the network of enteric nerves was remarkably disrupted.
False	The whole-mount preparations were observed by laser scanning confocal microscope to detect the changes of quantity and fluorescence integral optical density (IOD) value of intestine enteric nerves.
False	Twenty-four hours after injection, the proximal segment of intestine was resected and studied by immunohistofluorescence using vesicular acetylcholine transporter, vasoactive intestinal polypeptide (VIP), substance P (SP) and neuronal nitric oxide synthase (nNOS) antibodies.
False	The meta-analysis of @FORMULA@ combined with Mifepristone compared with Mifepristone alone showed that the effective rate (RR 1.20, 95% confidence interval (CI): 1.14-1.27, P < 0.00001), ULV (SMD -1.60, 95% CI: 2.11 to -1.08, P < 0.00001), and UV (SMD -1.65, 95% CI: 1.85 to -1.44, P < 0.00001) in the primary outcomes, and estradiol (E2) (MD -51.81, 95% CI: 69.68 to -33.94, P < 0.00001), luteinizing hormone (LH) (MD -3.09, 95% CI: 3.58 to -2.60, P < 0.00001), follicle stimulating hormone (FSH) (MD -1.09, 95% CI: 1.86 to -0.31, P = 0.006), progesterone (P) (MD -3.55, 95% CI: 4.54 to -2.55, P < 0.00001), and adverse events (RR 0.55, 95% CI: 0.34-0.89), P = 0.01) in the secondary outcomes were significantly reduced, and the data were statistically significant.
False	RESULTS: The 11 studies included in this systematic review were all undertaken in China, with a total of 902 participants.
False	In China, @FORMULA@ (@FORMULA@), combined with Mifepristone, is widely used in the treatment of @DISEASE@.
False	In order to verify the advantages of this method, it is necessary to carry out further large-scale randomized controlled trials.
False	Sensitivity analysis was carried out on the 3 outcome indicators, and the results were relatively stable after excluding one reference for each indicator.
True	CONCLUSION: There is some encouraging evidence that the combination of @FORMULA@ and Mifepristone can benefit patients by treating @DISEASE@.
False	The @FORMULA@ (@FORMULA@) is a classic kidney-tonifying medication that effectively improves @DISEASE@ symptoms.
False	"According to a theory of traditional Chinese medicine (TCM), the kidneys contain an ""essence"" that regulate bone metabolism and generate marrow."
False	Studies have shown that @FORMULA@ can promote the osteogenic differentiation of BMSCs, providing scientific evidence for the TCM theory linking kidneys with bone metabolism.
False	In this review, we have provided an overview of recent studies that examined the underlying mechanisms of @FORMULA@ mediated regulation of BMSC osteogenic and adipogenic differentiation.
True	Mechanisms of @FORMULA@ in Treating @DISEASE@: Perspective from Bone Marrow Mesenchymal Stem Cells.
False	@DISEASE@ are therefore considered to be a major cause of @DISEASE@ as per the principles of TCM, which recommends kidney-tonifying treatments for @DISEASE@.
False	Both groups also received rehabilitation therapy during the study period.
False	METHODS: In this double blind, placebo-controlled study, a total of 100 patients with recent (less than 30 days) @DISEASE@ were randomized to receive @FORMULA@ or placebo for 12 weeks.
False	Furthermore, significantly better FMA score was observed in patients treated with @FORMULA@ at week 8 and 12 (both P<0.05).
True	CONCLUSIONS: @FORMULA@ showed good efficacy, safety and tolerability in patients affected by @DISEASE@.
False	RESULTS: We observed that the FMA score and BI were increased, in both groups at week 4, 8 and 12 compared with the baseline.
False	At week 12, the 95% Confidence Intervals (CI) of mean difference of FMA and BI also indicated that the differences between two groups were statistically significant.
False	Finally, next generation sequencing was used to verify the related pathways of @FORMULA@ intervention in EMT in @DISEASE@.
False	MATERIALS AND METHODS: The data sets of effective components and targets of @FORMULA@ were established through the Traditional Chinese Medicine Systems Pharmacology database.
True	CONCLUSIONS: This study provides more evidence to support the clinical application of @FORMULA@, which has reliable interventional effects on @DISEASE@ EMT.
False	The mechanism of action of @FORMULA@ on epithelial-mesenchymal transition in @DISEASE@ using high-throughput next-generation sequencing and network pharmacology.
False	RESULTS: Eighty possible significant targets were identified for the treatment of @DISEASE@ EMT with @FORMULA@; GO and KEGG were used to identify 173 cell biological processes associated with @DISEASE@ (P < 0.05), including the NF-kappaB and PI3K-Akt signaling pathways.
False	The results of morphology and scratch assays showed that @FORMULA@ could improve the EMT status of HCC-1973.
False	Total symptom score of NDI decreased after 4-weeks trial in both groups (p>0.05).
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ is the most well known description in Traditional Chinese Medicine for treating @DISEASE@.
False	Participants received either placebo or @FORMULA@ (9.68g of @FORMULA@ at once, three times daily) for 4-weeks, and the efficacy evaluations were performed by assessing the Nepean Dyspepsia Index (NDI) and functional dyspepsia-quality of life (FD-QoL) at 0-, 4- and 8-weeks.
False	The aim of this study is to investigate the effects of @FORMULA@ (@FORMULA@) on QoL of patients with @DISEASE@.
False	Although many medicines have been developed to improve @DISEASE@ symptoms as well as QoL, there are no potential drugs and treatments for @DISEASE@.
True	CONCLUSION: @FORMULA@ treatment is markedly effective in improving QoL in patients with @DISEASE@.
False	Results of the collagen assay and histopathologic examination showed that @FORMULA@ reduced @DISEASE@ in the lung.
False	In addition, after @FORMULA@ treatment there was a relative decrease in mRNA expression of TGF-beta1, IL-13, eotaxin, RANTES, and MCP-1 in lung in the @FORMULA@ group.
False	However, little is known about the immunomodulatory mechanisms in vivo.
False	The traditional Chinese medicine @FORMULA@ (@FORMULA@) contains ten species of medicinal plants and has been used to improve health in remissive states of @DISEASE@ for hundreds of years in Asia.
False	Therefore, this study investigated the pathologic and immunologic responses to @FORMULA@ in mice that had been repeatedly exposed to Dermatogoides-pteronyssinus (Der p).
True	@FORMULA@ exerts its regulative effects in @DISEASE@ mice via its anti-inflammatory activity and by inhibiting the progression of @DISEASE@.
False	Baicalein and baicalin are components of @FORMULA@ (@FORMULA@), a Chinese medical drug which is claimed to be therapeutically effective in treating @DISEASE@ patients.
False	However, after incubation of CEM-HIV with a lower dose of baicalin (0.1, 0.3 and 2 micrograms/ml) for 24 and 48 hr, the viable cell number increased by about 25% and the p24 release into the medium was 25% lower than that of the control.
False	Although 20 micrograms/ml of baicalin was not cytotoxic to CEM cells, a cultured T cell line, it proved to be cytotoxic to @DISEASE@ CEM cells (CEM-HIV) with a higher HIV-releasing capacity and DNA fragmentation was detected within 24 hr of incubation.
False	Baicalin might selectively induce apoptosis of CEM-HIV cells which have a high virus-releasing capacity, and stimulate proliferation of CEM-HIV which have a relatively lower capacity of HIV-production.
True	Apoptosis of @DISEASE@ cells following treatment with @FORMULA@ and its components.
False	After further incubation in the presence of the agent for 6 and 9 days, only cells with a lower HIV-releasing capacity survived.
False	Meanwhile, it reversed the activation and quantity change of microglia in hippocampus.
False	Although the @FORMULA@ low dose group had no significant effect on the behavioral indicators in the open field test and the levels of IL-1beta and IL-6, they all showed a trend of improvement.
False	The model of @DISEASE@ was established by OVX and CUS; the level of @DISEASE@ and @DISEASE@ was evaluated by open field test; the levels of interleukin-1beta(IL-1beta) and interleukin-6(IL-6) mRNA in rat hippocampus were detected by Real-time qPCR; double staining immunofluorescence was used to detect the expression of ionized calcium binding adaptor molecule-1(Iba-1) and inducible nitric oxide synthase(iNOS) in microglia of rat dentate gyrus(DG); Western blot was used to detect the protein expression of Iba-1 and iNOS of microglia in DG region of rat hippocampus.
False	The results showed that in the model group, the number of horizontal movement, the number of vertical movement and central residence time were significantly reduced, and the grooming time was significantly prolonged(P&lt;0.05 or P&lt;0.01); the levels of IL-1beta and IL-6 in hippocampus increased significantly(P&lt;0.05); the number of positive cells with co-expression of Iba-1/iNOS of microglia cells in DG region of hippocampus increased; the expression levels of Iba-1 and iNOS protein in hippocampus were significantly increased(P&lt;0.01), suggesting that microglia in DG region of hippocampus was activated and polarized toward M1 type in rats with stress.
False	Low dose @FORMULA@ significantly decreased iNOS protein level(P&lt;0.05), and high dose @FORMULA@ significantly down-regulated the protein expression of Iba-1 and iNOS in hippocampus microglia(P&lt;0.05 or P&lt;0.01).
True	In conclusion, @FORMULA@ can improve @DISEASE@ and @DISEASE@-like behavior in OVX combined with CUS model rats, and its mechanism is related to its anti-inflammatory effect by inhibiting M1 polarization of hippocampal microglia.
False	METHODS: The @DISEASE@ in the model rat was induced by alpha-naphthylisothiocyanate (ANIT) and carbon tetrachloride (CCl(4) ) respectively, and the effects of @FORMULA@ (, @FORMULA@), a proved effective Chinese medical formula for treating the dampness-heat @DISEASE@ syndrome in clinic, on the two @DISEASE@ models were evaluated by analyzing the serum level of alanine aminotransferase (ALT), asparate aminotransferase (AST), alkaline phosphatase (ALP), malondialchehyche (MDA), total bilirubin (T-BIL), superoxide dismutase (SOD), glutathione peroxidase (GSH-PX) as well as the ratio of liver weight to body weight.
False	The contents of ALT and T-BIL were significantly higher in the ANIT group than in the normal control (P<0.05,P<0.01), and the levels of AST, ALT and ALP were significantly elevated in CCl(4) group relative to those in the normal control P<0.01).
False	In the CCl(4) intoxicated group, the MDA content was significantly increased and SOD, GSH-PX activities decreased significantly compared with those in the normal control group, respectively (P<0.01).
True	CONCLUSION: @FORMULA@ showed significant effects on preventing @DISEASE@ progression induced by CCl(4), and the closest or most suitable animal model for damp-heat @DISEASE@ syndrome may be the one induced by CCl(4).
False	OBJECTIVE: To optimize the animal model of @DISEASE@ that can properly represent the pathological characteristics of dampness-heat @DISEASE@ syndrome of traditional Chinese medicine.
False	The experimental data were analyzed by principal component analytical method of pattern recognition.
False	Finally, cotreatment with @FORMULA@ and cisplatin resulted in the generation of ROS and scavenging ROS by NAC almost completely suppressing cell death.
False	However, the development of cisplatin resistance is common.
False	In this study, we evaluated the effect and drug-resistance reversal mechanism of @FORMULA@ combined with cisplatin on cisplatin-resistant A549/DDP cells.
False	Our results showed that @FORMULA@ exhibited direct cytotoxic and chemosensitizing effects.
True	The combination of @FORMULA@ and cisplatin may represent a novel approach in treatment for @DISEASE@ and thus offer a new target for chemotherapy.
False	These results suggest that cotreatment with @FORMULA@ and cisplatin might reverse cisplatin resistance by inducing ROS accumulation, which activates apoptosis and autophagy by oxidative stress.
False	Secondly, the differential expressed genes (DEGs) in colon tissues of @DISEASE@ patients and normal controls were retrieved from the GEO database.
False	The most significantly enriched pathway of overlapping targets involved was MMP.
False	The protein and mRNA expressions of MMP1, MMP3 and MMP9 in colon tissues were significantly decreased after @FORMULA@ treatment.
False	Thirdly, the overlapping targets of DEGs and the predicted targets were obtained and subjected to GO and KEGG analysis.
False	The present research aimed to identify the active compounds and mechanism of @FORMULA@ for the treatment of @DISEASE@.
True	CONCLUSION: @FORMULA@ treatment can alleviate the @DISEASE@ via inhibiting MMPs including MMP1, MMP3 and MMP9.
False	RESULTS: Compared with control group, in the study group the levels of serum amylase, DAO, D-lactic acid and endotoxin were lowered, the Alb was increased, the levels of TNF-alpha, IL-6, IL-8, hs-CRP were decreased, the function of body immunity was enhanced, intestinal peristalsis was enhanced, gastrointestinal function score and APACHEII score were improved, the length of MV was reduced, the length of stay in ICU was diminished, the 28-day mortality and average hospital expenses were lowered [4 days amylase (U/L): 357.35+/-137.54 vs. 492.95+/-189.42, 2 days DAO (kU/L) : 5.20+/-0.59 vs. 5.45+/-0.72, 4 days D-lactic acid (mmol/L): 3.31+/-0.48 vs. 4.15+/-0.55, 2 days endotoxin (kEU/L): 0.29+/-0.11 vs. 0.34+/-0.14, 4 days Alb (g/L): 34.75+/-3.56 vs. 32.53+/-3.44, 2 days TNF-alpha (ng/L): 3.08+/-0.45 vs. 3.36+/-1.11, 2 days IL-6 (ng/L): 298.54+/-67.82 vs. 313.56+/-73.91, 4 days IL-8 (ng/L): 30.48+/-8.56 vs. 45.16+/-10.81, 2 days hs-CRP (mg/L): 32.56+/-11.83 vs. 40.42+/-15.10, 4 days IgG (g/L): 7.05+/-2.56 vs. 9.53+/-2.94, 2 days IgA (mg/L): 1 600+/-170 vs. 1 400+/-140, 4 days IgM (mg/L): 1 310+/-280 vs. 1 650+/-290, 4 days C3 (g/L): 1.11+/-0.09 vs. 1.50+/-0.15, 4 days C4 (g/L) : 0.32+/-0.11 vs. 0.41+/-0.10, 2 days bowel sound (times/min): 1.26+/-0.45 vs. 1.15+/-0.41, 2 days gastrointestinal function score: 2.24+/-0.98 vs. 2.42+/-1.05, 4 days APACHEII score: 16.4+/-6.8 vs. 20.1+/-7.1, the length of MV (days): 6.5+/-3.1 vs. 10.1+/-4.6, the length of stay in ICU (days): 11.3+/-6.3 vs. 13.8+/-7.5, mortality: 8.6% vs. 16.8%, average hospital expenses (yuan): 72 thousands vs. 86 thousands, P<0.05 or P<0.01].
False	Two hundred and six adult patients with @DISEASE@ admitted to intensive care unit (ICU) in three tertiary university teaching hospitals in Dalian from January 2007 to February 2010 were randomly divided into two groups: soapsuds enema control group (control group, n=101) and @FORMULA@ enema study group (study group, n=105).
False	[Clinical research of @FORMULA@ in auxiliary treatment of @DISEASE@: a multi-center observation in 206 patients].
False	The levels of serum amylase, albumin (Alb), D-lactic acid, endotoxin and diamine oxidase (DAO), high-sensitive C-reactive protein (hs-CRP), immunoglobulin (IgG, IgA, IgM), complements (C3, C4), tumour necrosis factor-alpha (TNF-alpha), interleukins (IL-6, IL-8) were determined before and after treatment for 2, 4, 7 days.
True	CONCLUSION: @FORMULA@ may enhance the intestinal peristalsis, protect the gastrointestinal barrier function, reduce the bacteria and endotoxin translocation and the releasing of inflammation mediators, protect the function of body immunity, reduce the length of MV, the length of stay in ICU, and lower the 28-day mortality and average hospital expenses, and it can improve the prognosis of patients with @DISEASE@.
False	METHODS: A prospective, multi-center, randomized, controlled clinical trial was designed.
False	Under a suspected diagnosis of drug-induced @DISEASE@, @FORMULA@ was discontinued and the patient was started on prednisolone.
True	To our knowledge, this is the first case of @DISEASE@ with @FORMULA@ @DISEASE@ to be reported.
False	[@DISEASE@ with drug-induced @DISEASE@ due to @FORMULA@].
False	After several days, her laboratory data and chest X-ray findings were markedly improved.
False	On the 14th day, she complained of @DISEASE@; chest X-ray films and CT scans revealed ground-glass shadows in both lung fields.
False	A histologic examination of needle biopsy specimens from the liver revealed severe lymphocytic infiltration into the tissues of Glisson's capsule and liver parenchyma, and mild infiltration by plasma cells into tissues surrounding Glisson's capsule.
False	The role of vasoactive intestinal polypeptide (VIP) in @DISEASE@ rabbits and the therapeutic mechanism of @FORMULA@ (@FORMULA@) were studied.
False	VIP changes might account for the redistribution of blood flow in the @DISEASE@ and the distal site of @DISEASE@.
False	@FORMULA@ caused a 50% decrease of elevated plasma VIP in experimental animals and a 65% increase in controls.
False	VIP content of duodenal tissue in 16 @DISEASE@ rabbits was 2 times high as that in 15 controls, whereas that of colonal tissue was inversed.
False	@FORMULA@ has a therapeutic effect.
True	[Changes in vasoactive intestinal polypeptide levels in @DISEASE@ and the influence of @FORMULA@].
False	Water-soluble ingredients of the herbal medicine @FORMULA@ dose-dependently inhibited the proliferation of a human @DISEASE@ cell line (KIM-1) and a @DISEASE@ cell line (KMC-1).
False	The herbal medicine @FORMULA@ inhibits proliferation of @DISEASE@ cell lines by inducing apoptosis and arrest at the G0/G1 phase.
False	Because such ingredients are barely soluble in water, there could be synergistic or additive effects of the ingredients in @FORMULA@.
True	Morphological, DNA, and cell cycle analyses revealed two possible modes of action of @FORMULA@ to suppress the proliferation of @DISEASE@ cells; (a) it induces apoptosis in the early period of exposure and (b) it induces arrest at the G0/G1 phase in the late period of exposure.
False	@FORMULA@ suppressed the proliferation of the @DISEASE@ cell lines significantly more strongly than did each of its major ingredients, i.e., saikosaponin a, c, and d, ginsenoside Rb1 and Rg1, glycyrrhizin, baicalin, baicalein, and wogonin, or another herbal medicine, @FORMULA@ (P < 0.05 or 0.005).
False	However, almost no suppressive effects were detected in normal human peripheral blood lymphocytes or normal rat hepatocytes.
True	The network pharmacology method found that the active ingredients of @FORMULA@ for @DISEASE@ may be quercetin,geraniol,beta-sitosterol,nerol,and eriodictyol, and the mechanism may be related to three signal pathways including Wnt, MAPK, and PI3K-Akt-mTOR.
False	[Study on Material Basis and Mechanism of @FORMULA@ prevent @DISEASE@ by network pharmacology].
False	The present study is to explore the material basis and mechanism of @FORMULA@ the prevented @DISEASE@ by using network pharmacology.
False	There are 5 ingredients such as quercetin,geraniol,beta-sitosterol,nerol,eriodictyol that could be verified from literature.This result initially revealed the material basis for @FORMULA@ for @DISEASE@ and the mechanism in terms of three signaling pathways.
False	The key target of @DISEASE@ was docked with the @FORMULA@ compounds, and the drugs-target combined with target-signal pathway network model was established by Cytoscape 3.2.1 software.
False	Thirty compounds have a strong interaction with key target of @DISEASE@ and three key pathways related with Wnt, MAPK and PI3K-Akt-mTOR.
False	Our previous studies had demonstrated that @FORMULA@ restored @DISEASE@ by inhibiting apoptosis of IECs.
False	Experimental @DISEASE@ was induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) in the Sprague-Dawley rats.
False	Impressively, treatment with @FORMULA@ for 7 days significantly attenuated the expressions of PI3K and p-Akt and the secretion of IL-2, IL-6, IL-17, and IL-23 and promoted the activation of PLC-gamma1, HSP70, and TGF-beta.
False	The present study explored the feasible pathway of @FORMULA@ (@FORMULA@) in inhibiting apoptosis of intestinal epithelial cells (IECs) by observing activation of phospholipase Cgamma-1 (PLC-gamma1) and PI3K/Akt signal in colonic mucosa from rats with @DISEASE@.
False	Meanwhile, assessments by ELISA revealed an increment in concentrations of IL-2, IL-6, and IL-17 and a reduction in level of TGF-beta after TNBS challenge.
True	@FORMULA@ Regulates Phospholipase Cgamma-1 and PI3K/Akt Signal in Colonic Mucosa from Rats with @DISEASE@.
False	Molecular docking results showed a high affinity between the critical ingredients and host cell target proteins.
False	METHODS: Public databases were searched to determine the putative targets of the active compounds of @FORMULA@ and @DISEASE@-related targets.
False	BACKGROUND: A @FORMULA@ (@FORMULA@) has been proven effective in treating @DISEASE@ (@DISEASE@) cases; however, the mechanism remains unclear.
False	Therapeutic mechanism of @FORMULA@ against @DISEASE@ based on network pharmacology and molecular docking technology.
False	OBJECTIVE: In the current study, we used network pharmacology and molecular docking technology to identify the effective components, potential targets, and biological pathways of @FORMULA@ against @DISEASE@.
True	CONCLUSION: This study uncovered the underlying pharmacological mechanism of @FORMULA@ against @DISEASE@.
False	@FORMULA@ is a traditional Japanese Kampo medicine.
False	Analysis of @DISEASE@ from @FORMULA@ Administration Using Japanese Adverse Drug Event Report (JADER) Database.
False	In recent years, it has been reported to be effective in the treatment of lifestyle-related diseases, and its use is increasing.
True	The results showed that @FORMULA@ presented a significant reporting odds ratio (ROR) signal [crude ROR 14, 95% confidence interval (CI) 12-17; p < 0.001], indicating @DISEASE@.
False	The results of logistic regression analysis in patients taking this agent showed that females in the aforementioned age range had higher odds of developing @DISEASE@ (adjusted ROR 5.5, 95% CI 2.8-11; p < 0.001).
False	However, side effects from @FORMULA@ administration are common, with @DISEASE@ being the most frequently reported complication.
False	Using a mouse model of cisplatin-induced @DISEASE@, we observed that pretreatment with @FORMULA@ attenuated cisplatin-induced elevations in blood urea nitrogen and creatinine levels, ameliorated @DISEASE@, reduced apoptosis, and accelerated tubular cell regeneration.
False	An in vivo study using implanted @DISEASE@ cells revealed that concurrent administration of @FORMULA@ and cisplatin did not alter the anti-tumor activity of cisplatin.
True	Therefore, @FORMULA@ may be useful in the clinic as a protective agent to prevent cisplatin-induced @DISEASE@.
False	Cisplatin-mediated elevations in tumor necrosis factor alpha (TNF-alpha) mRNA, interleukin-1 beta (IL-1beta) mRNA, and cyclooxygenase-2 (COX-2) protein in the kidney were also significantly suppressed by @FORMULA@ treatment.
False	Ancient Chinese Formula @FORMULA@ Protects Against Cisplatin-Induced @DISEASE@ Without Reducing Anti-tumor Activity.
False	In this study, we investigated whether @FORMULA@ (@FORMULA@), a popular traditional Chinese medicinal formula described 840 years ago, exhibits protective effects against cisplatin-induced @DISEASE@.
False	In @DISEASE@ mice administered with @FORMULA@, virus yield in the bronchoalveolar lavage fluid (BALF) of lungs was significantly lower than that in the control on day 3 after @DISEASE@.
False	Effect of interleukin-12 level augmented by @FORMULA@, a herbal medicine, on the early stage of @DISEASE@ in mice.
False	Thus the significant enhancement of IL-12 correlated with the reduction of virus yields in BALF in the early phase of @DISEASE@.
False	Oral administration of @FORMULA@ (@FORMULA@) (5.0 mg per mouse three times daily), a herbal medicine, for 8 days from 1 day before @DISEASE@ exhibited therapeutic efficacy in the @DISEASE@ mice.
False	On day 2 after @DISEASE@, only the level of IL-12 in the BALF increased significantly in @FORMULA@-administered mice as compared with the control.
True	This suggested a key role of IL-12 in the alleviation of @DISEASE@ in the @FORMULA@ mice.
False	Platelet derived growth factor (PDGF) is a vasoactive factor and has been implicated in @DISEASE@.
True	In conclusion, @FORMULA@ is a potent inhibitor of @DISEASE@ through inhibiting the pro-angiogenic effect of PDGF-BB.
False	@DISEASE@ was measured at P17.
False	Oxygen-induced @DISEASE@ in the mouse is the standard experimental model of @DISEASE@.
False	@FORMULA@ has been known to exert anti-angiogenic activities in several @DISEASE@ models, but the role of @FORMULA@ in @DISEASE@ remains unclear.
False	@FORMULA@ (@FORMULA@) is the most widely used traditional herbal formula in East Asia, also known as @FORMULA@ in Chinese and @FORMULA@ in Japanese.
False	Rats were given @FORMULA@ in chow for 30 weeks.
False	Recently it has often also been used for @DISEASE@.
False	One of the mechanisms involved is thought to be the improvement of endothelial dysfunction, but the details are still unclear.
False	Body weight, blood glucose, endothelium-dependent/-independent relaxation, vasocontraction by free radical-induced and contractive prostanoids, triglyceride, advanced glycation endproduct, lipid peroxides, serum NO2-/NO3- and blood viscosity were measured.
True	The WBN/kob rat is a useful study model for the @DISEASE@, and @FORMULA@ showed a protective effect against @DISEASE@ in the susceptible rat.
False	Effects of @FORMULA@ on vascular function and hemorheological factors in spontaneously @DISEASE@ (WBN/kob) rats.
False	METHODS: The model of water immersion restraint stress @DISEASE@ in mice, and the models of acetic acid impaired @DISEASE@ and pyloric ligation @DISEASE@ in rats were established.
False	CONCLUSION: @FORMULA@ has a significant anti-ulcerative effect, which may be related to improving the gastric mucosal defensive function.
False	[Effects of @FORMULA@ on experimental @DISEASE@ in rats and mice].
False	The effect of 5.0 or 10.0 g/kg group was obviously better than that of the normal saline control group (P<0.05 and P<0.01 respectively).
False	OBJECTIVE: To investigate the preventive and therapeutic effects of @FORMULA@ on @DISEASE@ in experimental animal models.
True	RESULTS: @FORMULA@ reduced the @DISEASE@.
False	Moreover, @FORMULA@ inhibited a production of IL-6, MCP-1, PYY, and GLP-1 and ameliorated @DISEASE@-induced @DISEASE@.
False	@FORMULA@ was more significantly effective in a treatment model where it was treated after @DISEASE@ and @DISEASE@ than in a prevention model where it was treated before @DISEASE@ and @DISEASE@ on the basis of parameters such as weights of muscles and whole body and food intakes.
False	Moreover, they correlate with a high mortality rate, poor response to chemotherapy, poor performance status, and poor quality of life.
True	Therefore, our in vivo studies provide evidence on the role of @FORMULA@ in @DISEASE@-associated @DISEASE@ and @DISEASE@, thereby suggesting that @FORMULA@ may be useful for treating @DISEASE@-associated @DISEASE@ and @DISEASE@.
False	@DISEASE@ @DISEASE@ is regulated by proinflammatory cytokines such as interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor- alpha (TNF- alpha).
False	@DISEASE@-associated @DISEASE@ and @DISEASE@ are a multifactorial condition described by a @DISEASE@ and @DISEASE@ with @DISEASE@, @DISEASE@, and @DISEASE@.
True	CONCLUSION: @FORMULA@ may alleviate @DISEASE@ by inhibiting the expression of COX-2 in prostate tissues.
False	RESULTS: The expression of COX-2 was strong in the model group, significantly lower in the high- and median-dose and the Celecoxib Capsules groups than in the model control (P < 0.01) as well as in the high-dose than in the median- and low-dose groups (P < 0.01).
False	[@FORMULA@ inhibits the expression of COX-2 in prostate tissues of @DISEASE@ rats].
False	Three days later, the @DISEASE@ model rats were again equally divided into 5 subgroups: model control, Celecoxib Capsules, high-, median- and low-dose @FORMULA@, receiving intragastric administration of distilled water, Celecoxib Capsules and different doses of @FORMULA@ respectively for 4 weeks.
False	OBJECTIVE: To study the effect of @FORMULA@ on the expression of COX-2 in the prostate tissues of rats with @DISEASE@, and the action mechanism of the drug alleviating the @DISEASE@.
False	METHODS: Sixty male Wistar rats were randomized into two groups, 10 as blank controls, injected with aqua pro injection into the ventral part of prostate, and the other 50 as @DISEASE@ models, given complete Freund's adjuvant (CFA).
False	To evaluate the efficacy and safety of @FORMULA@ combined with routine pharmacotherapy (RP) for the treatment of @DISEASE@ (@DISEASE@).
False	Participants were diagnosed with @DISEASE@ in the acute exacerbation stage.
False	English, Chinese, and Japanese databases were searched from their respective inceptions to June 2013.
False	Randomized controlled trials (RCT) evaluating @FORMULA@ for @DISEASE@ were included.
False	In addition, most of studies reported that they included participants with the Chinese medicine syndrome, phlegm-heat obstructing the Lung.
True	@FORMULA@ appeared to be beneficial for @DISEASE@ and well-tolerated when taken concurrently with RP, such as antibiotics, bronchodilators (oral and inhaled), and mucolytics.
False	METHODS: Twelve patients with @DISEASE@ and a past history of IFN-induced @DISEASE@ were enrolled in this study.
False	Each patient received a daily dose of 6 million units of IFN-beta for 8 weeks, and @FORMULA@ was given orally four times a day during the IFN-beta course.
False	Their mental state was evaluated by the self-rating depression scale (SDS)> or =40, or M-R of the Cornell medical index (CMI)> or =10.
False	RESULTS: All patients in this study completed a full course of IFN.
False	Mean erythrocyte aggregability and erythrocyte deformability had also significantly decreased at the end of treatment.
True	CONCLUSION: @FORMULA@ might be useful for preventing the incidence of @DISEASE@ in patients with @DISEASE@ being treated with IFN.
False	Comparison of immunopharmacological actions of 8 kinds of kampo-hozais clinically used in @DISEASE@ on @DISEASE@ in mice.
False	We studied here the effects of 8 kinds of kampo-hozais clinically used to treat @DISEASE@ (@FORMULA@, Toki-inshi, @FORMULA@, @FORMULA@, Ji-zuso-ippo, Jumi-haidoku-to, @FORMULA@, @FORMULA@) on @DISEASE@ (@DISEASE@), using three types of murine models such as picryl chloride (PC)-induced (@DISEASE@), sheep red blood cell (SRBC)-induced (Jones-Mote's reaction) and tuberculin-induced @DISEASE@ response, in order to clarify and to compare the immunopharmacological action of kampo-hozais.
False	We thought that these findings could help us understand how to use these kampo-hozais properly.
False	Most of the kampo-hozais investigated here suppressed PC-induced @DISEASE@, especially at the inductive phase.
False	On the other hand, Toki-inshi reduced @DISEASE@, tuberculin type @DISEASE@ response and Jones-Mote's reaction.
True	Ji-zuso-ippo and @FORMULA@ suppressed mainly Jones-Mote's reaction, and @FORMULA@, @FORMULA@ and Jumi-haidoku-to intensively suppressed @DISEASE@.
True	@FORMULA@ significantly reduced PC-induced and tuberculin-induced @DISEASE@ responses but not a SRBC-induced @DISEASE@ response.
True	CONCLUSION: @FORMULA@ may target CCL2 and MMP1 via its active ingredients to exert its therapeutic effects on @DISEASE@.
False	The active ingredients of Huangbai (Phellodendron) and Cangshu (Atractylodes), two main constituents of @FORMULA@, and their predicted target genes were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform.
False	RESULTS: A total of 16 potential targets for @FORMULA@ were found, with their significantly enriched GO terms as cytokine-mediated signaling pathways, oxidoreductase activity, cell space, etc., and the most enriched KEGG terms as an IL-17 signaling pathway, @DISEASE@, and NF-kappaB signaling pathway.
False	CCL2 and MMP1 were identified and verified to be the targets of both quercetin and wogonin, the two active ingredients of @FORMULA@, by molecular docking and molecular dynamics.
False	Our previous study has demonstrated that @FORMULA@ is effective in treating @DISEASE@.
False	Therefore, the purpose of this study was to decipher the potential mechanism of action of @FORMULA@ on @DISEASE@ (@DISEASE@) by bioinformatics, network pharmacology, molecular docking, and molecular dynamics.
True	Effect of @FORMULA@ (TJ-41), a Japanese herbal medicine, on the survival of mice @DISEASE@.
False	The antiviral effect of @FORMULA@ (TJ-41), a Japanese herbal medicine, was investigated using mice @DISEASE@.
False	These results suggest that TJ-41 exerts its inhibitory effect on @DISEASE@ via enhancement of the host immune responses in this experimental murine system.
False	In addition, TJ-41 elevated the level of IFN-alpha in BALF on day 2 after @DISEASE@.
False	TJ-41 was found to increase the survival rate, prolong the mean survival days, suppress viral growth in bronchoalveolar labage fluid (BALF) and inhibit the lung index (lung consolidation) on day 4 after @DISEASE@ in mice @DISEASE@, after the agent had been administered orally once daily from day 7 to 2 before @DISEASE@ and from day 0 to 4 after @DISEASE@.
False	Administration of TJ-41 decreased the BALF concentrations of IL-1alpha, IL-6 and GM-CSF, but not TNF-alpha or interferon-gamma (IFN-gamma), on day 4 after @DISEASE@.
False	The O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in @DISEASE@.
False	After then, we measured the levels of necroptosis and O-GlcNAcylation.
False	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
False	Traditional herbal formula @FORMULA@ alleviates TNBS-induced @DISEASE@ in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
False	It was found that @FORMULA@ increased colonic O-GlcNAcylation level and inhibited the activation of RIPK1, RIPK3 and MLKL.
True	CONCLUSION: Our work demonstrated that @FORMULA@ can alleviate TNBS-induced @DISEASE@ in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
False	These results show that @FORMULA@ extract was useful for suppressing the activation of Ito cells.
False	@FORMULA@, one of the most widely used Chinese herbal preparations, has long been used for the treatment of @DISEASE@.
False	Effects of @FORMULA@ extract on @DISEASE@ and regeneration of the liver in rats.
False	After treatment with @FORMULA@ extract hepatic function improved, histopathological results confirmed repair of liver tissue, and retinoid levels increased.
False	We have investigated its effect in retarding the process of @DISEASE@ and accelerating liver regeneration, especially its effect on Ito cells that are thought to be deeply involved with @DISEASE@.
True	When @FORMULA@ extract was administered to 70% hepatectomized normal and @DISEASE@ rats, liver weight, the number of S-phase-cells and retinoid levels increased with time.
False	The basic indicators such as body weight and blood glucose were monitored every week, and stool and intestinal contents were collected from the rats of 9 weeks old for 16 S rRNA sequencing and metabolomic analysis.
False	An automatic biochemical analyzer was used to measure the serum biochemical indicators, ELISA to measure serum insulin, and chipsets to measure leptin and inflammatory cytokines.
False	The variations in the serum levels of interleukin 1beta(IL-1beta) and monocyte chemoattractant protein-1(MCP-1) showed that @FORMULA@ could alleviate @DISEASE@ in rats.
False	Fifty rats were randomly divided into normal control group, model control group, low-dose @FORMULA@ group, medium-dose @FORMULA@ group, and high-dose @FORMULA@ group, with 10 rats in each group.
False	The results showed that @FORMULA@ reduced the body weight as well as blood glucose, glycosylated hemoglobin, and lipid levels.
True	In conclusion, @FORMULA@ can regulate intestinal flora and metabolites and relieve @DISEASE@ to control @DISEASE@ and prevent @DISEASE@.
False	The time-of-addition studies showed that @FORMULA@ (50, 100 and 200 microg/ml) added at various time of preinfection (-1 to -3 h), coinfection (0 h) and postinfection (1 approximately 3 h) could inhibit @DISEASE@.
False	Its CC50 (concentration of 50% cellular cytotoxicity) and SI (selective index) values were 945.75 microg/ml and 18.92, respectively.
False	Interestingly, @FORMULA@ also showed an inhibition on viral replication through the induction of IFN-alpha/beta expression.
False	The present study aimed to examine the antiviral activity of @FORMULA@ (@FORMULA@), a popular herbal drug for treating @DISEASE@ and @DISEASE@, against @DISEASE@ and its mechanisms of action.
False	@FORMULA@ inhibits @DISEASE@ of CCFS-1 cells through the induction of Type I interferon expression.
True	In conclusion, @FORMULA@ possessed antiviral activity against @DISEASE@.
False	The association of @FORMULA@ with Hetaokun could protect liver of the mouse S180.
True	[Effect of association of @FORMULA@ with Hetaokun on liver and immunity of @DISEASE@ mouse].
False	Compared with the control group, the immunity of the two @DISEASE@ mouse groups taking the medicine mentioned above was promoted obviously.
False	SGPT (P > 0.05) was compared with the common ones and the result showed that the association of @FORMULA@ with Hetaokun could make K value increase (P > 0.01).
False	RESULT: 12.5 mg x kg(-1) Hetaokun could obviously restrain the @DISEASE@ when it was singly used at 73.1%, but it increased SGPT at the same time.
False	With the promotion of immunity of the body, the efficiency is enhanced on the whole.
False	Western blotting was performed to detect fibrotic marker and TLR4/NLRP3 signaling pathway changes.
False	@DISEASE@ were also reduced.
False	Myeloperoxidase (MPO) activity, hydroxyproline (HYP), hyaluronic acid (HA), and inflammatory cytokine content were measured.
False	@FORMULA@ inhibited @DISEASE@ by decreasing the secretion of inflammatory cytokines and collagen deposition.
False	Intratracheal instillation of bleomycin (BLM) was performed to establish a @DISEASE@ rat model.
True	Thus, @FORMULA@ alleviates @DISEASE@ to inhibit @DISEASE@ pathology and should be considered as a candidate for the clinical treatment of @DISEASE@.
False	At the 15th day, the percentages of bone marrow cells at S stage in the treated group were 14.34%, 14.03% and 13.58% which were significantly higher than that in model group without treatment of @FORMULA@.
True	[Hematopoietic effect of @FORMULA@ in the mice with blood deficiency induced by compound method of @DISEASE@, @DISEASE@ and exhausting].
False	METHOD: The animal model of blood deficiency was established by a combination of @DISEASE@ with routine food at the rate of 75 g(-1) kg(-1) body weight per day, swimming 20 minutes and removing 0.4 mL blood every other day in each mouse.
False	The amount of peripheral blood cells, the cell cycle and the apoptosis of bone marrow cells and the percentage of CD34+ in bone marrow cells were detected by microcellcounter and flow cytometry.
False	RESULT: The amount of red blood cells in model mice was significantly increased by @FORMULA@ at different dosages, from 4.6 x 10(12) to 6.5, 7.1 and 7.0 x 10(12) respectively.
False	CONCLUSION: @FORMULA@ significantly improve the hematopoiesis in the mice with blood deficiency induced by compound method mentioned above.
False	In vivo analysis used female athymic nude mice implanted with MCF-7 cells; these mice were randomly assigned to 6 groups.
False	However, there was a significant decrease in LC3-II protein expression with the low-dose @FORMULA@ + Tam group but not with the middle- or high-dose @FORMULA@ + Tam groups compared with the Tam-alone group.
False	METHODS: In vitro cultured MCF-7 cells were cotreated with @FORMULA@ and Tam.
False	In addition, immunohistochemistry was used to detect autophagy among the @DISEASE@ cells.
True	Furthermore, using the MCF-7 xenograft mouse model, there were no significant changes between the @FORMULA@ (1.3-3.9 gm/kg) + Tam groups and the Tam-alone group in terms of @DISEASE@ weight and the protein expression levels of AKT, ERK, P38, and p27 (Kip1).
False	INTRODUCTION: There is epidemiological evidence that @FORMULA@ (@FORMULA@) is the most common Chinese medicine decoction coprescribed with tamoxifen (Tam) when @DISEASE@ is treated by hormonal therapy.
False	METHODS: We searched seven databases for randomized animal studies published until April 2015: Pubmed, four Korean databases (DBpia, Oriental Medicine Advanced Searching Integrated System, Korean Studies Information Service System, and Research Information Sharing Service), and one Chinese database (China National Knowledge Infrastructure).
False	Five studies used a Sprague Dawley rat model for acute psychological stress, @DISEASE@, and unpredictable mild stress @DISEASE@ whereas one study used a Kunming mouse model for prenatal depression.
False	However, additional systematic and extensive studies should be conducted to establish a strong conclusion.
False	The aim of this study is to investigate the effects of @FORMULA@ on @DISEASE@ in an animal model.
False	RESULTS: From a total of 258 hits, six randomized controlled animal studies were included.
True	CONCLUSION: Regardless of the dose and concentration used, @FORMULA@ significantly improved @DISEASE@-related outcomes in animal models.
False	The expression of toll-like receptors 4 (TLR4), nuclear factor-kappa B (NF-kappaB), p-NF-kappaB, myosin light chain kinase (MLCK), MLC, and p-MLC levels in colon was determined by Western blot or qPCR.
False	However, the mechanism of @FORMULA@ has not been fully clarified.
False	@FORMULA@ Enhances Colonic Tight Junction Integrity via TLR4/NF-kappaB/MLCK Signaling Pathway in @DISEASE@ Rats.
False	The expression of tight junction (TJ) proteins, occludin and claudin-1, in the colon was determined by Western blot and immunofluorescence.
False	BACKGROUND: @FORMULA@ (@FORMULA@), a sort of Chinese herbal medicine, has exhibited therapeutic effects on @DISEASE@ (@DISEASE@).
True	CONCLUSIONS: The therapeutic effect of @FORMULA@ on @DISEASE@ is at least partially through regulation of the secretion of some inflammatory cytokines and improvement of TJ integrity via TLR4/NF-kappaB/MLCK pathway.
False	@FORMULA@ relieves @DISEASE@ by regulating central and peripheral 5-HT in @DISEASE@ model rats.
True	CONCLUSION: @FORMULA@ has the pharmacological effect on relieving @DISEASE@ in @DISEASE@ model rats, possibly by affecting central and peripheral 5-HT.
False	@FORMULA@ (@FORMULA@), a clinical used formula to treat and prevent @DISEASE@ and @DISEASE@, has been reported to relieve the @DISEASE@ of @DISEASE@ and increase brainstem and blood serotonin (5-hydroxytryptamine, 5-HT) in @DISEASE@ model rats in previous studies; yet the mechanism is unclear.
False	Western blot analysis, immunohistochemistry and immunofluorescence determination, and 16S rRNA gene sequencing were performed.
False	@FORMULA@ could regulate the abundance of Anaerostipes and Acidifaciens.
False	BACKGROUND: @DISEASE@ (@DISEASE@) is a highly disabling and burdensome disease.
False	Two reviewers independently identified articles, extracted data, assessed quality, and cross-checked the results.
True	However, given the high risk of bias among the trials, we could not conclude that @FORMULA@ was beneficial to patients with @DISEASE@.
False	METHODS: Seven electronic databases were searched for randomized controlled trials designed to evaluate the clinical effectiveness of @FORMULA@ for @DISEASE@ published in any language prior to February 2015.
False	Meta-analysis indicated that @FORMULA@ was more effective at the levels of total cholesterol and triglycerides, while increasing the level of high-density lipoprotein cholesterol without serious adverse effects.
False	Revman 5.3 was used to analyze the data.
False	RESULTS: Only five randomized controlled trials with poor methodology were included in the analysis.
False	RESULTS: All patients were followed up until @DISEASE@ returned to normal, @DISEASE@ was found in 12 cases (13.33%) in the treatment group and in 39 cases(43.33%) in the placebo group, the treatment group was significantly better than the placebo group.
False	OBJECTIVE: To study the effect of soothing liver, relieving @DISEASE@, invigorating spleen and reinforcing blood on reducing @DISEASE@ in elderly patients with @DISEASE@.
False	[Clinical study of @FORMULA@(@FORMULA@) on preventing @DISEASE@ in elderly patients with @DISEASE@ after operation].
False	The age, sex, @DISEASE@ site, @DISEASE@ volume, postoperative drainage, operation time, anesthesia time, post-operative pain score, post-operative hemoglobin, post-operative CRP, delirium severity(DRS) score and @DISEASE@ occurrence were observed and compared between the two groups.
False	The monitoring indexes of the two groups were compared:post-operative pain score(P=0.002), post-operative hemoglobin(P=0.012), post-operative CRP(P=0.042).
True	CONCLUSIONS: @FORMULA@ can relieve liver @DISEASE@, invigorate spleen and invigorate blood circulation, reduce @DISEASE@, @DISEASE@ stimulation and supplement blood volume after operation, and significantly reduce the incidence of @DISEASE@ after operation.
False	The only values that were significantly increased by ACLT + low-dose @FORMULA@ compared with ACLT alone were bone mineral density and trabecular numbers.
False	MATERIALS AND METHODS: Thirty rats were randomly assigned to five groups (six animals each): arthrotomy alone (sham surgery, controls), ACLT only, ACLT + low-dose (1,000 mg/kg) @FORMULA@, ACLT + high-dose (3,000 mg/kg) @FORMULA@, and ACLT + celecoxib (30 mg/kg).
False	@DISEASE@ is typically treated with oral NSAIDs, which are commonly associated with gastrointestinal side effects or @DISEASE@.
False	RESULTS: At 6 weeks, compared with ACLT group only, ACLT rats administered high-dose @FORMULA@ or celecoxib exhibited the fewest weight-bearing deficits, the greatest improvements from baseline in articular cartilage architecture, and the lowest amounts of TNF-alpha and IL-1beta staining in cartilage and synovial sections (all values were significant compared with the ACLT-only group).
True	CONCLUSION: Our findings suggest that high-dose @FORMULA@ improves weight-bearing asymmetry, decreases @DISEASE@, and reduces levels of TNF-alpha and IL-1beta in the affected joint in ACLT-induced @DISEASE@ rats.
False	"The Traditional Chinese Medicine ""@FORMULA@"" Attenuates @DISEASE@-Induced Signs and Symptoms in an Experimental Rat Model of @DISEASE@."
False	TNF-alpha, IL-6, PGE2, and cAMP in rat serum or hypothalamus tissue were detected by ELISA kit.
False	RESULTS: The results showed that @FORMULA@ can alleviate LPS-induced @DISEASE@ in rats.
False	In order to explore the potential active ingredients and mechanism of antipyretic effect of @FORMULA@, we predicted the underlying antipyretic mechanism by using network pharmacology and then verified its mechanism by Western Blotting.
False	AIM: The aim of this study was to explore the antipyretic effect and potential mechanism of @FORMULA@ (@FORMULA@) on LPS-induced @DISEASE@ in rats.
False	MATERIALS AND METHODS: The @DISEASE@ rat model was established by LPS.
True	CONCLUSION: The findings suggest that @FORMULA@ has a good antipyretic effect on LPS-induced @DISEASE@ in rats, which may be closely related to the inhibition of MAPK signaling pathway.
True	@FORMULA@ promotes potent inhibitory activity for @DISEASE@ by decreasing VEGF, FGF2, and PAI-1 levels.
False	@FORMULA@ (@FORMULA@) is a frequently used oriental herbal formula in East Asian countries, and is also called Qui-pi-tang in Chinese and @FORMULA@ in Japanese.
False	Effect of @FORMULA@, a Traditional Herbal Formula, on @DISEASE@ in a Mouse Model of @DISEASE@.
False	The mice were then exposed to room air from P12 to P17 to induce @DISEASE@.
False	@FORMULA@ significantly decreased @DISEASE@ in @DISEASE@ mice, and protein arrays revealed that @FORMULA@ decreased PAI-1 protein expression levels.
False	On P17, @DISEASE@ was measured on P17, and the expression levels of 55 angiogenesis-related factors were analyzed using protein arrays.
False	RESULTS: There were 152,564 subjects who visited TCM clinics only for @DISEASE@ in Taiwan during 2004 and received a total of 387,268 CHM prescriptions.
False	The aim of this study was to determine the frequency of use and prescriptive patterns of Chinese herbal medicine (CHM) in treating @DISEASE@ by analyzing the claims data of traditional Chinese medicine (TCM) from the National Health Insurance (NHI) in Taiwan.
False	Subjects between 20 and 29 years of age comprised the largest number of those treated (25.5%).
True	According to the association rule, the most common prescribed pattern of 2-drug combination of CHM for treating @DISEASE@ was @FORMULA@ plus @FORMULA@, while the 3-drug combination of CHM was @FORMULA@, Rheum palmatum and @FORMULA@.
False	Further clinical trials are needed to evaluate the efficacy and safety of these CHMs in treating @DISEASE@.
False	@FORMULA@ was the most commonly prescribed herbal formula, while Da-huang (Rheum palmatum) was the most commonly used single Chinese herb.
False	CONCLUSION: @FORMULA@ has the ability of blood-activating and stasis-eliminating.
False	Blood flow and the across netting were also determined on capillary vessel of uterus microcirculation.
True	RESULT: @FORMULA@ reduce blood viscidity of the rats, reduce the @DISEASE@ of the murine, and promote the microcirculation of the uterus in rats.
False	The number of @DISEASE@ or dead after 1-15 min was calculated in mice, induced by tail intravenous injection of a mixture of collagen and Epinephrine.
False	The @DISEASE@ wet weight and @DISEASE@ dry weight were measured in the rat model of @DISEASE@, and the inhibitory rates in the formation of @DISEASE@ were calculated.
False	OBJECTIVE: To investigate the effects of @FORMULA@ on hemorheology, @DISEASE@ and microcirculation, and explore its approach and mechanism.
False	RESULTS: Inflammatory response factors were found in the serum of each group.
True	CONCLUSION: @FORMULA@ may prevent the development of @DISEASE@, perhaps by inhibiting the generation and release of the inflammatory response factors TNF-alpha, IL-1, IL-2, IL-6, and IL-8.
False	Rats were given normal saline (10 mL/kg) or 1.15, 2.3, or 4.6 g/kg @FORMULA@ by intragastric administration once a day for 7 days.
False	The serum was separated, and TNF-alpha, IL-1, IL-2, IL-6, and IL-8 protein levels were determined.
False	However, levels in @FORMULA@-treated groups were significantly lower than in the saline-treated group (P < 0.05).
False	METHODS: Fifty Wistar rats were randomly divided into five groups (10 rats in each group): control (without radiation), saline-treated, and low, medium, and high-dose ISG-treated groups.
False	Further analysis showed that @FORMULA@-treated rat serum promoted the apoptosis of SP cells in MKN-28 and HGC-27 cell lines by upregulating Bax, caspase-3 and PARP and downregulating bcl-2.
False	The apoptosis rate in MKN-28 and HGC-27 cells was also increased following treatment with @FORMULA@-treated rat serum.
False	@FORMULA@-treated rat serum induces apoptosis of side population cells in @DISEASE@.
True	These data revealed the therapeutic effect of @FORMULA@ rat serum on @DISEASE@.
False	@FORMULA@ (@FORMULA@) is a traditional Chinese herbal medicine.
False	Previous studies have indicated that @FORMULA@ exhibits antitumor activity.
False	Many patients cannot benefit from the current treatment regimen (interferon/ribavirin combinations) due to its side effects or ineffectiveness.
False	MATERIALS AND METHODS: Twenty four @DISEASE@ patients received @FORMULA@ at 2.5 g per os (p.o.) three times daily (t.i.d.) for 12 months.
False	Improvement of alanine aminotransferase (ALT) was seen in 18 (75%) patients.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @DISEASE@ is a major public health problem internationally.
False	Larger, controlled studies of this botanical formulation may be warranted.
True	CONCLUSIONS: @FORMULA@ (@FORMULA@ or @FORMULA@) may improve @DISEASE@ in selected @DISEASE@ patients who are not candidates for interferon based treatment.
False	@FORMULA@ (at dosage of 2 g/kg or 4 g/kg, qd, orally) was administered for 21 d from d 7 before @DISEASE@ until d 14 after @DISEASE@.
False	The neurological deficit scoring and the inclined board testing were performed within 35 d after @DISEASE@.
False	OBJECTIVE: To investigate the neuroprotective effects of Chinese herb medicine @FORMULA@ (@FORMULA@) on @DISEASE@ after @DISEASE@ in mice.
True	CONCLUSION: Chinese herb medicine @FORMULA@ has neuroprotective effects on @DISEASE@ after @DISEASE@ in mice.
False	METHODS: @DISEASE@ was induced by @DISEASE@ (@DISEASE@) for 15 min.
False	RESULT: @FORMULA@ increased the survival rate at dose of 4 g/kg; significantly reduced the @DISEASE@, @DISEASE@ volume and @DISEASE@ at doses of 2 and 4 g/kg after @DISEASE@; and significantly increased the neuron density in the @DISEASE@ hippocampal CA1 region, striatum and cortex at dose of 4 g/kg but only increase the density in hippocampal CA1 region at dose of 2 g/kg.
False	We herein describe the first known case of @DISEASE@ (@DISEASE@) associated with the administration of @FORMULA@, a Chinese herbal drug.
False	@DISEASE@ Associated with @FORMULA@ Administration.
False	@FORMULA@ was prescribed as an adjunctive treatment for @DISEASE@.
False	Immediately after drug ingestion, the patient expectorated @DISEASE@.
True	We diagnosed that the administration of @FORMULA@ was the responsible medication because the @DISEASE@ developed immediately after drug ingestion and resolved after the cessation of such medication with no subsequent recurrence.
False	A 64-year-old man with @DISEASE@ presented with @DISEASE@.
False	Anti-tumor effects of herbal medicines on @DISEASE@ via estrogen receptor-alpha-related mechanism.
False	The cell viability and expression of estrogen receptors (ER) were determined by MTT and RT-PCR.
True	The expression of ER-alpha mRNA, but not ER-beta mRNA was suppressed by @FORMULA@ or @FORMULA@ in an @DISEASE@ cell line.
False	This study was performed to examine the relationship between the anti-tumor effects of herbal medicine and @DISEASE@ with ER-related mechanisms.
False	An @DISEASE@ cell line (Ishikawa) was used for this study.
False	A dose-dependent decrease of viability and apoptosis of the @DISEASE@ cells was generated by exposure to the herbal medicines, @FORMULA@ or @FORMULA@.
False	The expression of alpha-SMA, vimentin, KDM7A, Wnt1 and beta-catenin were significantly down-regulated, and the E-cadherin, H3K9-Me2, H3K27-Me2, BMP-4, BMP-7, Runx2, osteocalcin, and Col1a1 were significantly up-regulated with @FORMULA@ treatment.
False	@FORMULA@ decreased the levels of TNF-alpha, IL-6, IL-8, IL-1beta, ALP, and TRAP, and increased the calcium, phosphorus in serum, as well as decreased the level of the calcium and phosphorus in the urine.
False	Therapeutic potential of @FORMULA@ against KDM7A and Wnt/beta-catenin signaling pathway in @DISEASE@.
False	The present study aimed to evaluate the effects of @FORMULA@ on KDM7A and Wnt/beta-catenin signaling pathway in @DISEASE@ rats and the high glucose-induced MC3T3-E1 cells.
False	The cell viability and differentiation capacity of high glucose-induced MC3T3-E1 cells were determined by CCK-8 assay, Alizarin Red staining, and alkaline phosphatase (ALP) staining, respectively.
True	The present study shows that @FORMULA@ has a therapeutic effect on @DISEASE@, in part, through down-regulation of KDM7A and Wnt/beta-catenin pathway.
False	By discontinuing @FORMULA@, the @DISEASE@ disappeared after 4 days, and urinalysis normalized.
False	The patient presented with @DISEASE@ with @DISEASE@ over a 3-month period.
False	Urine cytology specimens showed increased eosinophilic cells.
False	@FORMULA@ (@FORMULA@), one of many traditional Japanese medicines (Kampo medicines) is attracting attention for @DISEASE@ and @DISEASE@.
True	Resuming @FORMULA@ without physician approval resulted in @DISEASE@ and after cessation the symptoms rapidly subsided.
False	We report @DISEASE@ caused by 8-year @FORMULA@ usage in a 70-year-old female.
False	Moreover, we observed similar findings when we studied @FORMULA@ for inhibition of ER stress in a rat model of @DISEASE@.
False	Our in vitro and in vivo results indicated that the neuroprotective effect of @FORMULA@ against ER stress damage and apoptosis occurred mainly by blocking the GPR78-IRE1/PERK pathways.
True	Taken together, it provides reliable experimental evidence and explains the molecular mechanism of @FORMULA@ for the treatment of patients with @DISEASE@.
False	In this study, high-performance liquid chromatography fingerprint analysis was performed to learn the features of the chemical compositions of @FORMULA@.
False	However, the molecular mechanisms of @FORMULA@ for protecting neurons from oxygen and glucose deprivation (OGD)-induced endoplasmic reticulum (ER) stress and apoptosis after @DISEASE@ still remains elusive.
False	@FORMULA@ Inhibits Endoplasmic Reticulum Stress-Mediated Apoptosis Induced by Oxygen Glucose Deprivation and @DISEASE@ Through Blockade of the GRP78-IRE1/PERK Pathways.
False	And the increased AUCs of baicalin and wogonoside in @DISEASE@ rats after oral administration of @FORMULA@ extract resulted from neither the effects of other herbs contained in @FORMULA@ nor the effects of other components contained in Radix scutellariae.
False	RESULTS: The pharmacokinetic parameters (especially AUCs) of baicalin and wogonoside in @DISEASE@ rats after oral administration of @FORMULA@ extract were remarkably different from those in normal rats.
False	Comparative pharmacokinetic investigation on baicalin and wogonoside in @DISEASE@ and normal rats after oral administration of traditional Chinese medicine @FORMULA@.
False	MATERIALS AND METHODS: @FORMULA@ extract and Radix scutellariae extract were prepared and the contents of baicalin and wogonoside contained in two extracts were assayed with high performance liquid chromatography (HPLC).
False	Pharmacokinetics of baicalin in @DISEASE@ and normal rats after oral administration of pure baicalin was also investigated.
True	CONCLUSION: The pharmacokinetic behaviors of baicalin and wogonoside (especially the systemic exposure [AUCs] of baicalin and wogonoside) were significantly altered in @DISEASE@ rats after orally administrated @FORMULA@ extract.
False	UPLC/Q-TOFMS-Based Metabolomics Approach to Reveal the Protective Role of Other Herbs in @FORMULA@ Against the Hepatorenal Toxicity of Cinnabar and Realgar.
False	However, the application of @FORMULA@ is limited by the @DISEASE@- and @DISEASE@ of cinnabar and realgar.
False	The combination use of the other herbs in @FORMULA@ alleviated inflammatory cell infiltration and @DISEASE@ and @DISEASE@ and restored the disturbed serum metabolic profile induced by cinnabar and realgar insults.
False	Notably, lysophosphatidylcholines (LysoPCs) were the most elevated among all of the metabolites detected after cinnabar and realgar treatment, while these LysoPCs did not show overt differences between the @FORMULA@ and saline control groups, which was associated with relatively unaffected or even up-regulated expression of lysophosphatidylcholine acyltransferase 1 (LPCAT1) and autotaxin (ATX).
False	@FORMULA@ (@FORMULA@) is a well-known traditional Chinese medicine (TCM) recipe containing cinnabar (HgS) and realgar (As2S2).
True	These findings indicated that other herbs in @FORMULA@ could have a protective effect against cinnabar- and realgar-induced @DISEASE@ and @DISEASE@ via modulating the @DISEASE@.
False	Kidney histological analysis revealed decreased @DISEASE@ and @DISEASE@ in @DISEASE@ rats treated with @FORMULA@ accompanied with suppressed expression of TGF-beta1 and phosphorylated NF-kappaB/P65 (p-P65) as indicated by immunohistochemistry.
False	ELISA analysis demonstrated reduced serum levels of proinflammatory cytokines TNFalpha and IL-6.
False	Most importantly, intestinal microbiota analysis by 16s rRNA-seq showed that @FORMULA@ restored the @DISEASE@ and recovered the @DISEASE@ through reducing the @DISEASE@ and promoting the expansion of beneficial microbes in @DISEASE@ rats.
False	@DISEASE@ (@DISEASE@) has become a global health issue, and there is increasing evidence showing the beneficial roles of traditional Chinese medicine (TCM) in @DISEASE@ treatment.
False	The Herbal Formula Granule Prescription @FORMULA@ Ameliorated @DISEASE@ Which Was Associated with Restoration of @DISEASE@ of Intestinal Microbiota in Rats.
True	Collectively, our findings demonstrated that @FORMULA@ mitigated @DISEASE@ in @DISEASE@ rats which were associated with the restoration of @DISEASE@ of intestinal microbiota, implying its potential in clinical @DISEASE@ treatment.
False	Model mice were administered @FORMULA@ for 2 weeks, and @DISEASE@ tissues were then removed, weighed, sliced, and homogenized.
True	CONCLUSION: @FORMULA@ might promote Treg cell apoptosis in the @DISEASE@ microenvironment and further inhibit the @DISEASE@ growth of 4T1 mouse @DISEASE@.
False	RESULTS: @DISEASE@ weights were significantly lower in the @FORMULA@ groups compared with the untreated control group.
False	Treg cell apoptosis was detected by TdT-mediated dUTP nick end labeling. mRNA expression levels of MEKK1, SEK1, JNK1, and AP-1 in Treg cells in the @DISEASE@ microenvironment were detected by quantitative real-time PCR and their protein expression levels were detected by immunofluorescence staining and western blot.
False	The mechanism of @FORMULA@ may be related to upregulation of gene and protein expression of MEKK1, SEK1, JNK1, and AP-1 in Treg cells in the @DISEASE@ microenvironment.
False	The overall number of Treg cells in the @DISEASE@ microenvironment decreased while the number of apoptotic Treg cells increased with increasing doses of @FORMULA@. mRNA and protein expression levels of MEKK1, SEK1, JNK1, and AP-1 in Treg cells in the @DISEASE@ microenvironment increased with increasing doses of @FORMULA@.
False	The validation parameters (linearity, sensitivity, intra-/interday precision and accuracy, extraction recovery, and matrix effect) were within acceptable ranges, and biological extracts were stable during the entire storing and preparing process.
False	The blood was collected from the abdominal aorta of rats at predetermined time and preprepared with icariin and tetrahydropalmatine as internal standards (IS).
True	Thus, the established method was sensitive enough and successfully applied to the determination of seven effective components in plasma taken from 24 high fat-induced @DISEASE@ rats after oral administration of three dosages of @FORMULA@.
False	@FORMULA@ (@FORMULA@) has been used to treat @DISEASE@ and @DISEASE@ for many years in China.
False	In this paper, a rapid, specific, and sensitive ultra-high performance liquid chromatography-tandem mass spectrometry method was developed and fully validated for the simultaneous determination of seven main active constituents, i.e., baicalin, baicalein, wogonoside, wogonin, berberine, palmatine, jatrorrhizine in rat plasma.
False	Currently, the determination of effect components in @FORMULA@ is focusing either on the formula or on the extract, while quantification of that in biological samples is scarce, especially simultaneous determination of multicomponent.
True	In conclusion, this study demonstrated that the Kampo prescriptions, consisting mainly of @FORMULA@, retarded the progression of @DISEASE@.
False	The predicted pre-dialysis period was defined as an increase in serum Cr by 10 mg/dl.
False	The end points of the study were the slope of the reciprocal of the serum Cr concentration plot against time using Mitch's method, and the predicted period of pre-dialysis.
False	Eight patients aged 24-59 years with serum Cr 4.5 mg/dl were enrolled in the study for 40 to 402 weeks (mean; 228.1 +/- 118.8 weeks).
False	Previous studies have shown that Kampo (traditional Chinese) prescriptions, mainly @FORMULA@ (@FORMULA@, [symbol see: text]), have a useful effect in patients with @DISEASE@ (@DISEASE@).
False	The cause of @DISEASE@ was @DISEASE@ in 7 patients and @DISEASE@ in 1 patient.
False	METHODS: @DISEASE@ was induced in rats using 2,4,6-trinitrobenzene sulfonic acid on the basis of a model of spleen deficiency and dampness.
True	CONCLUSIONS: @FORMULA@ can regulate the structure and function of the intestinal flora, alter expression levels of certain metabolic pathways, and has the potential to treat @DISEASE@.
False	In this study, we investigated the effect of @FORMULA@ on intestinal flora in a rat model of @DISEASE@ with spleen deficiency and dampness.
False	The abundance of Actinobacteria (P < 0.001) and Bacteroides (P < 0.01) increased and that of Firmicutes decreased (P < 0.001), and the abundance of Bifidobacterium(P < 0.05) and Allobaculum increased.
False	PICRUSt analysis showed that the altered pathways between the groups were those of fatty acid and antibiotic biosynthesis, amino acid metabolism, and the pentose phosphate pathway.
False	RESULTS: Compared with the model group, rats in the @FORMULA@ group exhibited decreased levels of TNF-alpha(P < 0.05), and increased abundance and diversity of the intestinal flora.
True	CONCLUSIONS: Purgation therapy with @FORMULA@ could reduce the stimulation of pathogenic factors on hepatocytes, protect the tissues and organs from @DISEASE@ caused by @DISEASE@ reaction.
False	OBJECTIVE: To investigate the level of acute phase protein level (APP) synthesized in hepatocytes in pathogenic process of @DISEASE@ (@DISEASE@) and the effect of @FORMULA@ (@FORMULA@) on it.
False	METHODS: The levels of C-reactive protein (CRP), alpha 1-acid glycoprotein (alpha 1-AGP), alpha 1-antitrypsin total (alpha 1-AT), alpha 2-macroglobulin (alpha 2-MG), ceruloplasmine (Cp), hepatoglobin (Hp) and transferrin (Tf) synthesis were determined in 32 cases of @DISEASE@ patients and rat models of @DISEASE@ induced by @DISEASE@ and @DISEASE@.
False	After 3 days of @FORMULA@ treatment, it reduced significantly (P < 0.05).
False	[Clinical and experimental study of effect on acute phase protein level of @DISEASE@ treated with @FORMULA@].
False	The APP inhibiting effect of @FORMULA@ was dose dependent.
False	The expressions of PDGFra, PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2, and THBS1 were significantly down-regulated by @FORMULA@ (P < 0.001).
False	The expression of candidate genes was verified by qRT-PCR.
False	METHODS: We analyzed the profiles of differentially expressed genes (DEGs) in dimethylnitrosamine (DMN)-induced @DISEASE@ in rat.
False	BACKGROUND: @FORMULA@ (@FORMULA@) is used for @DISEASE@ and @DISEASE@ treatment in Chinese medicine.
False	This study aims to investigate the pharmacological actions of @FORMULA@ against @DISEASE@ in rats by high-throughput gene expression profiling, network analysis and real-time qRT-PCR.
True	CONCLUSION: @FORMULA@ down-regulated the expressions of PDGFra, PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2 and THBS1, and TGF-beta and PDGF signaling pathways in the DMN-induced @DISEASE@ in rats.
False	The Dahl salt-sensitive rat model was used to evaluate the therapeutic effects of @FORMULA@ against @DISEASE@.
False	RESULTS: A total of 112 active ingredients, 222 targets of @FORMULA@ and 341 @DISEASE@-related targets were obtained.
False	Pathway enrichment analysis results indicated that 56 overlapping targets were mainly enriched in several inflammation pathways such as the tumor necrosis factor (TNF) signaling pathway, Toll-like receptor (TLR) signaling pathway and nuclear factor kappa-B (NF-kappaB) signaling pathway.
False	METHODS: The active ingredients and corresponding targets were collected from the Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform (TCMSP).
False	Molecular docking confirmed that most active compounds of @FORMULA@ could bind tightly to the key targets.
True	CONCLUSION: The potential mechanisms and therapeutic effects of @FORMULA@ on @DISEASE@ may be attributed to the regulation of @DISEASE@ and @DISEASE@.
False	@FORMULA@ Exerts a Beneficial Effect on Cardiac Function by Possibly Improving the Microenvironment and Decreasing Mitochondrial Fission after @DISEASE@.
False	Hence, this may present a promising auxiliary strategy in the treatment of @DISEASE@ such as @DISEASE@.
False	No statistical differences were observed in the expression of mitochondrial LC3B and Mfn1 between the @FORMULA@ and control groups.
False	@FORMULA@ increased the ejection fraction (EF) and fractional shortening (FS) values in the rat hearts; however, no statistical difference was found between the @FORMULA@ and @DISEASE@ groups 4 weeks after treatment.
False	Notably, @FORMULA@ significantly decreased mitochondrial ROS production and Fis1 expression.
True	In summary, @FORMULA@ may possess a beneficial effect on cardiac function by improving the @DISEASE@ microenvironment and by decreasing mitochondrial fission after @DISEASE@.
False	To identify a potential mechanism of action, the gene and protein expression levels of Bax, Bcl-2, CDK4 and cyclin-D1 were measured in @FORMULA@-treated Huh7 cells.
False	Finally, @FORMULA@ altered the expression of Bax, Bcl-2, CDK4 and cyclin-D1, which halted cell proliferation and promoted apoptosis.
True	RESULTS: We found that @FORMULA@ reduced @DISEASE@ size and weight, as well as significantly decreased cell viability both in vivo and in vitro.
False	@FORMULA@ induced apoptosis in @DISEASE@ tissues and in Huh7 cells.
False	MATERIALS AND METHODS: Using a @DISEASE@ xenograft model, we investigated the in vivo efficacy of @FORMULA@ against @DISEASE@ growth by evaluating @DISEASE@ volume and weight, as well as measuring apoptosis and cellular proliferation within the @DISEASE@.
False	BACKGROUND: @FORMULA@ (@FORMULA@) is an extract of seven herbs with anticancer properties, but its mechanism of action is unknown.
False	In the cell experiment, CCK-8 detected the cell proliferation.
False	Western blot detected the expression of related proteins.
False	The results were consistent with the animal experiments on @DISEASE@-bearing @DISEASE@ mice.
False	In animal experiments, the @DISEASE@ volume of @DISEASE@-bearing mice was observed.
False	Network tools were used to analyze the potential molecules of @FORMULA@.
True	CONCLUSION: @FORMULA@ inhibited the expression of PD-L1 through multi-target and multi-pathway regulation of major oncogenes in @DISEASE@, thus effect cell proliferation and apoptosis.
False	RESULTS: Ingredient-@DISEASE@ target network analysis identified 20 natural compounds.
False	BACKGROUND: Chinese herbal medicines (CHMs) are a resource of natural compounds (ingredients) and their potential chemical derivatives with anticancer properties, some of which are already in clinical use.
False	Network analysis and mechanisms of action of Chinese herb-related natural compounds in @DISEASE@ cells.
False	Three of these compounds, ursolic acid, 2-(3R)-8,8-dimethyl-3,4-dihydro-2H-pyrano(6,5-f)chromen-3-yl)-5-methoxyphenol, and licochalcone A, inhibited the proliferation of A549 @DISEASE@ cells in a dose-dependent manner.
False	They also induced cell cycle arrest in S and G2/M phases and autophagy in A549 cells.
True	CONCLUSION: The pharmacological mechanisms of ingredients from @FORMULA@ on @DISEASE@ may be strongly associated with their modulatory effects on apoptosis, autophagy, cell cycle progression, and cell proliferation.
False	This progression of @DISEASE@ did not happen in the @FORMULA@-treated group between week 12 (26%) and 26 (27.4%).
False	@FORMULA@ did not improve the @DISEASE@ in the @DISEASE@ rabbits.
True	These results suggest that @FORMULA@ has inhibitory effects on the development of @DISEASE@ formation in @DISEASE@ model rabbits.
False	Inhibitory effects of @FORMULA@ (@FORMULA@) on the progression of @DISEASE@ in @DISEASE@ rabbits.
False	It is possible that the antioxidative effects of @FORMULA@ on LDL led to the beneficial effects observed in this study.
False	Antioxidative effects on LDL were seen in the @FORMULA@-treated group in weeks 16 and 18.
False	Interestingly, @FORMULA@ can alleviate @DISEASE@ of @DISEASE@ (@DISEASE@) patients, suggesting that it is a useful therapeutic agent for @DISEASE@.
True	This paper reviews the mechanism of @FORMULA@ for the treatment of @DISEASE@.
False	@FORMULA@: New Hope for @DISEASE@.
False	Juzep., Atractylodes macrocephala Koidz.), which has been widely used in oriental countries for the treatment of various @DISEASE@.
False	Recent studies show that @FORMULA@ has an effect on free radical-mediated @DISEASE@ and exhibits anti-inflammatory and antioxidant activities and reduces cell apoptosis in the hippocampus.
False	Wolf, Alisma orientalis (Sam.)
False	[Effects of early intestinal application of @FORMULA@ on immune function in post-operational patients of @DISEASE@].
False	OBJECTIVE: To assess the effects of early intestinal application of @FORMULA@ (@FORMULA@) on the immune function in post-operational patients of @DISEASE@.
False	METHODS: Ninety-two patients with @DISEASE@ were randomly divided into two groups.
False	Patients in both groups were given the isocaloric and isonitrogenous enteral nutritional support starting from the first day after operation for 1 week, but to the tested group, @FORMULA@ was given additionally.
False	RESULTS: At the end of the study, the concentration of IgA, IgG, 1gM, number of total lymphocyte, CD3, CD4 and CD4 lCD8, and serum IL-2 were obviously higher (P < 0.05), and levels of IL-6, TNF-alpha and CRP were obviously lower in the tested group than those in the control group (P < 0.05).
True	CONCLUSION: Early application of @FORMULA@ on the base of enteral nutritional therapy can lessen the degree of post-operational stress and @DISEASE@, and enhance the immune function of patients.
False	METHODS: Forty male SD rats were randomly divided into 4 groups for gastric lavage of normal saline or high, moderate or low doses of @FORMULA@ (twice daily) for 4 consecutive days.
False	The sera were collected from the rats for treatment of cultured human @DISEASE@ HepG2 cells.
True	CONCLUSIONS: @FORMULA@ can inhibit the formation of @DISEASE@ in @DISEASE@ cells in vitro possibly by inhibiting the RhoA/ROCK pathways and the expressions of VE-cadherin and PI3K.
False	RESULTS: Treatment with the sera from @FORMULA@-treated rats significantly inhibited formation of @DISEASE@ in HepG2 cells, and the diameters of @DISEASE@ formed were significantly greater than those in the positive control group (P < 0.01).
False	Treatments with @FORMULA@ and Y-27632 both inhibited the expression of RhoA and ROCK1 (P < 0.05) and significantly lowered the contents of VE-cadherin and PI3K in the culture supernatant (P < 0.05).
False	OBJECTIVE: To observe effects of @FORMULA@ on @DISEASE@ (@DISEASE@) cell @DISEASE@ (@DISEASE@) and explore the molecular mechanism by which @FORMULA@ inhibits @DISEASE@ metastasis and invasion.
False	@FORMULA@ alleviated pressure overload induced @DISEASE@ by suppressing Tgf-beta/Smads and MAPKs signaling activated @DISEASE@.
False	In this study, the effect of @FORMULA@ on pressure overload induced @DISEASE@ was investigated and possible mechanism underlying was explored.
False	Furthermore, activated classical pro-fibrotic signaling of Tgf-beta/Smads and MAPKs after TAC was dramatically suppressed by @FORMULA@ or Tel treatment.
False	@FORMULA@ (@FORMULA@), a traditional Chinese medicine recipe, is a representative prescription for the treatment of qi-deficiency and blood-stasis syndrome.
False	Rats were randomly divided into four groups: sham, transverse aorta constriction (TAC) with saline, TAC with telmisartan (TAC+Tel), and TAC with @FORMULA@ (TAC+@FORMULA@) for 16 weeks (n=6 approximately 8 in each group).
True	Taken together, it was demonstrated in this study that @FORMULA@ exerted a cardioprotective effect against pressure overload induced @DISEASE@ via inactivation of Tgf-beta/Smads and MAPKs signaling triggered @DISEASE@.
False	@FORMULA@ (@FORMULA@) is a popular traditional medicine for the therapies of @DISEASE@ and @DISEASE@.
False	AIM OF THE STUDY: The emerging resistance of @DISEASE@ to antibiotics arouses requirement on alternative nonantibiotic-based therapies.
False	For the in vivo study, mice were orally @DISEASE@ three times over the course of 1 week, and then subjected to daily administration of @FORMULA@ (120 or 600mg/kg) for 4 weeks or standard triple therapy for 1 week.
False	Further investigation showed that @FORMULA@ treatment reduced the @DISEASE@-induced phosphorylations of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases 1/2 (ERK1/2), c-Jun N-terminal protein kinase (JNK), and nuclear factor-kappa B (NF-kappaB).
False	In the mouse model, @FORMULA@ treatment significantly reduced @DISEASE@ colonization, @DISEASE@, and the levels of IL-1beta, IL-6, C-X-C motif chemokine ligand 1 (CXCL1), tumor necrosis factor alpha (TNF-alpha), COX-2, and iNOS in gastric mucosa.
True	CONCLUSIONS: Our findings collectively suggest that @FORMULA@ has anti-inflammatory activity and antibacterial activity against @DISEASE@ and could be an alternative to antibiotics for preventing @DISEASE@.
True	This study unveils novel molecular mechanism by which @FORMULA@ controls @DISEASE@ cell growth.
False	The negative feedback regulation loop of AMPKalpha further demonstrates the critical role of DNMT1 in mediating the overall effects of @FORMULA@ in this process.
False	CONCLUSION: Our results show that @FORMULA@ inhibits @DISEASE@ cell growth via AMPKalpha-mediated inhibition of transcription of Sp1, followed by the reduction of DNMT1 expression both in vitro and in vivo.
False	Chinese herbal medicine @FORMULA@ inhibited growth of @DISEASE@ cells through AMPKalpha-mediated inhibition of Sp1 and DNA methyltransferase 1.
False	In in vivo studies, we found that @FORMULA@ inhibited @DISEASE@ growth in xenograft nude mice model, which was accompanied by induction of phosphorylation of AMPKalpha and suppression of DNMT1 protein from xenograft @DISEASE@.
False	However, the molecular mechanisms underlying the therapeutic potential have not been well elucidated.
False	Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBIL), total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C) were measured to evaluate the protective effect of @FORMULA@ against chlorpromazine (CPZ)-induced @DISEASE@.
False	METHODS: We conducted an experiment on CPZ-induced @DISEASE@ in Wistar rats with and without @FORMULA@ for nine consecutive days.
True	CONCLUSIONS: Results indicated that @FORMULA@ exerted a protective effect on CPZ-induced @DISEASE@.
False	Several studies indicated that @FORMULA@ may improving hepatic triglyceride metabolism and anti-apoptotic response as well as decreasing oxidative stress .However, little is known about the role of @FORMULA@ in chlorpromazine (CPZ) -induced @DISEASE@.
False	BACKGROUNDS: @FORMULA@ (@FORMULA@), a commonly used as a traditional chinese medicine for @DISEASE@.
False	Chlorpromazine-induced perturbations of bile acids and free fatty acids in @DISEASE@ prevented by the Chinese herbal compound @FORMULA@.
False	Anti-Inflammatory Effects of @FORMULA@, a Traditional Herbal Formula, on @DISEASE@ in LPS-Sensitized Mice and -Raw 264.7 Cells.
False	Additionally, the translocation of NF-kappaB into nucleus and phosphorylation of mitogen-activated protein (MAP) kinase were significantly attenuated by the treatment of @FORMULA@ in LPS-sensitized @DISEASE@ mice.
False	@FORMULA@ ameliorated the LPS-induced @DISEASE@, alveolar wall thickening, and the shrinkage of the alveolar spaces in the @DISEASE@ mice model.
False	After 2 h of LPS sensitization, lung tissues were collected to confirm the lung histology and @DISEASE@-related inflammatory factors.
False	Proinflammatory cytokines including IL-6, TNF-alpha, and IFN-gamma in the lung tissue were significantly regulated in the @FORMULA@-treated groups compared to the LPS only-treated group.
True	This study demonstrates that @FORMULA@ has preventive effects on LPS-induced @DISEASE@ by regulating @DISEASE@ as an alternative for treating @DISEASE@.
True	@FORMULA@ increased the expression of aquaporin in the intestinal tract, reduced the water content of stool by promoting the absorption of water in the intestinal tract, inhibited the expression of aquaporin and its regulatory factors in nephridia tissue, and reduced the reabsorption of water to increase urine volume, to decrease the occurrence of @DISEASE@.
False	The tissue localization of aquaporin (AQP) was determined by immunohistochemistry.
False	To explore the effects of @FORMULA@ on the intestinal tract and aquaporin in Adriamycin-induced @DISEASE@, 45 specific pathogen free (SPF) Wistar rats were randomly divided into a blank control group (5 rats), Dosing control group (10 rats), Adriamycin @DISEASE@ model group (10 rats), @DISEASE@ group (10 rats), and an Adriamycin @DISEASE@ @DISEASE@ model group (10 rats).
False	@FORMULA@ promoted AQP2 expression in the @DISEASE@ model group and inhibited AQP2 expression in the @DISEASE@ group.
False	@FORMULA@ is a traditional Chinese medicine that has been used to open knots, benefit water, transform Qi, return fluid, and has a significant effect on strengthening the spleen and removing dampness.
False	It also regulates the levels of antidiuretic hormone (ADH) and arginine vasopressin (AVP), affects water absorption rate, and reduces the level of cyclic adenosine monophosphate (cAMP) in each tissue, thus reducing the absorption of AQP2 to water.
False	Intra-cystic pressure (ICP) of the two groups was measured during treatment.
False	RESULTS: On days 4 and 5 of treatment, the ICP was lower in the study group than in the control group (P < 0.05).
False	Patients in the control group received normal saline (NS) enema.
False	Patients in the study group received @FORMULA@ enema for 2 h and external use of Glauber's salt, once a day for 7 d.
True	CONCLUSION: @FORMULA@ enema and external use of Glauber's salt combined with routine non-operative conservative treatment can decrease the intra-abdominal pressure (IAP) of @DISEASE@ patients and have preventive and therapeutic effects on @DISEASE@ of @DISEASE@.
False	On days 3-5 of treatment, acute physiology and chronic health evaluation II (APACHE II) scores for the study and control groups were significantly different (P < 0.05).
False	Each mouse was given S180 cell 0.2 mL by celiac, and after 24 hours give cisplatin for Injective 3 mg x kg(-1), ip, once a week.
False	And give cyclophosphamide and 5-FU 3 mg x kg(-1), ig, once every day.
False	After 15 days, collect lively mice @DISEASE@ and give it for onefold normal mice.
False	METHOD: 18-22 gramme mice were divided into four groups for normal S180 @DISEASE@ cell group, matter by 70% ethanol with @FORMULA@ 100 mg x kg(-1) and 50 mg x kg(-1) in random.
False	RESULT: Matter by 70% ethanol with @FORMULA@ could obviously reduce the express of P170 and LRP, and the activiation of TOPO II.
True	CONCLUSION: Matter by 70% ethanol with @FORMULA@ can intervene the ocurrence of the multi-drug resistance of @DISEASE@ cells by regulating the biology gene.
False	ST segment elevation of Electrocardiograph (ECG) @DISEASE@ size, levels of lactate dehydrogenase (LDH), creatine kinase (CK), glutathione (GSH) and catalase (CAT), catalase (SOD), malondialdehyde (MDA), and inflammatory cytokines and phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, p38, c-Jun NH2 terminal kinases (JNK), nuclear factor (NF)-kappaBp65, inhibitory kappa B (IkappaB) alpha, IkappaB kinase (IKK) alpha and IKKbeta were evaluated in rats treated with or without @FORMULA@.
False	@FORMULA@ treatment significantly reduced the elevation of the ST segment of ECG, the @DISEASE@ size of @DISEASE@.
False	The elevated concentration of inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and IL-6 in @DISEASE@ rats were effectively reversed by the @FORMULA@ administration.
False	@DISEASE@ (@DISEASE@) model was induced in SD rats by surgical ligation of the left anterior descending coronary artery.
False	The level of LDH, CK and MDA were suppressed, the contents of SOD, GSH and CAT were enhanced with @FORMULA@.
True	The protective effect of @FORMULA@ against @DISEASE@ might be associated with MAPK/NF-small ka, CyrillicB pathway.
False	However, the @FORMULA@ containing high dose A. manshriensis can induce @DISEASE@.
False	The @FORMULA@ containing low dose A. manshriensis has relative security.
True	CONCLUSION: The @DISEASE@ of @FORMULA@ is correlated with the dose of A. manshriensis and the time of administration.
False	OBJECTIVE: To observe the @DISEASE@ in rats induced by @FORMULA@ (@FORMULA@) containing different dosages Aristolochia manshriensis.
False	The main @DISEASE@ location was in proximal convoluted tubule.
False	Renal functional parameters on 4,8,12 w were determined and changes of histomorphology in rats on the end of experiment were observed.
False	Traditional Chinese medicine (TCM) formulas have been widely used in @DISEASE@ and @DISEASE@ to improve life quality of patients in ethnomedicine.
True	This systematic review provided the evidences that TCM formulas combined with SSRIs might be helpful and safe in the treatment of @DISEASE@ of @DISEASE@, including @FORMULA@.
False	We aim to evaluate the efficacy of TCM formulas combined with SSRIs for @DISEASE@ @DISEASE@ in this systematic review.
False	Eleven randomized clinical trials involving 861 subjects were enrolled in this analysis.
False	However, the results are discordant and failed to be conclusive.
False	TCM formulas combined with selective serotonin reuptake inhibitors (SSRIs) also have a positive effect on @DISEASE@ @DISEASE@ compared with SSRIs as reported by several clinical studies.
False	CONCLUSION: @FORMULA@ could significantly lower MET content, it may be related to the effect of @FORMULA@ in inhibiting MET-1 gene expression and protein synthesis.
False	METHODS: Sprague-Dawley rats were randomly divided into 3 groups, the normal control group, the @DISEASE@ group and the @FORMULA@ group.
False	Immunohistochemical examination showed that MET-1 was mainly located at the cardiac muscle cells and vascular endothelial cells with the grey scale obviously lower in the @DISEASE@ group than that in the control group and the @FORMULA@ group (P < 0.01).
False	The content, immunohistochemical assay and gene expression of MET-1 were determined in all the three groups and compared.
False	While RT-PCR showed that the grey scale of PCR product band in the @DISEASE@ group was significantly higher than that in the other two groups (P < 0.01).
True	RESULTS: The content of MET in the @FORMULA@ group was significantly lower than that in the @DISEASE@ group (P < 0.01).
False	METHODS: A comprehensive search for randomized controlled trials of @FORMULA@ treatments for @DISEASE@ will be carried in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trial (CENTRAL), CINAHL, AMED and Chinese databases include CBM, CNKI, CQVIP, and Wanfang from their inceptions to May 2020.
False	Two experienced reviewers will independently search all databases.
False	Therefore, our study will provide efficacy assessments and adverse events assessments.
False	PROSPERO REGISTRATION NUMBER: CRD 42020164911.
False	@FORMULA@ is widely used in clinical treatment of @DISEASE@ in China.
True	CONCLUSION: The conclusion of this systematic review will provide evidence to judge whether @FORMULA@ is an effective therapeutic intervention for patient with @DISEASE@.
False	@FORMULA@, a 'Shu-Gan' formula in traditional Chinese medicine, is clinically used in the treatment of @DISEASE@.
False	@DISEASE@ is a @DISEASE@ comorbid risk factor for @DISEASE@ worldwide.
False	The aim of this study was to investigate whether @FORMULA@ improved glucose tolerance with its antidepressant activity in rat model of @DISEASE@ and explore the mechanisms underlying its action on @DISEASE@ axis.
False	Sucrose consumption test was used to assess animal @DISEASE@-like behaviors.
False	Western blot was used to detect the expression of key proteins in inflammatory signaling cascades including toll-like receptor 4 (TLR4), myeloid differentiation protein 88 (MyD88), nuclear factor-kappa B (NF-kappaB), Nod-like receptor family pyrin domain containing 3 (NLRP3), apoptosis-associated speck-like protein containing CARD (ASC), cysteinyl aspartate specific proteinase-1 (Caspase-1) and IL-1beta, as well as insulin signaling in liver and prefrontal cortex of rats.
True	These results provide direct evidence that @FORMULA@ can ameliorate @DISEASE@-like behaviors by inhibiting @DISEASE@ axis.
False	However, treatment for the above patients is not easy as steroid hormones and strong stimulators of ovulation should not be recommended because of the several side-effects it causes.
False	In the treatment of @DISEASE@, recent dynamic studies have revealed the mechanism by which @FORMULA@ stimulates the diencephalon-pituitary-ovarian axis in humans.
False	A number of herbal medicines have been used for many centuries in China and Japan for the treatment of @DISEASE@ and @DISEASE@.
False	In general, the traditional Chinese herbal prescriptions are rather inexpensive and safe with little side-effects, and have properties for normalizing biological balances.
False	@FORMULA@ is known to stimulate the synthesis and release of gonadotropins in the rat pituitary.
True	In this paper, we critically review the clinical data available (to date) in order to assess the efficacy of @FORMULA@ in inducing ovulation in several types of @DISEASE@.
False	Use of a Systematic Pharmacological Methodology to Explore the Mechanism of @FORMULA@ in Treating @DISEASE@.
True	CONCLUSIONS @FORMULA@ is able to regulate @DISEASE@-related, @DISEASE@-related, @DISEASE@, oxidative stress-related signaling pathways, and biological processes and targets, which suggests that @FORMULA@ may have a therapeutic effect on @DISEASE@.
False	BACKGROUND @DISEASE@, such as @DISEASE@ (@DISEASE@), are the leading cause of death in @DISEASE@ patients.
False	RESULTS Five network were constructed: (1) the @DISEASE@ gene PPI network; (2) the Compound-compound target network of @FORMULA@; (3) the @FORMULA@-@DISEASE@ PPI network; (4) the Compound-known target network of @FORMULA@; (5) and the @FORMULA@ known target-@DISEASE@ PPI network.
False	MATERIAL AND METHODS Based on the systematic pharmacological methodology, this research determined the genes of @DISEASE@ and the known targets of @FORMULA@, predicted potential compounds and targets of @FORMULA@, constructed networks for @DISEASE@ and @FORMULA@, and performed network analysis.
False	Several @DISEASE@ and treatment related targets, clusters, signaling pathways, and biological processes were found.
False	METHODS: Hepatic stellate cells were isolated from male Wistar rats.
False	The aim of our study was to elucidate in vitro whether @FORMULA@ exerted inhibitory effects on hepatic stellate cells.
False	Inhibitory effects of the herbal medicine @FORMULA@ (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells.
False	(ii) @FORMULA@ 500 and 1000 microg/ml significantly (p<0.0001) accumulated the cells in the G0/G1 phase (118.8+/-0.7%, 119.2+/-0.5%, respectively as compared with control) and significantly (p<0.0001) decreased cell numbers subsequently in G2/M phase (47.5+/-8.1%, 48.9+/-2.0%, respectively).
False	Morphological transformation was observed under a phase-contrast microscope.
True	@FORMULA@ could be a potent inhibitor in the pathogenesis of @DISEASE@.
True	This review discusses the properties of @FORMULA@ with regards to the treatment of @DISEASE@ and suggests the side effects of @FORMULA@.
False	@FORMULA@ significantly inhibits @DISEASE@ by inhibiting the activation of stellate cells, the major producers of collagen in the liver, as well as by inhibiting hepatic lipid peroxidation, promoting matrix degradation, and suppressing extracellular matrix (ECM) accumulation.
False	Most of the side effects were @DISEASE@ and @DISEASE@ induced by @FORMULA@ in Japan.
False	Various clinical trials have shown that @FORMULA@ protects against the development of @DISEASE@ in @DISEASE@ patients.
False	Unfortunately, some case reports have shown the side effects of @FORMULA@.
False	The traditional Chinese herbal medicine @FORMULA@ is a mixture of seven herbal preparations that has long been used in the treatment of @DISEASE@.
True	CONCLUSION: The effect of @FORMULA@ in treating @DISEASE@ was probably associated with its improvement of PI-3K p85 mRNA and protein expressions in skeletal muscle and adipose tissue of the @DISEASE@ rats.
False	Ten weeks later, serum fasting blood glucose (FBG), serum fasting insulin (FINS) and oral glucose tolerance test (OGTT) were routinely determined.
False	Meanwhile, a group of normal animals without any treatment was set up for normal control group.
False	METHODS: The male Wistar rats were injected with streptozotocin (STZ) 30 mg/kg through tail vein, and fed with high-fat and high-caloric diets to induce @DISEASE@.
False	RESULTS: Compared with the untreated group, the FBG and OGTT levels in @DISEASE@ rats treated with @FORMULA@ decreased significantly (P<0.05).
False	OBJECTIVE: To observe the effects of @FORMULA@ (@FORMULA@), a traditional Chinese compound herbal medicine, on p85 mRNA and protein expressions of phosphatidylinositol-3-kinase (PI-3K) in target tissues (skeletal muscular and adipose tissues) in rats with @DISEASE@ (@DISEASE@) and to investigate the molecular mechanism of @FORMULA@ in treating @DISEASE@.
True	CONCLUSION: These data suggest that @DISEASE@ in @DISEASE@ is inhibited by @FORMULA@ treatment.
False	RESULTS: NV score and % AVA decreased in the @FORMULA@ treated group compared to the WA group.
False	@DISEASE@ (@DISEASE@) was assessed by the NV score, and by the percentage of avascular area (% AVA), using a method previously reported.
False	Thus @DISEASE@ was inhibited significantly by @FORMULA@ treatment (p = 0.0185).
False	However, @DISEASE@ was seen in five cases of WA and in one case of the @FORMULA@ treated group.
False	METHODS: @DISEASE@ was induced by maintaining Sprague-Dawley neonatal rats in 80% oxygen for 12 days.
False	Lung specimens were stained with hematoxylin and eosin (HE) and Masson trichrome for histological evaluation of @DISEASE@ and @DISEASE@ by light microscopy.
False	RESULTS: @FORMULA@ reduced bleomycin-induced @DISEASE@, decreased the lung index and histological evidence supported the ability of @FORMULA@ to attenuate bleomycin-induced @DISEASE@ and consolidation.
False	Antifibrosis effects of total glucosides of @FORMULA@ in a rat model of bleomycin-induced @DISEASE@.
False	MATERIALS AND METHODS: Animals were randomly divided into six groups: (1) saline control group; (2) Bleomycin group in which rats were endotracheally instillated with bleomycin (5mg/kg); (3-5) Bleomycin and @FORMULA@ group, in which @FORMULA@ were given to rats daily (16.32 or 64mg/kg/day, i.g.) one day after bleomycin injection for 4 weeks until the end of the treatment; (6) Bleomycin and positive control group.
True	CONCLUSIONS: The findings of the present study provide evidence that @FORMULA@ may serve as a novel target for potential therapeutic treatment of @DISEASE@.
False	Body weight and lung index from various groups were measured, as well as TNF-alpha, TGF-beta1 and type I collagen concentrations in lung homogenates.
False	She presented with @DISEASE@ (potassium level, 1.7 mEq/L), increased urinary excretion of potassium (fractional excretion of K, 21.2%), abnormalities on an electrocardiogram (flat T waves in II, III, AVF, and V1-6), @DISEASE@ (creatine kinase level, 28,376 U/L), @DISEASE@, @DISEASE@ with respiratory compensation (O(2) flow rate, 2 L/min; pH, 7.473; pco(2), 61.0 mm Hg; po(2), 78.0 mm Hg; HCO(3), 44.1 mmol/L), @DISEASE@ (174/93 mm Hg), @DISEASE@ (blood glucose level, 200-300 mg/dL), frequent urination, suppressed plasma renin activity (0.1 ng/mL/hour), decreased aldosterone levels (2.6 ng/dL), and increased urinary cortisol levels (600.6 microg/day; reference range, 26.0-187.0 microg/day).
True	Medical practitioners prescribing @FORMULA@ should take into account the association between licorice, which is its main ingredient, and @DISEASE@.
False	CONCLUSIONS: In this case, the observed reduction in the urinary cortisol levels, from 600.6 to 37.8 microg/day, led to a definitive diagnosis of @DISEASE@ instead of the @DISEASE@.
False	CASE DESCRIPTION: A 79-year-old woman was brought to the emergency room.
False	@FORMULA@ induces @DISEASE@ characterized by @DISEASE@, @DISEASE@, @DISEASE@ with respiratory compensation, and increased urinary cortisol levels.
False	BACKGROUND: Licorice, the primary ingredient of the Japanese herbal medicine @FORMULA@, can cause @DISEASE@.
False	The results showed that the effective components of @FORMULA@ inhibited the release of heat-causing factors IL-6, IL-1beta and TNF-alpha, and reduced the increase of body temperature.
True	[Antipyretic effect of active components of @FORMULA@ and its correlation with pharmacokinetics in @DISEASE@ rats].
False	Combined with the pharmacokinetic data of the seven effective components in @FORMULA@, PK-PD(pharmacokinetics-pharmacodynamics) data fitting was conducted by using the analysis method of non-atrioventricular model, and then the pharmacodynamic parameters were calculated to determine the optimal binding model.
False	The @DISEASE@ rat models were induced by dry yeast, and intragastrically administered with the effective components of @FORMULA@ with different orthogonal compatibility ratios.
False	There was a significant lag between drug effect and blood drug concentration, which was consistent with Sigmoid-E_(max) model.
False	To investigate the antipyretic effect of active components of @FORMULA@ in @DISEASE@ rats, and explore its correlation with pharmacokinetics at different time points.
False	Though a temporary improvement was observed, @DISEASE@ relapsed and the patient died of @DISEASE@ and @DISEASE@.
False	[An autopsy case of @DISEASE@ probably induced by @FORMULA@].
False	Furthermore, reverse-transcriptase polymerase chain reaction techniques detected @DISEASE@-RNA in specimens of @DISEASE@.
False	She was admitted to our hospital because of @DISEASE@, @DISEASE@, and infiltrative shadows on chest x-ray films.
False	A 66-year-old woman had been treated for 3 years by her local physician with @FORMULA@ for @DISEASE@ and @DISEASE@.
True	It was speculated that the progression of @DISEASE@ in the present case may have been caused by @DISEASE@ in combination with @FORMULA@ @DISEASE@.
False	To detect the anticancer effect of @FORMULA@, cell viability assay, caspase activity assay, cell cycle analysis, DNA fragmentation analysis, and Western blot analysis were performed in A431 cells.
False	Furthermore, the molecular mechanisms behind effects of @FORMULA@ remain unclear.
False	@FORMULA@ induced the apoptosis through activating the caspase-8 in A431 cells.
False	In the present study, we explored the mechanism of chemopreventive/chemotherapeutic efficacy of @FORMULA@ against human @DISEASE@ without @DISEASE@ in normal cells and proved the efficacy of @FORMULA@ through performing in vivo xenograft assay.
True	Based on our study, @FORMULA@ could be useful in the management of @DISEASE@ as chemoprevention and chemotherapy remedy.
False	METHODS: For analysis of the constituents of @FORMULA@, high performance liquid chromatography (HPLC)-DAD system was performed.
False	In present study, the antimigrainic ingredients of @FORMULA@ were explored and optimized in nitroglycerin-induced @DISEASE@ rats through correlation analysis of decoction spectra-pharmacological effects and absorption spectra-pharmacological using entropy-weighted partial least squares regression method.
False	The decoction spectra and absorption spectra were obtained through the determination of nine main ingredients in ten kinds of @FORMULA@ and @FORMULA@' single-pass intestinal perfusion samples using high performance liquid chromatography-diode array detector.
False	The results showed that the final optimized sample, in which the concentrations of rutaecarpine, evodiamine, ginsendside Rb1, 6-gingerol, ginsendside Rg1, rutaevine, and limonin were 0.081, 0.565, 1.455, 0.159, 0.871, 0.178, and 0.009 mg.mL(-1), respectively, provided the best comprehensive effect than another optimized sample and the best uniform design sample.
False	And the optimization of key ingredients was acquired through uniform design experiment.
False	Then, the key ingredients influencing indexes were achieved through the correlation analysis.
True	Therefore, a new reliable method for rapidly recognizing and optimizing the effective constituents of @FORMULA@ treating @DISEASE@ was established.
True	Patients 2 was though to have a typical case of @FORMULA@ @DISEASE@, patient 1 was thought to have fulminating variant of this disease.
False	A chest radiograph and a CT scan showed bilateral diffuse fine granular and ground-glass opacities predominantly in the upper lung fields.
False	The response to prednisolone was good and he was discharged on the 40th hospital day in stable condition.
False	[Two cases of @DISEASE@ caused by @FORMULA@].
False	We describe two cases of @DISEASE@ caused by @FORMULA@.
False	Patient 2 was a 68-year-old man.
False	Our study aimed to evaluate the clinical efficacy and safety of @FORMULA@ combined with western medicine in the treatment of @DISEASE@.
False	METHODS: We searched 7 electronic databases for relevant studies and full-text articles involved in the evaluation of clinical effects difference between @FORMULA@ combined with western medicine and western medicine alone.
False	The results showed that @FORMULA@ combined with western medicine had a better improvement in decrease systolic blood pressure (SBP) (MD =12.33 mmHg; 95% CI: 3.37 to 21.28; P=0.007) and diastolic blood pressure (DBP) (MD =7.42 mmHg; 95% CI: 1.89 to 12.95; P=0.009) than western medicine alone, it also had a higher effective ratio (RR =1.20; 95% CI: 1.11 to 1.31; P<0.0001) and lower adverse reactions (RR =0.51; 95% CI: 0.30 to 0.86; P=0.01).
False	The results were robust and no obvious publication bias was observed in this study.
False	RESULTS: In total, 7 studies eventually met our inclusion criteria.
True	Clinical effects of @FORMULA@ in the treatment of @DISEASE@: a systematic review and meta-analysis.
False	@FORMULA@ (@FORMULA@) is a classic formula for @DISEASE@ with @DISEASE@, i.e., liver-depression and spleen-deficiency syndrome (LDSDS) in Chinese Medicine.
False	In CRS rats, @FORMULA@ alleviated @DISEASE@ behaviour and c-Fos expression.
False	@FORMULA@ regulates AMPA receptor homeostasis in chronic restraint stress-induced rat model of @DISEASE@ with liver-depression and spleen-deficiency syndrome.
False	@FORMULA@ also blocked the decrease of GluR1 and Glur2/3 in CA3, p-GluR1 in CA3, and p-GluR2 in CA1 and CA3.
False	Here a chronic restraint stress (CRS) induced rat model showed @DISEASE@ with LDSDS in food intake, metabolism, and behaviour tests.
True	Together, these results suggest that @FORMULA@ contains effective constituents and alleviates @DISEASE@ with LDSDS by regulating AMPA-type glutamate receptor homeostasis in amygdala and hippocampus.
False	Furthermore, @FORMULA@ increased ghrelin, CCK, VIP proteins and genes in the stomach.
False	By contrast, @FORMULA@ decreased the mRNA expression of these neuropeptides in the hypothalamus.
False	@FORMULA@ also increased ghrelin, CCK and VIP proteins in serum.
False	Brain-gut axis regulates food intake behaviour, and this regulatory mechanism is mediated by neuropeptides.
False	METHODS: In our experiment, the effect of @FORMULA@ on @DISEASE@ was evaluated in terms of food intake, sucrose preference test and electromyogram.
True	CONCLUSIONS: @FORMULA@ alleviated the symptoms of @DISEASE@ by upregulating the production of ghrelin, CCK and VIP and by increasing the levels of these neuropeptides in circulation.
False	The aim of this study was to investigate the curative effect of @FORMULA@ on @DISEASE@ (@DISEASE@) and further explore its underlying mechanism involving aquaporin (AQP)1 and AQP5.
False	The @DISEASE@ model was established based on the immune induction method, and the saliva flow, submandibular gland index, morphological structures of salivary glands, and AQP1 and AQP5 protein expression levels in the salivary glands were determined.
False	This result indicated that ZYE had a significant protective effect on @DISEASE@ via upregulation of the expression levels of AQP1 and/or AQP5.
False	@DISEASE@, @DISEASE@ and multiple focal lymphocytic infiltration were observed in the model group and were attenuated when subjected to IFN, ZYE and @FORMULA@ treatment.
False	The saliva flow and the submandibular gland index were significantly reduced in the model group (P<0.01, compared with those in the control group), and significantly increased following interferon (IFN), @FORMULA@ extraction (ZYE) and @FORMULA@ (@FORMULA@) treatment (P<0.01, compared with those of the model group).
True	Therapeutic effect of @FORMULA@ on @DISEASE@ via upregulation of aquaporin1 and aquaporin5 expression levels.
True	Therefore, @FORMULA@ is a potential candidate for the treatment of @DISEASE@.
False	@FORMULA@ improves @DISEASE@-like behaviors caused by decreasing allopregnanolone biosynthesis in an SKF mouse model of @DISEASE@.
False	@DISEASE@ are associated with the pathogenesis of @DISEASE@ (@DISEASE@).
False	@FORMULA@ dose-dependently attenuated sociability deficits and suppressed an increase in grooming behaviors in SKF-treated mice without affecting ALLO content in the prefrontal cortex.
False	We previously demonstrated that a selective type I 5alpha-reductase inhibitor SKF105111 (SKF) induced @DISEASE@-like behaviors, such as impaired sociability-related performance and repetitive grooming behaviors, in male mice.
False	On the other hand, the dopamine D2 receptor antagonist sulpiride and GABAA receptor antagonist bicuculline only attenuated the ameliorative effect of @FORMULA@ on repetitive self-grooming behaviors.
False	@FORMULA@ facilitates ovarian function through improving ovarian microenvironment and angiogenesis in a mouse model of @DISEASE@.
False	@FORMULA@ or dehydroepiandrosterone (DHEA) were administered via oral gavage for 28 consecutive days.
False	Moreover, @FORMULA@ significantly activated the Nrf2/HO-1 and STAT3/HIF-1alpha/VEGF signaling pathways to promote angiogenesis, resulting in a better fertility outcome when compared to the model group.
True	CONCLUSIONS: Our findings indicated that @FORMULA@ protected ovarian function of Cy-induced @DISEASE@ mice by improving the antioxidant ability and promoting ovarian angiogenesis, thereby providing scientific evidence for the treatment of @DISEASE@ using @FORMULA@.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @DISEASE@ (@DISEASE@) is a severe illness, characterized by @DISEASE@ with a @DISEASE@, which leads to @DISEASE@.
False	Ovarian function and pathological changes were evaluated by hormone levels, follicular development, and changes in angiogenesis.
False	The efficacy of @FORMULA@ on @DISEASE@ patients has not been fully assessed.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ (@FORMULA@) as a classic Chinese medicine prescription, has been extensively used in @DISEASE@, such as @DISEASE@ and @DISEASE@.
False	However, clinical trials had shown conflicting results of @FORMULA@ on improving pulmonary function and other related indicators of patients with @DISEASE@.
True	CONCLUSION: The methodological quality of included trials may limit the conclusions that indicate that modified @FORMULA@ may have a promising treatment for improving FEV1/FVC and MVV, increasing exercise endurance and life quality scores on @DISEASE@ patients.
False	RESULTS: A total of 770 @DISEASE@ participants from 11 trials that met the inclusion criteria were included.
False	The meta-analysis showed that modified @FORMULA@ could improve the exercise endurance, life quality scores of @DISEASE@ patients, and also showed the potential benefits to pulmonary function of @DISEASE@ patients than original @FORMULA@.
False	To evaluate the effect of different fractions of @FORMULA@ on ADP-induced @DISEASE@ and thrombin activity, and to exploit the bioactive constituents, ADP-induced @DISEASE@ rate in rabbits was determined by using the method of turbidity method.
False	This experiment provides scientific basis to further explore the bioactive constituents and mechanism of @FORMULA@ in treating blood stasis syndrome.
False	Alcohol precipitation supernatant fraction, water insoluble fraction and 40% to 70% alcohol elution fraction could significantly inhibit thrombin activity.
False	Alcohol precipitation deposition fraction, alcohol precipitation supernatant fraction and 20% to 30% alcohol elution fraction could significantly inhibit ADP-induced @DISEASE@.
False	UHPLC-Q-TOF-MS method was used to qualitatively analyze the chemical constituents of different parts.
True	The bioactive constituents of @FORMULA@ for inhibiting ADP-induced @DISEASE@ and thrombin activity include aromatic acids, glycosides and phthalides.
False	[Effects of @FORMULA@ on the expressions of Smad2 and Smad7 in isoproterenol induced @DISEASE@ rats].
False	The IOD value of Smad2 protein was 20 275 and the mRNA IOD of Smad2 protein was 0. 919 in the model group, while they were respectively 9 949 and 0. 561 in the @FORMULA@ group, indicating the protein and mRNA expressions of Smad2 were obviously higher in the model group than in the @FORMULA@ group (P < 0.05).
False	OBJECTIVE: To explore the effects of @FORMULA@ (@FORMULA@) on the expressions of Samd2 and Smad7 isoproterenol (Iso) induced @DISEASE@ rats.
False	Iso was injected to rats in the model group and the @FORMULA@ group, while normal saline was injected to rats in the control group.
False	METHODS: Totally 19 Wistar rats were randomly divided into 3 groups, i.e., the control group, the model group, and the @FORMULA@ group.
True	CONCLUSION: @FORMULA@ could effectively inhibit Iso induced @DISEASE@, and its mechanism may be associated with down-regulating the expression of Smad2 and up-regulating the expression of Smad7.
False	@DISEASE@ is considered as one of the common pathogeneses of @DISEASE@.
False	Rats were given @FORMULA@ (2, 4, and 8 g/kg, intragastrically), paroxetine (1.8 mg/kg, intragastrically), or an equivalent volume of saline for 42 days.
True	In conclusion, it was supposed that @FORMULA@ might be a potential Chinese medicine decoction for treating or alleviating complex symptoms of @DISEASE@ through BDNF-TrkB-CREB pathway.
False	Also @FORMULA@ decreased the number of microglia and the proinflammatory cytokines in hippocampus.
False	But there was no difference in the 5-HT and DA contents with @FORMULA@ treatment.
False	The @DISEASE@-related behaviors, including sucrose preference test (SPT), open field test (OFT), novel objective recognition task (NORT), and forced swimming test (FST), were detected. 5-Hydroxytryptamine (5-HT) and dopamine (DA) contents, microglial activation, proinflammatory cytokines, and brain derived neurotrophic factor (BDNF), tropomyosin receptor kinases B (TrkB), and cAMP-responsive element binding protein (CREB) expression were investigated.
False	However, the pathological change in the intestine during @DISEASE@ is still poorly understood.
False	The expression of pro-apoptotic molecules including Fas and Bax was increased in the intestinal epithelia in CCI4-treated mice compared with that in control.
False	The CCl4+@FORMULA@ mice were treated with @FORMULA@ from the beginning of the first week.
True	@FORMULA@ treatment ameliorated @DISEASE@, cell death, and tight junction disintegrity induced by CCl4 treatment, suggesting that @FORMULA@ inhibits CCl4-mediated @DISEASE@ at least in part by ameliorating the @DISEASE@.
False	The intestinal epithelial cell apoptosis was examined by TUNEL staining.
False	The CCl4-treated mice were divided into two groups: the CCl4-water group (n=8, CCl4) and the CCl4-@FORMULA@ group (n=8, CCl4+@FORMULA@).
False	Mechanistically, the increased hepatic TLR4 expression and its downstream JNK phosphorylation induced by MCD diet were suppressed by @FORMULA@.
False	RESULTS: Mice fed with four weeks of MCD diet displayed elevated serum levels of ALT and AST, while there was @DISEASE@.
False	The treatment effects of @FORMULA@ were confirmed by examining the change of body weight, serum alanine aminotransferase (ALT) and aspartate transaminase (AST) levels, Oil Red O staining, and hematoxylin and eosin (H&E) staining of the liver samples and accompanied by steatosis grade scores.
False	A @DISEASE@ mice model was established by feeding with a methionine- and choline-deficient (MCD) diet for four weeks.
False	Moreover, the upregulations of Caspase-8, gasdermin D (GSDMD), and cleaved-GSDMD in liver mediated by MCD diet were all inhibited by @FORMULA@.
True	CONCLUSIONS: Treatment with @FORMULA@ improves MCD diet-induced @DISEASE@ in part via blocking TLR4-JNK and Caspase-8-GSDMD signaling pathways, suggesting that @FORMULA@ has potential for clinical application in treating @DISEASE@.
True	CONCLUSION: If the increasing of the spontaneous activities of ICx and AII in @DISEASE@ rats means @DISEASE@, the use of @FORMULA@ could decrease this kind of changes.
False	The spontaneous spikes were recorded and analyzed from ICx and all in different group rats.
False	AIM: Observe the effects of @FORMULA@ (@FORMULA@, a compound of Chinese Traditional Medicine) on the spontaneous discharge of external cortex of inferior colliculus (ICx) and secondary auditory cortex (AII) of @DISEASE@ model rats induced by salicylate acid, to explore the neural mechanisms underlying @FORMULA@ preventing @DISEASE@.
False	And there was an increasing tendency of the average rate of spontaneous discharge recorded from the AII in the @DISEASE@ model group compared with that in the normal group. (2) Compared with the @DISEASE@ model group, the average rate of spontaneous discharge recorded from the ICx and AII in the @FORMULA@ prevention group significantly decreased than that in the @DISEASE@ model group (ICx: 2.41 +/- 0.21 Hz vs. 4.57 +/- 0.54 Hz, P < 0.01.
False	RESULTS: (1) Compared with normal control group, the average rate of spontaneous discharge recorded from the ICx in the @DISEASE@ model group increased significantly (4.57 +/- 0.54 Hz vs. 3.14 +/- 0.40 Hz, P < 0.05).
False	The average rate of spontaneous discharge and the interspike interval histogram of spontaneous activities were used as indexes.
False	METHOD: Experimental @DISEASE@ was induced by rectal administration of trinitrobenzene sulfonic acid (TNBS) dissolved in ethanol.
False	[Regulation of @FORMULA@ on Bax/Bcl-2 mRNA, Fas/FasL in colonic tissue from rats with @DISEASE@].
False	The expression of Fas in the colonic mucosa was obviously down-regulated (P < 0.05) and the ratio of Bcl-2 mRNA/Bax mRNA was significantly up-regulated (P < 0.05) in the groups treated with the three doses of @FORMULA@.
False	The model animals were divided into four groups: the induced @DISEASE@ but untreated group, the induced @DISEASE@ groups treated with the high, middle, low dose of @FORMULA@, and the induced @DISEASE@ group treated with salicylazosulfapyridine (SASP).
False	OBJECTIVE: To evaluate therapeutic effect of @FORMULA@ on experimental @DISEASE@, and explore its mechanism by expression of Bax/Bcl-2 mRNA, Fas/FasL in colonic tissue.
True	CONCLUSION: @FORMULA@ might postpone colonic epithelium apoptosis or improve inflammatory cell apoptosis by regulating the expression of Fas/ FasL and Bax/Bcl-2 mRNA in colonic tissue, which is possible potential path to effectively treat experimental @DISEASE@ by enema.
False	@FORMULA@ (@FORMULA@) is a well-known TCM formula for relieving @DISEASE@ (@DISEASE@) in clinic.
False	"In this study, a novel ""system to system"" strategy based on the correlation of drug-related and drug-induced ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UHPLC-Q-TOFMS) serum metabolomic profiles was developed to discover bioactive compounds of @FORMULA@ against isoproterenol-induced @DISEASE@."
False	Due to complex nature, the effective compounds of @FORMULA@ are still unknown.
False	Screening active constituents of traditional Chinese medicines (TCMs) is vital for lead compound discovery.
True	Canonical correlation analysis between the @FORMULA@ and @FORMULA@ metabolites revealed that 12 compounds had strongly correlated relationship with the protective effect of @FORMULA@ on @DISEASE@, and these compounds include isotalatizidine, songorine, fuziline, neoline, talatizamine, 14-acetyltalatizamine, liquiritigenin, benzoylmesaconitine, isoliquiritin, benzoylaconitne, benzoylhypaconitine and 6-gingerol.
False	Correlation of drug-induced and drug-related ultra-high performance liquid chromatography-mass spectrometry serum metabolomic profiles yields discovery of effective constituents of @FORMULA@ against @DISEASE@ in rats.
False	Eighty-seven active components of @FORMULA@ and 155 anti-HB targets were selected for further analysis.
False	Glycyrrhizae Radix (GR), one of the seven @FORMULA@ herbs, likely exerts some unique GO functions such as the regulation of interleukin-12 production, positive regulation of interleukin-1 beta secretion, and regulation of the I-kappaB/NF-kappaB complex.
False	Additionally, molecular docking verified that the active compounds (quercetin, chrysin, and capsaicin) could bind with the key targets.
False	Although the anti-HB activity of @FORMULA@ has been reported, systematic research on the exact mechanism of action is lacking.
True	The PPI network and KEGG pathway analysis results showed that @FORMULA@ affects @DISEASE@ mainly through modulating pathways related to @DISEASE@, immunity, @DISEASE@, signal transduction, and metabolism.
False	@DISEASE@ (@DISEASE@) is a globally prevalent @DISEASE@ caused by the @DISEASE@ virus.
False	CONCLUSION: This trial failed to show a significant improvement in @DISEASE@ severity, as assessed by the CIS-deprived response rate.
False	Nine grams of @FORMULA@ or placebo granules were administered to the patients for 8 weeks.
False	This study aimed to evaluate the effectiveness and safety of @FORMULA@ for treating @DISEASE@ (@DISEASE@).
False	BACKGROUND: @FORMULA@ (@FORMULA@, @FORMULA@ in Chinese) is a widely prescribed herbal medicine in traditional Korean medicine.
False	METHODS: Ninety-six eligible participants were randomly allocated to either the @FORMULA@ or placebo groups in a 1:1 ratio.
True	It merely showed that @FORMULA@ could alleviate the severity of @DISEASE@ and qi deficiency in patients with @DISEASE@.
True	CONCLUSIONS: The therapeutic effect of @FORMULA@ on @DISEASE@ is at least partially through improvement of TJ integrity and attenuation of @DISEASE@ @DISEASE@.
False	TEER was decreased in @DISEASE@ rats, but treatment with @FORMULA@ restored normal level of TEER and the expression of occludin and claudin-1 in @DISEASE@ rats.
False	Our findings highlight the molecular basis of @FORMULA@-based treatment of @DISEASE@ in human patients.
False	@FORMULA@ (@FORMULA@) is a traditional Chinese prescription that exhibits therapeutic effects in @DISEASE@, but the underlying mechanisms remain not well understood.
False	The expression of tight junction (TJ) proteins, occludin and claudin-1, in the duodenum was determined by Western blot and immunofluorescence.
False	The amount of tumor necrosis factor alpha (TNF-alpha) and interferon gamma (INF-gamma) in duodenal mucosa was detected by enzyme-linked immune sorbent assay (ELISA).
False	The animals were divided into four groups, the negative control group injected with Abeta(42-1), the Abeta group injected with Abeta(1-42), the @FORMULA@ group inhaled @FORMULA@ essential oil and received Abeta(1-42) injection, and the positive control group administered with docosahexaenoic acid (DHA, 10 mg/kg) and with subsequent Abeta(1-42) injection.
False	The mouse @DISEASE@ model was induced by a single injection of amyloid beta protein (Abeta(1-42)) into the hippocampus.
False	@FORMULA@ essential oil alleviates amyloid beta induced @DISEASE@ through inhibition of tau protein phosphorylation in mice.
False	The purpose of this study was to evaluate the potential beneficial effects of @FORMULA@ essential oil in @DISEASE@ such as @DISEASE@ (@DISEASE@).
False	@FORMULA@ (@FORMULA@), a traditional Chinese medicine, has been used orally for the treatment of @DISEASE@, @DISEASE@ and @DISEASE@.
True	The present study suggests that @FORMULA@ essential oil may have potential as a therapeutic inhalation drug for the prevention and treatment of @DISEASE@.
False	"Through the network, we screened the potential ""candidate targets,"" such as ITGB1, FN1, CASP3, and ITGA5 and FABP1, ABCB1, FABP2, and SLC51B."
False	Effect of @FORMULA@ on Colonic Gene Expression in Rats with @DISEASE@.
False	The degree of HE staining of colonic tissue was severe in the model group but reduced significantly in the @FORMULA@ group.
False	After a ten-day treatment, microarray analysis was performed from the colon segment of the rats.
False	These potential candidate targets were functionally related to immune responses, @DISEASE@, and metabolism.
True	@FORMULA@ exhibited protective effects against @DISEASE@ by inhibiting the @DISEASE@.
True	[Immunologic examination of @FORMULA@ (TJ-48) in @DISEASE@].
False	MATERIALS AND METHODS: Blast formation of mouse lymphocyte to which patient serum was added.
False	In this report an immunological examination was conducted on administration of TJ-48 for @DISEASE@.
False	TNF activities tended to decrease more after administration than before. 2-5AS activities indicated a tendency to decrease more after administration than before.
False	RESULTS: Blast formation of mouse lymphocytes after administration showed a tendency to increase more than before.
False	CONCLUSION: The action of non-specific immunosuppressive factor was suggested to be lowered after administration of TJ-48 for @DISEASE@.
False	"@FORMULA@ (@FORMULA@) (@FORMULA@) is a traditional Chinese/Japanese medical (Kampo) formulation that has been administered to patients with ""Oketsu"" (blood stagnation) syndrome."
False	In the present study, we examined the protective effects of @FORMULA@ and its constituent medicinal plants against NO donors, sodium nitroprusside (SNP) and 2,2'-(hydroxynitrosohydrazino)bis-ethanamine (NOC18)-induced @DISEASE@ in cultured rat cerebellar granule cells (CGCs).
False	MTT assay showed cell viability to be significantly increased by the addition of @FORMULA@ extract (KBGE) (100 microg/ml), Cinnamomi Cortex extract (CCE) (3, 10 and 30 microg/ml), Paeoniae Radix extract (PRE) (100 microg/ml) and Moutan Cortex extract (MCE) (10 and 30 microg/ml) compared with exposure to SNP (30 microM, 24 h) only.
False	Also, cell viability was significantly increased by the addition of KBGE (100 and 300 microg/ml), CCE (30 and 100 microg/ml), PRE (100 and 300 microg/ml) and MCE (30 and 100 microg/ml) compared with exposure to NOC 18 (100 microM, 48 h) only.
False	Protective effect of @FORMULA@ and its constituent medicinal plants against nitric oxide donor-induced @DISEASE@ in cultured cerebellar granule cells.
True	These results suggest that @FORMULA@ has protective effect against NO-mediated @DISEASE@ in cultured CGCs and that it is derived from Cinnamomi Cortex, Paeoniae Radix and Moutan Cortex.
False	Also, the expression of neurotrophic factors and inflammatory cytokines such as VEGF, BDNF, Cox-2, TNF-alpha, IL-1beta, and IL-1alpha was measured in @DISEASE@ hemisphere regions.
False	In this study, we investigated whether @FORMULA@ improves functional recovery and has neuroprotective effects on reducing the @DISEASE@ volume after @DISEASE@ (@DISEASE@).
False	The @FORMULA@-treated group showed both reduced @DISEASE@ volume and increased glucose utilization.
False	Behavior tests demonstrated a significant improvement compared to the control.
False	These results suggest that @FORMULA@ may improve functional outcome through the rapid restoration of metabolism and can be considered as a potential neuroprotective agent.
True	Also in the @FORMULA@ treated group, NeuN-positive cells were increased and number of astrocytes, microglia, and apoptotic cells was significantly decreased compared with the control group in the @DISEASE@ peri-@DISEASE@ area.
False	However, the effects of @FORMULA@ on @DISEASE@ are unknown.
False	RESULTS: Ozone produced significant @DISEASE@ and plasma extravasation, with an influx of neutrophils in BAL fluid.
False	Guinea-pigs were anaesthetized with pentobarbital sodium and mechanically ventilated.
False	OBJECTIVE: @FORMULA@ (@FORMULA@) is a Chinese herbal medicine that has been used as an anti-tussive agent.
False	@FORMULA@ (400 mg/kg p.o.) significantly inhibited @DISEASE@, but had no effect on neutrophil influx or plasma extravasation.
True	CONCLUSIONS: We demonstrated that @FORMULA@ can attenuate @DISEASE@ induced by ozone without affecting @DISEASE@, which suggests that @FORMULA@ may act on the subsequent mechanisms after the induction of @DISEASE@, such as mediator release.
False	@FORMULA@ attenuated the severity of the gross lesions and reduced the @DISEASE@.
False	Subsequently, @FORMULA@ (5.0, 10.0 and 30.0 g/kg) was intragastrically administered, and scores of the disease activity index (DAI) were calculated.
False	The normal group consumed distilled water.
False	A total of 40 male Wistar rats were randomly divided into 5 groups: Normal, model, low-dose @FORMULA@, moderate-dose @FORMULA@ and high-dose @FORMULA@ groups.
False	Compared with the model group, moderate and high doses of @FORMULA@ showed a restoration effect on all the aforementioned indexes, and the high dose was the most effective.
True	In conclusion, @FORMULA@ can ameliorate @DISEASE@ in DSS-induced @DISEASE@ rats.
False	Based on the results of our study, @FORMULA@ could be a useful herbal medicine for treating @DISEASE@.
False	However, @FORMULA@ decreased the levels of HIF-1alpha, SDF-1, CXCR4 and VEGF mRNA in @DISEASE@ mice.
False	@FORMULA@ significantly inhibited @DISEASE@ by downregulating HIF-1alpha, SDF-1, CXCR4 and VEGF.
False	Inhibitory effect of @FORMULA@ on @DISEASE@ in @DISEASE@.
False	RESULTS: @FORMULA@ reduced the area of the central retina and reduced @DISEASE@ in @DISEASE@ mice.
True	CONCLUSION: We are the first to elucidate that @FORMULA@ inhibits the @DISEASE@ induced by @DISEASE@ in @DISEASE@ mice.
False	A JAK2-STAT3-dependent pathway was involved in the suppression by @FORMULA@ of interactions between DCs and T lymphocyte.
False	More detailed studies indicated that @FORMULA@ regulated the maturation and function of DCs, decreased the percentage of merocytic dendritic cells (mcDCs) subset, and increased programmed death ligand-1 (PD-L1) expression in DCs.
False	In traditional Chinese medicine (TCM), @FORMULA@ (@FORMULA@) is an effective treatment of @DISEASE@.
False	@FORMULA@ also impeded T lymphocyte proliferation and promoted regulatory T cells (T(regs)) differentiation in vivo.
False	Interaction of dendritic cells and T lymphocytes for the therapeutic effect of @FORMULA@ to @DISEASE@.
True	In vivo, @FORMULA@ significantly inhibited insulitis, delayed the onset and development of @DISEASE@, promoted insulin secretion and sensitivity, and balanced partially normalized Th1 and Th2 cytokines in @DISEASE@ mice.
False	Meta-analysis showed that @FORMULA@ used alone showed no BP reduction effect; however, improvement on QOL was found in the @FORMULA@ group compared to antihypertensive drugs.
False	A significant reduction in systolic and diastolic BP was observed for @FORMULA@ plus antihypertensive drugs when compared with antihypertensive drugs alone.
True	CONCLUSIONS: Owing to insufficient clinical data, it is difficult to draw a definite conclusion regarding the effectiveness and safety of @FORMULA@ for @DISEASE@, and better trials are needed.
False	We assessed the methodological quality, extracted the valid data and conducted the meta-analysis according to criteria from the Cochrane group.
False	DESIGN: Seven electronic databases, including the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP), the Chinese Biomedical Literature Database (CBM) and the Wanfang Database, were searched up to March 2014.
False	The effect of Chinese herbal medicine @FORMULA@ for the treatment of @DISEASE@: a systematic review.
False	We report a case of @DISEASE@ and @DISEASE@ caused by @FORMULA@.
False	Consequently, @DISEASE@ and hepatic function markedly improved.
False	Challenge test using @FORMULA@ resulted in decrease of PaO2 and elevation of serum transaminases.
False	The levels of serum transaminases returned to normal within two months without specific treatment and he was discharged.
False	Lymphocyte stimulation test against @FORMULA@ was positive.
True	Based on these findings, the diagnosis of @DISEASE@ and @DISEASE@ induced by @FORMULA@ was established.
False	In this experiment, we established an animal model of @DISEASE@ rats using streptozotocin.
True	We can conclude that @FORMULA@ has the therapeutic effect on @DISEASE@.
False	Compared with @DISEASE@ rats as the control group, @FORMULA@ can change the indexes of fasting blood glucose, body weight, total cholesterol, insulin, and metabolism cage index significantly in @FORMULA@ @DISEASE@ group.
False	Using the rat model of @DISEASE@, the pregnant rats in 1-19d were divided into three groups: (1) @FORMULA@ @DISEASE@ group (group I, n = 12), (2) @DISEASE@ rats as the control group (group II, n = 11), and (3) rats of normal pregnancy group (group III, n = 11).
False	The therapeutic effect of @FORMULA@ in @DISEASE@ rats.
False	We found that @FORMULA@ had positive effects in increasing bone mineral content (BMC), strengthening bone biomechanical, promoting bone formation, inhibiting bone resorption, and mediating protein levels of TGF-beta1/Smads signaling pathway.
False	@FORMULA@ improves the dexamethasone-induced @DISEASE@ progression in zebrafish larvae.
False	Alizarin Red staining, calcium and phosphorus determination were performed to evaluate the effect of @FORMULA@ on bone mineralization.
False	The findings demonstrated that @FORMULA@ treatments inhibited the phosphorylation of TGF-beta and p-Smad 3 as well as the expressions of collagen I and collagen II by western blot.
True	Taken together, we demonstrated that @FORMULA@ may prevent @DISEASE@ via reversing the @DISEASE@ and activating the TGF-beta-Smad signal.
False	The current study was to evaluate the protective effects of Chinese medicine prescription @FORMULA@ (@FORMULA@) on @DISEASE@ (@DISEASE@) in zebrafish larvae induced by dexamethasone.
False	@FORMULA@ improves @DISEASE@ in rats as revealed by (1)H-NMR based metabolomics.
False	@DISEASE@ (@DISEASE@), a common @DISEASE@ around the world, is driven by multiple factors, making prevention and treatment a major challenge.
False	However, studies on @FORMULA@ improving @DISEASE@ are few.
False	A @DISEASE@ rat model was induced by multiple forms of mild stimulation, and proton nuclear magnetic resonance (1H-NMR) spectroscopy and multivariate data analysis were used to profile the fecal and urinary metabolome in the @DISEASE@ rats during @FORMULA@ intervention.
False	@FORMULA@ (@FORMULA@), a classical prescription of traditional Chinese medicine, has been proven to be effective in @DISEASE@.
True	Overall, our study highlighted the effect of @FORMULA@ on the @DISEASE@ in the @DISEASE@ rats, providing new insight into the mechanism of @FORMULA@ treatment for @DISEASE@ from the perspective of metabolomics.
False	At the same time, molecular docking showed that Stigmasterol and Akt1 had good docking conformation.
False	Western blot and qRT-PCR were used to analyze the protein and mRNA expressions of PI3K, Akt, and PTEN after treatment of Stigmasterol.
False	The Mechanism of @FORMULA@ in the Treatment of @DISEASE@ by Network Pharmacology and the Effect of Stigmasterol on the PI3K/Akt Pathway.
True	CONCLUSION: Stigmasterol as the one of the main compounds of @FORMULA@ suppresses @DISEASE@ cell activities through the PI3K-Akt signaling pathway.
False	The GeneCards and OMIM databases were used to screen common targets of @FORMULA@ in the treatment of @DISEASE@.
False	METHODS: The active compounds and targets of @FORMULA@ were studied by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP).
False	@FORMULA@ administered 3 days before @DISEASE@ significantly reduced @DISEASE@ size by 53.7% compared with vehicle treatment.
False	However, @FORMULA@ did not reduce @DISEASE@ in mice treated with the relatively specific endothelial NOS (eNOS) inhibitor, N(5)-(1-iminoethyl)-L-ornithine, suggesting that the neuroprotective effect of @FORMULA@ is primarily endothelium-dependent.
False	@FORMULA@ (@FORMULA@) is an herbal extract that is widely used in traditional Korean medicine to treat @DISEASE@ and @DISEASE@ by promoting blood circulation and relieving blood stasis.
False	@FORMULA@ (10-300 mug/mL) produced a concentration-dependent relaxation in mouse aorta, which was significantly attenuated by the nitric oxide synthase (NOS) inhibitor L-NAME, suggesting that @FORMULA@ causes vasodilation via a NO-dependent mechanism.
True	@FORMULA@ acutely improves CBF in eNOS-dependent vasodilation and reduces @DISEASE@ size in @DISEASE@.
False	This correlated with increased phosphorylation of eNOS in the brains of @FORMULA@-treated mice.
False	[Effect of fluticasone inhalation combined with @FORMULA@ on pulmonary function and serum interleukin-16 level in @DISEASE@ patients].
False	Before treatment, serum levels of IL-16 in all the three groups were significantly higher than those in the healthy control group (P < 0.01) and lowered after treatment respectively, the treated group was significantly lower than those of the other two groups (P < 0.05 or P < 0.01).
False	The IL-16 levels were determined by using ELISA.
False	OBJECTIVE: To observe the effect of Fluticasone inhalation combined with @FORMULA@ (@FORMULA@) on pulmonary function and serum interleukin-16 (IL-16) level in @DISEASE@ patients.
False	Meanwhile ten healthy volunteers were selected as healthy control group.
True	CONCLUSION: The effects of Fluticasone inhalation combined with @FORMULA@ on pulmonary function and serum IL-16 levels were superior to those of Fluticasone inhalation and @FORMULA@ alone in @DISEASE@ patients.
True	Inhibition by @FORMULA@ (TJ-9) of development of @DISEASE@ induced by N-nitrosomorpholine in Sprague-Dawley rats.
False	Pre-neoplastic and neoplastic lesions staining for gamma-glutamyl transpeptidase (GGT) or the placental type of glutathione-S-transferase (GST-P) were examined histochemically.
False	In Week 15, quantitative histological analysis showed that prolonged treatment with 0.5% TJ-9 significantly reduced the number and volume of GGT-positive and GST-P-positive @DISEASE@.
False	The effect of @FORMULA@ (TJ-9) on @DISEASE@ induced by N-nitrosomorpholine (NNM) was investigated in male Sprague-Dawley rats.
False	Administration of 0.5% TJ-9 also caused a significant increase in the proportion of helper T lymphocytes and a significant decrease in the labeling index of pre-neoplastic lesions.
False	Treatment with 1.0% TJ-9 inhibited the development of GGT-positive and GST-P-positive lesions, but was less effective than 0.5% TJ-9.
False	@FORMULA@ in the treatment of @DISEASE@: A systematic review and meta-analysis.
False	@FORMULA@, whether individually or combined with essential treatment, ameliorated @DISEASE@ regardless of the course of the disease or curative duration.
False	We calculated risk ratio (RR) and mean difference (MD) for dichotomous data and continuous variables with a 95% confidence interval (CI).
False	This benefit was mainly driven by regulating levels of serum markers, involving TC, TG, ALT, AST, GGT, and adiponectin.
False	R 4.0.5 software was employed for data synthesis.
True	CONCLUSION: Our findings provided evidence that @FORMULA@ is a therapeutic option to treat @DISEASE@ effectively and safely.
False	We observed body weight changes, mortality, clinical signs, and gross pathological findings.
False	ISSE significantly decreased levels of interleukin (IL)-4, IL-5, eotaxin, and OVA-specific immunoglobulin (Ig)E, and increased SOD activity.
True	Acute oral toxicity of @FORMULA@, a traditional herbal formula, in rats and its protective effects against ovalbumin-induced @DISEASE@ via anti-inflammatory and antioxidant properties.
False	BACKGROUND: @FORMULA@ (@FORMULA@ in Chinese) is a traditional herbal formula widely used for the treatment of @DISEASE@ in Korea and China.
False	METHODS: In a safety study, ISSE was administrated orally to rats of both sexes at single doses of 0 and 5000 mg/kg.
False	In this study, we investigated the acute oral toxicity of an @FORMULA@ water extract (ISSE) in rats and the antiasthmatic effects of ISSE and its mechanism in a model of @DISEASE@ induced by ovalbumin (OVA) in mice.
False	The effects of @FORMULA@ (@FORMULA@), a traditional Chinese medicine, on the production of PGE2 from monocytes, LTB4 and superoxide from polymorphonuclear cells (PMNC) in @DISEASE@ individuals were studied.
True	Effects of @FORMULA@ on production of prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and superoxide from peripheral monocytes and polymorphonuclear cells isolated from @DISEASE@ individuals.
False	Furthermore, our data indicates that inhibition of PGE2 or superoxide production will lead to indirect suppression of @DISEASE@, and enhancement of LTB4 will contribute to the upregulation of the immune reaction in @DISEASE@ individuals.
False	@FORMULA@ inhibited the production of PGE2 from monocytes stimulated by opsonized zymosan in all groups including the healthy control group and also inhibited the production of superoxide from PMNC after stimulation with FMLP.
False	These results suggest that @FORMULA@ has different effects on the production of prostanoids or superoxide from monocytes and PMNC.
False	On the other hand, @FORMULA@ enhanced the production of LTB4 when PMNC were stimulated by the calcium ionophore A23187.
False	To the best of our knowledge, this is the first report to describe the distribution of the active ingredients derived from @FORMULA@ in @DISEASE@ rat tissues.
False	Subsequently, liver, lung and kidney tissues were obtained from sudden death @DISEASE@ rats in the absorption phase (0.25 h), the distribution phase (1.0 h) and the elimination phase (8.0 h) after administration of the @FORMULA@ aqueous extract.
False	Novel pharmacokinetic studies of the Chinese formula @FORMULA@ in @DISEASE@ rats.
False	The results indicated that berberine, palmatine, baicalin and baicalein distributed rapidly and accumulated at high levels in the lung, while gardenoside distributed widely in the lung and the kidney.
False	Our previous studies showed that after oral administration of an @FORMULA@ (@FORMULA@) decoction, there is a higher concentration of the pure components, berberine, baicalin and gardenoside in the plasma of @DISEASE@ (@DISEASE@) rats than in sham-operated rats, The aim of the present study was to determine whether these components could be reliably measured in @DISEASE@ rat tissues.
True	The tissue distribution results provide a biopharmaceutical basis for the design of the clinic application of @FORMULA@ in @DISEASE@.
False	AIM OF THE STUDY: @DISEASE@ (@DISEASE@) is a kind of @DISEASE@ characterized by @DISEASE@, @DISEASE@ and autoantibodies.
False	CONCLUSIONS: This study indicated that the metabolomic strategy based on RRLC-TOF-MS is a useful tool to search potential biomarkers related to @DISEASE@ and to dissect the underlying mechanisms of TCM in treating @DISEASE@.
True	Taking potential biomarkers found in the study as screening indexes, it revealed that @FORMULA@ and its components could reverse the pathological process of @DISEASE@ through partly regulating the @DISEASE@.
False	Rapid-resolution liquid chromatography TOF-MS for urine metabolomic analysis of @DISEASE@ in rats and its applications.
False	By combining with partial least squares discriminant analysis, 24 potential biomarkers were identified and primarily involved in 12 metabolism pathways, such as tricarboxylic acids cycle metabolism, lipid metabolism, tryptophan metabolism and phenylalanine metabolism, which revealed a new insight into the @DISEASE@ network in vivo.
False	MATERIALS AND METHODS: Forty male Wistar rats were randomly divided into five groups, including model group, normal control group, dexamethasone group, @FORMULA@ group and the mixture of 13 components of @FORMULA@ group after immunized with bovine type II collagen.
False	Compared with those before treatment in each group and those of the control, the levels of FBG, fasting insulin, HbA1c after @FORMULA@ treatment were reduced (P < 0.05), but levels of CH and TG in all groups had no significant difference.
False	OBJECTIVE: To explore the clinical effect of @FORMULA@ (@FORMULA@) in treating @DISEASE@ (@DISEASE@) according to Liver in TCM.
False	[Clinical study in treating @DISEASE@ according to liver in TCM].
False	RESULTS: By the end of 3 months, the effect in treating @DISEASE@ in the treated group was better than that in the control group (P < 0.05).
True	CONCLUSION: @FORMULA@ could soothe the Liver to relieve @DISEASE@, which is effective in treating @DISEASE@ and could improve the symptoms of @DISEASE@ patients.
False	METHODS: Fifty-one @DISEASE@ patients were randomly divided into the treated group and the control group, 31 patients of the treated group were treated with conventional and @FORMULA@ therapy, while 20 patients in the control were treated with conventional therapy alone.
False	Methods: The @DISEASE@-@DISEASE@ model was induced by 3.5% sodium taurocholate.
False	Gut microbiome detected by 16S rRNA sequencing analysis and serum amino acid metabolome analyzed by liquid chromatography-mass spectrometry explained the underlying mechanism.
False	Amylase, lipase, creatinine, blood urea nitrogen, kidney injury molecule 1(KIM-1), and multiple organs' pathological examinations were used to assess the protective effect of @FORMULA@.
False	Moreover, principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), and hierarchical clustering analysis (HCA) presented a remarkable change in amino acid metabolome after @DISEASE@-@DISEASE@ induction and an apparent regulation by @FORMULA@ treatment (R2Y 0.878, P=0.01; Q2 0.531, P=0.01).
False	Rats were treated with normal saline or @FORMULA@ twice and sacrificed at 36 h after modeling.
True	Conclusions: @FORMULA@ attenuated @DISEASE@-@DISEASE@ by modulating the gut microbiome and serum amino acid metabolome, which may be a promising adjuvant treatment.
False	Effect on eNOS/NO Pathway in @DISEASE@ rats with preconditioning of GFPC from @FORMULA@.
True	CONCLUSION: These results indicate that @DISEASE@ preconditioning (IPC) of GFPC from @FORMULA@ plays a protective role in @DISEASE@ through regulating the eNOS/NO signal pathway, which could increase the eNOS gene expression and decrease the expression of iNOS mRNA.
False	RESULTS: In PPC group, real-time RT-PCR and western-blot analysis showed that eNOS mRNA and peNOS protein increased markedly (P < 0.05); iNOS mRNA and protein decreased significantly (P < 0.05).
False	OBJECTIVE: In order to discover whether the eNOS/NO (endothelial nitric oxide synthase/nitric oxide) pathway is involved in the protective mechanisms of @DISEASE@ of @FORMULA@ (@FORMULA@) in @DISEASE@ (@DISEASE@) SD rats.
False	MATERIALS AND METHODS: We made @DISEASE@ (@DISEASE@) model by ligating the left anterior-descending branch of the coronary artery (LAD) for 30 min and releasing the ligature for 120 min. eNOS (nitric oxide synthase) mRNA (message ribonucleic acid) and iNOS (inducible nitric oxide synthase) mRNA were measured by the methods of real-time RT-PCR (Real time Polychainase Chain Reaction), peNOS (phosphorylated eNOS) and iNOS protein were measured by the means of western blot.
True	CONCLUSIONS: @FORMULA@ combined with octreotide therapy could improve the clinical efficacy of @DISEASE@ patients, and its mechanism might be related to reducing the level of inflammatory factors, thereby inhibiting the @DISEASE@, and regulating the level of serum Amy.
False	The levels of inflammation parameters [white blood cell count (WBC), interleukin-6 (IL-6), procalcitonin (PCT), C-reactive protein (CRP)] and serum amylase (Amy) before and after treatment of patients between the two groups, as well as the occurrence of clinical efficacy indicators and adverse reactions were compared.
False	A total of 64 patients were finally enrolled in the analysis, including 32 cases in the @FORMULA@ group and 32 cases in the western medicine treatment group respectively.
False	METHODS: From March 2018 to February 2021, a total of 68 patients with @DISEASE@ (@DISEASE@) and @DISEASE@ (@DISEASE@) admitted to Shanghai Traditional Chinese Medicine-Integrated Hospital were included, and they were randomly divided into western medicine treatment group and @FORMULA@ group.
False	The total clinical effective rate of patients in the @FORMULA@ group was significantly higher than that of the western medicine treatment group [93.75% (30/32) vs. 71.88% (23/32), P < 0.05].
False	There was no obvious adverse event during the treatment and observation period in the two groups.
False	Finally, TCM with anticancer or symptom relief uses were discussed in detail with regard to their @DISEASE@ or hepatoprotective properties.
False	Traditional Chinese medicine (TCM) herbs are commonly regarded to be safe with minimal toxicities in Chinese communities.
False	A literature search on PubMed was performed to identify publications regarding TCM herbs and concoctions with hepatoprotective or @DISEASE@ properties.
False	In view of the wide range of evidence available, cases assessed by the well-established RUCAM (Roussel Uclaf Causality Assessment Method) algorithm were categorized as the highest level of evidence.
False	Lists of commonly used herbs and their causality levels were compiled.
True	More than one case of TCM herb-induced @DISEASE@ was confirmed by RUCAM in the following herbs and concoctions: Lu Cha (Camellia sinensis), Bai Xian Pi (Dictamnus dasycarpus), Tu San Qi (Gynura segetum), Jin Bu Huan (Lycopodium serratum), He Shou Wu (Polygoni multiflora), Ge Gen (Pueraria lobata), Dan Lu Tong Du tablet, Shou Wu Pian, @FORMULA@, Xiao Yin pill, and Yang Xue Sheng Fa capsule.
True	To the best of our knowledge, there have been no previous reports of @DISEASE@ induced by @FORMULA@.
False	[A case of @DISEASE@ due to @FORMULA@].
False	Two days later, he was admitted because a negative density, @DISEASE@-like shadow was noted on chest X-ray.
False	The clinical symptoms, @DISEASE@, and chest X-ray findings markedly improved.
False	A 16-year-boy who had taken a common over-the-counter @DISEASE@ remedy containing @FORMULA@, presented with @DISEASE@, @DISEASE@, sputum and @DISEASE@.
False	A diagnosis of drug-induced @DISEASE@ was strongly suspected, because an arterial blood gas analysis showed @DISEASE@ and @DISEASE@ with @DISEASE@, and the chest X-ray showed a diffuse negative density @DISEASE@ like shadow bilaterally.
True	Our results demonstrated that quercetin, as the main effective component of the @FORMULA@, has potent inhibitory activity on @DISEASE@ by regulating the ratio of Bax/Bcl-2.
False	@FORMULA@ (@FORMULA@) is a well-known traditional Chinese medicine used in the treatment of @DISEASE@, @DISEASE@, @DISEASE@, but the mechanisms of the medicine are not clear.
False	This study aimed to identify the active components of @FORMULA@ and elucidate the underlying mechanism on @DISEASE@.
False	First, @FORMULA@ was extracted with different solvents, and then the most effective extract was determined by assessing their effects on @DISEASE@ cell growth.
False	Second, several active compounds from @FORMULA@ were identified, and quercetin was the one of the important active ingredients.
False	Subsequently, the in vivo antitumor activity of quercetin was confirmed in a @DISEASE@ xenograft model in mice. 200 mu g/mL quercetin significantly reduced @DISEASE@ volume without affecting body weight of the mice.
False	Furthermore, the AS/GA combination group was better than the @FORMULA@ group in reducing the level of ALT in serum.
False	Uniform design method with 4-factor 8-level table was used to optimize the proportion of four ingredients from @FORMULA@, including astragaloside (AS), astragalus flavonoids (AF), glycyrrhizae acid (GA), and glycyrrhizae flavonoids (GF).
False	The AS/GA combination group was better than AS/GA used alone group in reducing the content of Hyp in the liver tissue and the level of ALT in serum.
False	[Uniform designed research on the active ingredients assembling of @FORMULA@ for inhibition of DMN-induced @DISEASE@].
False	RESULTS: The optimal proportion of AS and GA was 164:48.
True	CONCLUSIONS: AS and GA were effective ingredients of @FORMULA@, and the combination of AS and GA had obvious synergistic effect in reducing liver collagen deposition and decreasing serum ALT activity in DMN-induced @DISEASE@.
False	METHODS: Fifty patients with @DISEASE@ were randomly divided into two groups: @FORMULA@-treated group with 32 cases and control group with 18 cases.
False	The patients in the control group were given regular therapy, while the patients in the @FORMULA@-treated group were given @FORMULA@ additionally on the basis of regular therapy.
False	[Effects of @FORMULA@ on functions of vascular endothelium in patients with @DISEASE@].
False	Then the contents of serum endothelin (ET), nitric oxide (NO), soluble vascular cell adhesive molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) were examined by radioimmunoassay, enzymic method and enzyme-linked immunosorbent assay (ELISA) respectively.
False	RESULTS: The total response rate in the @FORMULA@-treated group was 93.75%, which was significantly higher than 66.67% in the control group (P<0.05).
True	CONCLUSION: @FORMULA@ can improve the functions of vascular endothelium by lowering the levels of endothelium-derived contracting substances, enhancing the levels of endothelium-derived relaxing substances, and reducing the cell adhesions, and hence to raise the therapeutic effects on @DISEASE@.
False	"The ""risk of bias assessment tool (Version 5.1.0)"" of Cochrane Handbook was applied to assess the quality of included trials and RevMan 5.3 software was used for data analysis."
False	Efficacy and safety of @FORMULA@ in combination with western medicine treatment of @DISEASE@ for @DISEASE@: a systematic review and meta-analysis.
False	RESULTS: A total of 111 studies was retrieved, seven studies including 460 cases were included, the methodological quality of included trials was poor.
False	There were significant differences in red blood cell (RBC) [WMD =-0.49, 95% CI: (-0.69, -0.28), P<0.00001], hematocrit (HCT) [WMD =-1.92, 95% CI: (-3.15, -0.69), P=0.002] and clinical efficacy [odd ratio (OR) =0.30, 95% CI: (0.13, 0.69), P=0.004] between @FORMULA@ combination group and control group, the experimental group was better than control group.
False	Randomized controlled trials reported results of efficacy and safety of @FORMULA@ in combination with western medicine treatment of @DISEASE@ for @DISEASE@.
True	CONCLUSIONS: @FORMULA@ in combination with conventional western medicine (CWM) for @DISEASE@ might be superior to CWM alone and there was no adverse event in the experimental group, it might be more effective when the ratio of Radix Astragali to Radix Angelicae Sinensis was 5:1.
False	Methods: A combination of high-fat diet (HFD) and streptozotocin (STZ) was used to induce @DISEASE@ in rats.
False	However, no study has explored the effect of @FORMULA@ on the gut microbiota in @DISEASE@ (@DISEASE@) yet.
False	Additionally, our results indicated that @FORMULA@ treatment could not only restore the gut @DISEASE@ in @DISEASE@ rats, which was proved by an increasing amount of short chain fatty acids (SCFAs)-producing and anti-inflammatory bacteria such as Parabacteroides, Blautia, and Akkermansia as well as a decreasing amount of conditioned pathogenic bacteria (e.g., Aerococcus, Staphylococcus, and Corynebacterium), but also modulate the @DISEASE@ in @DISEASE@ rats, including an up-regulation in bile acid biosynthesis as well as a reduction in glycolysis/gluconeogenesis and nucleotide metabolism.
False	Therefore, in this study, we investigated the modulation of gut microbiota induced by @FORMULA@ treatment in @DISEASE@ in order to unveil the underlying mechanism.
False	Bacterial communities in the fecal samples from the control group, the @DISEASE@ model group, and the @FORMULA@-treated @DISEASE@ group were analyzed by 16S gene sequencing, followed with a subset sample analyzed by shotgun sequencing.
True	Conclusion: @FORMULA@ treatment could ameliorate @DISEASE@ and restore the @DISEASE@ to a normal condition mainly by increasing SCFAs-producing bacteria and reducing conditioned pathogenic bacteria in @DISEASE@ rats, which provides insights into the mechanism of @FORMULA@ treatment for @DISEASE@ from the view of gut microbiota.
False	Post-oral TJ-8 administration significantly ameliorated decreases in liver SOD, catalase, and GSSG-R activities at 24 hrs after CCl4 injection, but did not affect liver Se-GSH-px and increased liver G-6-PDH activities at 24 hrs after the injection.
False	When TJ-8 (1.0 g/kg body weight) was administered orally to male Wistar rats aged five weeks 2 hrs after i.p. injection of CCl4 (1.0 ml/kg body weight), an apparent @DISEASE@ occurred.
False	Significant prevention against the progression of @DISEASE@ was found at 24 hrs after injection, judging from the activities of serum transaminases, indexes of @DISEASE@.
False	Liver cytosolic superoxide dismutase (SOD) activity decreased 2 and 24 hrs after CCl4 injection, while liver cytosolic catalase and glutathione reductase (GSSG-R) activities decreased 24 hrs after the injection.
True	Preventive effect of @FORMULA@ (@FORMULA@) extract on @DISEASE@ in rats with carbon tetrachloride-induced @DISEASE@.
False	In order to clarify the preventive action of @FORMULA@ (@FORMULA@) extract (TJ-8) on the progression of @DISEASE@ in rats intoxicated with carbon tetrachloride (CCl4), we examined the effect of post-oral TJ-8 administration on hepatic active oxygen metabolism following the progression of this @DISEASE@.
False	The therapeutic effect of @FORMULA@ was evaluated by macroscopic and microscopic observation; the mT cell, mTfh, and their subsets were analyzed by flow cytometry.
False	The mice @DISEASE@ were induced by dextran sulfate sodium (DSS) and were treated by @FORMULA@ for 7 days.
False	Flow cytometry showed that the percentages of CD4(+) and CD8(+) expressions on central memory T cells were enhanced after @FORMULA@ treatment, while the CD4(+) T cm, CD4(+) mTfh (memory T follicular helper) cells and their subpopulations were also significantly increased.
False	Moreover, @FORMULA@ inhibited the expression of JAK/STAT signaling pathway proteins JAK1, PIAS3, STAT5, p-STAT5, BIM, BAX, caspase-3, and beta-casein and promoted the expression of JAK3, PISA1, Bcl-2, and caveolin-1.
False	In the present study, @FORMULA@ significantly reversed @DISEASE@ and @DISEASE@ (colon weight increase and colonic length shortening) caused by 3% DSS in physiological saline solution.
True	In summary, @FORMULA@ can regulate immune homeostasis induced by mT cell and mTfh in DSS-induced @DISEASE@, which is potentially correlated with JAK/STAT signaling pathway activation.
False	The improvement of sperm motility may not be associated with the activity of COX, and the COX activity may be related to the mRNA expression of COX II but not that of COX.
False	[Effects of @FORMULA@ on mitochondrial cytochrome oxidase in the spermatogenic cells of rats with @DISEASE@].
False	Then all the animals were sacrificed and the epididymal and testicular tissues collected for examination of sperm motility with the color sperm dynamic detection system, measurement of the COX activity with the immunohistochemical DAB method, and determination of the mRNA expressions of COX and COX by RT-PCR.
False	OBJECTIVE: To explore the effects of @FORMULA@ (@FORMULA@) on mitochondrial cytochrome oxidase (COX) in the spermatogenic cells of rats with @DISEASE@.
False	At 7 days after inoculation, the rat models of testicular @DISEASE@ were treated orally with normal saline (group B), @FORMULA@ at 1 g per kg of the body weight per day (group C), and azithromycin at 0.105 g per kg of the body weight per day (group D), respectively, once daily for 21 days.
True	CONCLUSIONS: @DISEASE@ can reduce grades a and b sperm, linear, curvilinear and mean sperm velocities, and the mRNA expressions of COX and while @FORMULA@ can improve these parameters.
False	BACKGROUND: @DISEASE@ (@DISEASE@) is a @DISEASE@ under acute stress.
False	@FORMULA@ is a famous traditional Chinese medicine prescription, which has been used to treat @DISEASE@ for thousands of years.
False	Many clinical cases have proved that @FORMULA@ has a good effect on @DISEASE@.
False	In this study, we investigated the effect of the fecal microbiome in mice with @DISEASE@ by the 16S rDNA sequencing technology.
False	Effect of @FORMULA@ on the Intestinal Microbiome in @DISEASE@ (@DISEASE@) Mice.
True	CONCLUSIONS: @FORMULA@ might effectively promote the repair of @DISEASE@ and regulate the number and species of intestinal bacteria to maintain the stability of gastrointestinal microecology.
False	@FORMULA@ may achieve its pharmacological effects through anti-inflammatory and anti-oxidative effects, negative regulation of apoptosis and regulation of pancreatic secretion, involving multiple signals, such as IL-17, TNF and NF-kappaB signaling pathway.
False	Then, crucial targets were verified with relevant active chemical components via molecular docking.
True	In this study, it is the first time to use the method of network pharmacology to reveal the molecular mechanism of @FORMULA@ in the treatment of @DISEASE@ by multiple components and multi-signaling pathways, which provides a basis for further biological experiments of @DISEASE@.
False	Potential targets of components from @FORMULA@ and relevant pathogenic genes of @DISEASE@ were identified through database retrieval.
False	The network pharmacology was used to investigate the material basis and molecular mechanism of @FORMULA@(@FORMULA@) in the treatment of @DISEASE@(@DISEASE@).
False	DAVID enrichment analysis showed 438 biological process, 31 molecular functions, 17 cellular components and 96 KEGG pathways.
False	Moreover, GO enrichment and KEGG pathway analysis were performed to investigate the potential signaling pathways associated with @FORMULA@'s effect on @DISEASE@.
False	RESULTS: A total of 143 candidate active compounds and 129 relative drug targets were obtained, in which 61 targets were overlapped with @DISEASE@.
False	The KEGG pathway analysis demonstrated that 16 signaling pathways were closely correlated with @FORMULA@'s effect on @DISEASE@ with @DISEASE@ pathways, Th17 cell differentiation, and IL-17 signaling pathways as the most significant ones.
True	CONCLUSIONS: This study suggested that @FORMULA@ exerted its effect on @DISEASE@ via modulating multitargets with multicompounds through multipathways.
False	Then, the PPI and component-target-pathway networks were constructed.
False	Action Mechanism Underlying Improvement Effect of @FORMULA@ on @DISEASE@: A Study Based on Network Pharmacology and Molecular Docking.
False	Meanwhile, the clinical features including reducing blood pressure, blood lipid and traditional Chinese medicine (TCM) syndromes of the two groups were observed pre and post treatment.
False	Totally 96 elderly patients with spleen-kidney Yang deficiency type @DISEASE@ were selected in this study.
False	[Effect of @FORMULA@ combined with nifedipine for the treatment of elderly @DISEASE@ patients with spleen-kidney Yang deficiency syndrome].
False	It was treated with the @FORMULA@ combined nifedipine sustained-release tablets in the study group and only nifedipine sustained-release tablets for the control group.
False	Patients were randomly divided into study and control group.
True	Finally, the results showed that it could significantly reduce the @DISEASE@, @DISEASE@ and TCM syndromes in the study group compared with the control group (P < 0.05), which indicated that the combination of the @FORMULA@ with nifedipine sustained-release tablets was effective for the patients with @DISEASE@ with spleen-kidney Yang deficiency type, especially for decreasing TCM syndromes and the blood lipid.
False	In this paper, ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry(UHPLC-Q-TOF-MS)-based metabolomics approach was used to explore the mechanism of @FORMULA@(@FORMULA@) in treating @DISEASE@(@DISEASE@).
False	The routine indexes such as body weight, blood glucose, plasma insulin, IL-6 and related organ indexes were determined.
False	Eleven metabolites such as taurocholic acid and palmitic acid were down-regulated in @DISEASE@ mice, and five metabolites such as L-leucine and leukotriene E4 were up-regulated.
False	Metabolic profiling revealed 16 metabolites as the most potential biomarkers distinguishing mice in model group from those in control group.
False	The metabolomics pathway analysis(MetPA) was used to investigate the underlying metabolic pathways.
True	The significantly-altered metabolite levels indicated that @FORMULA@ can improve the progression of @DISEASE@ by increasing @DISEASE@, regulating @DISEASE@ and @DISEASE@, and relieving @DISEASE@.
False	Pharmacodynamics and metabonomics study of @FORMULA@ for treatment of @DISEASE@ rats with liver-yang hyperactivity syndrome.
True	@FORMULA@ reduced the BP in @DISEASE@ model and regulated the serum levels of NE, Ang II, ET, 5-HT, CRP, RENIN and ALD especially at @FORMULA@ bid group.
False	Blood pressure (BP) and indexes of renin-angiotensin-aldosterone system (RAAS system) were measured.
False	@FORMULA@ (@FORMULA@) is effective for the therapeutic of @DISEASE@ in China.
False	RESULTS: To better explain the role of @FORMULA@ on @DISEASE@, we detected three different frequencies of @FORMULA@ treatment with equal dosage.
False	Consisted with the antihypertension activity, @FORMULA@ bid group showed the significantly moderating effect on the regulating biomarkers.
False	@FORMULA@(@FORMULA@), @FORMULA@ (@FORMULA@), @FORMULA@ (@FORMULA@), and @FORMULA@ (@FORMULA@) were fed (500 mg/kg, in saline, po) to the rats before toxin administration.
False	Serum index of liver function and hepatic lipid peroxidation (LPO) were estimated.
False	All the animals were killed 48 h after toxin insulted.
False	Pre-treatment of four prescriptions showed a remarkable protective effect, and also was effective in counteracting the free radical toxicity by bringing about a significant decrease in peroxidative level.
False	AIM: To study the prophylactic effects of four Chinese traditional prescriptions against experimental @DISEASE@.
True	In rats, challenged with ANIT, receiving the pre-treatment of prescriptions of @FORMULA@, @FORMULA@, and @FORMULA@, the biochemical and morphological parameters of @DISEASE@ were significantly reduced.
False	OBJECTIVE: To screen the active ingredients of @FORMULA@ (@FORMULA@) by using rat @DISEASE@ model induced by mono-colonal antibody 1-22-3 (mAb) injection.
False	METHODS: The active ingredients of @FORMULA@ was screened by 5 successive times of experiment.
False	All the rats were killed 8 days after modeling to observe the effect of various drugs on @DISEASE@, morphological change of kidney and biochemical parameters.
False	[Effect of @FORMULA@ and its active ingredients on experimental @DISEASE@ in rats].
True	CONCLUSION: @FORMULA@ and its active ingredients had inhibition on mAb induced rat model of @DISEASE@, the active is saikosaponin-d.
False	Group 1 was treated with PBS as control, Groups 2-4 were treated separately with @FORMULA@ and its various ingredients, the medication was started 5 days before and lasted to 8 days after modeling by peritoneal injection, 13 days totally.
True	@FORMULA@ and Yanshu injection, as well known combination formulas and prescriptions in TCMs, have shown an excellent therapeutic effect on @DISEASE@.
False	The article focused on the antitumor properties of natural compounds and combination formulas or prescriptions in TCMs, described its influence on @DISEASE@ progression, @DISEASE@, @DISEASE@, and revealed its mechanisms of antitumor and inhibitory action.
False	A lot of valuable TCMs were applied as alternative or complementary medicines in the United States and Europe.
False	In TCMs, some specific herbs, animals, minerals and combination formulas were recorded and exploited due to their active ingredients and specific natural compounds with antitumor activities.
False	But these TCMs, as one of the main natural resources, were widely used to research and develop new drugs in Asia.
False	To discover and develop novel natural compounds, active ingredients, single herbs and combination formulas or prescriptions in traditional Chinese medicine (TCM) with therapeutic selectivity that can preferentially kill @DISEASE@ cells and inhibit the amplification of @DISEASE@ without significant toxicity is an important area in @DISEASE@ therapy.
False	Excessive lipid accumulation and chemical abuse can induce @DISEASE@ in fish, but the underlying mechanism and therapies are unknown.
False	In vivo, a total of 300 hybrid grouper with an average initial weight of 25.43+/-0.18g were fed diets containing five graded levels of @FORMULA@ at 150-1200mg/kg diet for 8 weeks.
False	Livers challenged with D-GalN/LPS exhibited extensive areas of vacuolization with the disappearance of nuclei and the loss of hepatic architecture.
False	Dietary @FORMULA@ down-regulated the expression of lipogenic-related genes (G6PD, DGAT2 and ME1) and up-regulated lipolysis-related genes (ATGL, PPARalpha and LPL) expression in the liver of hybrid grouper.
True	@FORMULA@ potently reduced hepatic lipid accumulation and enhanced antioxidant capability in hybrid grouper and may be a potential fish-feed additive to prevent @DISEASE@ onset and progression.
False	These pathological alterations were ameliorated by @FORMULA@ treatment.
False	Excessive free iron could accelerate oxidative damage, which may be involved in this process.
False	@FORMULA@ reduced the total iron in myocardial cells (0.72-fold) and mitochondrial iron by downregulating Mfrn2 (0.81-fold) and MtFt (0.78-fold) proteins, and upregulating ABCB8 protein (1.33-fold).
False	Cardiac and mitochondrial function, iron levels, apoptosis and mitophagy were determined.
False	@FORMULA@ diminishes iron toxicity damage in heart induced by @DISEASE@.
True	DISCUSSION AND CONCLUSIONS: These findings encourage the use of @FORMULA@ to resist @DISEASE@ and provide the theoretical basis for clinical treatment in @DISEASE@ patients.
False	CONTEXT: @DISEASE@ (@DISEASE@) causes @DISEASE@ (@DISEASE@), which results in mitochondrial dysfunction and generates reactive oxygen species (ROS) in the heart.
False	These biomarkers was mainly involved in glycine, serine, and threonine metabolism; aminoacyl-tRNA biosynthesis metabolism; and taurine and hypotaurine metabolism.
False	In this study, ultra-high-performance liquid chromatography coupled with quadrupole-Exactive mass spectrometry (UHPLC-Q-Exactive MS) based metabonomics was used to find the potential mitochondrial biomarkers and metabolic pathways of @FORMULA@ in @DISEASE@ rats, which focused on a specific organelle (mitochondria) isolated from gastric tissue samples.
False	Our previous study had revealed that energy regulation was one of the important mechanisms of @FORMULA@ action against @DISEASE@.
False	Mitochondria metabonomics of @FORMULA@ against @DISEASE@.
False	A total of 16 biomarkers from @DISEASE@ tissues were identified with 11 of these significantly regulated by @FORMULA@ treatment.
True	Our results show that @FORMULA@ could protect from @DISEASE@ by altering the mitochondrial function.
False	METHODS: Thirty-three patients were treated with @FORMULA@ and Vit B(6), with 15 cases taking orally prednisone acetate and 20 healthy volunteers as the control.
False	CONCLUSION: The activating blood circulation to remove stasis approach in treating @DISEASE@ with integrative Chinese and Western drugs got better results, and @DISEASE@ of tryptophan might be correlated with the etiology of @DISEASE@.
True	Follow-up efficacy of integrative Chinese and Western drugs on @DISEASE@ with vitamine B6 and @FORMULA@.
False	Their level of soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor-alpha (TNF-alpha) in the patients with @DISEASE@ before and after treatment were observed.
False	After treatment with Vit B(6) and @FORMULA@, the level of sIL-2R and TNF-alpha from the patients with @DISEASE@ decreased significantly (P < 0.01), but there were no difference between the group taking Vit B(6) plus @FORMULA@ and the group given prednisone.
False	RESULTS: The level of sIL-2R and TNF-alpha in the serum from the patients with @DISEASE@ were higher than those of healthy volunteers (P < 0.01).
False	@FORMULA@ Attenuates Cigarette Smoke and Lipopolysaccharide Induced @DISEASE@ via IkappaBalpha/NF-kappaB Signaling.
False	@FORMULA@ was administered by oral gavage at doses of 50 mg/kg or 100 mg/kg 1 h before exposure to CS.
False	Histological examinations revealed that @FORMULA@ suppressed inflammatory cell infiltration into lung tissue compared to untreated CS- and LPS-exposed mice.
False	@FORMULA@ reduced the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), as well as the phosphorylation of inhibitor of kappa-B subunit alpha (IkappaBalpha) and nuclear factor kappa-B (NF-kappaB) in CS- and LPS-exposed mice.
False	In this study, we investigated the anti-inflammatory effect of @FORMULA@ using a cigarette smoke (CS)- and lipopolysaccharide (LPS)-induced induced @DISEASE@ mouse model.
True	In conclusion, @FORMULA@ effectively suppressed CS- and LPS-induced @DISEASE@.
False	The Chinese medicine @FORMULA@ inhibits HBx-induced migration and invasiveness of human @DISEASE@ cells.
False	METHODS: In this study, we investigated the mechanisms underlying @FORMULA@-mediated inhibition of HBx-induced cell invasion and the inhibition of secreted and cytosolic MMP-9 production, using gelatin zymography and Western blot analysis in a human @DISEASE@ cell line (HepG2).
False	@FORMULA@ also suppressed HBx-induced inhibition of NF-kappaB nuclear translocation through IkappaB and suppressed HBx-induced activation of ERK/phosphatidylinositol 3-kinase/Akt upstream of NF-kappaB and AP-1.
False	Relative luciferase activity was assessed for MMP-9, NF-kappaB, or AP-1 reporter plasmid-transfected cells.
True	CONCLUSIONS: @FORMULA@ suppresses the invasiveness and @DISEASE@ potential of @DISEASE@ cells by inhibiting multiple signal transduction pathways.
False	@FORMULA@ suppressed HBx-induced AP-1 activity through inhibition of phosphorylation in the extracellular signal-related kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling pathways.
False	@FORMULA@ (per 6.25g/kg/d) was orally given to rats twice each day for 30 days after @DISEASE@, Nimodipine (per 10mg/kg/d) was orally given to rats twice each day for 30 days.
False	@FORMULA@ (@FORMULA@), as a traditional Chinese medicine, has been developed to treat @DISEASE@ for hundreds of years, but the underlying mechanisms remain unknown.
False	@FORMULA@ of intragastric administration also markedly increased the expression of Extracellular signal-regulated kinase 2 (ERK2) and Calcium/calmodulin-dependent protein kinaseII (CaMKIIIy)in the CA1 region.
False	In this research, the protective effects of @FORMULA@ on hippocampal neuron were examined in the rats of @DISEASE@.
False	In @DISEASE@+@FORMULA@ group rats, the @DISEASE@ in the hippocampal CA1 region was significantly less than that of @DISEASE@ group's.
True	Our results suggested that increased ERK2 and CaMKIIIy due to @FORMULA@ may partially account for its effect of neuroprotection standing against @DISEASE@ in the hippocampal CA1 region, and participated in the rebuilding of synapse, strengthened the expression of LTP, promoted the ability recover of learning and memory in @DISEASE@ rats.
False	Here, we examined the combined protective effects of Chinese herbal formula @FORMULA@ and @FORMULA@ on @DISEASE@ and @DISEASE@ in rats.
True	CONCLUSION: @FORMULA@ and @FORMULA@ synergistically ameliorated @DISEASE@ and @DISEASE@ in rats through upregulation of OAT1 and OAT3.
False	Combination of @FORMULA@ and @FORMULA@ also led to a greater increase in OAT1 and OAT3 expression than did @FORMULA@ alone.
False	METHODS: Rats were randomly divided into normal rats, @DISEASE@ rats, and @DISEASE@ rats orally administrated with benzbromarone (4.5 mg.kg(-)(1).d(-)(1)), @FORMULA@ (3.78 g.kg(-)(1).d(-)(1)) and @FORMULA@ plus @FORMULA@ (6.48 g.kg(-)(1).d(-)(1)) for 4 weeks.
False	RESULTS: @FORMULA@ plus @FORMULA@ lowered serum uric acid, creatinine, triglyceride and BUN levels to a greater degree than did @FORMULA@ alone.
False	BACKGROUND/AIMS: @DISEASE@ is an independent risk factor for @DISEASE@ and @DISEASE@.
False	AIM: To study the effects of @FORMULA@ freeze-dried powder on high fat diet-induced @DISEASE@ in mice.
False	The high fat diet group (FAT) and @FORMULA@ group (@FORMULA@) were allowed ad libitum access to a high fat diet.
False	After 12 wk, body weight, liver index, visceral fat index, serum alanine aminotransferase (ALT), portal lipopoly-saccharide (LPS), liver tumor necrosis factor (TNF)-alpha and liver triglycerides were measured.
False	BACKGROUND: @DISEASE@ (@DISEASE@) is a common @DISEASE@ worldwide.
False	Freeze-dried @FORMULA@ powder can ameliorate high fat diet-induced @DISEASE@.
True	CONCLUSION: The beneficial effects of @FORMULA@ freeze-dried powder on high fat diet-induced @DISEASE@ in mice may be associated with its anti-inflammatory and changing intestinal microbiota effects.
False	METHODS: Animals were administered orally every day for eight consecutive weeks except the mice of normal group and model group.
False	Meanwhile, histopathological changes in the renal were studied by hematoxylin-eosin (H&E) staining.
False	The expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT 3) in kidney tissue was observed by western blot (WB) and immunohistochemical (IHC) method.
False	Creatinine (Cr), blood urea nitrogen (BUN) and urine protein were measured for renal function evaluation.
False	Reno-protective effect and mechanism study of @FORMULA@ on @DISEASE@ MRL/lpr mice.
True	CONCLUSIONS: The study implied that @FORMULA@ may be a potential agent for the therapy of @DISEASE@, and the down-regulated p-STAT 3 expression suggesting that it may be one of the @DISEASE@ therapy targets for @FORMULA@.
False	The administration of TJ-9 clearly prevented the membrane protein damage arising from @DISEASE@ challenge.
False	Preventive effects of a traditional Chinese medicine (@FORMULA@) against oxygen toxicity and membrane damage during @DISEASE@.
False	Leakages of acid phosphatase and lactate dehydrogenase isozyme in serum were markedly lower in endotoxin-TJ-9-treated mice than those in mice given endotoxin.
False	The preventive effects of a traditional Chinese medicine @FORMULA@ (Kampo prescription, TJ-9) were determined from oxygen toxicity and membrane damage in liver during @DISEASE@.
False	In the mice pretreated with a TJ-9, the levels of alpha-tocopherol and nonprotein SH in liver tissue 18 h after endotoxin injection were markedly increased as compared to those in endotoxin-treated mice.
True	Kampo prescription @FORMULA@ thus appears to protect the liver plasma membrane from injury by free radicals which occur in a tissue @DISEASE@ state during @DISEASE@.
False	Additionally, IFN-gamma which @FORMULA@-augmented the production may contribute the protective effect against the @DISEASE@ by activating of phagocyte cells.
True	These results suggest that @FORMULA@ enhances the production of hematopoietic lymphokines, stimulates the proliferation of hematopoietic progenitor cells and consequently accelerates recovery from @DISEASE@ in CY-treated mice.
False	The effect of a Japanese ethical herbal drug, @FORMULA@ (@FORMULA@), on recovery from @DISEASE@ induced by cyclophosphamide (CY) was investigated.
False	Ginsenoside Rgl extracted from Ginseng radix, a major herb of @FORMULA@, was one of the active ingredients.
False	The frequencies of IL-3-, GM-CSF- and IFN-gamma-producing cells increased in the spleen, bone marrow, liver and IEL on @FORMULA@ treatment, and @FORMULA@ clearly augmented the expressions of IL-3, GM-CSF and IFN-gamma mRNA in the spleen, bone marrow, liver and IEL except IL-3 and IFN-gamma mRNA in the IEL.
False	The number of colony-forming units in the spleen (CFU-S) also increased in @FORMULA@-treated mice.
False	Several key profibrotic pathways, including TGF-beta/Smad and Wnt/beta-catenin pathways, were downregulated by @FORMULA@ treatment.
True	CONCLUSION: Our work demonstrated that @FORMULA@ can prevent @DISEASE@ and the mechanisms involved may be related to the inhibition of colon fibroblasts activation.
False	Immunofluorescence staining was used to evaluate fibroblasts proliferation and epithelial to mesenchymal transition (EMT), and the expression of key molecules in @DISEASE@ was analyzed by western blot.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ (@FORMULA@), a classic traditional Chinese herb medicine, is one of the most important formulations to treat @DISEASE@ from ancient times to the present.
False	Previous study showed that @FORMULA@ has satisfactory curative effects on experimental @DISEASE@, which motivating the application of @FORMULA@ on @DISEASE@-associated complications.
False	MATERIALS AND METHODS: The @DISEASE@-associated @DISEASE@ mice model was established by weekly intrarectal injection of 2,4,6-trinitrobenzene sulfonic acid (TNBS).
False	We matched with propensity score 3967 patients who received Chinese herbal medicine by age, sex, year of @DISEASE@ diagnosis, urbanization, comorbidities and @DISEASE@ medications.
False	OBJECTIVES: To investigate the effectiveness of Chinese herbal medicine for the treatment of @DISEASE@ in patients with @DISEASE@.
False	METHODS: We carried out a retrospective cohort study using the National Health Insurance Research Database.
False	All participants received follow-up visits until the end of 2013 to record the incidence rate of @DISEASE@.
False	CONCLUSION: The use of Chinese herbal medicine in @DISEASE@ patients can reduce their risk of @DISEASE@.
True	The Chinese herbal medicine prescription pattern analysis showed that Fritillariae thunbergii bulbus (Zhebeimu), Semen armeniacae amarum (Kuxingren), Platycodonis radix (Jiegeng), @FORMULA@ and @FORMULA@ constituted the core of Chinese herbal medicine prescriptions applied to treat @DISEASE@.
True	Thus, our results show that @FORMULA@ holds a great potential in @DISEASE@ treatment.
False	Notably, these in silico analysis results were further validated by a series of cellular functional and molecular biological assays.
False	To better understand the pharmacological activity of @FORMULA@ against @DISEASE@, we next constructed a drug/disease-target PPI network composed of 252 putative core therapeutic targets of @FORMULA@ using Cytoscape.
False	The subsequent enrichment analysis for these targets suggested that @FORMULA@ could affect the apoptosis and cell cycle of @DISEASE@ cells via impeding Akt/ERK signaling pathways.
False	The therapeutic effect of @FORMULA@ on @DISEASE@ was then validated by oral administration of @FORMULA@ in the @DISEASE@ mice bearing xenografted @DISEASE@ tumors.
False	"In this study, we first systemically explore the action mechanism of @FORMULA@ by using network pharmacology and bioinformatic analysis tools, which uncovered a potential ""new use of old drug"" for @FORMULA@ in @DISEASE@ treatment."
False	After the 1-month treatment, the combined therapy group showed significantly higher FMA and BI scores (P < 0.05) compared to the control group.
False	In the combined therapy group, the Ashworth and CSS scales were significantly improved compared to before the treatment (P < 0.05) and compared to the patients in the control group (P < 0.05).
False	To investigate the clinical effect and surface electromyography (sEMG) of rehabilitation exercise therapy in combination with total glucosides form @FORMULA@ in treating @DISEASE@ after @DISEASE@ @DISEASE@.
False	Clinical efficacy and sEMG analysis of a new traditional Chinese medicine therapy in the treatment of @DISEASE@ following @DISEASE@ @DISEASE@.
False	Composite @DISEASE@ scale (CSS), Fugl-Meyer assessment (FMA) and modified Barthel index were compared between the exercise only group and the combined therapy group before and 1 month after the treatment to scale muscular tension, function and activities of daily living.
True	The total glucosides form @FORMULA@ could significantly improve the efficacy of the rehabilitation exercise therapy in the treatment of @DISEASE@ after @DISEASE@ @DISEASE@, and its mechanism might involve the decrease of muscular tension.
False	The myocardial enzyme spectrum of 40 healthy children at the baby clinics during the same period were recruited as the control.
False	Compared with after treatment in the same group, CK decreased in the control group 3 months after treatment (P <0. 01).
False	METHODS: From January 2010 to December 2012, 156 @DISEASE@ children patients with AMES were randomly assigned to the treatment group (80 cases) and the control group (76 cases).
False	CK-MB, CK, LDH, and AST decreased in the control group 3 months after treatment (P <0.01, P <0.05).Compared with after treatment, CK decreased in the control group 3 months after treatment (P <0.01).
False	RESULTS: Compared with the control group, creatine kinase isoenzyme (CK-MB), creatine kinase(CK), and lactate dehydrogenase (LDH) increased in the two treatment groups (P <0.01), but there was no statistical difference in AST (P >0.05).
True	[Treating @DISEASE@ children with abnormal myocardial enzyme spectrum by @FORMULA@: an efficacy observation].
False	This study is aimed at clarifying the underlying mechanism of @FORMULA@ to protect against @DISEASE@ @DISEASE@.
False	Although @FORMULA@ (@FORMULA@) has been reported to treat various @DISEASE@ including @DISEASE@ induced by @DISEASE@, its mechanism is still poorly understood.
False	We found that @DISEASE@ @DISEASE@ rats exhibited @DISEASE@, reduced food intake, and @DISEASE@ and @DISEASE@.
False	As expected, @FORMULA@ suppressed @DISEASE@ and oxidative stress to alleviate @DISEASE@.
False	In addition, @DISEASE@ led to @DISEASE@, impaired secretory function and blood-testis barrier (BTB) of Sertoli cells, and elevated @DISEASE@ and oxidative stress.
True	@FORMULA@ exerts its anti-inflammatory and antioxidant effects via the MAPK signaling pathway, thus playing an important role in ameliorating @DISEASE@ and @DISEASE@.
False	@FORMULA@ attenuated the mRNA expression of pro-@DISEASE@ cytokines, TLR2, and TLR4 and decreased TLR4 and TLR protein levels as well as the phosphorylation of IkappaB in LPS-induced BV-2 cells.
False	The protein expression levels were measured by Western blots.
False	INTRODUCTION: @FORMULA@ (@FORMULA@) is composed of six traditional Chinese medicines, including Angelica sinensis, Paeoniae radix, Rhizoma Ligusticum, Poria cocos, Rhizoma Atractylodis Macrocephalae, and Rhizoma Alismatis.
False	The mRNA levels of @DISEASE@ factors were analyzed by quantitative real-time PCR (qRT-PCR).
False	@FORMULA@ attenuated the release of pro-@DISEASE@ factors, such as interleukin-1beta (IL-1beta), iNOS and tumor necrosis factor-alpha (TNF-alpha) in LPS-induced BV-2 cells.
True	CONCLUSION: This study demonstrated that @FORMULA@ has a protective effect on @DISEASE@ in LPS-induced BV-2 microglia cells through the TLRs/NF-kappaB signaling pathway.
False	Simple immune agar diffusion test was used to assay the contents of 12 plasma proteins in 70 cases of @DISEASE@ treated by @FORMULA@ ([symbol: see text]), with the other 70 cases who were not given @FORMULA@ as the control group.
False	In the treatment group, the levels of prealbumin, transferrin and fibronectin elevated obviously after treatment, and the contents of C-reactive protein, ceruloplasmin, haptoglobin, alpha 1-antitrypsin and alpha 1-acid glycoprotein decreased markedly (P < 0.01).
False	Effects of @FORMULA@ on plasma proteins in 70 cases of @DISEASE@.
False	In the control group, only the levels of ceruloplasmin and C-reactive protein decreased significantly (P < 0.05).
False	The total clinical effective rate in the treatment group was 90.0%, while that in the control group was 75.7%, with a statistically significant difference between the two groups (P < 0.05).
True	It is shown that @FORMULA@ may enhance the therapeutic effects for @DISEASE@, regulate the metabolism of plasma proteins, and improve the life quality of the patients.
False	The outputs of this study would provide scientific basis for future clinical applications of @FORMULA@ as prebiotics to treat cisplatin-induced @DISEASE@, and gut microbiota may be a promising therapeutic target for chemotherapy-induced @DISEASE@.
True	In the present study, we have demonstrated that gut microbiota mediates the protective effects of traditional Chinese medicine formula @FORMULA@ against cisplatin-induced @DISEASE@.
False	We found that @FORMULA@ treatment significantly attenuated cisplatin-induced @DISEASE@ and gut @DISEASE@, altered the levels of bacterial metabolites, with short-chain fatty acids (SCFAs) such as acetic acid and butyric acid increasing and uremic toxins such as indoxyl sulfate and p-cresyl sulfate reducing, and suppressed histone deacetylase expression and activity.
False	The essential role of gut microbiota was further verified by both the diminished protective effects with antibiotics-induced gut microbiota depletion and the transferable renal protection with fecal microbiota transplantation.
False	In the present study, the potential role of gut microbiota in the nephroprotective effects of @FORMULA@ was investigated.
False	Spearman's correlation analysis found that @FORMULA@-enriched fecal bacterial genera Akkermansia, Faecalibaculum, Bifidobacterium, and Lachnospiraceae_NK4A136_group were correlated with the altered metabolites, and these metabolites were also correlated with the biomarkers of @DISEASE@, as well as the indicators of @DISEASE@ and @DISEASE@.
False	RESULTS: @FORMULA@ (320 mg/kg b.w.) prevented body @DISEASE@, reduced polyurea, @DISEASE@, serum creatinine and blood urea nitrogen, although it did not alter the @DISEASE@.
False	At the end of the observation period, kidneys were isolated for histology, angiotensin II content determination, real time PCR and Western blot analyses.
True	CONCLUSIONS: Data from this study suggest that @FORMULA@ possess a protective effect on @DISEASE@ of STZ-induced @DISEASE@ in rats, by suppressing hyperactivity of renal renin-angiotensin system that turns in to modulate renal nephrin and podocin expressions, thereby protecting podocyte from injury.
False	It ameliorated glomerular @DISEASE@ and expansion of the mesangial area, swell and effacement of foot process.
False	It also suppressed the increased expression of angiotensin II, nephrin and podocin.
False	MATERIALS AND METHODS: Streptozotocin (STZ)-induced @DISEASE@ rats were orally administrated @FORMULA@ (80,320 mg/kg b.w.) once a day, for a period of 12 weeks.
False	To avoid of learning effect, three sequential gum tests were needed.
False	The effect of a traditional chinese medicine '@FORMULA@' was evaluated on salivary secretion in thirty-eight patients with @DISEASE@ (@DISEASE@) and the results were compared with a matchen control group of patients treated with @FORMULA@.
True	Finally, @FORMULA@ was very useful for managing oral manifestations in patients with @DISEASE@.
False	(r = 0.7290) Fourth, the improvement of salivary secretion under @FORMULA@ treatment was marked in stage I and stage II of sialographical abnormalities of the salivary gland.
False	Before looking into the effects of @FORMULA@ on salivary secretion, we must define the reliability of the gum test.
False	[The effect of @FORMULA@ on salivary secretion in @DISEASE@].
False	OJECTIVE: To observe the effect of @FORMULA@ (@FORMULA@) on the endothelial function and the renal protein expression of spontaneously @DISEASE@ rats, and to analyze its possible mechanism.
False	Rats in the captopril group were administered with captopril at the daily dose of 3. 375 g/kg. 2 mL/100 g distilled water was administered to rats in the SHR control group and the WKY control group.
False	The significantly deviated protein was verified by Western blot.
False	RESULTS: (1) Compared with the SHR control group, blood pressure was significantly lowered in rats (10 - 24 weeks old) of the captopril group (P <0.01, P <0.05).
False	[Effect of @FORMULA@ on the endothelial function and the renal protein expression in spontaneously @DISEASE@ rats].
True	CONCLUSION: @FORMULA@ could protect the endothelial function of the superior mesenteric artery in SHR, and its intervention mechanism of @DISEASE@ induced early @DISEASE@ might be relevant to regulating the NO system and antioxidative stress.
False	Apoptosis was detected using electrophoresis and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick endlabeling (TUNEL) assay.
False	@FORMULA@, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human @DISEASE@ cells in vitro and in vivo.
False	Our study reports here for the first time the anticancer effect of @FORMULA@ in two human @DISEASE@ cell lines, Hep G2 and PLC/PRF/5.
False	The inhibitory effect mediated by @FORMULA@ on cell growth was also demonstrated in a nude mouse model, in which the @DISEASE@ cells induced @DISEASE@ xenograft shrank considerably following treatment with @FORMULA@.
False	The activity of nuclear factor-kappa B (NF-kappaB) was determined by Trans-AM ELISA kit.
True	CONCLUSIONS: Taken together, these results suggest a potential anticancer effect of @FORMULA@ against human @DISEASE@ cells.
False	Collectively, these results suggest that @FORMULA@ and fJGT162 are safe and useful complementary and alternative anti-cancer herbal therapies, and that Lactobacillus fermentation improves the in vivo anti-cancer efficacy of @FORMULA@ significantly.
False	@FORMULA@ (@FORMULA@, @FORMULA@ in Chinese and @FORMULA@ in Japanese) is an oriental herbal formula that has long been used as a traditional medicine to treat @DISEASE@ and @DISEASE@.
False	Meanwhile, the daily oral administration of 120 mg/kg fJGT162 to HT1080-bearing BALB/c nude mice suppressed @DISEASE@ growth dramatically (up to 90%) compared with saline treatment, whereas the administration of non-fermented @FORMULA@ suppressed @DISEASE@ growth by ~70%.
False	Recent studies revealed that @FORMULA@ exhibited potent inhibitory effects on @DISEASE@, @DISEASE@, @DISEASE@, @DISEASE@, and @DISEASE@.
False	Several constituent herbs in @FORMULA@ induce apoptotic @DISEASE@ cell death.
True	@FORMULA@ Induces Apoptosis via the Mitochondrial Pathway and Lactobacillus Fermentation Enhances Its Anti-Cancer Activity in HT1080 Human @DISEASE@ Cells.
False	The ion m/z 664.3126 was found to correspond to ceramide (d18:1/25:0), providing further support for an involvement of the sphingomyelin signaling pathway in @DISEASE@ and the intervention effects of @FORMULA@.
False	This paper was designed to study metabonomic characters of the @DISEASE@ and the intervention effects of @FORMULA@ (@FORMULA@), a classic traditional Chinese medicine formula for treatment of @DISEASE@ and @DISEASE@ in China.
False	The positive ions m/z 664.3126 (9.00 min) was elevated in urine of alcohol-treated rats, whereas, ions m/z 155.3547 (10.96 min) and 708.2932 (9.01 min) were at a lower concentration compared with that in urine of control rats, however, these ions did not indicate a statistical difference between control rats and @FORMULA@-treated rats.
False	The greatest difference in metabolic profiling was observed from alcohol-treated rats compared with the control and @FORMULA@-treated rats.
True	Metabolic urinary profiling of @DISEASE@ and intervention effects of @FORMULA@ in rats using ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry.
False	The total ion chromatograms obtained from the control, alcohol- and @FORMULA@-treated rats were easily distinguishable using a multivariate statistical analysis method such as the principal components analysis (PCA).
False	The intersection of compound target and disease target was obtained and the coincidence target was imported into STRING database to construct a PPI network.
False	However, the main components and potential mechanisms of @FORMULA@ remain unclear.
False	@DISEASE@ targets were searched on OMIM and DisGeNET databases.
False	The protein with a higher degree in the PPI network is JUN, RELA, TNF.
False	We further performed GO and KEGG enrichment analysis on the targets.
True	CONCLUSION: This study reveals the active ingredients and potential molecular mechanism of @FORMULA@ in the treatment of @DISEASE@, and provides a reference for subsequent basic research.
False	METHODS: Forty Wistar male rats were randomly divided into 5 groups( n = 8)control group, model group, model + positive control group (mesalazine), @FORMULA@ treatment group, in addition, the @FORMULA@ treatment group was divided into middle and high dose group.
False	[Effect of @FORMULA@ on the expression of proinflammatory cytokines in @DISEASE@].
False	RESULTS: Compared with the model group, positive medicine and @FORMULA@ group, especially high-dose group, could effectively inhibit the expression of IL-1beta, IL-6 and TNF-alpha.
False	The expression of interleukin-1beta (IL-1beta), interleukin-6(IL-6) and tumor necrosis factor-alpha (TNF-alpha) were detected by real time PCR after extraction of RNA from colons.
True	CONCLUSION: @FORMULA@ could exert its effect in the treatment of @DISEASE@ by inhibiting the expression of proinflammatory cytokines.
False	OBJECTIVE: To investigate the molecular mechanisms underlying in the treatment of @DISEASE@ by @FORMULA@.
True	Our results suggest that supplementation with @FORMULA@ might be beneficial for the prophylaxis and treatment of @DISEASE@ associated with abnormal osteoclast activation.
False	We herein report that daily oral @FORMULA@ administration significantly inhibits osteoclast activation as well as the reduction in bone volume in ovariectomized mice.
False	Daily oral supplementation of @FORMULA@ prevents osteoclastic activation and @DISEASE@ in ovariectomized mice.
False	@FORMULA@, a Japanese traditional herbal medicine, is commonly used for the treatment of @DISEASE@ or @DISEASE@ after an illness; however, its effects on @DISEASE@ such as @DISEASE@ are not well known.
False	Bone remodeling is sophisticatedly regulated by two different cell types: bone-resorbing osteoclasts and bone-forming osteoblasts.
False	In this study, 60 patients @DISEASE@ to house dust mite allergen confirmed by skin test and MAST test were recruited and randomized.
False	The nasal symptomatic scores and the responses of polymorphonuclear neutrophils (PMN) to IL-4-stimulation were measured after treatment.
False	Antiinflammatory effects of @FORMULA@ in patients with @DISEASE@.
False	In contrast, no change was found in symptomatic scores in the control group (3.17+/-0.12 before treatment vs. 2.79+/-0.14 after treatment).
False	Moreover, total serum IgE and the IL-4-stimulated production of PGE(2) and LTC(4) by PMN was significantly suppressed in the experimental group after treatment compared to the control group.
True	These results suggest that @FORMULA@ but not @FORMULA@ was beneficial to the patients with @DISEASE@ via suppressed nasal @DISEASE@ by an antiinflammatory effect.
False	Protective effects of @FORMULA@ on @DISEASE@ and @DISEASE@ in animal model of @DISEASE@.
False	@FORMULA@ also adjusted the neurotransmitter levels, reduced the content of endothelin-1 (ET-1), and induced the activities of vascular endothelial growth factor (VEGF) in hippocampus.
False	The study showed that rats in @DISEASE@ treatment with @FORMULA@ for 14 days significantly improved behavioral function, increased densities of neuron, and induced @DISEASE@ in the brain compared with model rats.
True	These results suggested that @FORMULA@ might be developed as an effective drug for the prevention of @DISEASE@.
False	Moreover, the immunohistochemical staining and western blotting results also revealed that @FORMULA@ decreased apoptosis via upregulated B-cell lymphoma-2 (Bcl-2)/Bcl-2 associated X protein (Bax) ratio.
False	@FORMULA@ (@FORMULA@) as a traditional chinese medicine (TCM) has been developed to treat @DISEASE@ for hundreds of years, and @DISEASE@ (@DISEASE@) is a @DISEASE@ caused by @DISEASE@.
False	For the immediate early gene c-fos, the expression was reduced after @FORMULA@ treatment, and the difference was significant between the treatment and the model group.
True	Through the transcriptome analysis of the gene expression in hippocampus, Egr3, Nrg, Arc, and Ptgs2, closely related to @DISEASE@, had been proved to be downregulated by application of @FORMULA@.
False	In our results, the treatment of @FORMULA@ dose-dependently inhibited PTZ-induced @DISEASE@-like behavior and reduced the @DISEASE@ grades, LFP power spectral density, and brain wave of the epileptiform EEG component induced by PTZ.
False	All of the results not only highlight the antiepileptic effects of @FORMULA@ and its molecular mechanism, but also provide a modern validity theory for the clinical application of traditional Chinese medicine (TCM).
False	The present study was undertaken to investigate them by animal behavior, electroencephalogram (EEG), Morris water maze, immunohistochemistry, transcriptomics, and real-time PCR.
False	In Morris water maze tests, the learning and memory ability of kindled @DISEASE@ rats could be attenuated more efficiently by @FORMULA@.
False	OBJECTIVE: To study the effects of @FORMULA@ (, @FORMULA@) and @FORMULA@ (, @FORMULA@) on the expressions of brain-derived neurotrophic factor (BDNF) and cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling of axonal regeneration in the Lewis rats with experimental @DISEASE@ (@DISEASE@), in order to explore the possible mechanism of @FORMULA@ and @FORMULA@ on promoting axonal regeneration.
False	The @DISEASE@ model of rat was established by injecting antigen containing myelin basic protein (MBP)68-86.
True	Effects of @FORMULA@ () and @FORMULA@ () on the expression of brain-derived neurotrophic factor and cyclic adenosine monophosphate/protein kinase A signaling transduction pathways of axonal regeneration in model rats with experimental @DISEASE@.
False	The brain and spinal cord were harvested on the 14th and 28th day post-immunization (PI), the protein and mRNA expression of BDNF and PKA in the brain and spinal cord of rats were detected by Western blot analysis and real-time quantitative polymerase chain reaction (PCR), and the cAMP levels were detected by using enzyme-immunoassay method.
False	The cAMP level in spinal cord also significantly increased in @FORMULA@ group compared with MO, PA and @FORMULA@ groups, respectively (P<0.01). (3) On the 14th day PI, the PKA expression in spinal cord of rats in @FORMULA@ group was significantly decreased compared with MO and @FORMULA@ groups, respectively (P<0.05). (4) On the 28th day PI, there was a positive correlation between cAMP and PKA expression in the brain white matter of @FORMULA@ rats.
False	METHODS: The rats were randomly divided into normal control (NC), model (MO), prednisone acetate (PA), @FORMULA@ and @FORMULA@ groups.
False	Liver histopathology was microscopically observed and mRNA expression levels of ABCG5, ABCG8, SRBI, ABCB4, ABCB11 and NPC1L1 involved in cholesterol metabolism were measured using reverse transcription-quantitative PCR.
False	In addition, elevated expression of ATP-binding cassette subfamily G member 5/8, scavenger receptor class B type I and Niemann-Pick C1 Like 1 in the liver and small intestine were observed at the onset of @DISEASE@ but were reversed by @FORMULA@.
False	The condition of @DISEASE@ was evaluated using a six-level criteria.
False	Effect and related mechanism of @FORMULA@ on mice with lithogenic diet-induced @DISEASE@.
False	The results showed that feeding mice the LD induced @DISEASE@, along with abnormal serum biochemical indices and imbalances in biliary cholesterol homeostasis.
True	Taken together, results from the present study suggest that @FORMULA@ ameliorated LD-induced @DISEASE@ mice, which may be caused by improvements in biliary cholesterol supersaturation and regulation of cholesterol metabolism.
False	Effect of @FORMULA@ on the serum TH1 cytokines of elderly patients with @DISEASE@ complicated by bloody purulent stool.
False	ROC analysis showed that the area under the curve (AUC) of IL-2 was 0.797, the maximum Jordan index was 0.573, the sensitivity was 61.10%, and the specificity was 96.20%.
False	In the two groups, serum IL-2 and IFN-gamma levels were decreased significantly before and after treatment, but the decrease in the study group was significant (P < 0.05).
True	CONCLUSION: @FORMULA@ as an adjuvant therapy is a promising option for elderly patients with @DISEASE@ complicated by bloody purulent stool.
False	RESULTS: After treatment, the scores in the two groups were decreased significantly, and the decrease in the study group was significant (P < 0.05).
False	OBJECTIVE: To investigate the role of @FORMULA@ as an adjuvant therapy on the serum TH1 of elderly patients with @DISEASE@ complicated by bloody purulent stool.
False	AKT and mTOR expression were measured by western blot analysis.
False	Significant downregulation of AKT/mTOR/p70S6K proteins in brain tissues was observed after the administration of @FORMULA@ (especially at a dose of 9 g/kg).
False	@FORMULA@ (especially at a dose of 9 g/kg) markedly reduced the mNSS and levels of AA, TNF-alpha and IL-1beta.
False	@FORMULA@ (@FORMULA@) is an effective traditional Chinese medicine to treat @DISEASE@.
False	@FORMULA@, a traditional Chinese medicine, provides neuroprotection in a rat model of @DISEASE@ via an anti-inflammatory pathway.
True	@FORMULA@ may be a promising therapeutic strategy for reducing @DISEASE@ in @DISEASE@.
True	Some single herbs and their extracts (such as Astragali Radix, Scutellariae Radix, Ginkgo Folium) and some traditional Chinese medicine (such as @FORMULA@, Qilian decoction) can reduce the @DISEASE@ damage induced by renal tissue NF-kappaB signaling pathway and delay the progression of @DISEASE@.
False	In @DISEASE@ (@DISEASE@), @DISEASE@ during the progression of renal tissue and tissue injury related causes its progression to @DISEASE@.
False	Among them, nuclear factor (nuclear factor, NF)-kappaB signaling pathway by regulating the corresponding nuclear expression of target gene transcription, as well as affecting the synthesis of @DISEASE@ mediators, induction of @DISEASE@ lead to @DISEASE@ and renal @DISEASE@.
False	[Regulatory mechanism of NF-kappaB signaling pathway on @DISEASE@ in @DISEASE@ and interventional effect of traditional Chinese medicine].
False	Outstanding efficacy was also seen in hemorrhagic @DISEASE@.
False	The subjects consisted of 18 patients with @DISEASE@ (including 3 women), 77 patients with plastic induration of penis, 5 patients with @DISEASE@ (all men), and 67 patients with hemorrhagic @DISEASE@ (including 6 men).
False	The overall improvement rate in the patients with @DISEASE@ was 61.1%.
False	A joint multi-institution study was conducted on the efficacy of @FORMULA@, centering on urinary tract @DISEASE@.
True	[Clinical efficacy of @FORMULA@ in various @DISEASE@ centering on @DISEASE@].
False	Dividing the patients into irradiation and non-irradiation groups, respective overall improvement rates of 77.8% and 82.8% were obtained, with the non-irradiation group showing a slightly higher rate.
False	The scores for general malaise, @DISEASE@ and discomfort were significantly lower in the combination group than in control group.
False	Body temperature did not significantly differ between the two groups.
False	However, the exact mechanism by which @FORMULA@ is effective remains to be established.
False	Each patient received 6 million units of IFN-beta intravenously.
False	Plasma IL-6 level and IL-1ra were significantly elevated in the combination group compared to control (P = 0.0057 and 0.0003, respectively).
True	The effects of a herbal medicine (@FORMULA@) in patients with @DISEASE@ after injection of IFN-beta.
False	CONCLUSION: The anticancer activity of @FORMULA@ extracts may be partially achieved through attenuation of the 5-HTR1D-Wnt/beta-catenin signaling pathway.
False	Cell apoptosis was pronounced, and cell migration and invasion were suppressed.
False	Various subtypes of 5-Hydroxytryptamine receptor (5-HTR) have been shown to play a role in @DISEASE@ and @DISEASE@. 5-HTR1D, among the subtypes, is highly expressed in @DISEASE@ (@DISEASE@) cell lines and tissues.
False	The cells were respectively treated with GR127935 and different doses of @FORMULA@ extracts.
False	The present study aimed at investigating effect of @FORMULA@ extracts on the biological function of @DISEASE@ cells, the expression of 5-HTR1D, and molecules of Wnt/beta-catenin signaling pathway.
True	Extracts of @FORMULA@, a traditional Chinese medicine, phenocopies 5-HTR1D antagonist in attenuating Wnt/beta-catenin signaling in @DISEASE@ cells.
False	@FORMULA@ (@FORMULA@) is the first choice to treat cold @DISEASE@ in clinical settings.
False	However these levels were lower in group C and D than in group B (p<0.05), and there was no significant difference between groups C and D (p>0.05).
False	Regarding pathologic changes, the @DISEASE@ infiltrate in the lungs of groups C, D, and E was lower than that of group B, especially in group E.
False	Serum interleukin 1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), nuclear factor kappaB (NF-kappaB), and TSLP levels were higher in group B than in group A (p<0.05).
False	In this study, the role of the TSLP pathway in the onset of @DISEASE@ and the protective mechanism of @FORMULA@ were investigated.
True	We conclude that the TSLP pathway plays an important role in the course of @DISEASE@, and can be used as an important target for @DISEASE@ treatment; @FORMULA@ may play a role in reducing @DISEASE@ and relieving @DISEASE@ by regulating the TSLP signaling pathway.
False	The results of the in vitro and in vivo experiments indicated that the levels of LPS, TNF-alpha and IL-6 of the palmatine group were significantly lower than those of the @DISEASE@ model group (p<0.01).
True	This verifies that @FORMULA@ is a viable treatment option for @DISEASE@ given that there are multiple components in @FORMULA@ that neutralize LPS, decrease the release of IL-6 and TNF-alpha induced by LPS, and protect vital organs.
False	The anti-sepsis activity of the components of @FORMULA@ with high lipid A-binding affinity.
False	The levels of LPS in the blood were measured, and pathology experiments were conducted.
False	The LPS levels and mRNA expression analysis of TNF-alpha and IL-6 of the cell supernatant and animal tissue were evaluated to investigate the molecular mechanisms.
False	Palmatine showed the highest affinity to lipid A and was evaluated by in vitro and in vivo experiments.
True	@FORMULA@ can act on multiple targets through multi-pathway, to carry out its therapeutic role in @DISEASE@.
False	TCMSP, DrugBank, Swiss Target Prediction were utilized to search the active components and effective targets of @FORMULA@.
False	Co-targets between @FORMULA@ and @DISEASE@ are obtained by Draw Venn Diagram.
False	Combined microarray analysis, network pharmacology, and molecular docking for revealing the therapeutic targets and molecular mechanism of @FORMULA@ against @DISEASE@.
False	PPI (Protein-protein interaction) network was constructed by the STRING database.
False	IL6, TNF, IL1B, PTGS2, ESR1, and PPARG with the highest degree from PPI network were successfully docked with 19 core components of @FORMULA@, respectively.
False	It was suggested that @FORMULA@ is clinically a hopeful drug used to cure @DISEASE@ and attenuate the side effects of CY.
False	The techniques of culture of hematopoietic progenitor cell and hematopoietic growth factor assay were used.
False	The culture media of spleen cell, macrophage, lung and skeletal muscle treated with @FORMULA@ had much stronger stimulating effects on hematopoietic cells.
True	The bone marrow cells of the @DISEASE@ mice could yield TNF through @FORMULA@ treatment.
False	This study was designed to evaluate the effect of @FORMULA@ on @DISEASE@ induced by cyclophosphamide (CY) in mice.
False	[The influence of @FORMULA@ on hematopoietic modulator in @DISEASE@ mice].
False	@FORMULA@ Ameliorates Renal @DISEASE@ via TGF-beta/Smad Signaling Pathway In Vivo and In Vitro.
False	OBJECTIVE: Traditional Chinese Medicine compound @FORMULA@ is widely used in clinical treatment of @DISEASE@, but its role on renal interstitial @DISEASE@ and the underlying mechanism remains unclear.
False	Animals were sacrificed 14 days after the administration and ipsilateral kidney tissue was sampled for pathologic examinations.
True	CONCLUSION: The protective effect of @FORMULA@ for @DISEASE@ in mice was mediated by downregulating the TGF-beta/Smad signaling pathway.
False	TGF-beta1 was used in in vitro experiments to induce human kidney proximal tubule epithelial cells (HK2).
False	Similar results were found in in vitro studies.
False	Their chest radiograph showed diffuse ground-glass shadows in the whole lung fields and chest CT showed diffuse ground-glass-opacities predominantly in the lower lung fields of both lungs.
False	Their abnormal chest shadows disappeared after discontinuation of @FORMULA@.
False	Biochemical tests revealed @DISEASE@ and @DISEASE@ reactions.
True	We should be aware that @FORMULA@, as well as other Chinese herbal medicine, could be cause of drug-induced @DISEASE@.
False	[Two cases of @DISEASE@ caused by @FORMULA@, Chinese herbal medicine].
False	A 54-year-old woman and a 80-year-old man had taken @FORMULA@ for @DISEASE@ and @DISEASE@.
False	[Effect of @FORMULA@ on neuro-immuno-endocrine system in patients with @DISEASE@].
False	They were assigned to the @FORMULA@ group (32 cases, treated with @FORMULA@) and the control group (31 cases, treated with maprotiline).
True	CONCLUSION: @FORMULA@ is effective in improving symptoms of @DISEASE@ by regulating the levels of 5-HT, BDNF, CORT and IL-6.
False	After 4 and 6 weeks of treatment the total score and score of the three factors all reduced significantly in both groups (P < 0.01), with insignificant difference between the groups.
False	The curative effect was evaluated with Hamilton's @DISEASE@ scale (HAMD) before and at the end of the 2nd, 4th and 6th week of the treatment.
False	RESULTS: After 2 weeks of treatment, the total score of HAMD decreased remarkably in both groups (P < 0.01), and the total score, as well as the scores of the three factors, i. e. @DISEASE@/@DISEASE@, @DISEASE@ and feeling of despair, were lower in the @FORMULA@ group than that in the control group respectively (P < 0.05 or P < 0.01).
False	A randomized, double-blind, placebo-controlled trial of a traditional herbal formula, @FORMULA@ in elderly subjects with @DISEASE@.
False	Many conventional treatments for @DISEASE@ provide only temporary symptom relief, and have side effects.
False	However, participants with BMIs lower than 29.37kg/m(2) showed improvement of @DISEASE@ after 8 weeks of treatment with @FORMULA@ compared to placebo.
False	In addition, @FORMULA@ improved oral moisture, which is associated with subjective @DISEASE@ in the @FORMULA@ group, and the relationship between VAS for @DISEASE@ and YD was significant.
False	METHODS: This study was designed as a randomized, placebo-controlled, double-blinded, two center trial.
True	CONCLUSION: A trend was observed in which @FORMULA@ improved oral moisture status and subjective @DISEASE@ in elderly subjects with lower BMI and greater tendency toward YD.
True	CONCLUSIONS: The CLCF1 gene is an important gene associated with @DISEASE@ Shen-yin deficiency and the therapeutic effects of @FORMULA@ may be mediated by up-regulation of CLCF1 gene expression and activation of the JAK/STAT signaling pathway.
False	OBJECTIVES: To investigate the mechanism of @FORMULA@ (, @FORMULA@) in treating @DISEASE@ (@DISEASE@) with Shen (Kidney) yin deficiency.
False	In vitro, CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3.
False	Real-time polymerase chain reaction (RT-PCR) and Western blot techniques were used to observe the effects of @FORMULA@ treatment on the cardiotrophin-like cytokine factor 1 (CLCF1), ankyrin repeat and SOCS box containing 1 (ASB1), and prokineticin 2 (PROK2) genes and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway.
False	RESULTS: The mRNA (P<0.05) and protein (P<0.01) expression levels of the CLCF1 gene in Group A were significantly lower than the corresponding levels in Group N.
False	After 6-month treatment, the expression levels of CLCF1 mRNA and protein were significantly up-regulated (both P<0.01), and the average bone density of the top femur had significantly increased (P<0.05).
False	In addition, neutrophil chemotaxis, phagocytosis and calcium concentration, [Ca2+]i in neutrophils were also assessed.
False	On the other hand, the medicine did not markedly affect neutrophil chemotaxis, phagocytosis or [Ca2+]i in neutrophils.
False	TJ-50 significantly decreased neutrophil-generated O2-, H2O2 and OH. in a dose-dependent manner.
False	On the basis of recent reports that @FORMULA@ (TJ-50), an oral Japanese Kampo (herb) medicine, is clinically effective in treating @DISEASE@, and that tetracyclines are effective against @DISEASE@ by acting directly as an antioxidant on @DISEASE@, we investigated the effect of TJ-50 on the generation of reactive oxygen species (ROS), using human neutrophils and a cell-free, xanthine-xanthine oxidase system.
True	Effect of @FORMULA@, a Japanese kampo medicine, on neutrophil functions: a possible mechanism of action of @FORMULA@ in @DISEASE@.
False	Three kinds of ROS generated in the cell-free system were also reduced in the presence of TJ-50.
False	The effects of traditional Chinese medicine (@FORMULA@) on experimental @DISEASE@ induced in rats by monoclonal antibody (mAb) 1-22-3 injection was examined.
False	Suppressive effects of @FORMULA@ on monoclonal antibody 1-22-3-induced @DISEASE@: analysis of effective components.
True	It was concluded that Saikosaponin-d, as well as Bupleuri radix, Syo-saiko-to and @FORMULA@ can suppress @DISEASE@ and morphological changes in the rat @DISEASE@ model induced by mAb 1-22-3.
False	The suppressive effect of Syo-saiko-to was identified in its components (Bupleuri radix, Pinelliae tuber and Zingiberis rhizoma), but not in the other combined components (Ginseng radix and Zizyphi fructus).
False	This suppressive effect was caused by the major component of @FORMULA@, Syo-saiko-to but not by another component, Gorel-san.
False	The level of @DISEASE@ in the @FORMULA@-treated group was significantly lower than that in the PBS treated group.
False	OBJECTIVE: To examinie the synergistic effects of @FORMULA@ (, Known as @FORMULA@ in Korean) extract (@FORMULA@) on cisplatin-induced cytotoxicity in the A549 human @DISEASE@ cell lines.
False	METHODS: A549 cells were treated with varying concentrations (50-200 mug/mL) of cisplatin and @FORMULA@ alone or in combination for 96 h.
False	Furthermore, the apoptosis was inhibited by the pan-caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (z-VAD-FMK).
False	CONCLUSIONS: @FORMULA@ significantly potentiated apoptotic effects of cisplatin in A549 cells.
False	Effects of @FORMULA@ () on Cisplatin-Induced Apoptosis of Human A549 @DISEASE@ Cells.
True	Moreover, apoptosis induced by @FORMULA@ might be the pivotal mechanism mediating its chemopreventative action against @DISEASE@.
False	@FORMULA@ significantly prolonged the latency to bicuculline (2.0 mg/kg, s.c.)
False	The anticonvulsant effects of @FORMULA@ and its components on maximal electroshock @DISEASE@ and chemical @DISEASE@ were examined.
False	These findings suggest that @FORMULA@ has anticonvulsant effects.
False	On the other hand, @FORMULA@ had no effect on maximal electroshock @DISEASE@.
True	Efficacy of @FORMULA@, a traditional Chinese medicine formulation, against @DISEASE@ in mice.
False	Of the components of @FORMULA@, Shitei had almost the same effect as @FORMULA@ against the @DISEASE@ induced by the three chemical agents tested.
False	Efficacy of auxiliary therapy with @FORMULA@ No.1 in treating patients of @DISEASE@ at peri-operational stage.
False	The level of CYFRA21-1 and CEA, was immediately decreased after operation in both groups.
False	@FORMULA@ also shows an anti-tumor action to a certain degree.
False	OBJECTIVE: To observe the therapeutic efficacy of @FORMULA@ No.1 in treating patients of @DISEASE@ (@DISEASE@) at the peri-operational stage and its impact on the patients' immune function.
False	METHODS: Eighty-two @DISEASE@ patients were randomly assigned to two groups equally, the control group and the test group, they were given conventional treatment, while to the test group, @FORMULA@ were given additionally.
True	CONCLUSIONS: Applying @FORMULA@ to @DISEASE@ patients at an early post-operational stage could alleviate the impairment and accelerate the recovery of immune function of patients to enhance their immunity.
False	BACKGROUND AND OBJECTIVE: We aimed to predict the targets and signal pathways of @FORMULA@ (@FORMULA@) in the treatment of @DISEASE@ (@DISEASE@) based on network pharmacology, just as well as to further analyze its anti-CRC material basis and mechanism of action.
False	The active ingredients of @FORMULA@ interacted with most @DISEASE@ disease targets.
False	Our results showed that @FORMULA@ could play a role in @DISEASE@ treatment by regulating different signaling pathways.
False	Furthermore, we used the AutoDock Tools software to conduct molecular docking studies on the active ingredients and key targets to verify the network pharmacological analysis results.
False	The molecular docking experiment confirmed the correlation between five core compounds (quercetin, stigmasterol, kaempferol, baicalein, and acacetin) just as well as PTGS2, NR3C2, CA2, and MMP1.
True	CONCLUSION: In this study, we described the potential active ingredients, possible targets, and key biological pathways responsible for the efficacy of @FORMULA@ in @DISEASE@ treatment, providing a theoretical basis for further research.
True	Conclusion: This study revealed the potential bioactive components and molecular mechanisms of @FORMULA@, which may be useful for the treatment of @DISEASE@, and provided insights into the development of new drugs for @DISEASE@.
False	Based on GO enrichment analysis, all targets in the protein-protein interaction network were mainly involved in the response to oxidative stress and neuronal death.
False	The bioactive components of @FORMULA@ were selected for drug-likeness evaluation and binomial statistical model screening, which revealed 63 bioactive components and 72 targets.
False	The protein-protein interaction network of potential targets of @FORMULA@ in @DISEASE@ was constructed using the Cytoscape plug-in (v3.8.0), CytoHubba.
False	In this study, network pharmacological methods were used to analyze the potential therapeutic targets and pharmacological mechanisms of @FORMULA@ in @DISEASE@.
False	Network Pharmacology Analysis of @FORMULA@ Targets in @DISEASE@.
False	In Caco2 cell monolayers, we provided mechanistic evidence that @FORMULA@-induced increased TEER and decreased permeability after TNBS damage, which were mediated through claudin-2 and NF-kappaB pathway, including the upregulation of claudin-2, decreased activity of NF-kappaB p65, reduced level of NF-kappaB p65 and MLCK.
False	DAI, pathological scores and the expression of claudin-2 were evaluated.
False	@FORMULA@ (2.8 5.6, 11.2 g/kg) or salazosulfapyridine (SASP) (0.4 g/kg) was administrated orally in rats for 7 days.
False	RESULTS: @FORMULA@ significantly ameliorated the severity of TNBS-induced @DISEASE@ and downregulated the level of claudin-2 in colonic tissues.
False	The objective of this study was to investigate the protective effects of @FORMULA@ on TNBS-induced @DISEASE@ in rats and TNBS-damaged Caco2 cells.
True	CONCLUSIONS: Our results indicated that @FORMULA@ possesses protective effect of intestinal barrier towards TNBS-induced @DISEASE@ in rats and TNBS-damaged Caco2 cells in vitro.
False	METHODS: Seventy-two female Kunming mice were randomly assigned into six groups: a blank control group, a @DISEASE@ model group, a fluconazole group and three @FORMULA@ groups (dose levels: 22.5, 15.0 and 7.5 g/kg, respectively).
False	RESULTS: The @DISEASE@ mouse models were successfully developed.
False	OBJECTIVE: To explore the possible regulatory effect of @FORMULA@ on Th17 cells and inflammatory cytokines of @DISEASE@ (@DISEASE@) mice.
True	CONCLUSION: @FORMULA@ could inhibit the proliferation of vulvovaginal C. albicans and reduces the levels of inflammatory cytokines in @DISEASE@ mice.
False	The content of the transcription factor retinoid related orphan receptor gamma t (RORgammat) in vaginal tissues was detected by immunohistochemistry.
False	After treatment, the vaginal C. albicans burden of the fluconazole group and 22.5 g/kg @FORMULA@ group dropped significantly compared with that of the @DISEASE@ model group.
False	@DISEASE@ (@DISEASE@) is a @DISEASE@.
False	Microarray analysis reveals the molecular basis of antiarthritic activity of @FORMULA@.
False	However, the mechanism of the anti-arthritic action of this herbal remedy is poorly understood at the molecular level.
False	In LNC restimulated in vitro with the disease-related antigen mycobacterial heat-shock protein 65 (Bhsp65), 84 differentially expressed genes (DEG) (64 upregulated and 20 downregulated) versus 120 DEG (94 upregulated and 26 downregulated) were identified in @FORMULA@-treated versus vehicle (Water)-treated rats, respectively, and 62 DEG (45 upregulated and 17 downregulated) were shared between the two groups.
False	@FORMULA@ (@FORMULA@) is an herbal mixture that has been used in traditional Chinese medicine over several decades to treat @DISEASE@ including @DISEASE@.
True	The most affected pathways in response to @FORMULA@ treatment included immune response, @DISEASE@, cellular proliferation and apoptosis, and metabolic processes, many of which are directly relevant to @DISEASE@ pathogenesis.
False	G-CSF production increased along with the increase of TJ-9 levels, and this could induce excessive production of G-CSF in @DISEASE@ patients, and this may be a cause of @DISEASE@.
False	In patients with @DISEASE@ or @DISEASE@, G-CSF production in the absence of any stimulation was significantly lower than healthy controls (p < 0.01).
False	As @DISEASE@ is also induced by granulocyte colony-stimulating factor (G-CSF), we examined the effects of TJ-9 on G-CSF production in peripheral blood mononuclear cells.
False	"During the past 2 years, drug-induced @DISEASE@ was reported in 66 Japanese patients, mainly among @DISEASE@ patients, undergoing treatment with the Japanese herbal medicine ""@FORMULA@"" (TJ-9)."
True	In vitro effects of @FORMULA@ on production of granulocyte colony-stimulating factor by mononuclear cells from patients with @DISEASE@.
False	@FORMULA@ is one of the representative traditional herb medicines (Kampo formulae) and has been used historically for the treatment of @DISEASE@ in China and Japan.
False	@FORMULA@ did not inhibit the growth of HSV-1 in vitro.
True	Thus, @FORMULA@ induced strong @DISEASE@ to @DISEASE@ mice, which may have caused localisation of @DISEASE@ and reduction in the @DISEASE@ of treated mice.
False	@DISEASE@ (@DISEASE@) response to HSV-1 antigen was significantly stronger in treated mice than in untreated mice.
False	Efficacy of @FORMULA@, a traditional herb medicine, in @DISEASE@ in mice.
False	The efficacy of this preparation was characterised using a cutaneous @DISEASE@ in mice as a model for human @DISEASE@.
False	Misfolded tau proteins induce accumulation of free radicals and promote @DISEASE@ by activating microglia-releasing proinflammatory cytokines, leading to neuronal cell death.
False	This study examined the neuroprotection effects of formulated CHMs Bai-Shao (made of Paeonia lactiflora), Gan-Cao (made of Glycyrrhiza uralensis), and @FORMULA@ (@FORMULA@, made of P. lactiflora and G. uralensis at 1 : 1 ratio) in cell model of @DISEASE@.
True	The study results lay the base for future applications of @FORMULA@ on tau animal models to validate its effect of reducing @DISEASE@ and potential disease modification.
False	Our results showed that @FORMULA@ displayed a greater antioxidative and antiaggregation effect than Bai-Shao and Gan-Cao and a stronger anti-inflammatory activity than Bai-Shao but similar to Gan-Cao.
False	In conclusion, @FORMULA@ displays neuroprotection by exerting antioxidative and anti-inflammatory activities to suppress neuronal apoptosis in human tau cell models.
False	In inducible 293/SH-SY5Y cells expressing proaggregant human tau repeat domain (DeltaK280 tauRD), @FORMULA@ reduced tau misfolding and reactive oxygen species (ROS) level in DeltaK280 tauRD 293 cells and promoted neurite outgrowth in DeltaK280 tauRD SH-SY5Y cells.
False	We evaluated the blood and urine indices of metabolic and renal function, renal tissue histopathology, @DISEASE@, and @DISEASE@.
False	APF treatment also reduced type I and IV collagen, transforming growth factor-beta1 (TGF-beta1), and TGF-beta1 type II receptor expression levels, and decreased the phosphorylation of Smad2/3 in the kidneys of db/db @DISEASE@ mice.
False	To evaluate the effects of APF, in vivo, db/db @DISEASE@ mice were orally administered a low or high dose of APF (300 or 600 mg/kg, respectively) once a day for 8 weeks.
False	This study was aimed at determining the effects of APF on @DISEASE@ in @DISEASE@ and elucidating the underlying molecular mechanisms.
False	Our findings indicate that treatment with multi-component herbal therapeutic formulations may be a useful approach for the treatment of @DISEASE@.
True	Combination of active components of @FORMULA@ ameliorates @DISEASE@ through the inhibition of NF-kappaB and TGF-beta1/Smad pathways in db/db @DISEASE@ mice.
False	It might affect the allergen-induced TH1 and/or TH2 responses.
False	This study investigated whether the herbal medicine could affect cytokine synthesis by peripheral blood mononuclear cells (PBMCs) in response to the major Dermatophagoides farinae (D. farinae) allergen, Der f 1.
False	The herbal medicine @FORMULA@ is an effective agent in the treatment of @DISEASE@.
False	However, the mechanism by which it exerts its action in improving patient symptoms remains unclear.
False	PBMCs were obtained from 15 patients with @DISEASE@ due to D. farinae, and were stimulated for 96 h with 10 micrograms/ml Der f 1 in the presence or absence of 45 mg/ml @FORMULA@.
True	Our study suggests that the @FORMULA@ may alleviate nasal symptoms in @DISEASE@ through control of the allergen-induced @DISEASE@ process.
False	No side effects were observed.
False	Serum LH levels, which were shown to be above 30 mIU/ml in 7 patients were lowered to less than 30 mIU/ml in 5 patients by dexamethasone 1 mg daily administered for 6.5 days.
False	Effect of traditional herbal medicine on serum testosterone levels and its induction of regular ovulation in @DISEASE@ and @DISEASE@ women (author's transl).
False	All of these patients ovulated regularly by @FORMULA@.
True	Thus, @FORMULA@ is indicated for lowering serum testosterone levels and inducing regular ovulation and pregnancy in @DISEASE@ @DISEASE@ patients, especially in the patients whose serum LH levels were shown to be lowered to less than 30 mIU/ml by dexamethasone.
False	Six of 7 patients ovulated regularly and 2 of 6 patients conceived.
True	The results suggested that @FORMULA@ may play a role in the treatment of @DISEASE@ by reducing the @DISEASE@, reducing oxidative stress, inhibiting cell apoptosis, and promoting angiogenesis.
False	GO enrichment analysis and KEGG pathway analysis were carried out using DAVID database and ClueGO, and molecular docking was carried out using Autodock Vina and Pymol.
False	From GO enrichment analysis, 208 biological process terms, 38 molecular function terms, and 33 cellular component terms were obtained.
False	The &quot;active component-target&quot; network was constructed by Cytoscape software, and protein-protein interaction(PPI) network was drawn using STRING platform.
False	Finally, 226 active components of @FORMULA@ were obtained, 257 corresponding targets, 1 340 targets of @DISEASE@, and 109 drug and disease intersection targets were obtained.
False	Protein cluster analysis was carried out using MCODE.
False	In this paper, the related studies on the concerned basic theory and clinical application were reviewed.
False	Traditional Chinese medicine (TCM) holds that Pi-Wei is the essence of postnatal life, and the genesis and development of @DISEASE@ are chiefly due to the insufficiency of vital-qi, which makes the body open to the invasion of evil pathogens.
False	Starting from regulating the immune function of organisms, researchers recently obtained some therapeutic effects by applying the Chinese recipe, @FORMULA@, in the treatment of @DISEASE@.
True	Progress in research on applying @FORMULA@ in treating @DISEASE@.
False	Patients with @DISEASE@ always have their immune function, especially the cellular immunity, suppressed to a certain extent.
False	OBJECTIVE: @FORMULA@ (@FORMULA@), a classical traditional Chinese medicinal formula, has been commonly used to treat @DISEASE@ for thousands of years.
False	Anti-Inflammatory Effects of @FORMULA@ on Dextran Sulfate Sodium-Induced @DISEASE@ in Mice Through Regulation of the Gut Microbiota and Suppression of the Ras-PI3K-Akt-HIF-1alpha and NF-kappaB Pathways.
False	CONCLUSIONS: @FORMULA@ ameliorates DSS-induced @DISEASE@ through regulation of the gut microbiota, and suppression of Ras-PI3K-Akt-HIF-1alpha and NF-kappaB pathways.
True	Our results suggested that @FORMULA@ may be a potential candidate for treatment of @DISEASE@.
False	In addition, the gut microbiota was characterized using high-throughput Illumina MiSeq sequencing.
False	The messenger RNA (mRNA) expression levels of @DISEASE@ mediators were decreased following @FORMULA@ treatment.
False	PI3K/AKT was verified as a possible affected pathway that @FORMULA@ exerted the effectiveness against @DISEASE@.
False	Bioequivalence between ACC and @FORMULA@ was assessed from the aspects of intestine motility (somatostatin secretion), @DISEASE@ (IL-6 secretion) and @DISEASE@ (wound healing assay) in vitro and was further validated in @DISEASE@ rat model.
False	@FORMULA@ (@FORMULA@), a classical purgation prescription, has clinically been proven to be an effective treatment for @DISEASE@.
False	PURPOSE: Network pharmacology integrated with bioactive equivalence assessment was used to discover the quality marker (Q-marker) of @FORMULA@ against @DISEASE@.
False	Patients suffer from poor quality of life and tremendous financial pressure.
True	Network Pharmacology and Bioactive Equivalence Assessment Integrated Strategy Driven Q-markers Discovery for @FORMULA@ to Attenuate @DISEASE@.
False	Meta-analyses demonstrated that @FORMULA@ plus conventional medicine was more effective in improving overall gastroscopy outcome than western medicine alone for treatment of @DISEASE@ with the pooling result of overall improvement [OR 3.78 (1.29,11.06), P = 0.02].
False	In addition, the combination of @FORMULA@ with antibiotics has higher overall effect rate than antibiotics alone for the treatment of @DISEASE@ [OR 2.60 (1.49,4.54), P = 0.0007].
False	However, due to poor methodological quality, the beneficial effect and safeties of @FORMULA@ for @DISEASE@ could not be confirmed.
False	In randomized controlled trials (RCTs) comparing @FORMULA@ with placebo, no intervention and western medicine were included.
False	@FORMULA@ for Treatment of @DISEASE@: A Systematic Review of Randomized Clinical Trials.
True	@FORMULA@ has the potential of improvement of the patients' gastroscopy outcomes, Helicobacter pylori clearance rate, traditional Chinese Medicine syndromes, and overall effect rate alone or in combination use with conventional western medicine for @DISEASE@.
True	Effect of @FORMULA@ freeze-dried powder on sleep-waking cycle in @DISEASE@ rats.
False	Compared with pre-administration, W was significantly decreased and SWS1, SWS2, and the total sleeping time (TST) were markedly increased after administration of the medium dose.
False	METHODS: The @DISEASE@ rats were randomly divided into a high-, medium- or low-dose group of @FORMULA@ (equal to crude drug 8.8, 4.4, or 2.2 g/kg, respectively) for seven consecutive days.
False	RESULTS: Compared with pre-administration, SWS2 was significantly increased after administration of the low dose.
False	The effects of @FORMULA@ on sleep-wake cycle are dose-dependent.
False	CONCLUSION: The results suggest that @FORMULA@ extends SWS1 and SWS2, which increases the total sleeping time.
False	Chinese herbal medicines (CHMs) are used to treat @DISEASE@.
False	Among them, 11,180 received CHMs after @DISEASE@ diagnosis and 23,319 did not (non-CHM).
False	This study sought to determine whether CHM treatment effectively decreases the incidence of @DISEASE@ in @DISEASE@ patients receiving conventional Western medical treatment.
False	CHM use was associated with a trend for a lower cumulative incidence of @DISEASE@ compared with non-CHM use (p < 0.001).
False	The association between herbs and formulas was examined by NodeXL to perform a network analysis of CHM.
True	Among the 10 most commonly used single herbs and formulas used to decrease the risk of @DISEASE@ in @DISEASE@ patients, Fritillariae thunbergii was the most commonly used single herb and @FORMULA@ the most commonly used formula.
False	In the long-term experiment, 90 female ICR mice were given N-methyl-N-nitrosourea (MNU) into their uterine corpora.
False	In the short-term experiment, exposure to @FORMULA@ or @FORMULA@ significantly reduced estradiol-17beta (E(2))-stimulated expressions of COX-2 mRNA (p<0.05) as well as the protein.
False	@FORMULA@, a Kampo formula, originally consists of a mixture of @FORMULA@ and @FORMULA@ formulas together with two other crude ingredients.
False	Exposure of @FORMULA@ reduced the incidence of MNU- and E(2)-induced @DISEASE@ and @DISEASE@ at the termination of the experiment (30 weeks).
False	However, no effects on the expression of COX-1 were observed.
True	The above findings and our previous reports suggest that @FORMULA@ is responsible for the preventive effects of @FORMULA@ on estrogen-related @DISEASE@ in mice, through the inhibition of estrogen-related COX-2 as well as c-fos, IL-1alpha and TNF-alpha expressions.
False	Chinese patent medicine @FORMULA@ combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of @DISEASE@: a systematic review of randomized controlled trials.
False	However, the evidence remains weak due to the poor methodological quality of the included studies.
False	Objectives.
False	The quality of the included studies was assessed with the Jadad scale and a customized standard quality assessment scale.
False	Five major electronic databases were searched up to August 2012 to retrieve any potential randomized controlled trials designed to evaluate the clinical effectiveness of @FORMULA@ combined with antihypertensive drugs for @DISEASE@ reported in any language, with main outcome measures as blood pressure.
True	@FORMULA@ combined with antihypertensive drugs appears to be effective in improving blood pressure and symptoms in patients with @DISEASE@.
False	We identified a total of 48 active compounds mediating 30 PD-related targets to exert synergism, and the same target can be enriched in multiple signal pathways and biological processes, expounding that the decoction can exert synergistic effect on @DISEASE@ by multi-targets and multi-pathways.
False	The present study applied a creative approach called network pharmacology to explore the active compounds and therapeutic targets of @FORMULA@ (@FORMULA@) for treating @DISEASE@.
True	These results highlighted the molecular mechanisms underlying the efficiency of @FORMULA@ for @DISEASE@ treatment at a systematic level, investigating thoroughly the innovative therapeutic tactics for @DISEASE@ in traditional Chinese medicine.
False	A Network Pharmacology-Based Study of the Molecular Mechanisms of @FORMULA@ in Treating @DISEASE@.
False	@DISEASE@ (@DISEASE@) is another major @DISEASE@ following @DISEASE@, which not only seriously reduces the survival in patients, affecting patient's quality of life, but also imposes a tremendous burden on families and even the whole society.
False	It is urgent to find out effective drugs without side effects.
False	The rationality of compatibility methods and combination thinking ways of soothing Gan, nourishing blood, and invigorating Pi were clarified.
False	OBJECTIVE: To investigate the effect of @FORMULA@ (@FORMULA@) and its compatible prescriptions on the ethology, morphology, and activities of neurotransmitters, thus exploring their effects and mechanism in preventing and treating D-galactose induced @DISEASE@ (@DISEASE@) model mice, and clarifying the compatibility mechanism for soothing Gan, nourishing blood, and invigorating Pi.
False	Meanwhile, mice in the blank control group and the model group were administered with physiological saline (at the daily dose of 24 mL/kg) by gastrogavage.
False	On the 42nd day capability for learning and memory was tested.
False	METHODS: Sixty SPF mice were randomly divided into the blank control group, the model group, and the @FORMULA@ group, Shugan Jianpi group (SJ), Shugan Yangxue group (SY), and Jianpi Yangxue group (JY), 10 in each group.The @DISEASE@ mouse model was prepared by peritoneal injecting D-galactose.
True	CONCLUSIONS: @FORMULA@ could improve the ethology, morphology, and activities of neurotransmitters, and showed better effects on prevention and treatment of @DISEASE@.
False	OBJECTIVE: To study the effects of @FORMULA@ (@FORMULA@) on cisplatin (DDP) induced oxidative damage of organs in @DISEASE@ mice.
False	Fourteen days later, mice were sacrificed and the @DISEASE@ inhibition ratio was calculated.
False	The pathologic changes showed the same effect trend.
False	The pathologic changes were observed.
False	The weights of kidneys, livers, and lungs were weighed and the organ coefficient calculated.
True	[The protection of @FORMULA@ on cisplatin induced oxidative damage of organs in @DISEASE@ mice].
False	Regarding the ingredients of the @FORMULA@, those with significant regression coefficients were ginsenoside-Rg1, Re, Rb1, rutaevine (Rv), limonin (Li), evodiamine (Ev), rutaecarpine (Ru) and substance X (awaiting identification).
False	However, there have been few investigations to clarify the composition of @FORMULA@ for the treatment of @DISEASE@.
True	Identification of active ingredients in @FORMULA@ improving @DISEASE@ in mice by spectral efficiency association.
False	The ingredients and pharmacodynamic indices of the @FORMULA@ were analyzed using spectral efficiency association by partial least squares regression.
False	@FORMULA@ is a traditional Chinese medicine used for the effective treatment of @DISEASE@, termed 'Jueyin @DISEASE@', in China.
False	The level of NO in the brain tissues increased to 0.425 +/- 0.184 micromol/g protein and the activities of NOS in the brain tissues and sera increased to 0.719 +/- 0.477 U/mg and 50.688 +/- 8.132 U/ml, respectively.
True	It is therefore concluded that @FORMULA@ Decoction can lower serum indexes of @DISEASE@.
False	To study the clinical effects of @FORMULA@ ([symbol: see text]) Decoction on @DISEASE@. 56 patients with @DISEASE@ due to @DISEASE@ were randomly divided into a treatment group (30 cases treated with @FORMULA@ Decoction) and a control group (26 cases treated with colchicine).
False	The serum levels of hyaluronic acid (HA), procollagen III (PC-III), IV collagen (IV-C) and Laminin (LN) of the patients were determined, compared and analyzed before treatment and after 3-month treatment in the two groups.
False	Effects of @FORMULA@ decoction in 30 cases of @DISEASE@.
False	In the control group, only the HA level was obviously lowered (P < 0.05).
False	There was an significant difference (P < 0.05) in PC-III and IV-C and a very significant difference (P < 0.01) in HA after treatment between the two groups.
False	The chronic LH upregulated the expression of NMDA receptor subunits NR1, NR2A, and NR2B, which were all attenuated by @FORMULA@.
False	In the hippocampus, @FORMULA@ and fluoxetine both normalized brain-derived neurotrophic factor (BDNF) and PKA level.
False	Neural Plasticity Associated with Hippocampal PKA-CREB and NMDA Signaling Is Involved in the Antidepressant Effect of Repeated Low Dose of @FORMULA@ on Chronic Mouse Model of Learned Helplessness.
False	Furthermore, intracerebraventricular administration of NMDA blunted the antidepressant effect of @FORMULA@.
False	Repeated administration of @FORMULA@ following chronic LH remarkably alleviated all of @DISEASE@-like symptoms measured, whereas conventional antidepressant fluoxetine only showed a minor improvement.
True	These findings supported the antidepressant efficacy of repeated routine low dose of @FORMULA@ in a @DISEASE@ model and the critical role of CREB and NMDA signaling.
True	In conclusion, @FORMULA@ mitigated @DISEASE@ by down-regulating pro-inflammatory and Th2-related cytokines via JAK1/STAT6 signaling.
False	In addition, @FORMULA@ significantly inhibited the phosphorylation of JAK1 and STAT6 expressions.
False	Histopathological analysis demonstrated that @FORMULA@ suppressed @DISEASE@ cell infiltration, mucus hypersecretion and collagen deposition in the airway.
False	In this study, we investigated therapeutic effects of @FORMULA@ on @DISEASE@ in ovalbumin (OVA) and PM smaller than 10 mum (PM10)-induced @DISEASE@ mice.
False	To establish @DISEASE@ with @DISEASE@ by PM10, BALB/c mice were sensitized and challenged with OVA and PM10, and orally administered @FORMULA@.
False	Expression levels of Janus kinase 1 (JAK1)/signal transducer and activator of transcription 6 (STAT6), pro-inflammatory cytokines and type 2 T-helper (Th2)-related cytokines were analyzed in vivo and in vitro models.
False	Although @FORMULA@ (@FORMULA@) has shown anti-inflammatory effects in previous studies, its effects and mechanism of action underlying @DISEASE@ disorder are still largely unknown.
False	Additionally, it decreased ERK, p38, JNK, IKbeta-alpha, and p65 phosphorylation levels in the MAPKs/NF-kappaB pathway, inhibited p65 nuclear translocation, and reduced LPS binding to the RAW264.7cell membrane.
False	The protein expression levels of P-ERK/ERK, P-p38/p38, P-JNK/JNK, P-IKbeta-alpha, and P-p65 were measured through western blotting.
False	Therefore, administration of @FORMULA@ might be a potential treatment for @DISEASE@ in the clinical setting.
False	Effects and mechanism of action of @FORMULA@ in @DISEASE@-like @DISEASE@ in vivo and in vitro.
True	CONCLUSIONS: @FORMULA@ significantly improved @DISEASE@ symptoms via inhibition of the MAPKs/NF-kappaB pathway.
False	However, its underlying mechanism when combined with anticancer drugs is not clearly understood.
True	Our results suggested that anlotinib combined with @FORMULA@ may be a promising strategy for the treatment of @DISEASE@.
False	Additionally, 12 differentially-abundant metabolites were identified by untargeted metabolomics in the @FORMULA@/anlotinib group compared with the @FORMULA@ or anlotinib groups, and they were mainly enriched in fatty acid metabolism, lipid metabolism and amino acid metabolism pathways.
False	An Integrative Metabolomic and Network Pharmacology Study Revealing the Regulating Properties of @FORMULA@ That Improves Anlotinib Effects in @DISEASE@.
False	Anlotinib, 23 components in Shexiang, 2 components in Niuhuang, 30 components in Ruxiang and 60 components in Moyao work together to act on 30 targets to regulate hexadecanoic acid (also named palmitic acid), linoleic acid, lactosylceramide, adrenaline, arachidonic acid and lysoPC(18:1(9Z)).
False	We applied untargeted metabolomics to identify the differences metabolism and found that @FORMULA@ improved the effects of anlotinib on @DISEASE@.
False	CONCLUSION: @FORMULA@ could show its anti-tumor effect by enhancing the immune clearance function and increasing IL-2, IFN-gamma, CD3+ T, CD4+ T, B7-1 in peripheral blood.
False	[Experimental study on anti-tumor effect of @FORMULA@ and its immune clearance function].
False	The rats were randomly divided into five groups: the normal control group, the model control group, the lentinan group and @FORMULA@ low dose, middle dose and high dose groups, with 10 rats in each group, and continuously treated and given drugs for 14 d after modeling.
False	METHOD: Walker256 @DISEASE@ cells were adopted to establish the @DISEASE@-bearing rat model.
False	OBJECTIVE: To discuss the anti-tumor effect of @FORMULA@ on @DISEASE@-bearing rats and its effect on the immune clearance function of @DISEASE@-bearing organisms.
True	RESULT: The @DISEASE@ inhibition rate of the @FORMULA@ high dose group was 33. 1 percent.
False	The GO and KEGG enrichment analyses revealed 171 molecular targets and 59 pathways, which were associated with @FORMULA@ against @DISEASE@.
False	Finally, the miRNArelated molecular targets for @FORMULA@ activity against @DISEASE@ were identified using a standard NPA by finding the intersection between identified DE-miRs-related targets and @FORMULA@-related targets.
False	This study aims to explore the microRNA (miRNA)-related molecular targets of @FORMULA@ against @DISEASE@ using a network pharmacology approach (NPA) Methods: We randomly divided 20 male Sprague Dawley rats into two groups; 10 rats were normal controls, and the other 10 rats were fed a high-fat diet (HFD) for 12 weeks to establish an @DISEASE@ model.
False	A final list of 22 candidate targets was identified.
False	CONCLUSION: The identified molecular targets and pathways suggest that complex mechanisms are involved in @FORMULA@'s mechanism of action, and immune-@DISEASE@-related mechanisms are closely associated with the effects of @FORMULA@.
True	Exploring miRNA-related Molecular Targets of @FORMULA@ against @DISEASE@ using a Network Pharmacologic Approach.
False	RESULTS: According to the bacterial count of Shigella in the colon, Coptis chinensis franch and Scutellaria baicalensis Georgi are the main effective drugs, but they antagonized each other, so that the best combination protocol was Coptis chinensis Franch only.
False	OBJECTIVE: To investigate the relations between different compositions of @FORMULA@ and their effects on experimental @DISEASE@ in rabbits to explore the composition protocol of @FORMULA@.
False	The effects of different compositions of @FORMULA@ on the indexes of @DISEASE@ and the bacterial count of Shigella in the colon content and colon tissue were investigated by orthogonal design.
False	METHODS: Rabbit models of intestinal invasion induced by Shigella flexneri was established by directly inoculating the bacterium in the colon after cecum bypass operation.
False	CONCLUSION: Among the components of @FORMULA@, Coptis chinensis franch has the strongest pharmacological effect against bacteria and Glycyrrhina wralensis fisch is the most effective to ameliorate pathological lesions.
True	[Effects of different compositions of @FORMULA@ on experimental @DISEASE@ in rabbits].
False	Aim.
False	Collect @FORMULA@'s active compounds by traditional Chinese medicine (TCM) databases, and input them into PharmMapper to get their targets.
False	To explore the pharmacological mechanism of @FORMULA@ (@FORMULA@) on @DISEASE@ by a network pharmacology approach.
False	Conclusion.
False	Some biological processes can also be identified as @FORMULA@'s effects on @DISEASE@.
True	According to this network pharmacology approach some signal pathways of @FORMULA@ acting on @DISEASE@ are found for the first time.
False	RESULTS: @FORMULA@ significantly decreased @DISEASE@ scores between days 23-25 in the 2.30 g/kg group and 21-25 in the 4.60 g/kg group (p<0.05).
False	CONCLUSION: The data suggest that @FORMULA@ produces significant anti-arthritic effects that may be mediated by suppressing pro-inflammatory cytokines, and it appears to be safe.
False	ETHNOPHARMACOLOGICAL RELEVANCE: The herbal formula @FORMULA@ (@FORMULA@) and its modifications have been used in traditional Chinese medicine for about one hundred years to alleviate @DISEASE@ and @DISEASE@.
False	The maximum @DISEASE@ score per rat was 16.
False	MATERIALS AND METHODS: Male Lewis rats, 190-210 g, were immunized subcutaneously at the base of the tail with 200 microl of heat-killed Mycobacterium tuberculosis in mineral oil (5 mg/ml).
True	Extract of the Chinese herbal formula @FORMULA@ inhibited @DISEASE@ in rats.
False	Four formulas with therapeutic actions of pungent warmth or pungent coolness for superficial syndromes were chosen and four kinds of rat serum samples each containing one of the above-mentioned herbal formulas were collected, then the effects of @FORMULA@ syndromes' patient serum as well as the effects of sera containing the formulas after being stimulated by the patient serum samples on both the mRNA expression of certain toll-like receptor (TLR) subtypes and the release of some inflammatory cytokines in RAW264.7 cells were tested and analyzed in vitro.
False	CONCLUSION: Evidence from these experiments might contribute to the scientific explanation of both the pharmacological mechanisms of @FORMULA@ and also the CM theory that @FORMULA@ is specifically prescribed for the treatment of @FORMULA@ syndrome (The gearing formula to the symptom-complex).
False	Interestingly, the changes induced by the @FORMULA@ syndrome patients' sera were masked significantly after the macrophages were incubated with the sera from donors treated with @FORMULA@.
False	The products such as interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha and interferon (IFN)-beta from stimulated macrophages through TLR signaling pathways were also increased correspondingly.
False	Similarly, the three other exterior-releasing formulas were all effective in reversing the up-regulated changes of certain TLR subforms to different degrees, but both the number of targeted TLRs and efficacy of them seemed to be inferior to that of @FORMULA@.
True	RESULTS: The expression of TLR-3, TLR-4 and TLR-9 mRNA among the 9 tested TLR subforms were up-regulated in the macrophages stimulated by the sera from untreated @DISEASE@ patients with the @FORMULA@ syndrome (symptomcomplex).
False	The present study aims to evaluate the possible effects of @FORMULA@ on cardiac function in @DISEASE@ (@DISEASE@) and related mechanism.
False	@DISEASE@ model was established by ligation of the left anterior descending coronary artery followed by one-week @FORMULA@ treatment.
False	Our present data suggest that @FORMULA@ has potential therapeutic effects to improve cardiac function by regulation of apoptotic signaling pathway.
False	However, enalapril (an angiotensin-converting enzyme inhibitor) treatment did not show marked improvement of these parameters.
True	Traditional Chinese Medicine Formulation @FORMULA@ Improves Cardiac Function after @DISEASE@ in Rats.
False	Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining and western blot were applied to evaluate tissue apoptotic level.
False	Immunohistochemical staining was used to evaluate the growth and apoptosis of the colon epithelium.
False	@FORMULA@ also reduced the MPO activity and expression of IL-6 in the colon mucosa.
False	The myeloperoxidase (MPO) activity and IL-6 level in the colon mucosa were determined with the corresponding commercial kits.
False	RESULT: @FORMULA@ significantly improved the @DISEASE@, colonic shortening, DAI, @DISEASE@, and histopathological score of the rats with TNBS-induced @DISEASE@.
False	In the late stage, the Hippo pathway was activated, thereby inhibiting apoptosis and promoting intestinal mucosal differentiation.
True	CONCLUSION: @FORMULA@ alleviated the @DISEASE@ and promoted mucosal healing in rats with @DISEASE@, which was probably achieved through the Hippo pathway.
False	Abstract: @DISEASE@ (@DISEASE@) are leading causes of @DISEASE@ in the world, owing to noticeable incidence and @DISEASE@.
False	Systems pharmacology, as a novel approach that integrates systems biology and pharmacology plays a significant role in investigating the molecular mechanism of TCM.
False	And @FORMULA@ take part in cardiomyocyte protection, blood pressure regulation, and lipid regulation module in treatment of @DISEASE@ by cooperative way.
True	System-Pharmacology Dissection of Traditional Chinese herbs @FORMULA@ for Treatment of @DISEASE@.
False	However, the involved molecular mechanisms are exceedingly complicated and remain unclear.
False	In systems pharmacology approach, we use to systematically uncover the mechanisms of action in Chinese medicinal formula @FORMULA@ as an effective treatment for @DISEASE@, which mainly includes:1) molecular database building; 2) ADME evaluation; 3) target-fishing 4) network construction and analysis.
False	For example, 116.6 +/- 89.7 mg/day of @DISEASE@ was observed in control groups compared to 4.2 +/- 15.2 mg/day in the 400 mg/kg BW of @FORMULA@ treated group 2 days after mAb injection (P < 0.01).
False	Effect of traditional Chinese medicine (@FORMULA@) on monoclonal antibody-induced @DISEASE@ in rats.
False	The amount of @DISEASE@ was significantly suppressed in roughly a dose-dependent manner.
False	The effect of @FORMULA@ on a non-immunological model of @DISEASE@ was also examined.
False	Four hundred, 200 and 100 mg/kg body weight (BW) of @FORMULA@ and phosphate-buffered saline (PBS) as a control were injected intraperitoneally into four groups of female Wistar rats every day from 5 days before intravenous injection of mAb to the end of the experimental period.
True	The authors conclude that mAb-induced @DISEASE@ in rats is significantly suppressed by the traditional Chinese medicine, @FORMULA@.
False	The activities of gastrocnemius muscle mitochondrial respiratory chain complexes I, II, III, and IV in both the prednisone and @FORMULA@ groups was dramatically higher compared with the model group (P < 0.05).
False	The activities of mitochondrial respiratory chain complexes I, II, III, and IV was determined using the Clark oxygen electrode method.
True	CONCLUSION: @FORMULA@ improved pathological changes in muscle mitochondria and NMJ, enhanced the amount of ATP in gastrocnemius muscle mitochondria, and improved the activities of respiratory chain complexes I, II, III, and IV (especially I and III) of the @DISEASE@ rats.
False	The amount of ATP was assessed by high performance liquid chromatography.
False	OBJECTIVE: To investigate the protective role of @FORMULA@ in neuromuscular junction (NMJ) and muscle cell mitochondria ultrastructure; as well as its effects on the amount of adenosine triphosphate (ATP) and the activities of mitochondrial respiratory chain complexes I, II, III, and IV in @DISEASE@ rats.
False	After intervention with @FORMULA@, the above pathology changes were improved: muscle fiber structure was clear and complete; the mitochondria count was higher; and the NMJ structure was close to normal.
True	Huang-Qin, @FORMULA@, @FORMULA@, @FORMULA@, Ji-Sheng-Shen-Qi-Wan, Gan-Lu-Yin, @FORMULA@ and @FORMULA@ were significantly associated with lower risk of @DISEASE@.
False	Decreased risk of @DISEASE@ among patients with @DISEASE@ receiving Chinese herbal medicine: a population-based cohort study.
False	The greatest effect was in those receiving CHMs for more than 1 year.
False	Cox proportional hazards regression was used to compute the hazard ratio (HR) of @DISEASE@ by CHMs use.
False	This study investigated the effect that CHMs have on @DISEASE@ risk in patients with @DISEASE@.
False	All were followed through 2012 to record @DISEASE@ incidence.
False	Theoretical Study of the Molecular Mechanism of @FORMULA@ Against @DISEASE@: Network Pharmacology-based Strategy.
False	We investigated the active ingredients and the therapeutic targets of @FORMULA@ against @DISEASE@.
False	AIM AND OBJECTIVE: @FORMULA@ (@FORMULA@) decoction is a traditional Chinese medicine (TCM) prescription.
True	This study represents the first report on the molecular mechanism of @FORMULA@ against @DISEASE@.
False	Bioinformatics analyses revealed that @FORMULA@ could prevent and treat @DISEASE@ through anti-inflammatory and immunity-based actions involving activation of T cells, lymphocytes, and leukocytes, as well as cytokine-cytokine-receptor interaction, and chemokine signaling pathways.
False	Eighty-six active ingredients of @FORMULA@ hit by 19 therapeutic targets were screened out by analyses of a compound-compound target network.
False	However, @FORMULA@ groups significantly reduced the IL-1beta-ir neurons in the PVN and hippocampal regions compared to the control.
False	In the brain, the expression of IL-1beta positive neurons in the control group were significantly increased in the paraventricular nucleus (PVN) and hippocampus compared to the non-op.
False	The serum levels of corticosterone and IL-1beta in the @FORMULA@ groups were significantly lower than those in the control group.
False	The rats were exposed to immobilization stress (IMO) for 14 day (2 h/14 day), and @FORMULA@ (100 mg/kg and 400 mg/kg) was administrated during the same time.
False	TRIAL REGISTRATION: Our results suggest that @FORMULA@ may be useful for immune regulator in repeated stress-induced ovariectomized female rats.
True	CONCLUSION: The present results demonstrated that @FORMULA@ effectively reduced behavioral and patho-physiological @DISEASE@.
False	Participants in the treatment group were treated with @FORMULA@ or @FORMULA@ TCM formula granule, while the control group received placebo.
False	No remarkable differences were observed between the two groups with regard to AEs, lost rate and safety (P > 0.05).
False	OBJECTIVE: To evaluate the effect and safety of @FORMULA@ and @FORMULA@, classic Yin and Yang tonic formula (CYYTF), in the treatment of @DISEASE@ and the underlying mechanism.
False	Moreover, significant difference was observed at different time before and after treatment in terms of lumbar spine (L1-4) BMD, femoral BMD, @DISEASE@ VAS scores and health-related quality of life, and there was an crossover effect between the time and groups before and after treatment.
False	Secondary outcomes include @DISEASE@ intensity, health-related quality of life (HRQoL), bone turnover markers and safety.
True	CONCLUSION: @FORMULA@ or @FORMULA@ could improve BMD, ease @DISEASE@, relieve Kidney deficiency syndrome, improve the quality of life @DISEASE@ patients, inhibit bone conversion and regulate the coupling balance of bone formation and bone resorption, but long-term efficacy should be confirmed by a longer term follow-up and larger of samples clinical randomized controlled trials.
False	The protective effect of @FORMULA@ is reversed by an inhibitor of nitric oxide synthesis.
False	For in vitro studies, aortic tissues were treated with mice serum containing @FORMULA@ with or without adenoviral arginase 1 (Ad-A1) transduction in high glucose (HG) medium.
False	In vivo studies were performed using wild type mice as well as arginase 1 knockout specific in endothelial cells (EC-A1(-/-)) of control mice, @DISEASE@ mice and @DISEASE@ mice treated with @FORMULA@ (60 g crude drugs/kg/d) for 2 weeks.
False	A classic prescription of traditional medicine, @FORMULA@ (@FORMULA@) has been used for the treatment of various @DISEASE@ and @DISEASE@, which all are related with @DISEASE@.
False	We found that @FORMULA@ treatment restored STZ-induced impaired mean velocity and pulsatility index of mouse left femoral arteries, aortic pulse wave velocity and vascular endothelial relaxation accompanied by elevated NO production in the aorta and plasma, as well as reduced endothelial arginase activity and aortic arginase 1 expression.
True	This study demonstrates that @FORMULA@ improved STZ-induced @DISEASE@ through arginase 1 - NO signaling, specifically targeting endothelial arginase 1.
False	The present study aims to evaluate the effects of @FORMULA@ (@FORMULA@) granules on @DISEASE@-induced @DISEASE@ (@DISEASE@), and then to decipher the molecular mechanisms of @FORMULA@.
False	Consistent with network pharmacology analysis, experiments in vivo demonstrated that @FORMULA@ could prevent the development of @DISEASE@ in a @DISEASE@-induced mouse model and alleviate @DISEASE@.
False	The results showed that the effect of @FORMULA@ may be closely associated with AKT serine/threonine kinase 1 (AKT1), signal transducer and activator of transcription 3 (STAT3), and HIF-1 signaling pathways, as well as biological processes such as cell proliferation.
False	Based on network pharmacology, 147 potential targets of @FORMULA@ on @DISEASE@ were found, constructing a PPI network, and 13 hub genes were predicted.
False	Related genes and pathways were verified using a @DISEASE@-induced mouse model and @DISEASE@-treated pulmonary artery cells.
True	@FORMULA@ Granules Prevent @DISEASE@ @DISEASE@ via STAT3/HIF-1alpha/VEGF and FAK/AKT Signaling Pathways.
False	Participants in the CHM group had more prominent symptom relief on day 56 (the weekly @DISEASE@ activity score, UAS7, as 9.9 +/- 9.2 vs. 15.6 +/- 10.8, p = 0.038).
False	Symptom improvement was set as the primary outcome, and the influence on sleep quality and changes in serum markers were used as secondary outcomes.
False	The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in @DISEASE@: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
False	Trial registration: NCT01715740 (ClinicalTrials.gov).
False	Background: @DISEASE@ is a bothersome @DISEASE@, and Chinese herbal medicine (CHM) is commonly used as adjuvant therapy.
True	Conclusions: The combination of @FORMULA@ and @FORMULA@ tended to be feasible and tolerable adjuvant therapy for @DISEASE@ in addition to standard therapy.
False	Cytotoxicity was determined by tetrazolium dye colorimetric assay.
False	Effects of Chinese herbal medicine in combination with mitomycin C on @DISEASE@ cells.
False	Among these 3 CHM formulas, @FORMULA@ showed the most pronounced effect in augmenting MMC-induced cytotoxicity.
False	We subsequently examined apoptosis induction by quantitative florescent microscopy and single-strand DNA enzyme-linked immunosorbent assay, and found @FORMULA@ did not enhance MMC-induced apoptosis.
False	The viability of MKN-74 cells was decreased to 43.1% when treated with @FORMULA@ and MMC, compared to 94.9% with MMC alone.
True	Our findings indicate @FORMULA@ in combination with MMC induces cell death in @DISEASE@ cells via non-apoptotic mechanism.
False	METHODS: Forty Sprague-Dawley rats were equally randomized into four groups: the normal group, the model group, the positive control group and the Chinese medicine (CM) group.
False	OBJECTIVE: To observe the effect of @FORMULA@ (@FORMULA@) on alpha-smooth muscular actin (alpha-SMA, a marker of renal tubular epithelial phenotype transformation) in rats with cyclosporine A (CsA)-induced @DISEASE@ for investigate its mechanism of action in inhibiting @DISEASE@.
False	Excepting those in the normal group received gastrogavage with olive oil, rats in the other three groups were made into @DISEASE@ model by oral infusion of CsA 30 mg/ (kg x d) for 28 days.
False	[Inhibitory effect of @FORMULA@ on renal tubular epithelial phenotype transformation in rats with cyclosporine A-induced @DISEASE@].
False	The mRNA and protein expressions of alpha-SMA in rats' kidney were detected by RT-PCR, Western blot, immunohistochemical and flow cytometry, and the mRNA expressions of transforming growth factor-beta1 (TGF-beta1) and collagen type III (Col III) were determined by RT-PCR.
True	CONCLUSION: @FORMULA@ could retard the progress of @DISEASE@ by way of inhibiting renal tubular epithelial phenotype transformation.
False	A negative correlation was identified between expression of Bcl2L12 and IL-10 in @DISEASE@ Bregs.
False	The results showed that the number of peripheral Breg in @DISEASE@ patients was not significantly different from that in HA subjects, while the immune suppressor function of @DISEASE@ Breg was compromised.
False	The capacity of Breg in suppressing effector T cell (Teff) proliferation was observed in an in vitro experiment to be used as an indicator of immune suppressor function of Breg.
False	This study aims to restore the immune suppressor function in regulatory B cells (Bregs) collected from @DISEASE@ patients with a Chinese medical formula, @FORMULA@ (@FORMULA@).
False	In this study, Bregs were isolated from blood samples collected from @DISEASE@ patients and healthy (HA) subjects.
True	In conclusion, @FORMULA@ can restore the immune suppressor function of @DISEASE@ Bregs via inhibiting the expression of Bcl2L12.
False	By treatment of mice with anticancer agent CY or gamma ray irradiation, unfavorable side effects usually occurred to impair hematopoietic organs, causing @DISEASE@.
False	Colony-forming unit of bone marrow cells in the spleen adoptively transferred into syngeneic mice, that is defined as CFU-S, was extremely reduced by CY-treatment.
False	@FORMULA@ enhanced other leukocyte functions in CY-treated mice; i.e., superoxide production of neutrophils and phagocytic activity of macrophages.
False	The induction of serum CSF reached a peak at 3h after @FORMULA@ administration.
False	However, when @FORMULA@ was orally administered, CFU-S of CY-treated mice was markedly stimulated, suggesting that bone marrow cells were reactivated for further proliferation and mobilization.
True	Thus, oral administration of @FORMULA@ to CY-treated mice enforced protection against @DISEASE@.
False	The present study aimed to test such protective effects and elucidate the underlying mechanisms on @DISEASE@ in rats by phenotypic approaches (i.e. including the neurological functional score, @DISEASE@ area, neuron apoptosis, and brain oxidative stress status) and target-based approaches (i.e. involving the GSK-3beta/HO-1 pathway).
False	@FORMULA@ pre-treatment increased the expression of p-GSK-3beta(Ser9)/GSK-3beta (glycogen synthase kinase-3beta) ratio and heme oxygenase-1 (HO-1).
True	These results firstly revealed that short-term pre-treatment of @FORMULA@ could significantly protect the rats from injury caused by @DISEASE@, which support further clinical studies for disease prevention.
False	@FORMULA@ (@FORMULA@), a famous formula in traditional Chinese medicine, has been clinically used for centuries for treating @DISEASE@, but the protective effects of pre-treatment with @FORMULA@ on @DISEASE@ have not yet been reported.
False	Protective Effect of @FORMULA@ Pre-treatment Against Experimental @DISEASE@ via Regulating GSK-3beta/HO-1 Pathway.
False	The in vivo protective effect of @FORMULA@ pre-treatment could be associated with its antioxidant properties by the activation of GSK-3beta-mediated HO-1 pathway.
False	In this review, we systematically highlighted recent evidence on @FORMULA@ and @DISEASE@ data from clinical and animal studies, summarized the clinical application, pharmacological mechanism and the active compounds of @FORMULA@ for the treatment of @DISEASE@.
False	In traditional Chinese medicine (TCM), @DISEASE@ (@DISEASE@) is regarded as Xiao Ke disease.
True	Research progress on classical traditional Chinese medicine formula @FORMULA@ in the treatment of @DISEASE@.
False	This systematic review will provide an insightful understanding of TCM formulas, pharmacological mechanisms, medicinal-disease interactions, and will lay a foundation for the development of new drug therapy for @DISEASE@.
False	@FORMULA@ (@FORMULA@), a classical TCM formula, with the function of nourishing kidney yin, has been used for treating Xiao Ke disease in clinic.
False	Feces were collected, and fecal DNA was extracted.
False	CONCLUSION: Our study suggests that CR and @FORMULA@ improve metabolic parameters by modulating gut microbiota.
False	Profiles of gut microbiota were mapped by metagenomic sequencing.
False	RESULTS: We found that CR and @FORMULA@ treatment significantly reduced the body weight of mice fed with ND (28.71 +/- 0.29 vs 28.05 +/- 0.15, P < 0.05), but did not affect plasma total cholesterol or total triglyceride levels.
False	Control mice received either saline gavage or FMT from ND-fed mice receiving saline gavage as mentioned above.
True	@FORMULA@ attenuates diet-induced @DISEASE@ and @DISEASE@ via gut microbiota.
False	To be specific, DL-4-chlorophenylalanine(PCPA) was used to induce @DISEASE@ in rats.
True	These metabolic changes indicated that @FORMULA@ can improve the metabolism in @DISEASE@ rats by regulating amino acid metabolism.
False	The metabolic profile of rat serum samples was further analyzed by ultra-performance liquid chromatography-quadrupole-time of flight-tandem mass spectrometry(UPLC-Q-TOF-MS/MS).
False	Metabonomics analysis yielded 12 significantly changed potential metabolites: 5-aminovaleric acid, N-acetylvaline, L-proline, L-glutamate, L-valine, DL-norvaline, D(-)-arginine, pyroglutamic acid, 1-methylguanine, L-isoleucine, 7-ethoxy-4-methylcoumarin, and phthalic acid mono-2-ethylhexyl ester(MEHP), which were related with multiple biochemical processes including metabolism of D-glutamine and D-glutamate, metabolism of alanine, aspartate, and glutamate, metabolism of arginine and proline, arginine biosynthesis, glutathione metabolism.
False	The results showed that @FORMULA@ could improve the pathological changes of brain and liver tissues, increase the levels of neurotransmitters 5-HT, DA, and GABA in hippocampus and the level of PGD2 in hypothalamic-pituitary-adrenal axis(HPA axis), and reduce the levels of IL-1beta and TNF-alpha in serum of @DISEASE@ rats.
False	Principal component analysis(PCA) and orthogonal partial least squares-discriminant analysis(OPLS-DA) were combined with t-test and variable importance in projection(VIP) to identify differential metabolites, and MetaboAnalyst 5.0 was employed for pathway analysis.
False	The protective effect of @FORMULA@ (@FORMULA@; @FORMULA@), a traditional Chinese medicine, against @DISEASE@ and @DISEASE@ induced by @DISEASE@ was investigated in mice.
False	Protective effect of @FORMULA@ (@FORMULA@) against @DISEASE@ and @DISEASE@ induced by @DISEASE@ in mice.
False	Furthermore, @FORMULA@ significantly protected against @DISEASE@-induced reduction in the acetylcholine (ACh) content of the cerebral cortex, hippocampus and striatum.
False	@FORMULA@ (@FORMULA@; 2, 4 and 8 g/kg, p. o.) shortened the latency of escaping markedly onto the platform in the training trial and increased the percentage of crossing the former platform quadrant in the probe trial.
False	A reference drug, tacrine (0.5 and 1.0 mg/kg, p.o.), prevented the reduction of step-down latency in the passive avoidance task and shortened the escape latency in the Morris water maze task.
True	These results indicate that the protective effects of @FORMULA@ against the @DISEASE@ and @DISEASE@ induced by @DISEASE@ may be associated with preventing the decrease in the ACh content of the mouse brain.
False	To the treated group oral administration of @FORMULA@ 8 capsules was given additionally, 3 times per day until prednisone decreased to maintenance dose.
True	CONCLUSION: @FORMULA@ can markedly improve the therapeutic effectiveness and counteract the adverse reaction of hormonotherapy in treating @DISEASE@, and reduce the @DISEASE@ of the disease.
False	Urinary protein, plasma albumin, triglyceride (TG) and total cholesterol (TC) in both groups were obviously improved (P < 0.05 or P < 0.01).
False	METHODS: Patients allocated in two groups were medicated with initial dose of prednisone 1 mg/kg once a day at 8 am in the morning.
False	Scores of Yin-deficiency caused excessive Fire syndrome and incidence rate of adverse reaction in the treated group were lower than those in the control group (P < 0.05 or P < 0.01).
False	Then the medication was changed to that two days' dosage orally take once a day with the daily dose reduced by 5.0 mg/kg every 2 to 3 weeks, and maintained at 0.4 mg/kg once every two days.
False	There is no effective therapeutic modality against @DISEASE@.
False	RESULTS: @FORMULA@ could dose-dependently inhibit HRSV-induced plaque formation (p < 0.0001), especially in A549 cell. 300 mug/ml @FORMULA@ nearly abolished plaque formation in A549 cells.
False	@FORMULA@ was more effective when given before viral inoculation (p < 0.0001).
False	Therefore, @FORMULA@ is supposed to be beneficial for @DISEASE@.
False	Ability of @FORMULA@ to stimulate anti-viral cytokines was evaluated by enzyme-linked immunosorbent assay (ELISA).
True	CONCLUSIONS: @FORMULA@ has anti-HRSV activity that provides a basic support of its possible use in managing @DISEASE@.
False	As compared with the @DISEASE@ model group, @FORMULA@ promoted the recovery of @DISEASE@ and inhibited the @DISEASE@ in @DISEASE@ rats by reducing the mRNA or protein expression of NF-kappaB and p38MAPK, as well as activating the production of TLR2 in colon tissues.
False	Therapeutic efficacy and mechanism of @FORMULA@ in rats with experimental @DISEASE@.
True	Our results suggested that @FORMULA@ could improve @DISEASE@ and possesses favorable therapeutic action in TNBS-induced @DISEASE@, which provides direct pharmacological evidence for its clinical application.
False	However, there is less study on its application in @DISEASE@ (@DISEASE@) and the effects are not yet clearly defined.
False	And @FORMULA@ significantly reduced the DAI and tissue damage scores.
False	Following drug administration, the disease activity index (DAI) and tissue damage scores were recorded.
False	In such patients @DISEASE@ may be an inducer of wheeze.
False	RESULTS: @FORMULA@ significantly increased the @DISEASE@ threshold.
False	In addition influences of intensity of @DISEASE@, gender, type of @DISEASE@, and disease period on the effect of @FORMULA@ on the @DISEASE@ sensitivity were examined.
False	[Effects of @FORMULA@ (@FORMULA@) on @DISEASE@ sensitivity to capsaicin in @DISEASE@ patients with @DISEASE@].
False	UNLABELLED: Some patients with @DISEASE@ have increased @DISEASE@ sensitivity.
True	CONCLUSION: Our results suggest that @FORMULA@ may be an effective therapeutic preparation for @DISEASE@ in @DISEASE@ patients with @DISEASE@.
False	We observed the effects of a chinese herb medicine @FORMULA@ on the lethal and antitumor activities of recombinant human tumor necrosis factor (rhTNF) administered in mice.
False	@FORMULA@ was noted to protect the rhTNF-induced lethality in galactosamine-@DISEASE@ mice, and also @FORMULA@ pretreated mice was protected against the decrease of rectal temperature after rhTNF administration.
True	These results suggest that @FORMULA@ drug may protect mice from @DISEASE@ induced by rhTNF.
False	Preventive effects of a Chinese herb medicine (@FORMULA@) against lethality after recombinant human tumor necrosis factor administration in mice.
False	On the other hand, there was a remarkable enhancement of antitumor activity of rhTNF by @FORMULA@ pretreatment.
True	@FORMULA@ Exert Anti-Angiogenesis Effects through the Inhibition of TSLP-STAT3 Signaling Pathways in @DISEASE@.
False	More importantly, @FORMULA@ inhibited proliferation, expression of p-STAT3/STAT3, and tube formation of HUVECs induced by TSLP.
False	Tube formation assay was used to analyze the anti-angiogenic efficiency.
False	METHODS: High-performance liquid chromatography (HPLC) was used to certify the composition of @FORMULA@.
False	An orthotopic transplanted model of murine @DISEASE@ was entrenched.
False	Further study revealed that the expression of TSLP/TSLPR and p-STAT3/STAT3 was decreased by @FORMULA@.
False	@FORMULA@ reduced peroxynitrite and superoxide in vivo and in vitro and six active chemical compounds were identified from @FORMULA@ with peroxynitrite scavenging activity.
False	Furthermore, @FORMULA@ inhibited MMP-9 activity, and preserved tight junction protein claudin-5 and collagen IV in the @DISEASE@.
False	The antioxidant effects were also studied by using brain microvascular endothelial b.End3 cells exposed to 5 h of oxygen and glucose deprivation (OGD) plus 5 h of reoxygenation with t-PA treatment (20 microg/ml).
False	@FORMULA@ reduces @DISEASE@ and @DISEASE@ in @DISEASE@ rats with delayed thrombolysis: involvement of peroxynitrite-mediated MMP-9 activation.
False	Peroxynitrite and superoxide was detected by using fluorescent probes.
True	CONCLUSION: @FORMULA@ could be a potential adjuvant therapy with t-PA to protect the BBB integrity, reduce @DISEASE@, and improve therapeutic outcome in @DISEASE@ treatment via inhibiting peroxynitrite-mediated MMP-9 activation.
False	@DISEASE@ is an important health problem worldwide.
False	Five networks were constructed and analyzed: (1) @DISEASE@ genes' protein-protein interaction (PPI) network; (2) Compound-compound target network of @FORMULA@; (3) @FORMULA@-@DISEASE@ PPI network; (4) Compound-known target network of @FORMULA@; and (5) @FORMULA@ known target- @DISEASE@ PPI network.
False	@FORMULA@ (@FORMULA@) and its modification have a good clinical effect on @DISEASE@.
False	Several @DISEASE@ and treatment-related targets (eg.,.
False	However, the molecular mechanism of @FORMULA@ on @DISEASE@ has not been thoroughly explained.
True	The therapeutic effect of @FORMULA@ on @DISEASE@ may be achieved by interfering with the biological processes and signaling pathways related to the development of @DISEASE@.
False	RESULTS: Patients treated with @FORMULA@ had a significantly lower risk of re-hospitalization or @DISEASE@ after discharge; the HR was 0.82 (95% CI, 0.67-0.99) in 1-to-4 propensity score matching.
True	CONCLUSION: Our findings indicate that @FORMULA@ may have improved the tolerability of LAMA in advanced-age patients with @DISEASE@ and, therefore, reduced the risk of re-hospitalization or @DISEASE@ from @DISEASE@ exacerbation.
False	Reduction in exacerbation of @DISEASE@ in patients of advanced age using the Japanese Kampo medicine @FORMULA@: a retrospective cohort study.
False	However, bronchodilators may cause gastrointestinal adverse effects due to anticholinergic reactions, especially in advanced-age patients with @DISEASE@.
False	We performed subgroup analyses for patients with and without LAMA therapy.
False	We then compared the risk of re-hospitalization for @DISEASE@ exacerbation or @DISEASE@ between patients with and without @FORMULA@ using 1-to-4 propensity score matching.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ (@FORMULA@), a historically traditional Chinese medicine formula, was originally defined over 600 years ago.
False	Transfected cells were treated with 1-methyl-4-phenylpyridinium (MPP(+)), a PD-related mitochondrial complex I inhibitor, in the absence and presence of @FORMULA@.
False	In addition, overexpression of DJ-1 augmented the Akt phosphorylation on threonine 308 and serine 473.
False	Moreover, @FORMULA@ promoted the above effects in DJ-1 expressed cells.
False	The cell viability was assessed by Cell Counting Kit-8 assay.
True	Protective effects of DJ-1 medicated Akt phosphorylation on mitochondrial function are promoted by @FORMULA@ in 1-methyl-4-phenylpyridinium-treated human @DISEASE@ SH-SY5Y cells.
False	Children between 1-18 years of age with @DISEASE@ to multiple antipyretics were recruited.
False	All except one patient successfully tolerated an oral challenge of @FORMULA@.
False	BACKGROUND: Children with a diagnosis of cross-reactive @DISEASE@ to both paracetamol and nonsteroidal anti-inflammatory drugs are limited in their choice of antipyretics.
False	None of the patients developed symptoms of circulatory compromise or @DISEASE@.
False	Pilot study of the use of @FORMULA@ in children with @DISEASE@.
True	CONCLUSION: @FORMULA@ is generally well tolerated in patients with @DISEASE@.
False	Suppression by kampo medicine, @FORMULA@, on @DISEASE@ induced by 7,12-dimethylbenz(a)anthracene in mice.
True	Chronic oral administration of @FORMULA@ reduced the incidence and growth of @DISEASE@ with the reduction of activities of succinate-dehydrogenase and thymidylate synthetase, which were evaluated as the cell viability and DNA synthesis via the de novo pathway, respectively.
False	We examined the effects of @FORMULA@ on formation and growth of @DISEASE@ induced by 7,12-dimethylbenz(a)anthracene application in mouse skin.
False	@FORMULA@ (@FORMULA@) is a Japanese modified, traditional Chinese herbal medicine (Kampo medicine) consisting of seven medical plants.
False	It may be the mechanism that @FORMULA@ regulate the production of inflammatory cytokines and free radicals.
False	The 24 h survival rate, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels were compared.
False	METHOD: @DISEASE@ was induced in male Kunming strain mice by enterocoelia injecting the animals with D-Gal-N and LPS.
False	[Effect of @FORMULA@ on @DISEASE@ in mice].
False	Serum the levels of TNF-alpha and IL-1 and the levels of SOD, MDA, GR, GSH, NO and NOS in the liver were determined.
True	CONCLUSION: Treatment with @FORMULA@ can suppress the D-Gal-N/LPS-induced @DISEASE@.
False	RESULTS The results of our network pharmacology research showed that the @FORMULA@, composed of 6 Chinese herbs, contained 15 compounds, and 23 genes regulated the main signaling pathways related to @DISEASE@.
False	These core compounds were 6 of the 15 disease-related compounds in the network, kaempferol, quercetin, luteolin, Myricanone, beta-sitosterol, baicalein, and the core genes contained ADRB2, CALM1, HMOX1, JUN, PPARG, and VEGFA, which were regulated by more than 3 compounds and significantly associated with Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, and Ras signaling pathway.
False	However, the pharmacological mechanism is not clear.
False	Network Pharmacology Identifies the Mechanisms of Action of @FORMULA@ Against @DISEASE@.
False	The protein-protein interaction (PPI) was analyzed by using String database.
True	CONCLUSIONS This network pharmacological study can reveal potential mechanisms of multi-target and multi-component @FORMULA@ in the treatment of @DISEASE@, provide a scientific basis for studying the mechanism.
False	BACKGROUND: In the perspective of traditional Chinese medicine, few studies have focused on the compound preparations though there are many investigations.
False	And @FORMULA@ Granule was added at a dose of 12 g/kg in the mixed feedstuff for 8 weeks in the TCM group.
False	Male SD rats were divided randomly into 3 groups: sham operation group (n=8), operation group (n=15) and traditional Chinese medicine (TCM) group (n=15).
False	RESULTS: There was an increase in the weight of the heart in the operation group, with the left ventricule dominated (P<0.05).
False	Significant interstitial and collagen @DISEASE@ was shown in the operation group based on pathological analysis, and various improvements were proved in the TCM group, i.e. there was a significant decrease in CVF-T and CVF-NV (P<0.01) compared with the operation group; but no difference (P>0.05) was found when compared with the pseudo-operation group.
True	CONCLUSION: @FORMULA@ Granule could reduce the weight and volume of the heart, improve the cardiac function, inhibit @DISEASE@ of collagen, and reverse @DISEASE@ in rats with pressure-overloaded @DISEASE@.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ (@FORMULA@), a classical traditional Chinese medicine (TCM) formula, is used to treating @DISEASE@ in China.
False	Moreover, CDCA-induced HSCs proliferation and activation were weaken by @FORMULA@ (P<0.05) with down-regulated alpha-SMA, TGF-beta1, p-Smad2 and p-Smad3 expressions.
False	Chenodeoxycholic acid (CDCA)-induced hepatic stellate cells (HSCs) proliferation and activation were examined using MTS assay and Western blot.
False	@FORMULA@ and its compounds restored the increased bile acids to normal levels, and @FORMULA@ was more effected on parts of bile acids.
False	Concentrations of free bile acids and taurine conjugates were significantly increased in DMN group (P<0.05).
True	CONCLUSIONS: @FORMULA@ alleviated DMN-induced @DISEASE@ with a better effect than its compounds, which may be involved in the regulation of bile acid metabolism enzyme.
False	As a classic formula of traditional Chinese medicine (TCM), @FORMULA@ (@FORMULA@) has been clinically applied for treating @DISEASE@-related syndromes, but its anti-OA efficacy and mechanism remain unclear.
False	@FORMULA@ ameliorates @DISEASE@ and @DISEASE@ of @DISEASE@ rats through PI3K-Akt signaling pathway and its clinical retrospective evidence.
False	RNA sequencing (RNA-seq) and network pharmacology analysis were conducted and the overlapping data were used to predict the mechanism of @FORMULA@, followed by verification with qPCR and Western blot assays.
False	METHODS: UPLC/MS/MS was applied to identify the main components of @FORMULA@.
False	PURPOSE: To experimentally and clinically determine the anti-OA efficacy of @FORMULA@ and clarify the underlying mechanism.
True	CONCLUSION: The scientific innovation of this study was the determination of anti-OA efficacy of @FORMULA@ by experimental and clinical evidence and the discovery of its mechanism by integrated RNA-seq, network pharmacology, and molecular experiments, which suggests @FORMULA@ as a promising TCM agency for @DISEASE@ treatment.
False	Another group of rats intraperitoneally injected with phosphate buffered saline (PBS) was used as the control.
False	Effects of @FORMULA@ on @DISEASE@ in rat models.
False	Effects of @FORMULA@ (a decoction of medicinal herbs) on @DISEASE@ (@DISEASE@) in rats, a model similar to human membranous @DISEASE@, were examined.
True	It is therefore concluded that @DISEASE@ in @DISEASE@ can be significantly suppressed by @FORMULA@.
False	The decrease of serum albumin and total protein, and the increase of serum total cholesterol were significantly inhibited in the @FORMULA@ treated group as compared to that in the control group (P < 0.05, P < 0.05 and P < 0.01 respectively).
False	Four hundred mg/kg (body weight) of @FORMULA@, or 240 mg/kg B.W. of @FORMULA@, or 130 mg/kg B.W. of Chai Hu (Radix Bupleuri), Ban Xia (Rhizoma Pinelliae) and Sheng Jiang (Rhizoma Zingiberis Recens) were intraperitoneally injected respectively into three groups of female Wistar rats once a day starting from 5 days before intravenous injection of anti-FxlA antibody to the end of the experiment.
False	RESULTS: The outcomes of this study indicated that @FORMULA@ significantly improved the LVEF and LVFS, thickened both LVAWd and LVAWs, and reduced LVIDs in @DISEASE@ after @DISEASE@ in rats when compared with control group (P < 0.05).
False	Drugs were administered by oral gavage for eight weeks.
False	OBJECTIVE: To investigate the effectiveness and mechanism of the Chinese herbal formula @FORMULA@ (@FORMULA@) which consists of Aconitum carmichaelii (Fuzi), Zingiber officinale (Gan Jiang), and Glycyrrhiza uralensis (Gancao) in @DISEASE@ after @DISEASE@ in rats.
True	CONCLUSIONS: The Chinese herbal formula @FORMULA@ could improve left ventricular systolic function in @DISEASE@ after @DISEASE@ in rats and decreased the level of Plasma Renin, Angiotensin II, and Aldosterone, as well as downregulating the protein and gene level of ACE and AT1R.
False	Rats were randomly divided into six experimental groups: Sham operation group, HF group, Benazepril group, high dose of @FORMULA@ group, medium dose of @FORMULA@ group, and low dose of @FORMULA@ group.
False	The results of radioimmunoassay showed that @FORMULA@ decreased the level of Plasma Renin, Angiotensin II, and Aldosterone (P < 0.05).
False	An integrative neurofunctional and genomic approach was performed to elucidate the underlying molecular mechanisms of @FORMULA@.
False	Mining the functional modules and genetic networks of these 377 genes revealed a significant upregulation of neuroprotective genes associated with neurogenesis (6 genes) and nervous system development (9 genes), and a significant down-regulation of destructive genes associated with the induction of @DISEASE@ (14 genes), apoptosis (15 genes), angiogenesis (11 genes) and @DISEASE@ (7 genes) by @FORMULA@.
False	The changes in expression after treatment with @FORMULA@ are beneficial after @DISEASE@.
False	@FORMULA@ successfully restored brain function, ameliorated the @DISEASE@, and significantly improved the @DISEASE@ of the mice with a @DISEASE@.
False	Mice treated with @FORMULA@ (1.0g/kg) showed the greatest protective effect across all groups.
True	CONCLUSIONS: Our results suggested that @FORMULA@ is able to protect mice against @DISEASE@ and extend lifespan primarily through a significant down-regulation of genes involved in @DISEASE@, apoptosis, angiogenesis and @DISEASE@, as well as an up-regulation of genes mediating neurogenesis and nervous system development.
False	Histological analysis revealed that the @DISEASE@ of rats with @DISEASE@ was significantly reduced by @FORMULA@ treatment.
False	@FORMULA@ as a traditional Chinese herbal drug has been used for nourish kidney essence improve @DISEASE@ of @DISEASE@ by regulating the metabolism of calcium and phosphorus and participating in osteoblast metabolism.
False	Compared with model rats, the BMD of rat was significantly increased by @FORMULA@ treatment.
False	Compared with sham rats, the levels of serum phosphorus, PTH, iPTH and creatinine were significantly decreased, while the serum calcium level was significantly increased, and the Cbfa1 protein level was significantly decreased and FGF23 protein level was significantly increased by @FORMULA@ treatment.
False	In the present study, 5/6 nephrectomy rat model was used to reveal the mechanism of @FORMULA@ in treatment of @DISEASE@.
True	We inferred that @FORMULA@ exhibited potential therapeutic effects on @DISEASE@ in the rats by regulating bone metabolism and nourish kidney.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ (@FORMULA@) are an effective traditional Chinese formula being used clinically for the treatment of @DISEASE@ (@DISEASE@).
False	The pathology and morphology of the brain and spinal cord was examined.
False	METHODS: Female C57BL/6 mice were divided into six groups, including the non-treated @DISEASE@ model, prednisone acetate- and 1.2, 2.4 or 4.8g/kg @FORMULA@-treated @DISEASE@ groups, and a normal control group.
False	@FORMULA@ promote nerve regeneration by regulating netrin1, DCC and Rho family GTPases RhoA, Racl, Cdc42 in C57BL/6 mice with @DISEASE@.
False	The expression of MAP-2 was detected by immunofluorescent staining.
True	CONCLUSION: Our results demonstrated that @FORMULA@ exhibited a neuroprotective effect on promoting nerve regeneration at the brain and spinal cord in @DISEASE@ mice induced by MOG35-55.
False	The @DISEASE@ area, and the content of Leptin and ET-1, and the mRNA expression level of both were detected.
True	CONCLUSION: The pathogenesis of @DISEASE@ may be related with the down-regulation of concentration and mRNA expression level of Leptin, and upregulation of concentration and mRNA expression level of ET-1, the active components in @FORMULA@ may upregulated Leptin and inhibit ET-1 to accelerate the healing of @DISEASE@.
False	[Effect of @FORMULA@ on leptin and endothelin-1 of @DISEASE@ rat and the optimal combination screening of active components].
False	METHODS: Eighty-seven SD rats were randomly divided into normal group, sham-operated group and acetic acid-induced @DISEASE@ group, omeprazole group as a positive control, five active components (glycyrrhetic acid, beta-sitosterol, berberine, baicalin and ginsenoside) of @FORMULA@ were divided into groups by L16 orthogonal design.
False	Compared with model group, berberine could raise the mRNA expression level of Leptin (P < 0.01), and beta-sitosterol could lower the mRNA expression level of ET-1 (P < 0.01).
False	RESULTS: Among the sixteen orthogonal design groups, the @DISEASE@ area of these groups using both beta-sitosterol and berberine was the smallest (P < 0.05), the content of Leptin of these groups using both glycyrrhetic acid and ginsenoside was the highest in blood serum (P < 0.05), the group using glycyrrhetic acid had the minimum concentration of ET-1 in blood plasma.
False	This study aims to explore the potential pharmacological mechanism of @FORMULA@ in the treatment of @DISEASE@.
False	RESULTS: The number of targets in the overlap between @FORMULA@ putative targets and @DISEASE@-related drug targets accounted for more than 50% of the latter, and HTR3A, SLC6A4, and CYP3A4 were core targets.
False	METHODS: Network pharmacology was used to sort out the relationship between @FORMULA@ putative targets and @DISEASE@-related drug targets or disease targets, which indicated the mechanism of @FORMULA@ in treating @DISEASE@ from two aspects of clinical drugs approved by the Food and Drug Administration (FDA) and @DISEASE@-related diseases.
False	In @DISEASE@-related disease targets-@FORMULA@ putative targets PPI network, the Th17 cell differentiation pathway, and the IL-17 signaling pathway were key pathways, and the 1st module and the 7th module were central function modules that were highly associated with immunity and @DISEASE@.
False	However, its underlying mechanism remains to be studied.
True	CONCLUSION: @FORMULA@ has similar effects on lipid and drug metabolism as the current @DISEASE@ drugs, and is likely to treat @DISEASE@ by inhibiting Th17 cell differentiation and alleviating @DISEASE@.
False	Moreover, @FORMULA@ suppressed phosphorylation of nuclear factor-kappa B (NF-kappaB) as well as expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).
True	CONCLUSION: Collectively, our findings show that @FORMULA@ attenuates @DISEASE@ and airway remodeling caused by CS and LPS exposure; therefore, therapeutic applications in @DISEASE@ can be considered.
False	This experiment investigated the therapeutic effect of @FORMULA@ in a mouse model of cigarette smoke (CS)- and lipopolysaccharide (LPS)-induced @DISEASE@.
False	@FORMULA@ Attenuates Cigarette Smoke and Lipopolysaccharide-Induced @DISEASE@ in Mice.
False	@FORMULA@ was administered at doses of 100 and 200 mg/kg 1 hour before CS exposure for the last 4 weeks.
False	Traditionally, @FORMULA@ (@FORMULA@), a mixture of Pinellia ternate, Poria cocos, ginger, Chinese liquorice, and tangerine peel, has been prescribed for the treatment of @DISEASE@ caused by dampness phlegm.
False	As for the metabolomics research, 7 metabolites in the plasma samples, 28 in the urine samples and 6 in the liver samples were significantly altered due to the protective effect of @FORMULA@ on CCl4-induced @DISEASE@.
False	These endogenous metabolites are involved in amino acid metabolism, carbohydrate metabolism, glycerophospholipid metabolism and gut bacteria metabolism.
False	In this study, (1)H NMR and MS-based metabolomics analysis along with body weight change, serum liver function indexes, serum @DISEASE@ index and histopathological observations of liver were applied to evaluate the therapeutic effect of @FORMULA@ on @DISEASE@ and the mechanism associated with this.
True	These findings suggest that @FORMULA@ could treat @DISEASE@ by promoting urea circulation and reducing blood ammonia accumulation, improving carbohydrate metabolism and reducing oxidative stress, improving glycerophospholipid metabolism and protecting cell membrane, and regulating intestinal flora metabolism.
False	Investigation of the therapeutic effect of @FORMULA@ on CCl4-induced @DISEASE@ in rats by (1)H NMR and MS-based metabolomics analysis.
False	The results of the pharmacodynamics study show that @FORMULA@ has a significant therapeutic effect on @DISEASE@.
False	Network analysis revealed that miR-223-3p and miR-205-5p shared two targets POU2F1 (encoding POU class 2 homeobox 1) and FUT9 (encoding fucosyltransferase 9), suggesting they have a common role in certain pathways.
False	Twelve human @DISEASE@ SGC7901 cell xenograft nude mouse models were established.
False	Among them, 32 miRNAs were upregulated and 1 miRNA was downregulated.
False	High-throughput sequencing was used to analyze the microRNA (miRNA) expression profiles of @DISEASE@ tissues.
False	We identified 33 miRNAs that were differentially expressed in the @FORMULA@ group compared with the Model group.
True	This study provided novel insights into the anticancer mechanism of @FORMULA@ against @DISEASE@, which might be partly related to the modulation of miRNA expression and their target pathways in @DISEASE@.
True	Metabolic changes at the early stage of @DISEASE@ induced by cecal ligation and puncture in rats and the interventional effects of @FORMULA@.
False	Sixteen biomarkers involved in amino acid metabolism, unsaturated fatty acid metabolism, purine metabolism, and lipid metabolism were identified after Orthogonal Partial Least-Squares Analysis (OPLS).
False	@DISEASE@ is a disease with high @DISEASE@ that requires rapid diagnosis and treatment.
False	This study established the foundation for further research of the early diagnosis biomarkers and therapeutic evaluation biomarkers discovery of @DISEASE@.
False	Male SD rats were intragastrically administered 270mg/kg @FORMULA@ 2h prior to CLP, serum extracts were profiled by liquid chromatography/quadrupole time-of-flight mass spectrometer (LC-Q-TOF-MS) and multivariate analytical (MVA) methods were employed to evaluate the metabolic changes of extracts.
False	Among the 16 metabolites, 10 were regulated by @FORMULA@.
False	OBJECTIVE: The protective effects of @FORMULA@ in @DISEASE@ rats and their potential mechanisms were investigated.
False	@FORMULA@ ameliorate @DISEASE@ and alter proteomic hippocampus profiles induced by d-galactose and Abeta1-40 injection in ovariectomized @DISEASE@ model rats.
False	CONTEXT: @FORMULA@ are a classic Chinese medicine prescription, but their effects on @DISEASE@ (@DISEASE@) are not clear.
False	MATERIALS AND METHODS: An @DISEASE@ rat model was established by ovariectomy combined with d-galactose and Abeta1-40 injection.
False	Nano LC-LTQ-Orbitrap Proteomics determined potential targets and related signalling pathways.
True	DISCUSSION AND CONCLUSION: @FORMULA@ may serve as a potential agent for @DISEASE@ therapeutics by improving learning and memory.
False	Research on the mechanism of @FORMULA@ and @FORMULA@ in promoting axonal regeneration in model rats of @DISEASE@.
False	However, after the intervention of @FORMULA@ and @FORMULA@, the pathological changes and @DISEASE@ in rats' brain and spinal cord were much more alleviated, and the NGF expression was significantly higher than that in the model group at the acute stage (P<0.05).
False	And the expressions of Nogo A, an axon growth inhibitor, and its receptor (Nogo-66 receptor, Ng R) were significantly higher than those in the normal control at the acute stage (P<0.01).
True	CONCLUSIONS: @FORMULA@ and @FORMULA@ can prevent @DISEASE@ and promote the axonal regeneration in rats of @DISEASE@, and the possible mechanism is to increase the expression of NGF and reduce the expression of Nogo A and its receptor.
False	The rats treated with prednisone acetate were taken as controls.
False	RESULTS: Observation under the light microscope with HE staining showed a sleeve-like change in rats' cerebrospinal parenchyma with @DISEASE@ cell infiltration around the small vessels and neuronic denaturation, while silver staining showed excessive tumefaction and abscission of axon, and immunohistochemical analysis showed decreasing of nerve growth factor (NGF) expression at the acute stage of @DISEASE@, which was even more remarkable at the remission stage, showing significant difference as compared with the normal control (P<0.05).
False	In nutrient deprived @DISEASE@ cells with inactivated eEF2, the inhibitory effect of @FORMULA@ in @DISEASE@ cell expansion was interfered.
False	The @DISEASE@ suppressive effect of @FORMULA@ was determined on both @DISEASE@ cells and xenograft model.
False	ETHNOPHARMACOLOGICAL RELEVANCE: An oriental medicinal formulation, @FORMULA@ (@FORMULA@), has been well documented in few Traditional Chinese Medicine Classics 1300 years ago for treatment of heat and dampness-related diseases.
False	@FORMULA@ suppressed the synthesis of nascent protein via inactivation of eEF2 without deregulating the translation initiation factors.
False	Recent studies have postulated @FORMULA@ as a regimen for @DISEASE@ treatment, especially @DISEASE@, but the underlying mechanism is unknown.
True	CONCLUSION: Our results indicate that @FORMULA@ has potential in blocking @DISEASE@ progression with involvement of eEF2 inhibition.
False	In Chinese medicine, @FORMULA@ (@FORMULA@) has been used for the clinical treatment of @DISEASE@ for at least 1700 years.
True	Our study suggests that the renal protective role of @FORMULA@ with multiple effective ingredients involves inhibition of @DISEASE@ through downregulation of the nuclear factor- kappa B pathway, reducing renal advanced glycation end-products and receptor for advanced glycation end-product in @DISEASE@ rats.
False	Pharmacokinetic/pharmacodynamic analysis using partial least square regression revealed that 8 ingredients of @FORMULA@ were responsible for renal protective effects via actions on multiple molecular targets.
False	Rats with @DISEASE@ induced by high-fat diet and streptozotocin were treated with @FORMULA@ extract for 12 weeks.
False	The present study was conducted to investigate the effective ingredients of @FORMULA@ and their molecular mechanisms of antidiabetic nephropathy in rats.
False	Renal Protective Role of @FORMULA@ with Multiple Active Ingredients Involves Inhibition of @DISEASE@ through Downregulation of the Nuclear Factor-kappaB Pathway in @DISEASE@ Rats.
False	RESULTS: Animals with @DISEASE@ showed significantly increased absolute and relative prostate weights, increased dihydrotestosterone levels in the serum or prostate and increased PCNA expression in the prostate; however, @FORMULA@-treated animals showed significant reductions compared with the animals with TP-induced @DISEASE@.
False	In addition, we investigated proliferating cell nuclear antigen (PCNA) expression in the prostate using immunoblotting.
False	@FORMULA@ (200 or 400 mg/kg) was administered daily for 4 weeks to two groups by oral gavage concurrently with the TP.
False	One group was used as a control and the other groups received subcutaneous injections of TP for 4 weeks to induce @DISEASE@.
False	METHODS: A total of 30 rats were divided into five groups.
True	CONCLUSIONS: These findings indicate that @FORMULA@ effectively inhibited the development of @DISEASE@ and might be a useful drug clinically.
False	The aim of the present study was to investigate the therapeutic effects of water-soluble extracts of @FORMULA@, a classical traditional Chinese medicine formulation, on BALB/c mice with experimentally induced @DISEASE@ (@DISEASE@).
False	In addition, the expression levels of interleukin (IL)-5 and IL-13 mRNA in the colonic tissue were determined by fluorescent quantitative polymerase chain reaction.
False	Sulfasalazine (SASP) was administered intragastrically to OXA-treated mice to establish the SASP group (positive control).
False	The intragastric administration of water-soluble extracts of @FORMULA@ significantly lowered the DAI and histopathological @DISEASE@ score.
False	The mRNA expression levels of IL-5 and IL-13 in the colonic tissue were also significantly lowered.
True	In conclusion, the results from the present study demonstrate that water-soluble extracts of the traditional Chinese medicine formulation @FORMULA@ have a therapeutic effect on BALB/c mice with OXA-induced @DISEASE@.
False	The @DISEASE@ model was established by cecal ligation and puncture (CLP); rats in sham operation group received open and closed abdomen.
False	The rats in the @FORMULA@ group were given @FORMULA@ (0.3 g/kg) by gastric irrigation daily for 3 days before CLP, and the drugs were administrated 12 hours after modeling again.
False	Compared with the @DISEASE@ model group, the total score of neuroreflex scores in the @FORMULA@ group was significantly increased (6.57+/-1.90 vs. 4.43+/-1.40, P < 0.05), WBC, serum NSE, S100beta concentration, and the mRNA expressions of IL-6 and TNF-alpha in the brain were significantly reduced [WBC (x10(9)/L): 5.84+/-0.94 vs. 8.07+/-1.32, NSE (mug/L): 0.61+/-0.07 vs. 1.04+/-0.14, S100beta (ng/L): 97.72+/-15.41 vs. 255.62+/-30.25, IL-6 mRNA (2(-DeltaDeltaCt)): 3.605+/-1.014 vs. 5.668+/-2.195, TNF-alpha mRNA (2(-DeltaDeltaCt)): 1.746+/-0.710 vs. 18.996+/-0.913, all P < 0.05].
False	After 24 hours of CLP, the neuroreflex scores were evaluated, white blood cell count (WBC), the levels of serum neuron-specific enolase (NSE) and S100beta were detected.
False	Then the brain tissue was harvested.
True	CONCLUSIONS: The pretreatment of the @FORMULA@ can improve the @DISEASE@ of @DISEASE@ rats and reduce the expression of pro-inflammatory cytokines in the brain.
False	"The key targets were screened by using the plug-in ""cytoHubba"" of Cytoscape software, and the ""active compound-key target"" network was constructed."
False	The results of molecular docking showed that the important active compounds in @FORMULA@ had good binding ability with the key targets.
False	Background: @FORMULA@ (@FORMULA@), one of the classic Earth-cultivating and gold-generating prescriptions of traditional Chinese medicine, is widely used to treat various diseases.
False	Common targets for drugs and diseases were screened by using the bioinformatics and evolutionary genomics platform.
False	@DISEASE@ and @DISEASE@ disease targets were collected through DisGeNET, TTD, GeneCards, PharmGKB, OMIM, NCBI, The Human Phenotype Ontology, and DrugBank databases.
True	Conclusion: @FORMULA@ has played the role of treating different diseases with the same treatment on @DISEASE@ and @DISEASE@ through the characteristics of multicompound, multitarget, and multipathway of traditional Chinese medicine, which provides a theoretical basis for explaining the mechanism and clinical application of @FORMULA@ treating different diseases with the same treatment in @DISEASE@ and @DISEASE@.
False	The Review Manage Software 5.1.0 was used for data analysis.
False	But in terms of reducing the duration of @DISEASE@ and improvement of electrocardiogram, there were no statistical differences between @FORMULA@ group and isosorbide dinitrate group.
False	OBJECTIVE: To systematically assess the effects and safety of @FORMULA@ as an adjuvant therapy for patients with @DISEASE@.
True	@FORMULA@ as an adjuvant therapy for @DISEASE@: a systematic review of randomized controlled trials.
False	None of the trials reported the mortality due to @DISEASE@.
False	RESULTS: Six trials involving 453 participants were eligible.
False	@FORMULA@ at 400 mg/kg increased the survival rate.
False	@FORMULA@ (4 g/kg) and @FORMULA@ (400, 800 mg/kg) significantly attenuated the @DISEASE@, @DISEASE@ and @DISEASE@ volume after @DISEASE@.
False	@FORMULA@ (4 g/kg) and @FORMULA@ (200, 400, 800 mg/kg) were orally administered for 21 d from day 7 before @DISEASE@ to day 14 after @DISEASE@.
False	@FORMULA@ (@FORMULA@) is a traditional Chinese herbal formula which is widely used clinically.
False	@FORMULA@ extract protects against @DISEASE@ after @DISEASE@ via @DISEASE@-inducible-factor-1alpha-regulated vascular endothelial growth factor signaling in mice.
True	We conclude that @FORMULA@ and @FORMULA@ have neuroprotective effects on @DISEASE@ after @DISEASE@ and lead to accelerated angiogenesis by HIF-1alpha-regulated VEGF signaling.
False	Furthermore, @DISEASE@ was observed in association with the dominant CD8+ T-cell subset in bronchoalveolar lavage fluid.
True	We conclude that interferon- and/or @FORMULA@ @DISEASE@ may be due to @DISEASE@ mechanisms rather than toxicity, and that peripheral levels of soluble interleukin-2 receptor appear to be good markers of disease activity.
False	@DISEASE@ during interferon and/or herbal drug therapy in patients with @DISEASE@.
False	These cases shared common clinical features: @DISEASE@, @DISEASE@, @DISEASE@, @DISEASE@, diffuse infiltrates both on chest radiography and chest computed tomography, @DISEASE@, and @DISEASE@ on examination of transbronchial lung biopsy, all of which suggest @DISEASE@.
False	"We report four cases of @DISEASE@ due either to interferon, or a herbal drug, ""@FORMULA@"", or both in combination, in patients with @DISEASE@, focusing on its pathogenesis and response to prednisolone therapy."
False	All patients responded to oral prednisolone therapy.
False	METHODS: A rat @DISEASE@ (@DISEASE@) model was developed using lipopolysaccharide (LPS) combined with bacillus Calmette Guerin (BCG).
False	RESULTS: @DISEASE@ in the pulmonary tissue and the bronchus of @DISEASE@ rats was significantly reduced in the @FORMULA@-treatment groups, AM and AM+RA groups demonstrating the efficacy of @FORMULA@.
False	Serum samples collected at different times from rats after administration of @FORMULA@, AM and AM+RA demonstrated increased proliferation of splenic lymphocytes with area under the effect curve (AUE) of 552.6%, 336.3% and 452.0%, respectively.
False	Treatment of alveolar macrophages with serum samples in @FORMULA@, AM or AM+RA group inhibited interleukin-8 (IL-8) in the cell culture media, and the effect was much better in the @FORMULA@ group compared with AM or AM+RA group, with a higher maximal effect (Emax, P<0.05) and larger AUE (P <0.01 and P<0.05).
True	CONCLUSION: @FORMULA@ demonstrated anti-inflammatory and immunoregulatory effects in a rat model of @DISEASE@, and timedependent relationships were demonstrated in vitro.
False	Bge (AM) and Astragalus membranaceus (Fisch.)
False	@FORMULA@ enhances the amelioration of bone mesenchymal stem cells on @DISEASE@ progression.
False	The cell proliferation antigen Ki67 in the @DISEASE@ tissues were detected by immunofluorescence assay and PCR, respectively.
False	The protective effect of @FORMULA@ or BMSCs in @DISEASE@ tissues can be enhanced by the combination of @FORMULA@ and BMSCs.
False	Histological changes in the liver tissues were examined by hematoxylin-eosin (H&E) staining and Van Gieson (VG) staining.
False	METHODS: Flow cytometry was used to identify BMSCs isolated from BALB/c mice.
True	CONCLUSIONS: These results proved the inhibitory role of @FORMULA@ + BMSCs in @DISEASE@ development through regulating miR-140 and Wnt/beta-catenin signal pathway.
False	MATERIALS AND METHODS: Anti-HRSV activity of a hot water extract of @FORMULA@ was examined by plaque reduction assay in both human upper (HEp-2) and low (A549) respiratory tract cell lines.
False	RESULTS: Hot water extract of @FORMULA@ dose-dependently inhibited HRSV-induced plaque formation in both HEp-2 and A549 cells (P<0.0001), particularly when given before viral inoculation (p<0.0001).
False	@FORMULA@ (@FORMULA@) inhibited cytopathic effect of human respiratory syncytial virus in cell lines of human respiratory tract.
False	Most of the @DISEASE@ are caused by virus.
False	Human respiratory syncytial virus (HRSV) is one of the most common respiratory viral pathogens without effective management.
True	CONCLUSIONS: @FORMULA@ is effective against @DISEASE@ on airway epithelia by preventing viral attachment, internalization, syncytial formation, and by stimulating interferon secretion.
False	"@FORMULA@ could ascend platelets,which was considered as "" oriental interleukins"" for the ancients."
False	In conclusion,it may be a shortcut to restore and explain @FORMULA@ formula syndromes based on modern pathophysiology and severe cases of critical care.
False	However,the clinical evidence,relevant genes and targeting network need to be deepened in future studies.
False	The indications of @FORMULA@ include @DISEASE@,@DISEASE@,and @DISEASE@; @DISEASE@( @DISEASE@,@DISEASE@)with long interval or conduction block,during or after @DISEASE@ or @DISEASE@; @DISEASE@ due to @DISEASE@ after radiotherapy and chemotherapy,malignant fluid state of @DISEASE@,@DISEASE@,terminal stage of @DISEASE@ after major operation,and @DISEASE@ after control of @DISEASE@ and other major diseases; @DISEASE@,phlegm and @DISEASE@ due to @DISEASE@,@DISEASE@,@DISEASE@,after @DISEASE@ surgery; increased heart rate and decreased blood pressure due to insufficient capacity after acute blood loss; the symptoms included @DISEASE@,@DISEASE@,sweating,lassitude,lacking in strength,shortness of breath,syncope,@DISEASE@,@DISEASE@,expectoration,excessive phlegm,clear and dilute sputum,emaciation,dry and haggard skin,@DISEASE@,@DISEASE@,@DISEASE@,enjoy sweet taste,red tongue without moss,knotted pulse,intermittent pulse,thready rapid pulse,and weak pulse.
False	This study is expected to enrich the guidelines for modern medical diagnosis and treatment.
True	@FORMULA@ could treat @DISEASE@,@DISEASE@,and @DISEASE@ in @DISEASE@ and after @DISEASE@ surgery; @DISEASE@ due to @DISEASE@ after @DISEASE@ surgery,@DISEASE@ and acute blood loss,which all belonged to the scope of @DISEASE@.
False	@FORMULA@ reduced 6-OHDA-induced intracellular ROS production and GSH depletion and inhibited mitochondrial membrane instability, cytosolic cytochrome c release, and caspase-3 activation.
False	Recent clinical and experimental studies have reported aging and anti-neurodegenerative effects of @FORMULA@.
False	AIM OF THE STUDY: @FORMULA@ (@FORMULA@) is a multi-herbal formula that has long been widely used in traditional Oriental medicine to treat @DISEASE@, including @DISEASE@.
False	To determine mitochondria-mediated apoptotic activity, we examined mitochondrial membrane potential, cytochrome c release, and caspase-3 activation.
False	MATERIALS AND METHODS: To evaluate the protective effects of @FORMULA@, we analyzed viability in SH-SY5Y @DISEASE@ cells and tyrosine hydroxylase (TH) staining in primary DA cells.
True	@FORMULA@, a medicinal herbal formula, protects dopaminergic neurons from 6-hydroxydopamine-induced @DISEASE@.
False	@FORMULA@ as an effective treatment for @DISEASE@ based on network pharmacology and experimental validation.
False	METHODS: In this study, potential components of @FORMULA@ and putative targets were screened by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP).
False	Then we got 52 core targets which enriched in cell cycle, apoptosis, proliferation, MAPK activation etc. and obtained TOP30 pathways.
False	In signaling pathways, @FORMULA@ inhibited the phosphorylation of extracellular regulatory protein kinase 1/2 (ERK1/2) and NF-kappaB p65 (S468) on SCC-25 and CAL-27.
True	CONCLUSIONS: @FORMULA@ played a potential therapeutic role on @DISEASE@ via inhibiting p-ERK1/2 and p-NF-kappaB p65 (S468).
False	Then we did the in vitro experiments to verify the major biological processes (cell cycle, apoptosis and proliferation) and signaling pathways (mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF-kappaB), protein kinase B (AKT)) on @DISEASE@ cell lines, SCC-25 and CAL-27.
False	Many traditional Chinese medicine tonifying prescriptions for kidney and spleen have been proved to play various roles in @DISEASE@.
False	Furthermore, AOD and @FORMULA@ significantly increased the expressions of BMP2, Runx2, Collagen I and Opn, while reduced the levels of PINP and beta-CTX in serum compared to OVX model group.
False	BMD was increased in AOD and @FORMULA@ treatment.
False	Finally, the levels of Alkaline phosphatase (ALP), procollagen type I N propeptide (PINP) and beta-C-terminal telopeptide of type I collagen (beta-CTX) were detected.
False	An experimental research into the potential therapeutic effects of Anti-Osteoporosis Decoction and @FORMULA@ on ovariectomy-induced @DISEASE@.
True	In conclusion, AOD and @FORMULA@ exert regulatory effects on @DISEASE@ in ovariectomized rats.
False	PURPOSE: @FORMULA@ (@FORMULA@) is a widely used traditional herbal medicine for relieving @DISEASE@.
False	However, quality of life measured using the EORTC QLQ-C30 improved in both arms compared with the baseline, and the global health subscale was significantly better in the @FORMULA@ group than in the placebo group (P = .02).
False	This randomized, placebo-controlled, preliminary study evaluated @FORMULA@ for @DISEASE@-related @DISEASE@, which is the most common symptom experienced by patients with @DISEASE@.
False	No significant toxicities were observed.
False	Traditional Herbal Medicine, @FORMULA@, for @DISEASE@-Related @DISEASE@: A Randomized, Placebo-Controlled, Preliminary Study.
True	CONCLUSION: @FORMULA@ may improve @DISEASE@ @DISEASE@ and quality of life in patients with @DISEASE@.
False	@FORMULA@ improved @DISEASE@ in @DISEASE@ rats model.
False	The IMD was significantly higher, while BI, TP, MP, and RV were significantly lower and bladder pathological changes were alleviated in the @FORMULA@ (10, 5 g/kg), finasteride, and terazosin groups.
False	RESULTS: In the model group, the PI, BI, serum DHT, serum PAP, threshold pressure (TP), micturition pressure (MP), and residual urine volume (RV) were significantly higher.
True	CONCLUSION: @FORMULA@ could relieve symptoms of @DISEASE@ in @DISEASE@ rats but with no apparent effect on reducing the volume of the enlarged prostate itself.
False	OBJECTIVE: To investigated the effect and mechanism of @FORMULA@ (@FORMULA@) on @DISEASE@ induced by @DISEASE@ (@DISEASE@) in rats.
False	Urodynamics were assessed in rats under anesthesia.
False	Interestingly, the urothelial epithelium infiltrated by lymphocytes and subepithelial @DISEASE@ cells strongly expressed cell boundary PD-L1.
False	After five cycles of treatment, the patient was referred to the hospital for sudden onset urinary frequency, @DISEASE@, and @DISEASE@.
False	Successful treatment of immune-related @DISEASE@ by @FORMULA@ (@FORMULA@) in a @DISEASE@ patient: Case report and literature review.
False	CASE SUMMARY: A 56-year-old man with @DISEASE@ received sintilimab plus paclitaxel and tegafur therapy.
True	CONCLUSION: This report shows that @FORMULA@ is safe and effective for treating immune-related @DISEASE@.
False	BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the landscape of advanced @DISEASE@ treatment.
False	PURPOSE: We investigated the effects of a modificated @FORMULA@ water extract (@FORMULA@) against @DISEASE@ caused by CS and lipopolysaccharide (LPS) in mice and cigarette smoke condensate (CSC)-stimulated NCI-H292 cells.
False	Expression levels of matrix metalloprotease-9 (MMP-9) and extracellular signal-regulated kinase (Erk) were analyzed by western blotting.
False	@FORMULA@ is a traditional polyherbal mixture composed of four different herbs.
False	BACKGROUND: Cigarette smoke (CS) is a major contributor to the high incidence of @DISEASE@ (@DISEASE@) featured as @DISEASE@ and @DISEASE@.
True	CONCLUSION: Overall, @FORMULA@ effectively inhibited the @DISEASE@ and MMP-9 expression caused by the CS and LPS exposure, which was closely involved in suppression of Erk phosphorylation.
False	One hour before CS exposure, animals were received @FORMULA@ (50 or 100mg/kg) by oral gavage.
False	METHODS: A literature search was conducted to confirm the effects of @DISEASE@ on psychological and mental health of survivors.
False	A series of treatment plans were prescribed for @DISEASE@ survivors with psychological and @DISEASE@.
False	The symptoms of @DISEASE@ were analyzed, and the TCM syndrome of the @DISEASE@, @DISEASE@ and @DISEASE@ after recovered from @DISEASE@ was interpreted as internal heat and Yin deficiency.
False	From the perspective of Traditional Chinese Medicine: Treatment of @DISEASE@ in @DISEASE@ survivors.
False	@FORMULA@, Huanglian Ejiao Decoction and Zhizi Chi Decoction were suggested for @DISEASE@.
True	CONCLUSION: Lily Bulb, Rhizoma Anemarrhena Decoction and @FORMULA@ were used to treat @DISEASE@.
False	However, the cellular and molecular mechanisms underlying the effects of @FORMULA@ remain elusive.
False	We investigated the potential protective effect of @FORMULA@ against @DISEASE@ and used bioinformatics analysis to identify its underlying mechanism in a mouse model of cyclophosphamide (CP)-induced diminished ovarian reserve.
True	@FORMULA@ ameliorates oocyte damage due to cyclophosphamide-induced @DISEASE@ in mice.
False	Gene expression analysis revealed that the expression of fertilisation- and ovarian follicle development-related genes was altered by CP treatment but normalized after @FORMULA@ administration.
False	@FORMULA@ (@FORMULA@), a traditional herbal medicine, has been used to treat @DISEASE@ and @DISEASE@.
False	Although @FORMULA@ administration did not prevent CP-induced follicle loss in mice, the quality of oocytes was better in CP + @FORMULA@ mice than in CP mice.
False	METHODS: @DISEASE@ was induced in male DBA/IJ mice by immunization with 2 injections of bovine type II collagen (CII).
False	@FORMULA@ inhibited the production of specific anti-CII antibody, IL-6, and TNF-alpha, and tended to normalize the proportions of cells in lymphocyte subsets.
False	Suppressive effect of @FORMULA@ on @DISEASE@ in DBA1J mice.
True	CONCLUSION: @FORMULA@ suppresses the development of @DISEASE@, and @FORMULA@ redistributes the population of lymphocytes in lymph node and blood and inhibits IL-6 and TNF-alpha secretion in @DISEASE@ mice.
False	RESULTS: @FORMULA@ caused suppression of @DISEASE@ development in a dose dependent fashion and exerted a suppressive effect on @DISEASE@ when administered from the first CII immunization or from the onset of @DISEASE@, but not when administered for 2 weeks before CII immunization.
False	The incidence of @DISEASE@, @DISEASE@ index, levels of anti-CII antibody, interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) and lymphocyte subsets were examined.
False	It is thought that the components @FORMULA@, a component known to improve @DISEASE@, and @FORMULA@, a vital energy supplementing component, were the main ingredients that conferred the improvements in @DISEASE@ and @DISEASE@.
False	The patient underwent nutritional treatment with a kampo medicine (@FORMULA@), which was administered as a medication due to difficulties with swallowing the powdered form.
True	"[Successful use of ""@FORMULA@"", a kampo medicine, for the treatment of perioperative @DISEASE@ and @DISEASE@]."
False	On the 18th day after admission, @DISEASE@ (hemoglobin, 8.9 g x dl(-1)) and @DISEASE@ (3.6 g x dl(-1)) improved, as did @DISEASE@ and @DISEASE@.
False	These findings suggest that Chinese herbal medicine for the nutritional treatment of the elderly has minimal side effects.
False	The patient and her family refused transfusion, despite @DISEASE@, stating their affiliation with Jehova's Witnesses.
False	MATERIALS AND METHODS: @FORMULA@ and n-butanol extraction of @FORMULA@ (@FORMULA@-Bu) were prepared and administered to ISO-treated mice once a day for 7 consecutive days.
False	The doses were equivalent to the raw medicinal herbs of @FORMULA@ 5.72, 2.86 and 1.43 g/kg/d, respectively.
False	Screening and identifying the @DISEASE@ protective ingredients from @FORMULA@.
False	Both @FORMULA@ and @FORMULA@-Bu significantly attenuated the myeloperoxidase activities (from 42 to 56%) and malondialdehyde levels (from 25 to 45%) compared with the model group.
False	These biochemical results were supported by electrocardiogram (ECG) and histopathological observations.
True	CONCLUSION: These findings suggested that @FORMULA@ was the mainly active fraction of @FORMULA@ which exerted its beneficial effects on @DISEASE@ mainly through protecting myocardial tissue and reducing oxidative damage, and the ginsenosides and lignans may serve as active ingredients of @FORMULA@ for the treatment of @DISEASE@.
False	METHODS AND DESIGN: In this retrospective cohort study using a nationwide inpatient database in Japan, we performed propensity score matching to compare patients who did or did not receive kampo medicine after surgery for @DISEASE@.
False	RESULTS: The proportions of @DISEASE@ were not significantly different between the 424 propensity-matched pairs with and without kampo medicine (11 versus 8, P = 0.644).
False	PRIMARY OUTCOME MEASURES: @DISEASE@ complications.
False	BACKGROUND: @DISEASE@ after @DISEASE@ surgery are common in the elderly.
False	INTERVENTION: Kampo medicine after surgery for @DISEASE@.
True	CONCLUSION: The present study suggests that @FORMULA@ or @FORMULA@ postoperatively is not associated with decreased occurrence of @DISEASE@ in patients who underwent surgery for @DISEASE@.
False	[Effects of nine prescriptions on @DISEASE@ in rats induced by endotoxin].
False	In this paper in is reported that nine prescriptions often used in traditional Chinese medicine for the treatment of diseases with @DISEASE@ were tested experimentally for the effect on @DISEASE@ of rats induced by endotoxin.
True	The results are as follows: @FORMULA@, @FORMULA@, @FORMULA@, Cai-hao-mixture, Da-huang-huang-lian-jie-du-decoction, Tao-ren-cheng-qi-decorction, @FORMULA@, Yin-qiao-jie-du-decoction etc. can notably reduce @DISEASE@ in rats induced by endotoxin with the exception of @FORMULA@ that has no obvious effect on @DISEASE@.
False	Additionally, the expressions of nuclear factor-kappa B (NF-kappaB) and muscle RING finger protein-1 (MuRF-1) decreased in the gastrocnemius muscle when the herbal combination was applied.
False	BACKGROUND: @DISEASE@ is characterised by the @DISEASE@ and directly compromises immune response and the quality of life of @DISEASE@ patients.
False	Thus, S. baicalensis and @FORMULA@ were evaluated for their combinaton effects on the @DISEASE@-induced @DISEASE@ murine upon receiving 5-FU chemotherapy.
False	This combination otherwise increased both Th1/Th2 ratio and NK cytotoxicity.
False	In the mice receiving with or without 5-FU, the serum levels of monocyte chemoattractant protein-1 (MCP-1) increased by all means but otherwise decreased when the herbal combination was administrated.
True	CONCLUSION: Our results revealed that the combination of S. baicalensis and @FORMULA@ is able to ameliorate @DISEASE@ and positively stimulate anti-tumour immunity while undergoing chemotherapy in animal model.
False	This meta-analysis aimed to evaluate the efficacy and safety of @FORMULA@ as an adjuvant therapy in patients with @DISEASE@ (@DISEASE@) and @DISEASE@ (@DISEASE@).
False	RESULTS: Eighteen trials involving 1,601 patients were identified and analyzed.
False	Risk ratio (RR) or weighted mean difference (WMD) with their 95% confidence interval (CI) was calculated between with and without @FORMULA@ therapy.
False	Moreover, @FORMULA@ significantly improved the Glasgow @DISEASE@ Scale in patients with @DISEASE@ (WMD 1.18; 95% CI 0.79-1.56) and @DISEASE@ (WMD 2.28; 95% CI 1.37-3.19).
False	Randomized controlled trials evaluating @FORMULA@ as an adjuvant therapy for @DISEASE@ were selected.
True	CONCLUSIONS: Adjuvant treatment with @FORMULA@ appears to improve the total response rate and @DISEASE@ score in patients with @DISEASE@ and @DISEASE@.
False	We conducted a longitudinal cohort study to compare the effect of CHMs use on the subsequent @DISEASE@ risk in @DISEASE@ individuals.
False	Use of Chinese herbal medicines by @DISEASE@ patients was associated with lower risk of @DISEASE@: A retrospective cohort study.
True	The following seven commonly-prescribed CHMs were found to lessen the @DISEASE@ risk: Dan-Shen, Tian-Hua-Feng, Fu-Zi, @FORMULA@, @FORMULA@, @FORMULA@, and @FORMULA@.
False	The use Chinese herbal medicines (CHMs) is increasing, but whether they can reduce the risk of developing @DISEASE@ remains unclear.
False	CHMs use was associated with 38% (adjusted HR: 0.62; 95% confidence interval: 0.54-0.73) lower subsequent risk of @DISEASE@.
False	CONCLUSION: The CHMs use was associated with lower risk of @DISEASE@ for @DISEASE@ patients, suggesting that it could be integrated into conventional therapy to prevent subsequent @DISEASE@ incident.
False	Then, metabonomic analysis was performed.
False	METHOD: The hydrophilic or lipophilic constituent group of @FORMULA@ was extracted by distilled water or acetic ether respectively.
False	CONCLUSION: Our study indicated that the developed metabonomic technology based on HPLC-UV might be used as a potentially powerful tool for estimating the anti-inflammation effect of @FORMULA@ with sensitivity and integrity.
False	RESULT: The high dosage of @FORMULA@ extraction (16.5 g x kg(-1))could inhibit the swell of rat palm significantly, but there are not statistically significant effect of low dosage group.
False	The anti-inflammation effects of different @FORMULA@ dosages and extractions were measured by traditional method respectively.
True	Nevertheless, the metabonomic study showed that @FORMULA@ extraction could restore obviously the rat HPLC-UV urinary profiling disturbed by @DISEASE@ in low dosage, especially the hydrophilic constituent group.
False	METHODS: The rats were randomly divided into four groups: control, model, @FORMULA@-treated, and Estazolamtreated groups (n=15 in each group).
False	The mRNA expression of KCC2 was signifificantly decreased in @DISEASE@ rats (0.62+/-0.35 vs. 2.29+/-0.56; P=0.044), while @FORMULA@ showed a tendency to increase the mRNA of KCC2 in @DISEASE@ rats (P>0.05).
False	Na-K-Cl-cotransporter (NKCC1) and K(+)/Cl(-) cotransporter (KCC2) in the hippocampus were tested by immunohistochemistry, real-time polymerase chain reaction, and western blot.
False	These fifindings would have major implications in the mechanism of @FORMULA@ to relieve @DISEASE@.
False	By contrast, the mRNA expression of NKCC1 was signifificantly increased in the hippocampus of @DISEASE@ rats (6.58+/-1.54 vs. 2.82+/-0.32; P=0.011), while @FORMULA@ decreased the mRNA expression of NKCC1 (6.58+/-1.54 vs. 2.79+/-0.81; P=0.016).
True	CONCLUSIONS: Chinese medicine @FORMULA@ could alleviate @DISEASE@ of @DISEASE@ rats by regulating cation-chloride cotransporters, such as NKCC1 and KCC2.
False	A Chinese herbal medicine @FORMULA@ (@FORMULA@) was orally administered (1.8 g/kg daily) to DMN-induced @DISEASE@ rats for 2 weeks.
False	The HFU scoring results among the normal controls, 2-week DMN-treated rats, 4-week DMN-treated rats, and combined 2-week @FORMULA@ therapy with 4-week DMN-treated rats also reached statistical significance.
False	In this study, @DISEASE@ was induced by administering dimethylnitrosamine (DMN) in SD rats, aged 8 weeks, for three consecutive days per week for up to 4 weeks.
False	@FORMULA@ herbal treatment remarkably prevented rats from DMN-induced @DISEASE@.
True	Thus, HFU is an accurate tool for the longitudinal analysis of @DISEASE@ progression in small-animal models, and the @FORMULA@ may be useful in reversing the development of @DISEASE@.
False	The animals used in @DISEASE@ studies must usually be sacrificed.
False	II.
True	II mainly for @DISEASE@, and @FORMULA@ combined with drugs for clearing away heat and toxic substances are used for treatment of @DISEASE@.
False	I and No.
False	[Professor ZHANG Ji's clinical experience].
False	Modified Guanjie No.
False	I is mainly used for treatment of @DISEASE@, and modified Guanjie No.
False	Pattern recognition, clustering analysis and metabolic pathway analysis were used to analyse the metabolomic data of three groups (a sham-operated group, a @DISEASE@ model, and an @FORMULA@-treated @DISEASE@ model).
False	Metabolomic technique can be used to explore the mechanisms underlying the treatment of @DISEASE@ with @FORMULA@.
False	The results showed that @FORMULA@ reversed the abnormalities in the levels of small-molecule metabolites (such as L-acetylcarnitine, L-tryptophan, indoleacrylic acid, gamma-aminobutyric acid, hypotaurine, LysoPC(18:1)(11Z), creatine, L-phenylalanine and L-leucine) in @DISEASE@ rats through six metabolic pathways (including phenylalanine, tyrosine and tryptophan biosynthesis; phenylalanine metabolism; valine, leucine and isoleucine biosynthesis; taurine and hypotaurine metabolism; tryptophan metabolism; and alanine, aspartate and glutamate metabolism) involved in the therapy process.
True	This study revealed the holistic and dynamic metabolic changes caused by @FORMULA@ in rats with @DISEASE@ and provided important research methods and approaches for exploring the multiple metabolites and metabolic pathways involved in the therapeutic effect of @FORMULA@ on @DISEASE@.
False	However, the mechanism of the therapeutic process is still not fully understood.
False	It has been widely reported that @FORMULA@ (@FORMULA@), a traditional Chinese medicine, is effective in the treatment of @DISEASE@ (@DISEASE@).
False	RESULTS: The analysis includes 9 RCTs involving 681 patients.
False	Due to the low methodological quality, small sample size, and significant heterogeneity of RCTs, more rigorous and scientific clinical trials are required to further evaluate the efficacy and safety of @FORMULA@.
True	CONCLUSION: Our systematic evaluation and meta-analysis showed that @FORMULA@ combined with WM or @FORMULA@ alone was beneficial for improving sleep quality and relieving @DISEASE@.
False	Clinical efficacy and safety of traditional Chinese medicine @FORMULA@ in @DISEASE@ combined with @DISEASE@.
False	The incidence of adverse events with @FORMULA@ as an ancillary drug or used separately was lower than that in the WM.
False	This study aims to evaluate the efficacy and safety of @FORMULA@ in the treatment of @DISEASE@ combined with @DISEASE@.
False	Moreover, a total of 106 overlapping genes were revealed between drug targets and @DISEASE@ molecular targets.
True	CONCLUSION: VEGFA and EGFR might be potential therapy targets of @FORMULA@ in @DISEASE@.
False	These hub nodes such as VEGFA and EGFR were mainly enriched in GO functions including positive regulation of MAP kinase activity, activation of protein kinase activity, regulation of MAP kinase activity, and pathways like proteoglycans in @DISEASE@, @DISEASE@, and estrogen signaling.
False	OBJECTIVE: To investigate the potential therapy targets and pharmacological mechanism of traditional Chinese medicine (TCM) @FORMULA@ in @DISEASE@ based on network pharmacology.
False	Moreover, the PPI network and module was constructed based on overlapping genes and hub nodes, respectively, followed by the pathway enrichment analysis.
False	RESULTS: A drug ingredients-target network was established with 1184 nodes and 11035 interactions.
False	To investigate the effect of @FORMULA@ on expression of cytokines and NF-kappaB p65 in rats with @DISEASE@ (@DISEASE@), and to probe into its underlying mechanisms of action.
False	The food intake and body weight of model group rats were lower than that of control group.
False	The mode of @DISEASE@ rats with cell immunoreactivity was made using compound method (trinitrobenzene sulfonic acid and ethanol).
False	NF-kappaB p65 may be involved in the pathogenesis of @DISEASE@, and @FORMULA@ can inhibit the relative activity of NF-kappaB p65, and decrease the expression levels of NO, IL-6, TNF-alpha and PGE2.
False	The expression levels of NO, IL-6, TNF-alpha, PGE2 in serum and NF-kappaB p65 protein of colon tissue in model group were higher than that of control group.
True	[Effect of @FORMULA@ on the regulatory NF-kappaB p65 signal pathway in rats with @DISEASE@].
False	TH increased, CHAT decreased, and TH/CHAT increased in the myocardial homogenate of the model group (P<0.05).
False	After 4 weeks, the model rats were divided into the model group, the methycobal group, and the @FORMULA@ group, 9 rats in each group.
False	OBJECTIVE: To observe abnormalities in heart rate variability (HRV) in @DISEASE@ rats and to explore the effects of treatment with @FORMULA@ ([symbols; see text]) on @DISEASE@.
False	The normal group was randomly selected, and the remaining rats were used to establish streptozocin (STZ)-induced @DISEASE@ model.
False	Compared with the model group, CNTF in the interventricular septum increased in the methycobal group (P<0.05); GAP-43 increased, NGF decreased, and CNTF increased (P<0.05) in the @FORMULA@ group.
True	CONCLUSION: @FORMULA@ was effective in improving the function of the vagus nerve, and it could alleviate @DISEASE@.
False	@DISEASE@ (@DISEASE@), a pregnancy-specific syndrome with the major molecular determinants of placenta-borne oxidative stress and consequently impaired nitric oxide (NO) generation, has been considered to be one of the leading causes of maternal morbidity as well as @DISEASE@ and @DISEASE@ worldwide.
False	In human @DISEASE@ placental explants, reactive oxygen species (ROS) levels were elevated and NO production was inhibited, while @FORMULA@ treatment at different periods effectively down-regulated the H2O2-induced ROS levels and significantly up-regulated the H2O2-suppressed NO production in human TEV-1 cells.
False	Here, we report that @FORMULA@ (@FORMULA@), which is used clinically for @DISEASE@ treatment, regulates oxidative stress and NO production in human extravillous trophoblast-derived TEV-1 cells.
False	Several medical conditions have been found to be associated with increased @DISEASE@ risk, however, the treatment of @DISEASE@ remains unclear.
False	More importantly, @FORMULA@ administration not only increased the weight gain during pregnancy and revealed a @DISEASE@ effect, but also improved the placental weight gain and attenuated fetal growth restriction in an NG-nitro-L-arginine methyl ester (L-NAME)-induced mouse @DISEASE@-like model.
True	Our results thereby provide new insights into the role of @FORMULA@ as a potentially novel treatment for @DISEASE@.
False	Therefore, we explore the mechanism of @FORMULA@ on MNNG-induced @DISEASE@ by integrating approaches.
False	Then, UPLC-Q-TOF/MS was used for plasma and urine metabolomic analysis to screen the specific potential biomarkers and metabolic pathway of @FORMULA@ in ameliorating @DISEASE@ and to explore its possible mechanism.
False	@FORMULA@ significantly ameliorate the pathological injury of gastric tissue, increase levels of PGI and PGI/II, and reduce the expression level of proinflammatory factors.
False	Metabolomic Study of @FORMULA@ in Relieving 1-Methyl-3-nitro-1-nitrosoguanidine-Induced @DISEASE@.
False	Through metabolomic analysis, 9 potential metabolic differences were identified and 6 related metabolic pathways were enriched.
True	These findings indicate for the first time the potential mechanism of @FORMULA@ in improving @DISEASE@ induced by MNNG and are of great significance to the clinical development and application of @FORMULA@ drugs.
False	RESULTS: Compared with the control group, the airway wall and airway smooth muscle of murine pulmonary tissues significantly thickened and massive @DISEASE@ cells infiltration occurred around the bronchus in the model group, and the cell counts of WBC and EOS in BALF were also apparently increased, which indicated the rat @DISEASE@ model was successfully established.
False	@FORMULA@ mitigates @DISEASE@ and regulates IL-21/STAT3 signaling pathway in rat @DISEASE@ model.
False	MATERIALS AND METHODS: Specific pathogen free SD rats were randomly divided into 6 groups: normal control group, model group, positive group (Compound methoxyphenamine), @FORMULA@-treated groups at doses of 10ml/kg, 5ml/kg and 2.5ml/kg, 10 rats in each group.
False	At 24h after the last excitation, bronchoalveolar lavage fluid (BALF) of every rat was drawn and the number of @DISEASE@ cells was analyzed using cell counting method.
False	@FORMULA@ or Compound methoxyphenamine not only alleviated the pulmonary inflammatory pathological damages, but also down- regulated the numbers of WBC and EOS in BALF.
True	CONCLUSION: @FORMULA@ intervention demonstrated a strong inhibitory action on the secretion of @DISEASE@ mediators as well as the @DISEASE@ cell infiltration in pulmonary tissues of @DISEASE@ rats, and also depressed the protein expressions of IL-21, IL-21R, STAT3 and p-STAT3 in pulmonary tissues.
False	Our results demonstrated that @FORMULA@ extracts could increase the sensitivity of SGC-7901/DDP cells to DDP by increasing the concentration of DDP in cytoplasm and enhance the proapoptosis of DDP by upregulating the JNK and Bax expression, downregulating the Bcl-2 expression, increasing the accumulation of Cytochrome C in cytoplasm, and promoting the activities of caspase-3 and caspase-9.
False	A traditional Chinese medicine (TCM) formula, @FORMULA@ (@FORMULA@), has been found as an anticancer drug in human @DISEASE@.
True	Our results implied that @FORMULA@ might serve as a synergistic drug with chemotherapeutic drugs DDP in the treatment of @DISEASE@.
False	Synergistic Effect of @FORMULA@ on DDP-Induced Apoptosis in Human @DISEASE@ SGC-7901/DDP Cells.
False	In conclusion, in vitro and in vivo, @FORMULA@ extracts could enhance the proapoptotic effect of DDP by promoting the activation of JNK and the expression of Bcl-2, inhibiting the Bax expression, followed by increasing the release of Cytochrome C from mitochondria to cytoplasm, and finally activating the caspase cade reaction.
False	In this study, we investigated the synergistic effect of @FORMULA@ extracts on DDP-induced apoptosis in human @DISEASE@ SGC-7901/DDP cells.
True	The results provide some preclinical evidence on the protective effects of @FORMULA@ for the treatment of @DISEASE@.
False	@FORMULA@ (@FORMULA@) has been used in the treatment of @DISEASE@ (@DISEASE@) in China for many years.
False	Rhein is regarded to be the active compound of rhubarb and can be expected to be a new compound for the treatment of @DISEASE@.
False	The results showed that rhubarb significantly increased blood perfusion of pancreatic tissue, reversed mitochondrial damage, and promoted pancreatic acinar and stellate cell proliferation.
False	The aim of the current study was to examine the principal ingredient rhubarb of @FORMULA@ and its potential link to the pancreatic repair effects in rats with @DISEASE@.
False	Protective Effects of Rhubarb in Rats with @DISEASE@ and the Role of Its Active Compound Rhein on Mitochondria of Exocrine Cells.
False	@DISEASE@ (@DISEASE@) is a common @DISEASE@ driven by a T-cell-mediated immune response, with @DISEASE@ and @DISEASE@ being its main clinical manifestations.
False	@FORMULA@ significantly reduced clinical symptoms and @DISEASE@ in @DISEASE@-like mice by inhibiting the production of cytokines [histamine, interleukin (IL)-3, IL-4, IL-5, IL-13, IL-17A, IL-31, and IL-33], substance P (SP), transient receptor potential cation channel subfamily V member 1 (TRPV-1), and gastrin-releasing peptide (GRP).
False	We aimed to clarify the anti-inflammatory and anti-pruritus mechanisms of @FORMULA@ in @DISEASE@ treatment.
False	We performed immunohistochemistry, Western blotting, reverse transcriptase-polymerase chain reaction, Luminex-based direct multiplex immunoassay, enzyme-linked immunosorbent assays, and flow cytometry to address the abovementioned aims.
False	@FORMULA@ (@FORMULA@), which is an ancient Chinese medicine herbal formula derived from Wai-Tai-Mi-Yao, is a potentially effective treatment for @DISEASE@.
True	Our findings indicate that @FORMULA@ can treat @DISEASE@ by regulating the antigen presentation function of dendritic cells, weakening T-lymphocyte activation, and subsequently exerting anti-inflammatory and anti-pruritus effects.
False	"In this study,Cinnamomi Ramulus-Paeoniae Radix Alba drug pair was used as the research object and the molecular mechanism of its treatment of @DISEASE@ was investigated by analyzing the chemical compositions with integrative pharmacology platform( TCMIP,http://www.tcmip.cn/),predicting disease target,analyzing gene function and pathway of "" Cinnamomi Ramulus-Paeoniae Radix Alba"" in treatment of @DISEASE@,and establishing a multi-dimensional network relationship of "" Chinese medicine-chemical components-core targets-key pathways""."
False	[Molecular mechanism of Cinnamomi Ramulus-Paeoniae Radix Alba drug pair against @DISEASE@ based on integrative pharmacology platform of traditional Chinese medicine].
False	"The prediction results of "" Cinnamomi Ramulus-Paeoniae Radix Alba"" drug pair showed that its anti-sepsis effect was associated with 45 active components,and the active components played an anti-sepsis role through multiple targets and pathways,involving inflammatory targets such as PF4,MyD88,TLR4,BDKRB2,CD14,and NOS3."
False	However,due to the complexity of the prescription,its anti-sepsis mechanism is difficult to be clarified.
False	It is effective in the treatment of @DISEASE@ in clinical practice.
True	This study provides a scientific basis for further development of Cinnamomi Ramulus-Paeoniae Radix Alba drug pair and @FORMULA@ against @DISEASE@.
False	Hereafter, we investigated the effects of paeoniflorin and its predicted target, the results suggest that it can reverse the @DISEASE@ produced by CORT and could be a neuroprotective effect by promoting the phosphorylation of Akt.
False	To further investigate the mechanism of antidepressant effects of @FORMULA@, a compound-@DISEASE@ targets (C-DTs) network was constructed, and Gene Ontology (GO) functional and KEGG pathway enrichment analyses were performed for the 99 targets.
True	Enrichment results revealed that @FORMULA@ could regulate multiple aspects of @DISEASE@ through these targets, related to metabolism, neuroendocrine function, and neuroimmunity.
False	The present study conducted a comprehensive network pharmacological analysis of @FORMULA@ and sorted all pharmacologically active components (149) through the TCMSP webserver.
False	However, the system mechanism of these effects has not been fully characterized.
False	Prediction and analysis of protein-protein interactions resulted in selection of three hub genes (AKT1, TP53, and VEGFA).
False	Cox proportional hazards regression was used to compute the adjusted hazard ratio of @DISEASE@ associated with CHMs use.
False	During follow up, 3,328 CHMs users and 6,988 non-CHMs users developed @DISEASE@ at incidence rates of 17.24 and 37.97 per 1,000 person-years, respectively.
False	This study aimed to investigate the effect of CHMs on the risk of @DISEASE@ among individuals with @DISEASE@.
False	CHMs users had a lower @DISEASE@ risk than the non-CHMs users (adjusted hazard ratio = 0.44; 95% Confidence Interval, 0.42-0.46).
False	Use of Chinese Herbal Medicines Is Related to a Reduction in @DISEASE@ Risk Among Patients With @DISEASE@: A Matched Cohort Study.
True	Gegen, Huangqin, Dan-Shen, Beimu, Dahuang, Shegan, @FORMULA@, @FORMULA@, @FORMULA@ and @FORMULA@ were significantly associated with a lower risk of @DISEASE@.
False	These results suggest that @FORMULA@ has effect on inhibiting hepatic lipid accumulation through regulation of cholesterol synthesis and AMPK activity in vitro.
False	In in vivo study using @DISEASE@ rats, @FORMULA@ reduced retroperitoneal and perirenal fat, serum lipids, atherogenic index, cardiac risk factor, media thickness, and @DISEASE@ score, when compared to @DISEASE@ control rats.
False	The present study was conducted to investigate the effect of @FORMULA@ on the @DISEASE@ in a rat model of @DISEASE@ and lipid accumulation in methyl-beta-cyclodextrin-induced HepG2 cells.
False	Moreover, @FORMULA@ reversed the methyl-beta-cyclodextrin-induced decrease in the protein levels of critical molecule involved in cholesterol synthesis, sterol regulatory element binding protein-2, and low-density lipoprotein receptor and inhibited protein levels of 3-hydroxy-3-methylglutaryl coenzyme A reductase as well as activity.
True	These observations support the idea that @FORMULA@ is bioavailable both in vivo and in vitro and could be developed as a preventive and therapeutic agent of @DISEASE@ in postmenopausal females.
False	Phosphorylation level of AMP-activated protein kinase was stimulated by @FORMULA@.
False	However, the mechanisms contributing to the multiscale treatment of @DISEASE@ at the systematic level remain unclear.
False	The module analysis revealed that nine hub genes exhibited ubiquitin-protein ligase activity.
False	Therefore, @FORMULA@ significantly alters the expression of ubiquitination-related genes and, thus, plays an important therapeutic role in the treatment of @DISEASE@.
False	The gene chip analysis was initially performed, followed by network pharmacology to identify differentially expressed genes (DEG) and a functional enrichment analysis.
False	In conclusion, hub genes may provide a more detailed understanding of the molecular mechanisms of action of as well as candidate targets for @FORMULA@ therapy.
True	Clarifying the pharmacological mechanisms of action of @FORMULA@ on @DISEASE@ using a network pharmacology approach.
False	After injection, the rats in @FORMULA@ group were given @FORMULA@ (3.75 g x kg(-1) x d(-1), p.o.).
False	The mRNA expression of Cu-Zn SOD and Mn SOD were also detected by RT-PCR.
True	CONCLUSION: The data suggest that oxidative stress is present in the mitochondria of myocardium in ADR-induced @DISEASE@ rats and it can be eased by @FORMULA@.
False	Three weeks later, cardiac function, content of malondialdehyde (MDA) of both myocardium and mitochondria and activity of Cu-Zn SOD and Mn SOD were measured.
False	RESULT: Compared with control group, LVSP and +/- dp/dt max were obviously decreased, while LVEDP was markedly increased in the @DISEASE@ group.
False	[Protective effects of @FORMULA@ on adriamycin-induced @DISEASE@ and its mechanism: role of superoxide dismutase].
False	However, its anti-osteoporotic effect and mechanism of action remain unclear.
False	RESULTS: The decrease of BMD and destruction of bone microarchitecture were significantly reduced in the OVX-induced @DISEASE@ rat model after 12 weeks of @FORMULA@ treatment.
False	The aim of the present study was to evaluate the anti-osteoporotic effect of @FORMULA@ in ovariectomized (OVX) rats.
False	MATERIALS AND METHODS: Sprague-Dawley rats were divided into five groups as follows: sham-operated, ovariectomized (OVX), OVX rats treated with 100 g/kg/day 17-estradiol, and OVX rats treated with 0.3 and 1.0 g/kg/day @FORMULA@ for 12 weeks.
False	The anti-osteoporotic effect of @FORMULA@ in an ovariectomized rat model mediated by inhibition of osteoclast differentiation.
True	CONCLUSIONS: These results suggest that @FORMULA@ possess potent anti-osteoporotic activity in OVX rats and may be a useful remedy for the treatment of @DISEASE@.
False	Effects of @FORMULA@ (see text) for @DISEASE@ in rats and study of the mechanism.
False	Rats in the model and treatment groups were fed with high-fat forage for 10 weeks to prepare the @DISEASE@ model, and the rats in the treatment group were administrated with @FORMULA@ from the 6th week for 5 weeks.
False	Hepatic pathological changes were detected by HE staining.
False	METHODS: Total 18 male SD rats were randomly divided into a normal control group, a model group and a treatment group, 6 rats in each group.
False	OBJECTIVE: To observe the effects of @FORMULA@ (see text) for @DISEASE@ (@DISEASE@) in rats and study the mechanism.
True	CONCLUSION: @FORMULA@ has good therapeutic effects for @DISEASE@, protecting the liver function and reducing the fatty deposition in liver, which are possibly related with reduction of FFA content and inhibition of TNF-alpha expression.
False	Mean arterial pressure and renal blood flow after the onset of @DISEASE@ were significantly lower in @DISEASE@ rats than in control rats.
True	The results of the present study suggest that @FORMULA@ protects against @DISEASE@ by reducing iNOS-dependent NO and peroxynitrite production during @DISEASE@.
False	There is evidence that the induction of inducible nitric oxide synthase (iNOS) and peroxynitrite by @DISEASE@ may lead to @DISEASE@.
False	@FORMULA@, a Chinese herbal medicine, protects against @DISEASE@ during @DISEASE@ in the rat.
False	Pretreatment with @FORMULA@ resulted in a prolongation of survival time in @DISEASE@. 4.
False	Urethane-anaesthetized rats were exposed to @DISEASE@ (ambient temperature 43 degrees C) to induce @DISEASE@.
False	The introduction of integrative pharmacology provided a feasible approach to solve the problem of the fragmentation of TCM.
False	"[Correlation analysis of ""compound-target-pathway"" of @FORMULA@ for @DISEASE@ based on computed prediction]."
False	Chinese medicine prescription is the main form and means to treat diseases in traditional Chinese medicine (TCM).
False	"Based on the analysis of the functional integration of Internet-based Computation Platform V1.0 version software, the ""core components-key target- main pathway"" multidimensional network of @FORMULA@ in treatment of @DISEASE@ was constructed to explore the potential molecular mechanism of @FORMULA@ in treatment of @DISEASE@ from multiple perspectives."
False	Internet-based computation platform method was adopted in this study to explore the active molecular mechanism of @FORMULA@ in the treatment of @DISEASE@.
True	@FORMULA@ in treatment of @DISEASE@ may be associated with energy metabolism and lipid metabolism.
False	@FORMULA@ is a formula used for the treatment of @DISEASE@ and @DISEASE@.
False	One of the mechanisms involved is thought to be the improvement of blood circulation, but the details are still unclear.
False	In this study, it was supposed that @FORMULA@ had a protective effect on the endothelium.
False	Rats were given @FORMULA@ in drinking water for eight weeks.
False	The results indicated that @FORMULA@ caused a decrease in blood pressure and an increase in erythrocyte deformability and NO function.
True	SHR-SP is a useful model for human @DISEASE@, and @FORMULA@ showed a protective effect against @DISEASE@ in the susceptible rat.
False	METHODS: In this study, we identified 32 active ingredients and 200 @DISEASE@ proteins and established a compound-predicted target network and a @DISEASE@ protein-protein interaction network by using Cytoscape 3.6.1.
True	CONCLUSION: The results of this study preliminarily verified the basic pharmacological effects and related mechanisms of the @FORMULA@ in the treatment of @DISEASE@.
False	This decoction have long been used in China for clinically treating @DISEASE@ and other liver and gallbladder damp heat-accumulation disorders.
False	In addition, we analyzed the mechanism of action of the predicted targets by the Kyoto Encyclopedia of Genes and Genomes and gene ontology analyses.
False	RESULTS: This study adopted a network pharmacology approach, mainly comprising target prediction, network construction, module detection, functional enrichment analysis, and molecular docking to systematically investigate the mechanisms of action of the @FORMULA@ in @DISEASE@.
False	BACKGROUND: Globally, more than 170 million people are @DISEASE@, a major cause of @DISEASE@ and @DISEASE@.
False	OBJECTIVE: To investigate the @DISEASE@ in two rat models of Pi-deficiency syndrome (PDS) to study the effect of @FORMULA@ (@FORMULA@) on @DISEASE@ (@DISEASE@).
True	[Effect of @FORMULA@ on the @DISEASE@ in two rat models of Pi-deficiency syndrome].
False	CONCLUSION: The H' of intestinal microflora in the two kinds of PDS models were significantly lowered, and could be recovered to the normal level by @FORMULA@ treatment (P<0.05).
False	Accumulative curves of Cs showed that the proportion of Cs accounting for less than 60% was 0 in Group A and 19% in Group B before modeling, 75% and 52% for them respectively after modeling, and 4% and 24% after rehabilitation with @FORMULA@.
False	RESULTS: The intestinal microflora in both groups obviously changed after modeling and recovered to the primary level after treated with @FORMULA@.
False	ERIC-PCR fingerprints can be used as a bio-criterion for evaluating intestinal microflora in patients with PDS.
False	During the study, Pittsburgh Sleep Quality Indices (PSQIs) and @DISEASE@ Severity Indices (ISIs) decreased significantly in both groups.
False	"Additionally, subjects were divided into two oral microbiota types (""orotypes"")."
False	The reduction in PSQI in orotype 1 during the 6-week treatment period was greater than in orotype 2.
False	The genera Prevotella, Veillonella, or Neisseria were abundant in each orotype.
False	Several studies have reported that heart function and @DISEASE@ are interrelated, and few have explored associations between @DISEASE@, oral microbiota, and tongue diagnosis.
True	In conclusion, this study shows that @FORMULA@ could be used to treat @DISEASE@ in patients with a HYD pattern as determined using tongue diagnosis and oral microbiota distributional patterns.
False	Macrophage accumulation in the peritoneal cavity after ip inoculation of L. monocytogenes was observed in both untreated and @FORMULA@-treated mice.
False	Such an activity was maintained at the same level from 1 to 3 days in @FORMULA@-treated mice.
False	The numbers of bacteria in the peritoneal cavity and liver were smaller in @FORMULA@-treated mice from one day after the @DISEASE@.
False	Augmented resistance against bacterial growth in the thigh muscle in ip @FORMULA@-treated mice may be caused by such mechanisms.
True	The effect of @FORMULA@ observed at an early stage of @DISEASE@ may be T cell-independent, since such an effect was observed in athymic nude mice and delayed footpad reaction could not be detected at such a timing in euthymic normal mice.
False	Although rates of such increases were almost the same between both groups, the absolute number of macrophages was larger in @FORMULA@-treated than in untreated mice because of a higher level of the macrophage number at 4 days after ip injection of @FORMULA@.
False	Protein expression related to the liver Toll-like receptor 4 (TLR4)/Nod-like receptor family pyrin domain-containing 3 (NLRP3) signalling pathway was assessed using Western blot analysis.
False	However, its specific mechanisms are not fully understood.
False	It also ameliorated liver microcirculation and ultrastructural abnormalities.
True	CONCLUSION: @FORMULA@ can inhibit NLRP3 inflammasome activation and interleukin-1beta release by suppressing LPS-induced TLR4 expression in rats with HFD-induced @DISEASE@.
False	Further, high-throughput screening of 29 related inflammatory factors in liver tissue was performed using a cytokine array.
False	In this study, we assessed the anti-NAFLD effect of @FORMULA@ in vivo.
True	These data indicate that @FORMULA@ is effective to inhibit antigen synthesis induced by chemical promoters without affecting EBV-antigen induction after @DISEASE@.
False	Concomitant treatment of @DISEASE@ cells (Raji and A2L/AH) with TPA and ether extract resulted in effective inhibition of EBV-antigen induction.
False	Inhibitory effects of kampo medicine on Epstein-Barr virus antigen induction by @DISEASE@ promoter.
False	The effect of ether extract of @FORMULA@ was also studied on the induction of EBV by @DISEASE@ with EBV from P3HR-1 cells (P3H-EBV).
False	We have investigated the possible interaction of Japanese Kampo medicine; @FORMULA@ with Epstein-Barr virus (EBV) induction by TPA (12-O-tetra-decanoyl-phorbol-13-acetate) in EBV-genome harboring cells.
False	However, in the experiments to test the influence of ether extract on EBV induction by superinfecting Raji cells with P3H-EBV, ether extract did not affect the percentage of EBV-antigen-positive cells.
False	METHODS: 64 patients with @DISEASE@ were randomly assigned to two groups (32 each) to receive Western therapy only (group X) and Western therapy + Modified @FORMULA@ (group L).
False	In patients with @DISEASE@, platelet PAC-1 expression correlated significantly to PLT ( r = - 0.409, P< 0.01 ) negatively, and MPV, PDW, platelet TLR4 expression, plasma sCD40L ( r (1) = 0.262, r (2) = 0.318, r (3) = 0.341, r(3) = 0.519, all P< 0.01) positively; sCD40L and TNF-alpha was positively correlated ( r = 0.542, P < 0.01 ) in these patients.
False	[Platelet parameters and platelet Toll-like receptor 4 (TLR4) expression in patients with @DISEASE@, and the effect of a joint treatment-plan integrating traditional Chinese and western medicine: a clinical study].
False	The values of: platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), the expression of TLR4 and procaspase activating compound-1 (PAC-1) in platelets, plasma concentration of soluble CD40 ligand (sCD40L) and tumor necrosis factor-alpha (TNF-alpha) were collected on the day of admission, and 3, 5, 9 days after treatment.
False	Acute physiology and chronic health evaluation II (APACHE II) score, length of stay in intensive care unit (ICU), @DISEASE@ events and 28 day @DISEASE@ in these patients were also analyzed.
True	The joint application of Western medicine and Modified @FORMULA@ may suppress such up-regulation in TLR4/other @DISEASE@ mediators, and alleviate platelet activation/@DISEASE@ in these patients.
False	After pregnancy, offspring rats were divided into 4 groups: control group, high fat and sugar as the control group, @DISEASE@ group, and @FORMULA@ @DISEASE@ group.
False	Body weight, abdominal fat weight, the ratio of abdominal fat weight and body weight, fasting plasma glucose, 2hPG, insulin, leptin, total cholesterol, and low density lipoprotein (LDL) of @FORMULA@ @DISEASE@ group were significantly lower than @DISEASE@ group.
False	Rats in high fat and sugar as the control group, @DISEASE@ group, and @FORMULA@ @DISEASE@ group were fed with high fat and sugar diet.
False	Rats in control group were fed the basic diet.
True	And we concluded that giving @FORMULA@ to @DISEASE@ rats can have a preventive effect on the offsprings' IGT induced by high fat and sugar diet.
False	The means of 2hPG were higher than 7.8 mmol.L(-1) and lower than 11.1 mmol.L(-1) on the rats of @DISEASE@ group on week 15, and IGT models were successful.
False	@FORMULA@ markedly improved abnormal pathological conditions of the aorta and heart, and helped to prevent myocardial apoptosis.
False	Components of the @FORMULA@ formulation, including Bovis Calculus Sativus, Pulvis Bubali Comus Concentratus, Moschus, Margarita, Cinnabaris, Realgar, Coptidis Rhizoma, Scutellariae Radix, Gardeniae Fructus, Curcumae Radix, and Bomeolum Syntheticum, have been used for the treatment of @DISEASE@, @DISEASE@ and @DISEASE@ across Asia, especially in China for hundreds of years.
False	Experimental drugs (either simvastatin or @FORMULA@) or normal saline were administered intragastrically once daily for 9 weeks starting from the 8th week.
False	Pathological and histological analysis was completed using artery tissue from different experimental different groups to assess the effects of @FORMULA@.
False	A carotid artery ultrasound was performed at the 17th week to determine whether @DISEASE@ had been induced.
True	CONCLUSIONS: We have demonstrated that @FORMULA@ has robust ant-atherosclerosis and cardio-protective effects on a high-fat and vitamin D3 - induced rodent model of @DISEASE@ due to its antiplatelet aggregation, lipid regulatory, antioxidant, anti-inflammatory and anti-apoptotic properties.
False	Importantly, 24-h incubation with a @FORMULA@ active component Japanese Pepper increased the mRNA and protein expression levels of TRPA1 in InMyoFibs, which in turn negatively regulated collagen synthesis.
False	The active ingredients of @FORMULA@, i.e., hydroxy alpha-sanshool and 6-shogaol, induced Ca(2+) influxes in InMyoFib, and this was antagonized by co-treatment with a selective TRPA1 channel blocker, HC-030031.
False	AIM: To investigate the anti-fibrotic effects of the traditional oriental herbal medicine @FORMULA@ (@FORMULA@) associated with transient receptor potential ankyrin 1 (TRPA1) channels in intestinal myofibroblasts.
False	A one-week enema administration of @FORMULA@ reduced @DISEASE@ in wild-type but not in TRPA1-KO mice.
False	@FORMULA@ counteracted TGF-beta1-induced expression of Type I collagen and alpha-smooth muscle actin (alpha-SMA), which were accompanied by a reduction in the phosphorylation of Smad-2 and p38-mitogen-activated protein kinase (p38-MAPK) and the expression of myocardin.
True	CONCLUSION: The effects of @FORMULA@ on the expression and activation of the TRPA1 channel could be advantageous for suppressing @DISEASE@, and benefit @DISEASE@ treatment.
False	@FORMULA@ for treating @DISEASE@: A systematic review and meta-analysis of randomized controlled trials.
False	Randomized controlled trials involving @FORMULA@ alone or @FORMULA@ combined with conventional treatment were enrolled.
False	However, the methodological quality of the randomized controlled trials was generally low.
False	There was also an improvement of neck disability index (MD = 9.2; 95% CI: 8.28-10.11; Z = 19.75; P < .00001).
False	BACKGROUND: @FORMULA@ (@FORMULA@) is a common prescription for the treatment of @DISEASE@ (@DISEASE@).
True	CONCLUSION: @FORMULA@ alone or @FORMULA@ plus other treatment may be helpful to patients with @DISEASE@.
False	@FORMULA@ (@FORMULA@) has been traditionally used to treat @DISEASE@ in China and Japan.
False	The present study was carried out to assess the protective effect of @FORMULA@ in Adriamycin-induced (ADR) @DISEASE@ rats and investigate the potential anti-NS mechanisms of @FORMULA@.
False	We further demonstrated that miR-92b directly regulated AQP2 expression by targeting 3'-UTR of AQP2.
False	Additionally, we determined miRNAs expression patterns in @DISEASE@ rats.
False	Importantly, @FORMULA@ increased the expression of Aquaporin-2 (AQP2) which play key roles in maintaining body water homeostasis.
True	These finding suggest that @FORMULA@ may reduce @DISEASE@ in Adriamycin-induced @DISEASE@ via regulating AQP2 and miR-92b.
False	In this study, we investigated the role of @FORMULA@ in reducing @DISEASE@ during @DISEASE@, using a high-fat diet-induced ApoE(-/-) mouse model of @DISEASE@.
False	It also regulated pro- and anti-inflammatory cytokine expression in the aorta in a similar manner.
False	Protective Effects of @FORMULA@ on @DISEASE@ in ApoE(-/-) Mice by Reducing the @DISEASE@.
True	These results indicate that @FORMULA@ can ameliorate the development of @DISEASE@, mainly by reducing @DISEASE@ instead of acting as an antihyperlipidemic drug.
False	Therefore, targeting @DISEASE@ pathways to prevent @DISEASE@ progression is an ideal strategy.
False	This agent also reduced the Th17/CD4(+)T ratio and mRNA expression of IL-6 and increased the Treg/CD4(+)T ratio and mRNA expression of TGF-beta1.
False	Immunological restoration and anti-tumor effect by Japanese herbal medicine in aged mice.
True	A significant decrease was observed in @DISEASE@ of B16 @DISEASE@ cells both in young and old mice treated with @FORMULA@ for 16 weeks.
False	@FORMULA@ (TJ-41) was remarkably effective in the restoration of impaired immune functions of old mice, in terms of number of T cells and NK cells, and anti-SRBC antibody response, while it was not effective in enhancing immune functions of young mice.
False	@FORMULA@ was also effective in increasing the number of T cells, remarkably, and NK cells, slightly, in the aged mice.
False	While a significant increase was not observed in young mice.
False	We examined the effect of two Japanese herbal medicines (Kampo-Hozai) on immunological functions and anti-tumor activity in old mice.
False	The median overall survival (OS) rates in the single TACE plus GKR and @FORMULA@ combined group were 11.3 months (95% CI: 9.168-13.435) and 15.8 months (95% CI: 13.244-18.339), respectively (p = 0.00047).
False	BACKGROUND: The potential advantages of @FORMULA@ (a compound Chinese herbal medicine) combined therapeutic strategies compared with non-@FORMULA@ therapeutic strategies for @DISEASE@ (@DISEASE@) with @DISEASE@ (@DISEASE@) remain unclear.
False	RESULTS: It was statistically insignificant between the two groups in baseline characteristics.
False	Procedure-related adverse events (AEs) were observed and compared and most of them were not serious which were easily controlled or subsided naturally.
True	CONCLUSIONS: @FORMULA@ combined with TACE plus GKR is safe in @DISEASE@ patients with @DISEASE@ and this Chinese herbal medicine is worthy to be promoted because of better prognosis which needs further research.
False	Patients were followed up by outpatient examination and telephone till November 2018.
False	The influence of Kampo formulae on patients' quality of life (QOL) was also assessed by the SF-36 (NBS).
False	Patients with Yusho suffer from @DISEASE@ (@DISEASE@, liability to suppuration and @DISEASE@), @DISEASE@ (@DISEASE@ and expectoration of sputum), @DISEASE@ (@DISEASE@ and paresthesia of extremities), @DISEASE@ and @DISEASE@, and no effective treatment has yet been developed.
False	In this clinical trial, four Kampo formulae (@FORMULA@, @FORMULA@, @FORMULA@ and @FORMULA@) were administered to four representative Yusho symptoms (@DISEASE@, @DISEASE@, @DISEASE@ and @DISEASE@), respectively.
False	The effectiveness of Kampo formulae was estimated by changes in the intensity of symptoms measured by a visual analogue scale (VAS) of 100 mm recorded at baseline and after administration of each formula.
False	In contrast, @FORMULA@ impaired patients' QOL in the context of physical functioning and vitality, compared with other formulae.
True	This study demonstrated for the first time that a Kampo formula @FORMULA@ is useful for treating @DISEASE@ caused by dioxins.
True	It could explain the mechanisms of @FORMULA@ in relieving @DISEASE@.
False	RESULTS: The results showed that plasma ghrelin levels were inversely correlated with the gastric ghrelin levels and adaptive thermogenesis in rats undergone both thyroidectomy and IBA removal.
False	MATERIALS AND METHODS: In litter-matched rats, @DISEASE@ was developed with both thyroidectomy at d1 and interscapular brown adipose (IBA) removal at d42, @DISEASE@ was induced with both high fat diet and fasting-feeding cycle from d56; the littermates with @DISEASE@ and @DISEASE@ were administrated with @FORMULA@ from d70.
False	Adaptive thermogenesis, thyroid hormones, metabolites, ghrelin dynamics were measured at d98.
False	@FORMULA@ compensates @DISEASE@-@DISEASE@ via ghrelin release.
False	This study aims to explore @FORMULA@ regulating ghrelin to compensate @DISEASE@ in rats with @DISEASE@ and @DISEASE@.
False	Both the duration and the volume of the @DISEASE@ demonstrated negative correlation with the proportions of Th1 and Th17 cells, whereas showed positive correlation with Th2 and Treg cells.
False	CONCLUSION: Th1/Th2/Th17/Treg paradigm bias was involved in RU486 medical abortion.
False	However, its therapeutic mechanism still remains unclear.
False	Moreover, the mRNA expression of the characteristic cytokines of Th1/Th2/Th17/Treg paradigm (IFNgamma, IL-4, IL-17A, TGF-beta) were analyzed by RT-PCR assay.
True	@FORMULA@ reduced the @DISEASE@ efficiently by inducing Th1 and Th17 skews in the maternal-fetal of RU486 medical abortion patients.
False	RESULT: Compared with RU486 group, both the @DISEASE@ volume and duration reduced significantly in @FORMULA@-RU486 group.
False	Mechanism of @FORMULA@ and its effective fraction in alleviating @DISEASE@ in mice: Regulating arachidonic acid metabolism and glycerophospholipid metabolism.
False	METHODS: The acute @DISEASE@ model of BABL/c mice was induced by 3.5% (w/v) dextran sodium sulfate drinking water.
False	Finally, we use molecular simulation docking technology to further explore the molecular regulatory mechanism of @FORMULA@ and @FORMULA@-NBA on potential target metabolic pathways.
False	In addition, the plasma metabolites of mice in each group were detected and analyzed by ultra-high performance liquid chromatography quadrupole time of flight mass spectrometry and multivariate statistical analysis method.
False	During the experiment, the clinical symptoms of mice were recorded and the physiological and biochemical indexes of mice were detected after the experiment.
True	CONCLUSIONS: Our experiments revealed that @FORMULA@ and @FORMULA@ can alleviate @DISEASE@ of mice by regulating arachidonic acid metabolism and glycerophospholipid metabolism, which points out the direction for further research and development of @FORMULA@ as a new anti-ulcer drug.
True	Our study showed @FORMULA@ administration effectively alleviated BCAA @DISEASE@ and improved @DISEASE@.
False	This study aimed to explore the potential bio-signatures in @DISEASE@ and the effect of @FORMULA@ (@FORMULA@), a traditional Chinese herbal prescription, on dust mite-induced mouse @DISEASE@.
False	@FORMULA@ administration reversed the levels for 7 of the 10 identified metabolites, chiefly affecting BCAA metabolism.
False	Chinese herbal remedies have long been used for enhancing immunity and treating @DISEASE@.
False	On 16S DNA sequencing, disordered Der p-induced gut microbiota was significantly alleviated by @FORMULA@.
False	Extract of Dermatophagoides pteronyssinus (Der p), a dust mite, was intratracheally administered to induce @DISEASE@ in mice.
False	To address these concerns, mice were given orally cinnabar (300mg/kg), cinnabar-containing @FORMULA@ daily for 44days, and @DISEASE@ was examined and compared with that of methylmercury (MeHg, 2.6mg/kg) and mercuric chloride (HgCl(2), 32mg/kg).
False	Expressions of metallothionein-1 and heme oxygenase-1, biomarkers for Hg toxicity, were increased by MeHg and HgCl(2,) but were not altered in cinnabar- and @FORMULA@-treated mice.
False	Liver is a major organ for drug metabolism, whether the long-term use of @FORMULA@ would affect hepatic P450 enzymes is unknown.
True	Taken together, the results demonstrate that @FORMULA@ is much less @DISEASE@ than common mercurials, and that the use of total Hg content to evaluate the toxicity of cinnabar-containing traditional Chinese medicines appears to be inappropriate.
False	Is @FORMULA@ safe?
False	@FORMULA@ (@FORMULA@) is a patent traditional Chinese medicine for @DISEASE@.
False	Exploring the Mechanism of @FORMULA@ Against @DISEASE@ by Network Pharmacology and Experimental Validation.
False	Consistently, @FORMULA@ downregulated levels of ALT (alanine transaminase) and AST (aspartate transaminase), reduced production of proinflammatory cytokines-TNF (tumor necrosis factor) -alpha and IL (Interleukin) -1beta in serum and liver from mice with @DISEASE@, and inhibited hepatic stellate cell (HSC)-T6 cells proliferation.
False	@FORMULA@ (@FORMULA@) has been demonstrated to be effective in treating @DISEASE@, @DISEASE@, and @DISEASE@.
False	@FORMULA@ decreased TGF (transforming growth factor) -beta1 and alpha-SMA (smooth muscle actin) expression as well, maintained MMP (matrix metalloprotein) 13-TIMP (tissue inhibitor of metalloproteinases) 1 balance, leading to mitigated ECM (extracellular matrix) deposition in vivo and in vitro.
False	In the study, we tried to elucidate the pharmacological efficacy and mechanism of @FORMULA@ against @DISEASE@ and predicate potential active ingredients and targets via network analysis and experimental validation.
True	Overall, our results suggest that @FORMULA@ aims at multiply targets and impedes the progression of @DISEASE@ by ameliorating @DISEASE@ and ECM deposition, thereby serving as a novel regimen for treating @DISEASE@ in clinic.
False	Three weeks later, cardiac function, mitochondrial swelling, content of malondialdehyde (MDA), activity of Mn SOD, Na+-K+ ATPase and Ca2+ ATPase were measured.
False	The mechanism may be closely related to the protective effects on mitochondria.
True	CONCLUSION: The data suggests that oxidative stress is present in the mitochondria of myocardium in ADR-induced @DISEASE@ rats and it can be reduced by @FORMULA@.
False	[The protective effects of @FORMULA@ on mitochondrial function in adriamycin-induced @DISEASE@ rats].
False	The mRNA expression of Mn SOD was also detected by RT-PCR.
False	METHODS: SD rats were randomly divided into three groups, control group, @DISEASE@ group (model group) and @FORMULA@ group.
False	The latent period was one and a half to three months.
False	The results of the [13C]aminopyrine breath test, performed in one patient, were low before the challenge test and even lower after the challenge.
False	These findings suggest that the herbal medicine syo-saiko-to may induce @DISEASE@ or the hepatocellular pattern with @DISEASE@.
True	@DISEASE@ induced by herbal medicine, syo-saiko-to (@FORMULA@).
False	All of the patients showed a rise in aminotransferases after readministration or challenge test.
False	@DISEASE@ was seen in two patients.
False	@FORMULA@ (@FORMULA@), comprising the combination of four herbs, Rehmanniae, Angelica, Chuanxiong, and Paeoniae, is one of the most popular traditional Chinese medicines for women's diseases.
False	In the Ames test, @FORMULA@ demonstrated an antimutagenic activity against mutagenicity induced by the chemical carcinogen 7,12-dimethylbenz(a)anthracene (DMBA).
False	Exploring traditional medicines may lead to the development of low-cost and non-toxic @DISEASE@ preventive agents.
False	In JB6 P+ cells, a non-cancerous murine epidermal model for studying @DISEASE@ promotion, @FORMULA@ inhibited epidermal growth factor (EGF)-induced @DISEASE@.
True	These findings demonstrate, for the first time, that @FORMULA@ prevents @DISEASE@ promoter and chemical-induced @DISEASE@ in vitro and in vivo, partly by inhibiting DNA damage and blocking the activation of AP-1 and NF-kappaB.
False	Inhibition of @DISEASE@ and Chemically-Induced @DISEASE@ in Mice by Traditional Chinese Medicinal Formula @FORMULA@.
False	@FORMULA@ may exert its inhibitory effects against @DISEASE@ by acting on key targets such as JUN, TP53, and MAPK1.
False	RESULTS: The network pharmacology analysis results showed that 41 compounds and 130 putative target genes of @FORMULA@ were associated with anti-pancreatic cancer effects.
False	Bioinformatics analysis, including protein-protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, was conducted to identify important components, potential targets, and signaling pathways through which @FORMULA@ affects @DISEASE@.
False	BACKGROUND AND AIM: @DISEASE@ is one of the most @DISEASE@ worldwide.
False	However, the active compounds present in @FORMULA@ and the potential mechanisms through which @FORMULA@ acts against @DISEASE@ have not been thoroughly investigated.
True	CONCLUSION: This study preliminarily investigated the pharmacological effects of @FORMULA@, which appear to be mediated by multiple compounds, targets and pathways, and its potential therapeutic effect on @DISEASE@.
False	Urinary and plasma metabolic profiling revealed that perturbation of energy metabolism, lipid metabolism, oxidative injury and some amino acids metabolism occurred in @DISEASE@ (@DISEASE@).
False	Our previous studies have indicated that @FORMULA@ has therapeutic potential in @DISEASE@ treatment.
False	RESULTS: Administration of @FORMULA@ and its constituents combination in @DISEASE@ rats not only significantly reduced arthritic scores and serum levels of IL-1beta but also improved histopathologic changes in joint architecture.
False	Our results also indicated that the disturbed urinary levels of succinic acid, citric acid, creatine, uridine, pantothenic acid, carnitine, phenylacetylglycine, allantoin and plasma levels of phenylpyruvic acid in model rats were gradually restored to normal after administration of @FORMULA@.
True	CONCLUSIONS: Our study indicates that @FORMULA@ and its constituents combination treatment can ameliorate @DISEASE@ through partially regulating the perturbed energy metabolism.
False	Partial least-squares discriminate analysis (PLS-DA) models were built to evaluate the therapeutic effects of @FORMULA@ and its constituents combination. 15 identified @DISEASE@ biomarkers were investigated to explain its therapeutic mechanism.
False	In addition, more large-scale clinical trials should be carried out to further confirm its clinical efficacy and safety.
False	In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of @FORMULA@ in detail.
True	Conclusion: @FORMULA@ might decrease @DISEASE@ and alleviate symptoms in @DISEASE@.
False	Finally, adverse events were also calculated as the index of safety.
False	The symptom scores of abdominal distension (P=0.004), belching (P=0.010), and @DISEASE@ (P=0.019) were alleviated by @FORMULA@, but @DISEASE@ and @DISEASE@ were not (P=0.616).
False	@FORMULA@ can also be considered safe with no obvious adverse effects.
False	BACKGROUND: @DISEASE@ is a global public problem, which has a significant negative impact on both physical and mental health, while increasing the economic burden placed on both sufferers and society.
False	In two trials, adverse events were reported, but no serious adverse effects were reported.
False	No placebo was involved in treatment.
False	Therefore, the effectiveness and safety of @FORMULA@ in the treatment of @DISEASE@ are studied and systematically evaluated in this study.
False	METHODS: Search was conducted for various databases including Pubmed, Chinese Biomedicine Database(CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wan-fang.
True	CONCLUSION: Our systematic evaluation will provide evidence for the clinical effectiveness and safety of @FORMULA@ in the treatment of @DISEASE@, and the side effects of western medicine are addressed.
False	The latter treatment appeared to inhibit the colonization of @DISEASE@ mice.
False	The protective effect of a Kampo medicine, @FORMULA@ (TJ-41) on experimental @DISEASE@ in immunosuppressed mice was investigated.
True	These results suggest that @FORMULA@ can be used as a therapeutic agent against @DISEASE@ in patients with glucocorticoid-induced immunosuppression.
False	Protection of immunosuppressed mice from @DISEASE@ by oral administration of a kampo medicine, @FORMULA@.
False	ICR mice were immunosuppressed by injection of prednisolone or cyclophosphamide, given TJ-41 orally and challenged intravenously with Candida albicans (day 0).
False	Treatments with a daily dose of 1 g/kg/day of TJ-41 for 8 days from day-4 or for 4 days from day 0 significantly prolonged the life span of the @DISEASE@ mice pretreated with prednisolone.
False	Methods.
False	These changing genes were involved in many cellular functions such as regulating smooth muscle contraction, Ca(2+) homeostasis, and NO pathway.
False	@DISEASE@ is one of the most common @DISEASE@ with @DISEASE@.
False	The gene change profile of thoracic aorta after JHD treatment was assessed by GeneChip(GC) analysis using the Agilent Whole Rat Genome Oligo Microarray.
False	Effect of @FORMULA@ on thoracic aorta gene expression in @DISEASE@ rats.
True	This study provides the potential novel insights into @DISEASE@ and antihypertension effects of @FORMULA@.
False	Interleukin (IL)-4 production by spleen T cells in response to OVA was significantly suppressed, while Interferon (IFN)-gamma production was increased in mice treated with @FORMULA@ in the induction phase.
True	These results suggest that the oral administration of @FORMULA@ dichotomously modulates @DISEASE@ in a murine model for @DISEASE@, thus offering a different approach for the treatment of @DISEASE@.
False	To determine the potentiality of prophylactic and/or therapeutic approaches using a traditional herbal medicine, @FORMULA@ (Japanese name: @FORMULA@, @FORMULA@), for the control of @DISEASE@, we examined the effects of oral administration of @FORMULA@ on a murine model of @DISEASE@ responses.
False	The serum levels of OVA-specific immunoglobulin (Ig)E and IgG1 were significantly decreased, whereas the level of OVA-specific IgG2a was increased.
False	When oral administration of @FORMULA@ was begun at the induction phase immediately after OVA sensitization, @DISEASE@ and Th2-type cytokine production in the airway were reduced in OVA-sensitized mice following OVA inhalation.
False	On the other hand, @FORMULA@ given in the eliciting phase induced a predominant Th2 response with increased IgE production in OVA-sensitized mice following OVA inhalation.
False	The established metabolomic platform was also used for clearing the effective mechanism of a Traditional Chinese Medicine (TCM) named @FORMULA@ (@FORMULA@).
False	Through functional analysis of these biomarkers and the established network, lipid metabolism, cholesterol metabolism, energy cycle, and @DISEASE@ were considered as the most relevant pathological changes in gastrointestinal tract of @DISEASE@ mice.
False	The intestinal microbiota and their metabolites are closely related to the formation of @DISEASE@ (@DISEASE@).
False	Totally, sixteen potential biomarkers in faeces of @DISEASE@ mice were identified and 5 of them could be reversed by @FORMULA@.
False	In this study, a metabolomic approach based on the reversed-phase liquid chromatography/quadrupole time-of-flight mass spectrometry (LC-Q-TOF-MS) platform was established to analyze the metabolic profiling of fecal extracts from @DISEASE@ mice model.
True	This metabolomic study also demonstrated that @FORMULA@ had the therapeutic effectiveness on @DISEASE@ through partly reversing the lipid metabolism, @DISEASE@ and energy metabolism.
False	With the altered metabolism pathways as possible drug targets, we systematically analyze the therapeutic effect of @FORMULA@, which demonstrated that @FORMULA@ administration could provide satisfactory effect on @DISEASE@ through partially regulating the perturbed myocardial energy metabolism.
False	BACKGROUND: In spite of great advances in target-oriented Western medicine for treating @DISEASE@ (@DISEASE@), it is still a leading cause of @DISEASE@ in a worldwide epidemic.
False	METHODOLOGY/PRINCIPAL FINDINGS: A urinary metabonomic method based on nuclear magnetic resonance and ultra high-performance liquid chromatography coupled to mass spectrometry was developed to characterize @DISEASE@-related metabolic profiles and delineate the effect of @FORMULA@ on @DISEASE@.
False	With Elastic Net for classification and selection of biomarkers, nineteen potential biomarkers in rat urine were screened out, primarily related to myocardial energy metabolism, including the glycolysis, citrate cycle, amino acid metabolism, purine metabolism and pyrimidine metabolism.
True	Metabonomic profiles delineate the effect of traditional Chinese medicine @FORMULA@ on @DISEASE@ in rats.
False	CONCLUSIONS/SIGNIFICANCE: Our results showed that metabonomic approach offers a useful tool to identify @DISEASE@-related biomarkers and provides a new methodological cue for systematically dissecting the underlying efficacies and mechanisms of TCM in treating @DISEASE@.
False	RESULTS: Compared with the placebo group, patients in the CHM group showed significant improvements in the scores of PDSS, HADS, SS, SF-36 and CGI scale (P < 0.05 or P < 0.01).
False	Efficacy and safety of @FORMULA@ for @DISEASE@: A multi-center randomized double-blind placebo-controlled clinical study.
True	CONCLUSION: @FORMULA@ offered significant symptomatic improvement in patients with @DISEASE@.
False	Two hundred and sixteen subjects diagnosed with @DISEASE@ according to ROME III criteria and confirmed by upper gastrointestinal endoscopy and @DISEASE@ and Qi-stagnation syndrome were selected to receive @FORMULA@ or placebo for 4 wk in a 2:1 ratio by blocked randomization.
False	METHODS: We performed a randomized, double-blind, placebo-controlled trial with patients from three centers.
False	The subjects also received follow-up after the 4-wk intervention.
False	Fecal samples were analyzed by 16 S ribosomal DNA sequencing.
True	CONCLUSION: @FORMULA@ treatment alleviated gut microbiota @DISEASE@, ameliorated the @DISEASE@, inhibited @DISEASE@, and protected against DDC-induced @DISEASE@.
False	Barrier function as well as @DISEASE@ and @DISEASE@ was analyzed by real-time PCR and western blotting.
False	Importantly, increased hepatic expression of pro-inflammatory factors and the NLRP3 inflammasome, which have a positive correlation with differential bacteria, were characteristics found in DDC-induced @DISEASE@ mice that were alleviated upon treatment with @FORMULA@.
False	Moreover, @DISEASE@ promoted disruption of the intestinal barrier in @DISEASE@ mice.
False	Hepatoprotective effects of @FORMULA@ (Astragali Radix and Glycyrrhizae Radix et Rhizoma) on @DISEASE@ in mice: Involvement of alleviating intestinal microbiota @DISEASE@.
False	MATERIALS AND METHODS: This study investigated the anti-inflammatory effects of @FORMULA@ and @FORMULA@ on signaling molecules involved in p38 mitogen-activated protein kinase (p38 MAPK), pathway on hepatocytes of @DISEASE@ (@DISEASE@), rats induced by high fat diet.
False	The rats of @DISEASE@ model were induced by feeding a high-fat diet.
True	CONCLUSION: To some extent, @FORMULA@ and @FORMULA@ may be a potential alternative and complementary medicine to protect against @DISEASE@, alleviate the @DISEASE@, moderate @DISEASE@ progression.
False	The proteins of TLR4, phosphor-p38 MAPK and p38 MAPK involved in p38 MAPK signal pathway were assayed.
False	BACKGROUND: Traditional Chinese Medicine (TCM), has over thousands-of-years history of use.
False	SD male rats were randomly divided into 8 groups: negative control group, model control group, high (9.6g/kg/day)/low (3.2g/kg/day)-dose @FORMULA@ group, high (30g/kg/day)/low (10g/kg/day)-dose @FORMULA@ group, high (39.6g/kg/day)/low (13.2g/kg/day)-dose integrated group.
False	A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of @FORMULA@ In Treating @DISEASE@.
False	RESULTS: The comprehensive network pharmacology approach was successfully to identify 45 active ingredients in @FORMULA@. 45 active ingredients hit by 163 potential targets related to @DISEASE@.
False	METHODS: A network pharmacology approach including drug-likeness evaluation, oral bioavailability prediction, virtual docking, and network analysis has been used to predict the active ingredients and potential targets of @FORMULA@ in the treatment of @DISEASE@.
False	BACKGROUND: Traditional Chinese medicine (TCM) formulations have proven to be advantageous in clinical treatment and prevention of disease.
True	CONCLUSION: Based on a systematic network pharmacology approach, our works successfully predict the active ingredients and potential targets of @FORMULA@ for application to @DISEASE@ and helps to illustrate mechanism of action on a comprehensive level.
False	@FORMULA@ may play a role in the treatment of @DISEASE@ and its @DISEASE@ (@DISEASE@ and @DISEASE@) through the AGE-RAGE signaling pathway, TNF signaling pathway, and NF-kappa B signaling pathway.
False	Urethane-anesthetized rats were exposed to @DISEASE@ (ambient temperature of 43 degrees C) to induce @DISEASE@.
False	Aminoguanidine, an iNOS inhibitor, was evaluated at the same time as a reference (positive control).
False	Control rats were exposed to 24 degrees C.
False	@FORMULA@, a Chinese herbal medicine protects against rat @DISEASE@ by reducing inflammatory cytokines and nitric oxide formation.
False	The serum levels of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha were all increased after the onset of @DISEASE@.
True	These results suggest that @FORMULA@ or aminoguanidine protects against @DISEASE@ @DISEASE@ and @DISEASE@ by inhibition of iNOS-dependent NO overproduction in the brain and excessive accumulation of several inflammatory cytokines in the peripheral blood stream.
False	Mechanisms and Molecular Targets of the @FORMULA@ Formula for Treatment of @DISEASE@: A Network Pharmacology Study.
False	However, intersection analysis only screened out 37 shared targets.
False	We identified 61 active compounds, 155 drug targets, and 5443 disease targets.
False	The @FORMULA@ (@FORMULA@) formula, a classic prescription of traditional Chinese medicine, has long been used for the treatment of @DISEASE@ (@DISEASE@).
False	A gene pathway network was constructed to screen the core target genes.
True	Therefore, the present study suggested that the @FORMULA@ formula has an action mechanism involving multiple compounds and network targets for the treatment of @DISEASE@.
False	OBJECTIVE: To observe the effect of @FORMULA@ and MSCs interventional therapy on the early stage of @DISEASE@ (@DISEASE@) and its role of improving revascularization and reossification.
False	Real-time fluorescence quantitative RT-PCR detection: the expression of VEGF mRNA in group D was significantly higher than that of other groups (P < 0.05), the expression of VEGF in groups B, C and D was higher than that of group A (P < 0.05).
False	[Research of @FORMULA@ and MSCs interventional therapy on early @DISEASE@].
False	Three weeks after modeling, groups C and D received 1 mL MSCs with artery perfusion [(0.5-1.0) x 10(6)/mL)], groups B and D received intragastric administration of 100 mL @FORMULA@ per day, groups A and C received intragastric administration of 100 mL distilled water.
False	Histopathology and immunohistochemistry staining: compared with group A, the structure of groups B, C and D were obviously improved, the positive expression of VEGF in group D was significantly higher than that of other groups (P < 0.05), the positive rate of BrdU, the number of positive osteoblast and the number of positive blood vessel in group D was obviously higher than that of group C (P < 0.05).
True	CONCLUSION: The combination of @FORMULA@ and MSCs interventional treatment has significant therapeutic effects on the early-stage @DISEASE@, can improve the blood supply of the @DISEASE@, promote repair and prevent collapse.
False	The data showed that @FORMULA@ could extend exhaustive swimming time of mice, as well as decrease the BLA and BUN contents and increase the liver glycogen and muscle glycogen contents.
False	@FORMULA@ (@FORMULA@) is a famous traditional Chinese herbal medicine formula, which has traditionally been used in China for about one thousand years.
False	After 28 days, the anti-physical @DISEASE@ effect of @FORMULA@ was evaluated by using a forced swimming test, along with the determination of blood lactic acid, blood urea nitrogen (BUN), liver glycogen and muscle glycogen contents.
True	Effect of @FORMULA@, a traditional Chinese herbal medicine formula, on @DISEASE@ in mice.
False	Group I received isotonic saline solution as control; Group II, III and IV obtained 5, 10 and 20ml/ kg body weight of @FORMULA@ solutions, respectively.
False	The present study investigated the effect of @FORMULA@ on @DISEASE@. 32 male mice were randomly divided into 4 groups with 8 in each group.
False	There were no significant differences in the overall @DISEASE@ or quality of life between the @FORMULA@ and placebo groups.
False	In traditional Korean medicine, @FORMULA@ (@FORMULA@) is a famous herbal prescription for @DISEASE@.
False	@DISEASE@ and power ratios were also significantly improved by @FORMULA@.
False	@DISEASE@ (@DISEASE@) is highly prevalent, and no standard treatments exist for this condition.
False	Herbal prescriptions are widely used to treat @DISEASE@.
True	The Effects of @FORMULA@ on @DISEASE@ and Gastric Motility in Cases of @DISEASE@: A Randomized, Double-Blind, Placebo-Controlled, and Two-Center Trial.
False	The @DISEASE@ was classified into two types; general cystic and peripheral cystic patterns.
False	The plasma testosterone concentration in the case of the general cystic pattern was significantly higher than that of peripheral cystic pattern, and the pregnancy rate in those with the general cystic pattern was lower.
False	Effect of a traditional herbal medicine (@FORMULA@) on testosterone secretion in patients with @DISEASE@ detected by ultrasound.
True	The efficacy of @FORMULA@ therefore seems to vary according to the type of @DISEASE@ treated.
False	Plasma testosterone was decreased in 18/20 (90%) and 5/20 (25%) became pregnant.
False	In 20 infertile Japanese with @DISEASE@ @FORMULA@ was used to lower plasma testosterone levels and hence to induce pregnancy.
False	In addition, @FORMULA@ significantly suppressed the NF-kappaB and MAPKs pathways.
False	In Chinese medicine practice, @FORMULA@ is commonly prescribed to treat various @DISEASE@, such as @DISEASE@ (@DISEASE@) and @DISEASE@.
False	@FORMULA@ ameliorates @DISEASE@-like @DISEASE@ induced by 2,4-dinitrobenzene in mice via suppression of MAPKs and NF-kappaB pathways.
False	At the end of experiment, the clinical @DISEASE@ scores of the mice were calculated to evaluate the therapeutic effect of @FORMULA@, and serum, ears and dorsal skin of the mice were collected for unravelling molecular mechanisms.
False	AIM OF THE STUDY: The present study aimed at investigating the therapeutic effect of @FORMULA@ (@FORMULA@) and to elucidate the underlying molecular mechanisms of action in the 1-chloro-2,4-dinitrobenzene (DNCB)-induced @DISEASE@-like mice.
True	CONCLUSION: @FORMULA@ significantly improved the @DISEASE@ symptoms on the DNCB-sensitized mice through mitigating the production of @DISEASE@ mediators via suppressing MAPKs and NF-kappaB pathways.
False	METHODS: Four different polar solvent extracts of @FORMULA@ such as petroleum ether (PE), methylene chloride (CH2Cl2), ethyl acetate (EtOAc), and n-butanol (n-butanol (.
False	OBJECTIVE: The aim of this study was to evaluate the antiarthritic effects of different polar solvent extracts of @FORMULA@ (@FORMULA@) on model rats with @DISEASE@ (@DISEASE@) and screen the effective pats of @FORMULA@ in the treatment of @DISEASE@.
False	And the result of UHPLC analysis indicated that the effective parts of @FORMULA@ contain berberine and atractylodin.
False	RESULTS: Administration of EtOAc and CH2Cl2 parts remarkably inhibited the paw swelling, decreased the index of @DISEASE@, decreased the @DISEASE@, and improved the changes of histopathology.
False	Furthermore, the concentrations of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) were significantly lower, while the anti-inflammatory cytokine (IL-10) was remarkably higher compared with that in the model group.
True	CONCLUSIONS: EtOAc and CH2Cl2 are the effective parts of @FORMULA@ that can improve @DISEASE@.
True	@FORMULA@ for the treatment of @DISEASE@: a systematic review.
False	The data showed that the effects of @FORMULA@ for the treatment of @DISEASE@ were superior to the control group (n = 867, RR =1.33, 95%CI: 1.24-1.42, Z = 8.11, P < 0.00001).
False	In the treatment groups, all 10 trials used herbs alone as the treatment, whereas all control groups used prokinetic medicine.
False	Three classes were used to evaluate treatment efficacy: significant effective, effective, and ineffective, and all trials used the clinical effective rate (based on the gastric emptying test and changes in GI symptoms) to evaluate efficacy.
False	Two trials recorded adverse events, and one trial reported follow-up.
False	CONCLUSION: @FORMULA@ could restore the gastric emptying rate and improve symptoms.
False	Effect of @FORMULA@(@FORMULA@) on HBeAg clearance in children with @DISEASE@ and with @DISEASE@.
False	Four of those seven patients developed anti-HBe.
True	@FORMULA@ seemed to promote clearance of HBeAg in children with @DISEASE@ and with @DISEASE@.
False	Seven of fourteen patients (50.0%) became HBeAg negative in the average observation period of 0.47 years(0.2-0.9 years).
False	The annual SN rate in the She-saiko-to treated group was apparently higher than the natural annual SN rate (22.7%) of 22 untreated patients retrospectively reviewed from the onset of @DISEASE@.
False	We studied the effect of @FORMULA@ (@FORMULA@) on HBeAg clearance rate (SN rate) in fourteen children with @DISEASE@ and with @DISEASE@.
False	Rats in all groups were starved with free access to drink.
False	Increase in levels of Proteobacteria and reduction levels of Bacteroidetes induced by @DISEASE@ were observed, and these two disturbed gut microbiota phyla could be regulated after @FORMULA@ treatment.
False	Sham-operated rats in NCG were served as operation control, while rats in both MCG and SFDG were exposed to CLP, a procedure to develop experimental @DISEASE@.
False	The indicators of @DISEASE@ [the peritoneal @DISEASE@ by Simon's method Classification as well as serum concentrations of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by enzyme linked immunosorbent assay (ELISA)] in survival rats were evaluated.
False	Rats in SFDG were administered with @FORMULA@ by gavage (3 mg/g of body weight, twice a day) 2 h prior to CLP and directly after successful CLP, while rats in NCG and MCG were gavaged with equivalent volume of sterilized water.
True	CONCLUSION: @FORMULA@ may play a protective role in @DISEASE@ by alleviating @DISEASE@ @DISEASE@ and @DISEASE@ in rats.
False	Using the software Cytoscape 3.6.0, a visual network was established using the active components of @FORMULA@ and the targets of @DISEASE@.
False	Quercetin, kaempferol, beta-sitosterol, isorhamnetin, and stigmasterol were identified as the vital active compounds, and AKT1, IL6, MAPK1, TP53 as well as VEGFA were considered as the major targets.
False	This study aimed to screen out the effective active components of @FORMULA@ (@FORMULA@) using network pharmacology, estimate their potential targets, screen out the pathways, as well as delve into the potential mechanisms on treating @DISEASE@.
False	The PyMOL software was utilized to visualize the docking results of active compounds and protein targets.
False	With the Database for Annotation, Visualization, and Integrated Discovery (DAVID) server, the gene ontology (GO) biological processes and the Kyoto encyclopedia of genes and genomes (KEGG) signaling pathways of the targets enrichment were performed.
True	CONCLUSIONS: As predicted by network pharmacology strategy and validated by the experimental results, @FORMULA@ exerts anti-tumor effectsthrough multiple components, targets, and pathways, thereby providing novel ideas and clues for the development of preparations and the treatment of @DISEASE@.
True	These results suggest that @FORMULA@ and @FORMULA@ prevent the progression of @DISEASE@ by creating a sounder antioxidant defense system than vitamin E.
False	Twenty-four male Japanese white rabbits (2 kg body weight) were divided into four groups.
False	All four groups were kept on these diets for 8 weeks.
False	At the end of the experiments, the percentage of surface area of the total thoracic aorta with visible plaque was significantly reduced in the @FORMULA@ and @FORMULA@ groups.
False	Furthermore, the urinary 8-hydroxydeoxyguanosine levels of the @FORMULA@ and @FORMULA@ groups were considerably lower than that of the vitamin E group.
False	The serum thiobarbituric acid reactive substances of the vitamin E group showed a significantly low value compared with the control group, whereas the serum lipid peroxide levels of the @FORMULA@ and @FORMULA@ groups were considerably lower than that of the control groups as well as that of the vitamin E group.
False	[Effect of @FORMULA@ on intestinal miR-19a expression in mice with @DISEASE@].
False	The disease activity index (DAI) of the mice in each group was recorded daily.
False	@DISEASE@ was induced in the mice by feeding them with 3.5% DSS in drinking water, and the mice in the control group were given water only.
False	RESULTS: Compared with the control group, the model group showed significantly increased DAI and histological scores, and administration of @FORMULA@ significantly lowered the DAI and histological scores of the DSS-treated mice.
False	OBJECTIVE: To investigate the therapeutic effect of @FORMULA@ on dextran sodium sulphate (DSS)-induced @DISEASE@ in mice and explore its mechanism involving miR-19a.
True	CONCLUSION: @FORMULA@ has therapeutic effects on DSS-induced @DISEASE@ in mice, and this effect is probably mediated by enhancement of miR-19a expression in the intestines.
False	RESULTS: The pills significantly inhibited the growth of the implanted @DISEASE@ and reduced the expression of PCNA in the @DISEASE@.
False	METHODS: Mice bearing @DISEASE@ induced by H22 cell inoculation were randomized into 4 groups, namely the negative control group, positive control group (with cyclophosphamide treatment), and high- and low-dose @FORMULA@ group.
False	OBJECTIVE: To study the anti-tumor effect of @FORMULA@ and explore its mechanism.
False	The tumor-bearing mice received corresponding treatments for 15 consecutive days, after which their thymuses and spleens were isolated and weighed to calculate the thymus and spleen indices.
True	CONCLUSION: One of the possible mechanisms of the anti-tumor effects of @FORMULA@ might be associated with the inhibition of PCNA expression in the @DISEASE@.
False	Immunohistochemistry was performed to evaluate the expression intensity of proliferating cell nuclear antigen (PCNA) in the @DISEASE@ tissue.
True	The results indicate that @FORMULA@ can ameliorate @DISEASE@ through immune modulation and may act to normalize cytokines and their related signaling pathways.
False	The swimming endurance capacity was measured on day 28.
False	Rats were subjected to a combination of food restriction and forced swimming to induce @DISEASE@, and rats were gavaged once daily with either 12 or 24 g/kg @FORMULA@ for 28 days.
False	Rats that received @FORMULA@ exhibited increased body weight and endurance capacity, corrected T cell subsets counts, increased (3) H-TdR incorporation and decreased mRNA levels of IL-1beta, TNF-alpha, NF-small ka, CyrillicB, p38MAPK and JNK compared with rats that did not receive @FORMULA@.
False	@FORMULA@ (@FORMULA@), a Chinese medicinal decoction that contains Radix Angelicae sinensis (Danggui) and Radix Astragali (Huangqi) at a ratio of 1:5, is used commonly for treating women's ailments.
False	A Chinese herbal decoction, @FORMULA@, improves @DISEASE@ induced by food restriction and forced swimming in rats.
False	Additionally, the expressions of key enzymes of gut microbe-derived SCFAs biosynthesis and key targets in the signaling pathway of energy metabolism were investigated by ELISA and qPCR analysis.
False	AIM OF THE STUDY: This study aimed to unravel the molecular mechanism of @FORMULA@ on the amelioration of @DISEASE@.
False	However, the mechanism of @FORMULA@ on the fermentation of gut bacteria and further improvement of @DISEASE@ is not yet clear.
True	CONCLUSIONS: Taken together, our data provided a novel insight into the role of @FORMULA@ in @DISEASE@ from energy metabolism regulation, which unraveled the molecular mechanism of @FORMULA@ on the alleviation of @DISEASE@ and fat heterotopic accumulation.
False	Our previous study found that @FORMULA@ markedly ameliorated the composition of the gut microbiota, especially for some short chain fatty acids (SCFAs) producing bacteria, and then notably increased SCFAs production.
False	@FORMULA@ (@FORMULA@), a compound recipe composed of Dahuang (Rheum palmatum L.), Huangqin (Scutellaria baicalensis Georgi) and Huanglian (Coptis chinensis Franch.), has been reported to have hypoglycemic and hypolipidemic effects, but its mechanism remains unclear.
False	In addition, the expressions of SPTLC2, CERS2, and SMPD1 in Abeta25-35-stimulated BV2 cells were increased significantly, while the expressions of GALC, SPHK2, and SGMS1 were decreased.
False	Methods: The level of sphingolipids in the brains of APP/PS1 mice and in the supernatant of beta-amyloid (Abeta)25-35-induced BV2 microglia was detected by HPLC-QTOF-MS and HPLC-QTRAP-MS techniques, respectively.
False	Involvement of @FORMULA@ on Microglia with @DISEASE@ in @DISEASE@.
False	In addition, real-time quantitative reverse transcription-polymerase chain reaction was conducted to determine the mRNA expression of SPTLC2, CERS2, SMPD1, SGMS1, galactosylceramidase (GALC), and sphingosine kinase 2 (SPHK2) in Abeta25-35-stimulated BV2 microglia.
False	The levels of sphingosine, sphinganine, sphingosine-1-phosphate, sphinganine-1-phosphate and sphingomyelin were significantly reduced, while the levels of ceramide-1-phosphate, ceramide, lactosylceramide and hexosylceramide significantly increased in Abeta25-35-stimulated BV2 cells.
True	Conclusion: @FORMULA@ is a good candidate for treating @DISEASE@.
False	After assembling the gene information from Sham, model and @FORMULA@ groups, we constructed three DGE libraries based on each group.
False	RESULTS: Among them, 511 and 352 differentially expressed genes were found in comparison with sham/model and model/@FORMULA@, respectively.
False	METHODS: Animal models of @DISEASE@ were established by permanent ligation of the left anterior descending coronary artery.
False	Capillary density was quantified by using Factor VIII immunohistochemical staining.
False	Differentially expressed genes were explored by a short-read sequencing technology combined with a tag-based digital gene expression profiling (DGE) system.
True	CONCLUSION: The DGE profiling data provide comprehensive gene expression information at the transcriptional level that could facilitate our understanding of the pharmacological mechanisms of @FORMULA@ in ventricular remodeling post-myocardial infarction.
False	The neuroprotective effect of @FORMULA@ and @FORMULA@ against MPTP was evaluated in mice by behavioral, biochemical, and immunohistochemical studies.
False	Simultaneously, both formulae significantly prevented the MPTP induced dopaminergic neuron loss assessed by tyrosine hydroxylase in the midbrain.
False	The DNA damage induced by MPTP was also prevented by both formulae.
False	In the behavioral study, both @FORMULA@ and @FORMULA@ significantly reversed the @DISEASE@ induced by MPTP.
False	The present study was designed to evaluate the preventive effect of antioxidative traditional oriental medicine formulae, @FORMULA@ (@FORMULA@) and @FORMULA@ (@FORMULA@), against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (i.p 30 mg.kg(-1) for 5 consecutive days) induced @DISEASE@.
True	Although a little difference in the protective functions was observed between the two formulae, such as in DNA damage and behavioral studies, the results indicate that both @FORMULA@ and @FORMULA@ with antioxidant property act as a good candidate applicable for the antioxidant based complementary therapies of @DISEASE@.
False	However, further thorough investigation, large-scale, proper study designed, randomized trials of @FORMULA@ for @DISEASE@ will be required to justify the effects reported.
False	Our review showed that @FORMULA@ was more effective in improving total effects (RR: 1.22 [1.08, 1.37]; P=0.0009), compared with anti-arrhythmic drugs alone. 13 trials reported adverse events, while the others did not mention them, indicating that the safety of @FORMULA@ remains uncertain.
False	The results of the meta-analysis showed that @FORMULA@ combined with anti-arrhythmic drugs had significant effect on improving total effects (RR: 1.30 [1.22, 1.38]; P<0.00001) and relieving number of @DISEASE@ (MD: -6.66 [-12.94, -0.37]; P=0.04) compared with anti-arrhythmic drugs alone.
False	The methodological quality of the included trials was evaluated as generally low.
False	BACKGROUND: To systematically assess the current clinical evidence of @FORMULA@ for @DISEASE@ (@DISEASE@).
True	CONCLUSIONS: @FORMULA@ appears to have beneficial effects on improvement of total effects, reduction of number of @DISEASE@ in participants with @DISEASE@.
False	Body weight and abdominal circumference were detected.
False	@FORMULA@ (@FORMULA@) is a traditional Chinese medicine prescription, which is used in the treatment of @DISEASE@, @DISEASE@, @DISEASE@, @DISEASE@, @DISEASE@, and other diseases caused by retention of phlegm dampness.
False	Real-time PCR was used to measure the CDKAL1 gene expression and western blot was used to measure the protein expression.
True	Therefore, we speculate that the potential molecular mechanism of @FORMULA@ is to promote the CDKAL1 expression, ameliorate islet cell function, and raise insulin levels to regulate the @DISEASE@.
False	Through the research, it was found that @FORMULA@ showed markedly lower body weight and abdominal circumference than those in the HFD group.
False	Blood lipid levels and insulin were measured using biochemical assay kit.
False	It is proved by experiments that @FORMULA@ may play an effective role by regulating the expression of IL-6 and caspase-3, and getting involved in apoptosis, @DISEASE@ and other pathways.
False	The visual regulation network of &quot;active ingredient-disease target&quot; of @FORMULA@ was constructed by Cytoscape software, and the protein-protein interaction network was constructed by STRING database.
False	KEGG pathway enrichment analysis showed that 120 items were involved in human @DISEASE@, @DISEASE@, apoptosis, @DISEASE@ and other pathways.
False	Mouse experiments showed that @FORMULA@ could down-regulate the expression of target proteins IL-6 and caspase-3 and inhibit intestinal epithelial cell apoptosis.
True	[Mechanism and experimental verification of @FORMULA@ in treatment of @DISEASE@ based on network pharmacology].
False	The treatment of @DISEASE@ with @FORMULA@ is the result of the interaction among multi-components, multi-targets and multi-pathways.
False	The relative morphological parameters were measured in the undecalcified tibial slices.
False	"OBJECTIVE: To reveal the mechanism of @FORMULA@ (see text) in treatment of glucocorticoid-induced @DISEASE@ from the angle of the Wnt signal transduction pathway and to provide further experimental evidence for expounding the scientific connotation of ""the kidney dominating the bones"" in TCM."
False	RESULTS: Compared with the control group, TBV% and TFS% decreased significantly, while TRS% increased significantly, and the protein expression of Wnt1, LRP-5 and beta-catenin in OB and BMC decreased significantly in the model group.
False	METHODS: Forty-two male Wistar rats were selected and randomly divided into three groups, control group (n = 12), model group (n = 15) and @FORMULA@ group (n = 15).
True	CONCLUSION: @FORMULA@ can prevent and treat glucocorticoid-induced @DISEASE@ in rats by up-regulating the expression of the key signal molecules Wnt1, LRP-5 and beta-catenin in Wnt signal transduction pathway.
False	Form the beginning, The rats were injected dexamethasone for eight weeks to make the model of @DISEASE@, and the @FORMULA@ were administered intragastrically to the rats of @FORMULA@ group for eight weeks.
False	@FORMULA@ (@FORMULA@) is used frequently as a herbal prescription to treat deficiency syndromes in traditional Korean medicine.
False	@FORMULA@ increased the phosphorylation of AMP-activated protein kinase (AMPK) in accordance with the phosphorylation of Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2).
False	Moreover, administration of @FORMULA@ for 4 consecutive days to mice significantly reduced the alanine aminotransferase and aspartate aminotransferase activities induced by carbon tetrachloride, and the numbers of degenerated hepatocytes, infiltrated inflammatory cells, nitrotyrosine-positive cells, and 4-hydroxynonenal-positive cells in liver tissue.
True	Therefore, @FORMULA@ protects hepatocytes from oxidative stress via CaMKK2-dependent AMPK activation and has the therapeutic potential to prevent or treat oxidative stress-related @DISEASE@.
False	@FORMULA@ pretreatment reduced arachidonic acid (AA) plus iron-mediated cytotoxicity in a concentration-dependent manner and prevented changes in apoptosis-related protein expression.
False	@FORMULA@ Alleviates Oxidative Stress-Mediated @DISEASE@ through Activation of the CaMKK2-AMPK Signaling Pathway.
False	After intervention of @FORMULA@, the fluorescence IOD value of enteric nerves were significantly increased (P<0.05), and the network structure of ENS was repaired.
False	Undergoing @DISEASE@, fluorescence integral optical density (IOD) value of enteric nerve fibers were significantly decreased (P<0.05), and the network structure of ENS was destroyed.
True	Interventional effects of @FORMULA@ on enteric nerve system in a rat model of @DISEASE@.
False	In conclusion, the @DISEASE@ undergoing @DISEASE@ may be closely related to the morphology destroy of ENS and down regulation of neurotransmitters (ACh, SP, VIP and NOS) expression.
False	In this study, we investigate the morphologic changes of enteric nerve system (ENS) and the expression of neurotransmitters, acetylcholine (ACh), substance P (SP), vasoactive intestinal peptide (VIP) and nitric oxide synthase (NOS), in small bowel of rats undergoing @DISEASE@ (@DISEASE@).
False	The expression of ACh, SP, VIP and NOS was inhibited, IOD value of the four neurotransmitters was significantly decreased (P<0.05).
True	This finding indicates that @FORMULA@ is appropriate for use in treating @DISEASE@ in women with various constitutions (as determined by the matching theory of eight-principle pattern identification) in clinical practice and may prove to be a potent therapeutic agent with a wide therapeutic spectrum.
False	Effects of switching to @FORMULA@ (@FORMULA@) from preceding herbal preparations selected by eight-principle pattern identification on endocrinological status and ovulatory induction in women with @DISEASE@.
False	Fifty-four women who failed to ovulate after an 8-week treatment were randomly allocated to continuation of treatment with the preceding Kampo prescription (continuation group, n = 27) or treatment with @FORMULA@ (switching group, n = 27).
False	In the group switched from @FORMULA@, a tendency towards increase in plasma estradiol level was observed (1.51-fold, p = 0.055), which was significant compared with that in the group switched from @FORMULA@ (p = 0.032).
False	After Kampo diagnosis, subjects received matched Kampo preparations (43 cases: @FORMULA@, 21 cases: @FORMULA@) selected by the matching theory of eight-principle pattern identification and Kampo diagnosis based on concepts of the qi, blood, and fluids as the physiologic activity.
False	The objective of this study was to investigate the effects of switching therapy to @FORMULA@ (@FORMULA@) from previous selected herbal preparations on endocrine levels and induction of ovulation in women with @DISEASE@ (@DISEASE@).
False	This study was designed to investigate the mechanism by which @FORMULA@ improves lung function, and observe the effect of @FORMULA@ on endoplasmic reticulum stress(ERS) in alveolar type II epithelial cells (AECIIs) of @DISEASE@ rats. @DISEASE@ animal model was established by intratracheal injection of BLM at a dose of 6mg/kg body weight.
False	It may provide a new method for the treatment of @DISEASE@.
True	The finding of this study revealed that @FORMULA@ can improve lung function in rats with @DISEASE@ by reducing the occurrence of ERS and cell apoptosis of AECIIs.
False	@FORMULA@ Improves Pulmonary Function in Rats With @DISEASE@ by Inhibiting Endoplasmic Reticulum Stress in AECIIs.
False	Overall, Thirty male SPF Sprague-Dawley rats were randomly divided into control group, BLM group and BLM+@FORMULA@ group.
False	@FORMULA@ improves pulmonary function of @DISEASE@ rats and reduces the occurrence of endoplasmic reticulum stress in AECIIs.
False	H9C2 cell viability and apoptosis were quantified using MTT and Annexin V-FITC assays, respectively.
False	METHODS: HG-induced H9C2 cells were established as the experimental model, and then treated with @FORMULA@ at 25, 50, and 100 mug/mL.
False	Furthermore, Bcl-2/Bax signalling pathway protein expression and Fas and FasL gene expression levels were quantified using western blotting and RT-PCR, respectively.
False	Moreover, @FORMULA@ treatment at 100 mug/mL significantly downregulated Fas and FasL expression level (p < 0.05) when compared to the @DISEASE@ group.
True	CONCLUSION: @FORMULA@ protects H9C2 cells from @DISEASE@ apoptosis probably by downregulating p53 expression and upregulating the Bcl-2/Bax ratio.
False	This study aimed to explore the molecular mechanisms of @FORMULA@ on @DISEASE@ (@DISEASE@)-induced apoptosis in H9C2 cells.
False	@DISEASE@ (@DISEASE@) is among the most usual @DISEASE@ globally.
False	We established that @FORMULA@ significantly repressed the proliferation, @DISEASE@ and infiltration of @DISEASE@ cells.
False	In China, @FORMULA@ (@FORMULA@), Traditional Chinese Medicine clinical prescription, is broadly utilized for the prevention and therapy of @DISEASE@.
False	@FORMULA@ Inhibits @DISEASE@ and @DISEASE@ via the Akt/GSK-3beta/Snail Signaling Pathway in @DISEASE@.
False	In vivo @DISEASE@ xenograft results indicated that @FORMULA@ delayed @DISEASE@ development and efficiently inhibited @DISEASE@.
True	Taken together, @FORMULA@ was shown to be an effective therapeutic agent against @DISEASE@ through repression of the Akt/GSK-3beta/Snail signaling cascade and EMT.
False	"AIM OF THE STUDY: Traditional Chinese medicine @FORMULA@ (@FORMULA@) is a well-known PentaHerbs formula from ""Treatise on @DISEASE@""."
False	The neuroprotective effect of dopaminergic neurons from the striatum and frontal cortex of brain was detected by high performance liquid chromatography with electrochemical detection (HPLC-ECD).
True	Ameliorative and neuroprotective effect in MPTP model of @DISEASE@ by @FORMULA@ (@FORMULA@), a traditional Chinese medicine.
False	This study is to elucidate its neuroprotective effect and mechanism of ameliorative effect of the syndrome of @DISEASE@ (@DISEASE@).
False	MATERIALS AND METHODS: The ameliorative effect of @FORMULA@ on symptom of @DISEASE@ through behavior tests including: swimming test, the tail suspension test and open-field test was investigated.
False	RESULTS: This study proved that @FORMULA@ could ameliorate the typical symptom of @DISEASE@ and protect dopaminergic system.
False	Second, rats were divided into a sham-operated group [NG(b)] and three treatment groups [4hG(b), 12hG(b) and 24hG(b)] with three corresponding control groups [MG(b)s].
False	Optimal timing for the oral administration of @FORMULA@ based on the pharmacokinetic and pharmacodynamic targeting of the pancreas in rats with @DISEASE@.
False	RESULTS: The concentrations of emodin, naringin, honokiol, naringenin, aloe-emodin, chrysophanol and rheochrysidin in the 12hG(a) group were higher than those in the 4hG(a) group in the pancreatic tissues (P < 0.05).
False	The 12hG(a) group had a higher Cmax than the other two model groups.
False	Plasma samples were collected from the tails at 10 min, 20 min, 40 min, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h after a single dosing with @FORMULA@.
True	CONCLUSION: Late-time dosing may have higher concentrations of the most major components of @FORMULA@, with better pharmacokinetics and pharmacodynamics of anti-inflammation than early-time dosing, which showed the late time to be the optimal dosing time of @FORMULA@ for @DISEASE@.
False	[A case of @DISEASE@ due to @FORMULA@].
True	Based on these findings, we diagnosed this case as @DISEASE@ due to @FORMULA@.
False	She gave informed consent after receiving an explanation of the challenge test.
False	@DISEASE@ was heard on physical examination of the chest and a chest X-ray film revealed diffuse reticulo-nodular shadow in both lung fields.
False	Consequently her complaints, laboratory data and chest X-ray findings markedly improved.
False	She was tested with 2.5 g @FORMULA@ twice and developed @DISEASE@ and @DISEASE@ with @DISEASE@, while the chest X-ray film also revealed diffuse infiltrative shadows similar that on admission.
True	To our knowledge, there has been no previous case of @DISEASE@ due to @FORMULA@ reported in the world.
False	Inhibition of Akt, mTOR, and FOXO1 by specific inhibitors or siRNA could interpose the apoptotic induction.
False	The aim of this study is to evaluate the effects of @FORMULA@ on the growth inhibition and apoptosis in @DISEASE@ U-87 MG cells.
False	Furthermore, @FORMULA@ affected the Akt/mTOR/FOXO1 pathway via inhibiting the phosphorylation of Akt, mTOR, and FOXO1 and increasing both prototype and nuclear translocation of FOXO1.
False	@FORMULA@ Induces Apoptosis of Human @DISEASE@ U-87 MG Cells via Targeting ROS-Mediated Akt/mTOR/FOXO1 Pathway.
False	Cell viability, cell cycle arrest, generation of reactive oxygen species (ROS), and apoptosis were measured by CCK-8 assay, PI/RNase staining, DCFH-DA assay, TUNEL assay, Annexin V-FITC/PI double staining, and JC-1 assay, respectively.
True	In conclusion, we demonstrate for the first time that @FORMULA@ may regulate @DISEASE@ U-87 MG cell apoptosis via ROS-mediated Akt/mTOR/FOXO1 pathway.
False	Orexin-A plays a key role in the sleep-wake cycle, while leptin function is opposite to orexin-A.
False	@FORMULA@ improves negative emotions in @DISEASE@ rats by regulating orexin-a and leptin expression.
False	@FORMULA@ treatment normalized the behavior and upregulated orexin-A, leptin, orexin receptor 1 and leptin receptor in brain.
False	Thus, orexin-A and leptin may be important factors in @DISEASE@.
False	Orexin-A and leptin levels in blood serum increased after @DISEASE@ but decreased in brain compared to the control group. mRNA expressions of orexin receptor 1 and leptin receptor after @DISEASE@ were decreased in the prefrontal cortex but were increased in hypothalamus.
True	The findings suggest that @FORMULA@ treatment may regulate @DISEASE@ negative emotions by regulating orexin-A and leptin expression.
True	Experimentally, @FORMULA@ significantly alleviated CFA-induced @DISEASE@ without any visible side-effects.
False	Based on it, 387 genes related to these identified compounds in @FORMULA@ and 3807 genes related to @DISEASE@ were collected by network pharmacology.
False	MATERIALS AND METHODS: Serum pharmacochemistry mediated by the UPLC-Q-Exactive MS/MS method was employed to identify the absorbed phytochemical compounds in serum derived from @FORMULA@, which were commonly considered as the potential bioactive compounds.
False	And then, these components were used to construct a compound-target network for @DISEASE@ using a network pharmacology approach, to predict the possible biological targets of @FORMULA@ along with potential signaling pathways.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ (@FORMULA@) has been recognized by the Chinese National Administration of Traditional Chinese Medicine (TCM) as a classic TCM formula.
False	Furthermore, this result was also corroborated by immunohistochemistry analysis.
True	Compared to the @DISEASE@ model group without any treatment, the treatment of @FORMULA@ significantly reduced the expression of both mRNA and protein targets in the PI3K/AKT signaling pathway.
False	@DISEASE@ volumes in the XZM group were significantly lower than those in the CNM and TSM groups (all P<0.05).
False	MATERIALS AND METHODS: U251 cells were divided into five groups: CNC (cells were cultured with normal saline), TSC (cells were treated with @FORMULA@ [@FORMULA@]), XSC (cells were treated with @FORMULA@), THC (cells were treated with homogenate of @FORMULA@), and XHC (cells were treated with homogenate of @FORMULA@).
False	The mRNA and protein expression of VEGF/VEGFR, CXCR4/CXCL12, and TIMP1/MMP9/MMP2 were measured by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting, respectively.
False	Moreover, MTT assay, transwell assay, wound-healing assay, and flow cytometry were conducted to assess the cell viability, cell migration and invasion, cell motility, and cell apoptosis of U251 cells, respectively.
True	CONCLUSION: @FORMULA@ may suppress @DISEASE@ growth and decrease expression levels of VEGF, CXCL12, MMP9, and MMP2.
False	This study was intended to assess the effects of @FORMULA@ on @DISEASE@ along with its anticancer mechanism.
False	We will assess all the documents from the database establishment to January 31, 2019.
False	The RevMan V.5.3 software will be used to calculate the data synthesis and perform a meta-analysis when the literature is appropriate.
True	CONCLUSION: The systematic review will provide evidence for assessing the effectiveness and safety of @FORMULA@ in the treatment of @DISEASE@.
False	At present, it is necessary to update the existing research, re-evaluate the effectiveness and safety of @FORMULA@, and provide the latest evidence for @DISEASE@.
False	Effectiveness and safety of @FORMULA@ for treating @DISEASE@: A systematic review and meta-analysis.
False	Adverse events are also included.
False	From these results, @FORMULA@ inhibit PGE(2) production in C6 cells, mainly due to Mao but also due to Saishin at least in part, and the counteraction of Bushi.
False	@FORMULA@ and Mao inhibited and Bushi enhanced A23187-induced PGE(2) production while Saishin had no effect.
False	The former effect is mediated by formation of cAMP and resulting inhibition of ERK1/2-phosphorylation.
False	Effect of @FORMULA@ (@FORMULA@: @FORMULA@) on prostaglandin E(2) (PGE(2)) production was investigated using C6 rat @DISEASE@ cells.
False	Concomitantly, Mao inhibted, but Bushi fascilitated, histamine- and A23187-induced phosphorylation of extracellular signal-regulated kinase (ERK)1/2.
True	Inhibitory effect of @FORMULA@ on prostaglandin E2 synthesis in C6 rat @DISEASE@ cells.
False	[Changes in Wnt pathway inhibiting factors in nitrosamine-induced @DISEASE@ and effect of @FORMULA@].
False	At the 10th week, esophageal tissues were collected to observe the pathological changes of esophageal mucosa, detect SFRP1, sFRP4, Axin1, Axin2 and GSK-3beta mRNA levels.by fluorescent quantitation PCR analysis and beta-catenin protein level by Western blotting.
False	METHOD: Wistar rats were subcutaneously injected with MBNA (3.5 mg x kg(-1) for twice per week to establish the model.
False	CONCLUSION: Up-regulated beta-catenin protein level and down-regulated Wnt pathway could enhance Wnt pathway activity of MBNA-induced @DISEASE@.
False	The model group showed lower gene transcription levels of esophageal tissues sFRP1, sFRP4, Axin1 and Axin2 (P < 0.05 or P < 0.01) and higher beta-catenin protein expression level (P < 0.01) than the normal control group.
True	@FORMULA@ could down-regulate the beta-catenin protein level and up-regulate the transcription level of Wnt pathway inhibiting factors, but could not block MBNA-induced @DISEASE@.
False	The patient recovered after discontinuation of @FORMULA@ alone.
False	A 65-year-old man was admitted to our hospital because of @DISEASE@, @DISEASE@, and @DISEASE@ about one month after treatment with @FORMULA@.
False	BALF showed an increase in the total cell number and the percentage of lymphocytes.
False	We diagnosed Bofu-tsusho-san-induced @DISEASE@.
False	TBLB revealed @DISEASE@.
True	[A case of @DISEASE@ induced by @FORMULA@].
False	This study aimed to compare the effect of L-Glutamine and @FORMULA@, and to discuss the validity of these agents for the paclitaxel-induced @DISEASE@/@DISEASE@.
False	[The effect of L-Glutamine and @FORMULA@ for paclitaxel-induced @DISEASE@/@DISEASE@].
False	Our results suggested that @FORMULA@ showed no remarkable effects against paclitaxel-induced @DISEASE@/@DISEASE@ as had been reported before; however, both L-Glutamine and @FORMULA@ decreased the duration of grade 2 toxicity (CALGB Expanded Common Toxicity Criteria) in comparison with those who were not treated.
True	L-Glutamine and @FORMULA@ might therefore a preventive effect against @DISEASE@/@DISEASE@ during paclitaxel-treated chemotherapy.
False	L-Glutamine was reported as a neuroprotective agent for vincristine-induced @DISEASE@.
False	Further trials are needed to confirm the value of these drugs.
False	CONCLUSION: Low-quality evidence was suggestive of @FORMULA@'s efficacy for @DISEASE@, but the present results may be overestimated.
False	Some studies have shown its effectiveness in the treatment of @DISEASE@.
False	@FORMULA@ versus placebo for patients with @DISEASE@: systematic review and meta-analysis.
False	METHODS: We included randomized controlled trials comparing @FORMULA@ with placebo for patients with @DISEASE@ or @DISEASE@.
True	Regardless, @FORMULA@ can be one of the choices for the treatment of @DISEASE@ as it is well tolerated.
False	Studies with a larger sample size and conducted over longer periods should be performed.
True	[A comparison of the protective activity of @DISEASE@ induced by D-galact-osamine between @FORMULA@ and their metabolites by human intestinal bacteria].
False	OBJECTIVE: To compare the protective activity of @DISEASE@ induced by D-galactosamine (GalN) between @FORMULA@ and their metabolites by human intestinal bacteria(HIB).
False	The metabolites of the constituents by intestinal bacteria were the real active components in vivo.
False	RESULT: In conventional mice, large and medium doses (20 and 10 g.kg-1) of @FORMULA@ decoction significantly reduced the increase of serum ALT activity after 18 h GalN treatment.
False	In pseudo-germfree mice, metabolites significantly reduced the ALT levels.
False	METHOD: The @DISEASE@ in conventional and pseudo-germfree mice were induced by GalN.
False	Rat @DISEASE@ model was induced by feeding high fat forage and intraperitoneal injection of isoprenaline (ISO).
False	Compared with the model group, the high and low dose groups of @FORMULA@ and trimetazidine could inhibit the descent of S-T segment, reduced serum TC, AST, CK, LDH and GLU levels (P0.05), and decreased collagen III expression in heart (P0.05), and alleviated @DISEASE@ as well.
False	Subsequently, Electrocardiograph (ECG) was examined, serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and glucose (GLU) were detected using an automatic biochemical analyzer.
False	The protein expressions of Collagen I and Collagen III in heart were evaluated by Western blot.
False	[Effects of @FORMULA@ on @DISEASE@ in rats].
True	Conclusion: @FORMULA@ could improve heart function and alleviate the @DISEASE@, especially the high lose.
False	MATERIALS AND METHODS: A prospective cohort study was conducted to evaluate the efficacy of @FORMULA@ as a complementary medicine to mesalamine for patients with @DISEASE@ (n = 48).
False	The therapeutic outcome was assessed at 8 weeks.
False	@FORMULA@ combined with mesalamine has been demonstrated to result in improve its curative effects without increasing any adverse reactions, but the underlying mechanism remains unclarified.
False	AIM OF THE STUDY: Our study aimed to illuminate the potential therapeutic effects and mechanisms of @FORMULA@, which is a medicine complementary to mesalamine, in the treatment of @DISEASE@.
False	RESULTS: Our results showed that the combination of @FORMULA@ and mesalamine could significantly improve the clinical signs of @DISEASE@ by achieving mucosal healing and relieving @DISEASE@.
True	CONCLUSION: @FORMULA@ combined with mesalamine is effective in improving the clinical and endoscopic outcomes of patients with @DISEASE@.
False	Cellular infiltration and T-cell subsets in the bronchoalveolar lavage fluid (BALF) of allergen-challenged mice were analyzed.
False	In this study, a house-dust-mite (Dermatophagoides pteronyssinus [Der p])-sensitized murine model of @DISEASE@ was used to evaluate the immunomodulatory effect of @FORMULA@ on the allergen-induced @DISEASE@ in @DISEASE@.
False	However, the administration of @FORMULA@ to sensitized mice 24 h after AC (group B) did not have the same inhibitory effect on the @DISEASE@ as @FORMULA@ given before AC.
False	METHODS: Three different protocols were designed to evaluate the treatment and/ or long-term prophylactic effect of @FORMULA@ in Der p-sensitized mice.
False	@FORMULA@ extracts (1 gm/kg) were administered to sensitized mice 1 h before allergen challenge (AC) (group A), 24 h after AC (group B), and every other day six times before AC (group C), respectively.
True	CONCLUSIONS: The administration of @FORMULA@ before AC has the immunomodulatory effect of reducing @DISEASE@ in the allergen-sensitized mice.
False	In three cases, @DISEASE@ and abnormally low CD4/8 ratios were found on examination of bronchoalveolar lavage fluid.
False	In all 5 cases the underlying disease was @DISEASE@ or @DISEASE@ caused by hepatitis C virus.
False	[Five cases of drug-induced @DISEASE@ due to @FORMULA@ or interferon-alpha or both].
True	Therefore, @DISEASE@ due to @FORMULA@ and to interferon-alpha is more likely to occur if these two drugs are given simultaneously.
False	Lymphocyte stimulation tests were done in four cases, and in all four cases the only positive results were against @FORMULA@ or against interferon-alpha.
False	We encountered five cases of drug-induced @DISEASE@ due to @FORMULA@ or interferon-alpha or both.
False	"[Exploration on mechanisms of @FORMULA@ in treating @DISEASE@ and @DISEASE@ with concept of ""treating different diseases with same method"" based on network pharmacology]."
False	TCMSP(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform) and SymMap databases were used to search all the chemical components and targets related to @FORMULA@.
False	BioGPS showed that the key common targets were mainly distributed in heart, amygdala, pineal, liver and smooth muscle.
False	About 1 004 @DISEASE@ targets and 578 @DISEASE@ targets were obtained, and 37 common targets were obtained after intersection with herbal targets.
False	About 1 355 compounds of @FORMULA@ were found by TCMSP and Symmap database; 161 active compounds were screened out according to standard of oral bioavailability>/=30% and drug like index>/=0.18; 274 herbal targets were obtained and the &quot;herbs-compounds-targets&quot; network was constructed.
True	In conclusion, the main mechanism of @FORMULA@ in treating @DISEASE@ and @DISEASE@ with concept of &quot;treating different diseases with same method&quot; was related to neuroendocrine system, metabolism, immune @DISEASE@ and oxidative stress-related signal pathway, providing reference for further experimental verification, potential pharmacological mechanism and clinical application.
False	In the present study, we investigated the effects of @FORMULA@ on muscle mass and function in aged mice.
False	Muscle samples were further used for histological analysis to assess @DISEASE@, and the expression of transforming growth factor-beta was investigated via western blotting and immunohistochemistry.
False	PURPOSE: @FORMULA@ (@FORMULA@), a traditional herbal formula composed of 12 medicinal herbs, is used for the treatment of age-related diseases.
False	At the end of the experimental period, muscle strength was examined using the wire hang test, and the tibialis anterior and gastrocnemius muscles were weighed.
False	@FORMULA@, a traditional herbal formula, improves muscle function and attenuates @DISEASE@ in aged mice.
True	CONCLUSION: In conclusion, @FORMULA@ has beneficial effects on @DISEASE@.
False	METHODS: Mice were administered orally with four respective representative RR, @FORMULA@, @FORMULA@, @FORMULA@, and Renshen Dihuang Decoction.
False	Then the @DISEASE@ latent periods were recorded and SOD vitalities in brain and lung were determined.
False	RESULTS: Compared with the control groups, the @DISEASE@ latent period of @FORMULA@ group was prolonged significantly (P < 0.01) and its SOD vitality in lung was maintained higher (P < 0.01) after @DISEASE@, while the other three RR results have no significant difference (P < 0.05).
False	[Experimental study on preventive effect of traditional Chinese medicine replenishing recipe on @DISEASE@ caused by hyperbaric oxygen].
True	CONCLUSION: @FORMULA@ has certain preventive effect on acute oxygen @DISEASE@.
False	OBJECTIVE: To seek for the effective traditional Chinese medicine (TCM) replenishing recipe (RR) prescription that being able to prevent the onset of oxygen @DISEASE@ and to offer some clues in preventing the oxygen @DISEASE@ with TCM-RR.
False	Real-time-PCR was used to detect the mRNA level of caspase-3, endothelial nitric oxide synthase (eNOS), and Bcl-2.
False	Rats were randomly divided into non-intervention group, metformin group, simvastatin group, and early-, middle-, late-stage @FORMULA@ groups.
False	Western blots were used to detect the expression of AMP-activated protein kinase alpha1 (AMPKalpha1) and peroxisome proliferator-activated receptor 1alpha (PGC-1alpha).
True	Early intervention with @FORMULA@ enhances mitochondrial energy metabolism by regulating the AMPK signaling pathway and therefore may play a role in strengthening the defense function of large vascular endothelial cells and postpone the development of @DISEASE@.
False	The study aimed to investigate the intervening role of @FORMULA@ (@FORMULA@) at different times in macrovascular endothelial defense function, focusing on its effects on the AMP-activated protein kinase (AMPK) signaling pathway.
False	Compared to the @DISEASE@ non-intervention group, a significant increase in the expression of AMPKalpha1 and PGC-1alpha were observed in the early-stage, middle-stage @FORMULA@ groups and simvastatin group (P < 0.05).
False	Muller cells were stimulated by blood serum obtained from rats with blood-stasis syndrome and then treated by @FORMULA@.
False	Western blot analysis, RT-PCR and ELISA were used to measure the expression of VEGF.
False	AIMS: This research was aimed to investigate whether @DISEASE@ blood-stasis syndrome had a relationship with ERK1/2-VEGF signaling pathway in rat retina Muller cells and Traditional Chinese Drugs designed for promoting blood circulation to remove blood stasis had effectiveness for @DISEASE@ (@DISEASE@) treatment.
False	And treatment of @FORMULA@ could weaken this phenomenon.
False	RESULTS: Stimulation of Muller cells by blood serum of rat with @DISEASE@ blood stasis increased the secretion of VEGF, activated ERK1/2 and AP-1 DNA-binding activity.
True	Effect of @DISEASE@ blood-stasis syndrome and @FORMULA@ on ERK1/2-VEGF signal pathway in rat retina Muller cells.
True	These findings suggest that @FORMULA@ is responsible for the inhibitory effects of @FORMULA@ on the estrogen-related @DISEASE@ in mice.
False	In the present study, the constituents of @FORMULA@ responsible for this effect were explored using a short-term experiment.
False	We have found that @FORMULA@ has a preventive effect on @DISEASE@ in mice (Carcinogenesis 22 (2001) 587).
False	A similar trend was not found upon treatment with @FORMULA@.
False	Thirty female ICR mice were divided into five groups: Group 1 was given a diet containing 0.2% of @FORMULA@ and 5ppm estradiol-17beta (E(2)); Group 2 was given a diet containing @FORMULA@ (0.07%) and E(2) (5ppm); Group 3 received @FORMULA@ (0.08%) and E(2) (5ppm) in the diet; Group 4 was given 5ppm E(2) in the diet; and Group 5 served as a control.
False	@FORMULA@ is the agent in @FORMULA@ responsible for the prevention of @DISEASE@ in mice.
False	Inhibition of MAPK p38 (p38) in the hippocampus was observed after @FORMULA@ and emodin treatment.
False	Behavior tests, proteomic analysis, morphological studies, and western blotting were performed.
False	RESULTS: The @DISEASE@ in the @DISEASE@ rats recovered with @FORMULA@ and emodin on the 14(th) day after @DISEASE@.
False	The numbers of amoebic microglia in the CPu and M2 microglia in both CPu and hippocampus were significantly increased after @FORMULA@ and emodin treatment.
False	Emodin is an active compound found in rhubarb.
True	CONCLUSION: The protective effects of @FORMULA@ on @DISEASE@ were confirmed in this study, and its mechanism may be related to the inhibition of MAPK and activation of M2 microglia.
False	To understand the mechanism of anti-asthmatic property of @FORMULA@, a guinea pig model of @DISEASE@ was used to investigate the effects of @FORMULA@ on Dermatophagoides pteronyssinus-induced early and late @DISEASE@ responses and @DISEASE@, and examine direct beta2-adrenoceptor agonist activity in guinea-pig isolated trachea.
False	The precise mechanism of action of @FORMULA@ in @DISEASE@ remains to be elucidated.
False	@FORMULA@ caused concentration-dependent relaxation in strips of guinea pig trachea contracted with carbachol, and ICI-118551, a selective beta2-adrenoceptor antagonist, significantly inhibit the relaxation caused by @FORMULA@.
True	The effects of @FORMULA@ on @DISEASE@ and @DISEASE@ in @DISEASE@ guinea pigs.
False	@FORMULA@ (@FORMULA@), a traditional Chinese medicine, has been used in treatment of the @DISEASE@ for several centuries.
False	Administration of @FORMULA@ (10 g/kg) extracts significantly inhibited the antigen induced immediate @DISEASE@ responses (IAR) in actively sensitized guinea pig.
False	Metabonomic analysis of the therapeutic effect of @FORMULA@ in treatment of streptozotocin-induced @DISEASE@.
False	AIM OF THE STUDY: Traditional Chinese medicines (TCMs) usually operate in vivo through multi-components, multi-ways and multi-targets.
False	ETHNOPHARMACOLOGICAL RELEVANCE: @FORMULA@ (@FORMULA@) is one of ancient traditional Chinese medicines (TCMs), which is usually used for the treatment of kidney deficiency for thousands of years in China.
False	However, the molecular mechanisms of TCMs remain unclear.
False	Our work may be of benefit to both evaluation of the therapeutic effect of TCM and elucidation of the underlying molecular mechanism.
True	CONCLUSION: Our study indicates that @FORMULA@ treatment can ameliorate @DISEASE@ symptoms by intervening in some dominating metabolic pathways, such as inhibiting glucose and lipid metabolism, enhancing methylamine metabolism.
False	The results indicated that the clinical symptoms of rats and pathological changes of gastric mucosa were improved in @FORMULA@ group.
False	The content of NO in the gastric mucosa was tested by nitrate reductive enzymatic.
False	[Effects of @FORMULA@ on TLR signal pathway in gastric mucosa tissues of rats with Helicobacter pylori-induced @DISEASE@].
False	ELISA was applied to detect the expressions of TNF-alpha and IL-6 in the serum, and the activity of iNOS in gastric mucosa.
False	In the rats model, HP infection results in @DISEASE@ through the activation of TLR2, TLR4/MAPK/NF-kappaB/iNOS/NO signal pathway.
True	@FORMULA@ can eradicate H. pylori and alleviate @DISEASE@.
False	@FORMULA@ can treat such symptoms as @DISEASE@, @DISEASE@, fullness of head, @DISEASE@; @DISEASE@, @DISEASE@ and @DISEASE@; dysphoria, @DISEASE@, @DISEASE@, @DISEASE@, @DISEASE@ and @DISEASE@; @DISEASE@ with bitter taste and sweeting; @DISEASE@ of limbs and @DISEASE@ in loin and legs; @DISEASE@ with burning sensation during urination; a solid or @DISEASE@; red tongue, slippery and rapid pulse, wiry and rapid pulse over to Cunkou.
False	As we known, @FORMULA@ is a classical formula for treating @DISEASE@.
False	However, with the regular monitoring of biomedical index, long-term treatment with Caulis Polygoni Multiflori(3-10 g.d~(-1) for 3 to 6 months) didn't show @DISEASE@.
False	@DISEASE@ is a global major public health problem.
False	The pharmacological activity of @FORMULA@ coincided with the pathology and disease mechanism of newly-diagnosed and young @DISEASE@.
True	Therefore, @FORMULA@ was the specific recipe for newly-diagnosed and young @DISEASE@.
False	In order to improve and reestablish the standard of quality control of Chinese herbal medicines, the authors attempted a method that would incorporate the composition of inorganic elements as part of the quality control.
False	Yet, in studies of chemical composition and quality control of Chinese herbal medicines for stimulating blood circulation and relaxing muscles and joints, inorganic substances are often overlooked.
False	In the present study, the authors used atomic absorption spectrophotometry to measure the contents of fifteen inorganic elements, namely, Cu, Ca, Fe, K, Mg, Mo, Ni, Sr, V, Mn, Zn, Na, Cr, Cd, and Hg, in several Chinese herbal medicines, including @FORMULA@.
False	[Exploration of quality control of inorganic elements in Chinese herbal medicines for stimulating blood circulation and relaxing muscles and joints by atomic absorption spectrophotometry].
False	The measurement and analysis of inorganic elements in @FORMULA@ will also provide evidences and references for the fingerprint establishment of @FORMULA@ in the future.
True	The authors' results showed that the amounts of trace elements Fe, Cu, Mn and Zn found in Chinese herbal medicine @FORMULA@ are related to the following curative effects of @FORMULA@: relieving @DISEASE@, rectifying breathing and alleviating phlegm, stimulating blood circulation and relaxing muscles and joints.
